[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsCQq8120nwKkMWU5tcLlEw67ADaS5rHsSDn9RRJidb0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"Stanford University",[4],2121,false,470,82,4917693,182,1450,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",57,{"name":18,"count":19},"Obesity",55,{"name":21,"count":22},"Depression",53,{"name":24,"count":25},"Pain",39,{"name":27,"count":28},"Autism Spectrum Disorder",33,{"name":30,"count":31},"Anxiety",31,{"name":33,"count":34},"Chronic Pain",29,{"name":36,"count":37},"Insulin Resistance",26,[39,44,49,54,58,63,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT02346253","High-Dose Brachytherapy in Treating Patients With Prostate Cancer","2021-12-14","Bicalutamide",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03233854","CD19\u002FCD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","2023-06-20","Chimeric Antigen Receptor T-Cell Therapy",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04313712","Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure","2025-02","ibogaine with magnesium treatment",{"nctId":55,"briefTitle":56,"date":57,"intervention":48},"NCT03241940","Study of CD19\u002FCD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w\u002F Recurrent or Refractory B Cell Malignancies","2025-04-03",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05973734","Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy","2025-05","Infusion of recipient T regulatory cell",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05119296","Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic\u002FUndifferentiated Thyroid Cancer","2025-05-16","Pembrolizumab",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05305365","Study Assessing QBS72S For Treating Brain Metastases","2025-06-20","QBS72S",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06650930","Pharmacokinetics of Oral Calcium Carbonate in Parturients","2025-08","Oral calcium carbonate",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04577300","Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma","2025-08-15","NT-501",{"nctId":84,"briefTitle":85,"date":81,"intervention":86},"NCT02862938","Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration","NT-501 ECT implant",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,195,279,333,366,407,443,471,489,507,525,551,576,594,620,638,664,682,820,881,925,963,989,1007,1030,1058,1076,1107,1133,1160,1178,1204,1232,1250,1275,1324,1368,1394,1507,1570,1605,1641,1677,1790,1874,1907,1986,2057,2090,2127,2159,2196,2229,2259,2277,2295,2313,2341,2359,2382,2404,2427,2449,2473,2491,2516,2540,2570,2596,2614,2635,2659,2677,2695,2713,2731,2749,2767,2785,2803,2827,2851,2869,2891,2915,2933,2951,2969,2987,3005,3031,3049,3073,3096,3115,3140,3163,3181,3203,3221,3239,3264,3282,3352,3391,3417,3552,3578,3609,3631,3653,3694,3754,3835,3869,3891,3973,4028,4060,4092,4144,4170,4188,4206,4224,4246,4267,4285,4309,4327,4350,4378,4396,4414,4432,4450,4468,4491,4518,4541,4559,4583,4601,4625,4643,4668,4686,4711,4735,4753,4777,4795,4813,4831,4849,4867,4885,4903,4929,4947,4965,4998,5033,5051,5073,5095,5119,5144,5169,5191,5225,5246,5274,5301,5330,5348,5366,5384,5402,5432,5454,5477,5500,5588,5633,5678,5713,5749,5776,5807,5829,5860,5890,5914,5946,5970,5995,6019,6037,6061,6079,6101,6119,6143,6161,6184,6202,6226,6250,6268,6294,6312,6334,6357,6379,6402,6426,6447,6470,6488,6506,6530,6553,6571,6592,6616,6641,6659,6683,6701,6723,6741,6763,6781,6806,6824,6846,6868,6893,6914,6938,6959,6984,7002,7029,7054,7081,7106,7132,7150,7176,7194,7212,7235,7253,7276,7299,7323,7346,7368,7386,7409,7427,7445,7463,7481,7513,7531,7549,7572,7596,7614,7638,7663,7681,7699,7724,7742,7760,7778,7796,7853,7891,7940,7991,8013,8047,8075,8108,8141,8167,8185,8211,8236,8261,8279,8297,8315,8333,8356,8378,8396,8414,8432,8455,8473,8491,8513,8531,8557,8575,8597,8615,8639,8657,8680,8698,8722,8750,8768,8793,8818,8836,8859,8877,8900,8929,8947,8968,8989,9014,9032,9050,9072,9095,9113,9138,9156,9174,9197,9219,9292,9341,9379,9409,9454,9484,9523,9578,9604,9630,9656,9682,9719,9745,9786,9826,9864,9890,9912,9938,9971,10002,10030,10060,10088,10110,10132,10154,10176,10205,10242,10272,10294,10316,10342,10364,10386,10419,10454,10486,10508,10526,10549,10575,10598,10616,10645,10667,10691,10714,10738,10768,10786,10804,10822,10840,10858,10880,10898,10922,10940,10964,10982,11000,11018,11042,11060,11084,11111,11133,11154,11179,11201,11226,11251,11272,11296,11314,11332,11350,11368,11390,11408,11434,11458,11481,11504,11522,11540,11558,11576,11598,11622,11645,11663,11681,11699,11724,11742,11760,11783,11801,11825,11849,11867,11892,11910,11928,11954,11972,11990,12013,12035,12053,12071,12089,12114,12138,12161,12179,12202,12223,12249,12272,12290,12315,12339,12357,12375,12400,12418,12436,12459,12485,12507,12528,12552,12570,12591,12614,12638,12660,12682,12700,12722,12747,12768,12793,12817,12835,12853,12871,12892,12913,12934,12957,12981,12999,13027,13045,13070,13092,13110,13128,13151,13172,13194,13223,13241,13259,13283,13307,13325,13343,13361,13389,13407,13425,13447,13465,13487,13505,13544,13579,13601,13622,13647,13670,13692,13714,13740,13761,13782,13805,13827,13852,13876,13894,13918,13936,13961,13983,14001,14027,14057,14075,14093,14111,14129,14147,14171,14197,14215,14242,14265,14292,14318,14343,14361,14383,14401,14424,14447,14468,14486,14504,14527,14550,14571,14593,14616,14639,14662,14686,14709,14727,14755,14773,14791,14814,14839,14857,14875,14893,14911,14932,14997,15019,15037,15055,15077,15095,15117,15148,15183,15218,15241,15266,15290,15308,15331,15354,15377,15395,15422,15440,15458,15483,15501,15525,15548,15572,15597,15620,15638,15659,15680,15757,15812,15868,15922,15959,15998,16028,16067,16101,16142,16183,16212,16248,16283,16316,16342,16376,16402,16431,16468,16490,16518,16550,16580,16602,16634,16656,16685,16711,16741,16770,16800,16827,16858,16890,16919,16944,16975,17004,17029,17060,17083,17104,17122,17148,17171,17192,17214,17236,17254,17275,17297,17318,17336,17354,17378,17400,17421,17442,17467,17489,17507,17529,17551,17574,17596,17618,17636,17657,17683,17701,17724,17745,17769,17791,17813,17834,17856,17874,17897,17918,17941,17963,17984,18002,18023,18046,18064,18085,18107,18125,18143,18165,18183,18201,18226,18244,18262,18287,18305,18323,18344,18366,18391,18409,18427,18445,18470,18488,18506,18529,18551,18573,18594,18617,18641,18665,18683,18705,18728,18749,18773,18791,18809,18831,18853,18871,18897,18915,18933,18954,18976,18997,19015,19037,19063,19086,19104,19126,19151,19172,19190,19208,19232,19250,19268,19293],{"intervention":96,"totalTrials":97,"cells":98},"Ketamine",7,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":116,"PHASE3":153,"PHASE4":155,"NA":182},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":115,"soonestReadout":109},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT04861051","Understanding Ketamine's Dissociative Effects (KD Study)","RECRUITING",[89],"2028-08-01","2021-07-26",20,[113],"Epilepsy",[96],1,{"trials":117,"activeCount":152,"soonestReadout":147},[118,129,142],{"nctId":119,"briefTitle":120,"status":107,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT05940324","Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)",[90],"2028-11","2024-02-24",150,[126],"Obsessive-Compulsive Disorder",[96,128],"Naltrexone Pill",{"nctId":130,"briefTitle":131,"status":132,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":101,"conditions":137,"interventions":139},"NCT05945147","Ketamine and Midazolam Infusions for CRPS: Feasibility Study","WITHDRAWN",[90],"2099-04-30","2099-05-31","2099-01-01",[138],"Complex Regional Pain Syndromes",[96,140,141],"Midazolam","Normal Saline",{"nctId":143,"briefTitle":144,"status":145,"phases":146,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":151},"NCT02624596","Understanding How Ketamine Brings About Rapid Improvement in OCD","ACTIVE_NOT_RECRUITING",[90],"2026-06","2016-06",120,[126],[96,140],2,{"trials":154,"activeCount":101},[],{"trials":156,"activeCount":115,"soonestReadout":176},[157,172],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":170},"NCT03861988","Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery","COMPLETED",[92],"2022-09-22","2022-09-27","2019-08-22",45,[167,168,169],"Major Depressive Disorder","Surgery","Orthopedic Disorder",[96,171],"Normal saline",{"nctId":173,"briefTitle":174,"status":145,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":181},"NCT06317636","Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression",[92],"2026-11","2026-12","2025-01-28",40,[33,21],[96,171],{"trials":183,"activeCount":101},[184],{"nctId":185,"briefTitle":186,"status":160,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT03475277","Stanford Regulating Circuits of the Brain Study- Ketamine",[],"2022-11-30","2024-07-01","2019-08-19",13,[193],"Healthy",[96],{"intervention":196,"totalTrials":197,"cells":198},"Propofol",6,{"EARLY_PHASE1":199,"PHASE1":213,"PHASE2":237,"PHASE3":252,"PHASE4":254,"NA":265},{"trials":200,"activeCount":115,"soonestReadout":205},[201],{"nctId":202,"briefTitle":203,"status":107,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT04992572","Study Comparing Local\u002F MAC Anesthesia in Lumbar Decompression",[88],"2026-12-31","2028-12-31","2021-12-01",100,[210],"Lumbar Spinal Stenosis",[196,212],"Lidocaine Hydrochloride, Injectable",{"trials":214,"activeCount":101},[215,226],{"nctId":216,"briefTitle":217,"status":160,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT00683956","Evaluation of a Closed-Loop Control System for Administering Patient-Specific Anesthesia",[89],"2009-07","2009-09","2008-05",35,[224],"Anesthesia, General",[196],{"nctId":227,"briefTitle":228,"status":160,"phases":229,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT01591148","A High Resolution Pharmacokinetic\u002FPharmacodynamic Model of Propofol in Morbidly Obese Subjects",[89],"2017-07","2011-01",30,[234],"Morbid Obesity",[236],"propofol",{"trials":238,"activeCount":115,"soonestReadout":244},[239],{"nctId":240,"briefTitle":241,"status":242,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT07479550","Study of Psilocybin Under Anesthesia Controlled by EEG","NOT_YET_RECRUITING",[90],"2027-07","2027-08","2026-07",10,[249],"Major Depression",[251,196],"Psilocybin",{"trials":253,"activeCount":101},[],{"trials":255,"activeCount":115,"soonestReadout":245},[256],{"nctId":257,"briefTitle":258,"status":259,"phases":260,"primaryCompletion":245,"completion":245,"start":261,"enrollment":247,"conditions":262,"interventions":264},"NCT07161518","Characterizing Transcranial Focused Ultrasound Neuromodulation During Sedation","ENROLLING_BY_INVITATION",[92],"2025-09-01",[263],"Healthy Participants",[196],{"trials":266,"activeCount":101},[267],{"nctId":268,"briefTitle":269,"status":160,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT00417664","Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients",[],"2004-01","2004-04","2002-04",90,[276],"Delirium",[278,196,140],"Dexmedetomidine",{"intervention":171,"totalTrials":197,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":302,"PHASE4":304,"NA":314},{"trials":282,"activeCount":101},[],{"trials":284,"activeCount":101},[],{"trials":286,"activeCount":101},[287,291],{"nctId":130,"briefTitle":131,"status":132,"phases":288,"primaryCompletion":134,"completion":135,"start":136,"enrollment":101,"conditions":289,"interventions":290},[90],[138],[96,140,141],{"nctId":292,"briefTitle":293,"status":160,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT04638881","Magnesium for Peroral Endoscopic Myotomy",[90],"2023-04-13","2020-12-28",92,[299],"Esophageal Spasm",[301,141],"Magnesium sulfate",{"trials":303,"activeCount":101},[],{"trials":305,"activeCount":115,"soonestReadout":176},[306,310],{"nctId":158,"briefTitle":159,"status":160,"phases":307,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":308,"interventions":309},[92],[167,168,169],[96,171],{"nctId":173,"briefTitle":174,"status":145,"phases":311,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":312,"interventions":313},[92],[33,21],[96,171],{"trials":315,"activeCount":152,"soonestReadout":176},[316,325],{"nctId":317,"briefTitle":318,"status":242,"phases":319,"primaryCompletion":176,"completion":176,"start":320,"enrollment":111,"conditions":321,"interventions":323},"NCT06953661","Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome",[93],"2025-10-13",[322],"Postural Tachycardia Syndrome",[324,171],"Ropivacaine",{"nctId":326,"briefTitle":327,"status":242,"phases":328,"primaryCompletion":177,"completion":177,"start":329,"enrollment":111,"conditions":330,"interventions":332},"NCT07087015","Efficacy of Cervical Sympathetic Blocks for PTSD",[93],"2025-10",[331],"PTSD",[324,141],{"intervention":324,"totalTrials":334,"cells":335},3,{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":356},{"trials":337,"activeCount":101},[],{"trials":339,"activeCount":101},[],{"trials":341,"activeCount":101},[],{"trials":343,"activeCount":101},[],{"trials":345,"activeCount":115,"soonestReadout":177},[346],{"nctId":347,"briefTitle":348,"status":107,"phases":349,"primaryCompletion":177,"completion":177,"start":350,"enrollment":351,"conditions":352,"interventions":355},"NCT03230565","Continuous Infusions vs Scheduled Bolus Infusions",[92],"2018-06-01",240,[353,354],"Surgical Procedure, Unspecified","Pain, Postoperative",[324,324],{"trials":357,"activeCount":152,"soonestReadout":176},[358,362],{"nctId":317,"briefTitle":318,"status":242,"phases":359,"primaryCompletion":176,"completion":176,"start":320,"enrollment":111,"conditions":360,"interventions":361},[93],[322],[324,171],{"nctId":326,"briefTitle":327,"status":242,"phases":363,"primaryCompletion":177,"completion":177,"start":329,"enrollment":111,"conditions":364,"interventions":365},[93],[331],[324,141],{"intervention":367,"totalTrials":152,"cells":368},"Tirzepatide",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":387,"PHASE4":389,"NA":405},{"trials":370,"activeCount":101},[],{"trials":372,"activeCount":101},[],{"trials":374,"activeCount":115,"soonestReadout":379},[375],{"nctId":376,"briefTitle":377,"status":107,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":386},"NCT05912621","Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight\u002FObesity",[90],"2028-06","2029-12","2023-11-09",66,[18,384,385],"Overweight and Obesity","Overweight",[367],{"trials":388,"activeCount":101},[],{"trials":390,"activeCount":115,"soonestReadout":395},[391],{"nctId":392,"briefTitle":393,"status":107,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":403},"NCT06657209","Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide",[92],"2027-12-15","2025-01-13",104,[399,400,401,402],"Diabetes Mellitus, Type 2","Diabetes","Type 2 Diabetes","Pre Diabetes",[367,404],"Pioglitazone",{"trials":406,"activeCount":101},[],{"intervention":408,"totalTrials":152,"cells":409},"Metformin",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":426,"PHASE4":428,"NA":441},{"trials":411,"activeCount":101},[],{"trials":413,"activeCount":101},[],{"trials":415,"activeCount":115,"soonestReadout":420},[416],{"nctId":417,"briefTitle":418,"status":107,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":425},"NCT04500756","Limiting AAA With Metformin (LIMIT) Trial",[90],"2028-06-30","2022-02-28",314,[424],"Abdominal Aortic Aneurysm",[408],{"trials":427,"activeCount":101},[],{"trials":429,"activeCount":115,"soonestReadout":434},[430],{"nctId":431,"briefTitle":432,"status":242,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT06682351","Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention",[92],"2027-12","2024-11",200,[438],"Prediabetes \u002F Type 2 Diabetes",[408,440],"GLP-1A",{"trials":442,"activeCount":101},[],{"intervention":444,"totalTrials":115,"cells":445},"Sulfadoxine pyrimethamine + Amodiaquine",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":469},{"trials":447,"activeCount":101},[],{"trials":449,"activeCount":101},[],{"trials":451,"activeCount":101},[],{"trials":453,"activeCount":101},[],{"trials":455,"activeCount":115,"soonestReadout":460},[456],{"nctId":457,"briefTitle":458,"status":242,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":465},"NCT07322068","Perennial Malaria Chemoprevention in the Malaria Vaccine Era",[92],"2033-06","2026-09",1290,[464],"Malaria, Falciparum",[444,466,467,468],"Dihydroartemisinin Piperaquine","Dihydroartemisinin Piperaquine Placebo","Sulfadoxine pyrimethamine + Amodiaquine placebo",{"trials":470,"activeCount":101},[],{"intervention":466,"totalTrials":115,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":487},{"trials":474,"activeCount":101},[],{"trials":476,"activeCount":101},[],{"trials":478,"activeCount":101},[],{"trials":480,"activeCount":101},[],{"trials":482,"activeCount":115,"soonestReadout":460},[483],{"nctId":457,"briefTitle":458,"status":242,"phases":484,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":485,"interventions":486},[92],[464],[444,466,467,468],{"trials":488,"activeCount":101},[],{"intervention":467,"totalTrials":115,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":505},{"trials":492,"activeCount":101},[],{"trials":494,"activeCount":101},[],{"trials":496,"activeCount":101},[],{"trials":498,"activeCount":101},[],{"trials":500,"activeCount":115,"soonestReadout":460},[501],{"nctId":457,"briefTitle":458,"status":242,"phases":502,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":503,"interventions":504},[92],[464],[444,466,467,468],{"trials":506,"activeCount":101},[],{"intervention":468,"totalTrials":115,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":523},{"trials":510,"activeCount":101},[],{"trials":512,"activeCount":101},[],{"trials":514,"activeCount":101},[],{"trials":516,"activeCount":101},[],{"trials":518,"activeCount":115,"soonestReadout":460},[519],{"nctId":457,"briefTitle":458,"status":242,"phases":520,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":521,"interventions":522},[92],[464],[444,466,467,468],{"trials":524,"activeCount":101},[],{"intervention":526,"totalTrials":115,"cells":527},"Amiodarone",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":549},{"trials":529,"activeCount":101},[],{"trials":531,"activeCount":101},[],{"trials":533,"activeCount":101},[],{"trials":535,"activeCount":101},[],{"trials":537,"activeCount":115,"soonestReadout":542},[538],{"nctId":539,"briefTitle":540,"status":107,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT03868150","Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment",[92],"2030-12-31","2050-12-31","2017-03-01",600,[547],"Postoperative Atrial Fibrillation",[526],{"trials":550,"activeCount":101},[],{"intervention":552,"totalTrials":115,"cells":553},"Anti-convulsant medications",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":574},{"trials":555,"activeCount":101},[],{"trials":557,"activeCount":101},[],{"trials":559,"activeCount":101},[],{"trials":561,"activeCount":101},[],{"trials":563,"activeCount":115,"soonestReadout":568},[564],{"nctId":565,"briefTitle":566,"status":107,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT04441034","Stanford Pragmatic Effectiveness Comparison",[92],"2027-04-30","2022-04-12",450,[33],[552,573],"Anti-depressant medications",{"trials":575,"activeCount":101},[],{"intervention":573,"totalTrials":115,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":586,"NA":592},{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":101},[],{"trials":583,"activeCount":101},[],{"trials":585,"activeCount":101},[],{"trials":587,"activeCount":115,"soonestReadout":568},[588],{"nctId":565,"briefTitle":566,"status":107,"phases":589,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":590,"interventions":591},[92],[33],[552,573],{"trials":593,"activeCount":101},[],{"intervention":595,"totalTrials":115,"cells":596},"Low sodium oxybate",{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":618},{"trials":598,"activeCount":101},[],{"trials":600,"activeCount":101},[],{"trials":602,"activeCount":101},[],{"trials":604,"activeCount":101},[],{"trials":606,"activeCount":115,"soonestReadout":611},[607],{"nctId":608,"briefTitle":609,"status":242,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":617},"NCT07077278","Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome",[92],"2027-09","2025-10-01",25,[615,616],"Idiopathic Hypersomnia","POTS - Postural Orthostatic Tachycardia Syndrome",[595],{"trials":619,"activeCount":101},[],{"intervention":440,"totalTrials":115,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":636},{"trials":623,"activeCount":101},[],{"trials":625,"activeCount":101},[],{"trials":627,"activeCount":101},[],{"trials":629,"activeCount":101},[],{"trials":631,"activeCount":115,"soonestReadout":434},[632],{"nctId":431,"briefTitle":432,"status":242,"phases":633,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":634,"interventions":635},[92],[438],[408,440],{"trials":637,"activeCount":101},[],{"intervention":639,"totalTrials":115,"cells":640},"OnabotulinumtoxinA 100 UNT [Botox]",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":662},{"trials":642,"activeCount":101},[],{"trials":644,"activeCount":101},[],{"trials":646,"activeCount":101},[],{"trials":648,"activeCount":101},[],{"trials":650,"activeCount":115,"soonestReadout":655},[651],{"nctId":652,"briefTitle":653,"status":107,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":111,"conditions":658,"interventions":660},"NCT06216886","OnabotulinumtoxinA for Trigeminal Neuralgia",[92],"2027-02-01","2027-09-01","2024-06-01",[659],"Trigeminal Neuralgia",[639,661],"Sodium Chloride 0.9% for Injection, Preservative Free",{"trials":663,"activeCount":101},[],{"intervention":661,"totalTrials":115,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":680},{"trials":667,"activeCount":101},[],{"trials":669,"activeCount":101},[],{"trials":671,"activeCount":101},[],{"trials":673,"activeCount":101},[],{"trials":675,"activeCount":115,"soonestReadout":655},[676],{"nctId":652,"briefTitle":653,"status":107,"phases":677,"primaryCompletion":655,"completion":656,"start":657,"enrollment":111,"conditions":678,"interventions":679},[92],[659],[639,661],{"trials":681,"activeCount":101},[],{"intervention":683,"totalTrials":684,"cells":685},"Acetaminophen",8,{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":769,"PHASE4":782,"NA":806},{"trials":687,"activeCount":101},[],{"trials":689,"activeCount":101},[],{"trials":691,"activeCount":101},[692,713,732,752],{"nctId":693,"briefTitle":694,"status":160,"phases":695,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":703},"NCT00186628","Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD",[90],"2010-11","2010-12","2005-06",36,[701,702],"Leukemia, Mast-Cell","Mantle-cell Lymphoma",[704,705,706,707,708,709,710,683,711,712],"Rituximab","Anti-thymoglobulin, rabbit","Cyclosporine","Mycophenylate mofetil","Filgrastim","Granisetron","Solumedrol","Diphenhydramine","Hydrocortisone",{"nctId":714,"briefTitle":715,"status":716,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":720,"interventions":725},"NCT00482053","Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","TERMINATED",[90],"2010-05","2006-10",[721,722,723,724],"Lymphoma, B-cell","Lymphoma, Non-Hodgkin","Diffuse Large B-cell Lymphoma (DLBCL)","Malignant Lymphoma, Non-Hodgkin",[704,726,727,708,728,706,729,730,683,711,712,731],"Carmustine","Etoposide","Anti-thymocyte globulin","Mycophenolate mofetil","Cyclophosphamide","Methylprednisolone",{"nctId":733,"briefTitle":734,"status":160,"phases":735,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":738,"interventions":747},"NCT00185692","Allogeneic Transplantation From Related Haploidentical Donors",[90],"2000-08",16,[739,740,741,742,743,744,745,746],"Blood Cancer","Leukemia","Graft Versus Host Disease","Malignancy","CLL","NHL","Hodgkin's Disease","MDS",[748,706,749,750,710,683,751,712],"Anti-Thymocyte Globulin","Mycophenolate Mofetil","G-CSF","Diphenydramine",{"nctId":753,"briefTitle":754,"status":160,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":765},"NCT00899847","Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG",[90],"2014-04","2014-12","2009-05",9,[761,762,763,764],"Transplantation, Homologous","Transplantation, Autologous","Multiple Myeloma","Blood and Marrow Transplant (BMT)",[708,730,766,706,767,768,710,711,683,712],"Melphalan","Rabbit anti-thymocyte globulin","Mycophenolate Mofetil 250mg",{"trials":770,"activeCount":101},[771],{"nctId":772,"briefTitle":773,"status":160,"phases":774,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT00000425","Toward Better Outcomes in Osteoarthritis",[91],"2001-04","1996-07",900,[779],"Osteoarthritis",[781,683],"Nonsteroidal anti-inflammatory drugs",{"trials":783,"activeCount":115,"soonestReadout":798},[784,794],{"nctId":785,"briefTitle":786,"status":160,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":793},"NCT03445390","The Effect of Intravenous Acetaminophen on Post-Operative Pain After Craniotomy",[92],"2017-10-01","2017-11-01","2014-05-01",27,[24],[683],{"nctId":795,"briefTitle":796,"status":242,"phases":797,"primaryCompletion":798,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":804},"NCT07203079","Oral Versus Intravenous Acetaminophen in Lumbar Spine Surgery",[92],"2026-10","2027-01","2026-01",180,[803],"Postoperative Pain",[805,683],"Acetaminophen Oral",{"trials":807,"activeCount":101},[808],{"nctId":809,"briefTitle":810,"status":160,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":816},"NCT02605187","Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management",[93],"2017-05-22","2015-11",160,[803],[817,683,818,819,819,819],"Ibuprofen","Gabapentin","Morphine",{"intervention":404,"totalTrials":821,"cells":822},5,{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":849,"PHASE4":851,"NA":868},{"trials":824,"activeCount":101},[],{"trials":826,"activeCount":101},[],{"trials":828,"activeCount":101},[829,840],{"nctId":830,"briefTitle":831,"status":160,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT01186250","Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation",[90],"2013-08","2013-12","2010-07",18,[838],"Cardiac Allograft Vasculopathy",[404],{"nctId":841,"briefTitle":842,"status":716,"phases":843,"primaryCompletion":718,"completion":718,"start":844,"enrollment":152,"conditions":845,"interventions":847},"NCT00825266","Insulin Resistance in Pulmonary Arterial Hypertension",[90],"2008-09",[846],"Hypertension, Pulmonary",[848,404],"bosentan",{"trials":850,"activeCount":101},[],{"trials":852,"activeCount":115,"soonestReadout":395},[853,864],{"nctId":854,"briefTitle":855,"status":160,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":862},"NCT01559857","Pioglitazone in Patients With Mood Disorders",[92],"2014-01","2014-06","2011-11",37,[167,36],[404,863],"Sugar Pill",{"nctId":392,"briefTitle":393,"status":107,"phases":865,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":866,"interventions":867},[92],[399,400,401,402],[367,404],{"trials":869,"activeCount":101},[870],{"nctId":871,"briefTitle":872,"status":160,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":165,"conditions":877,"interventions":880},"NCT02192684","Obesity, Sleep Apnea, and Insulin Resistance",[93],"2014-07","2015-03","2010-09",[878,879],"Insulin Sensitivity","Obstructive Sleep Apnea",[404],{"intervention":882,"totalTrials":334,"cells":883},"N-acetylcysteine",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":911,"PHASE4":921,"NA":923},{"trials":885,"activeCount":101},[],{"trials":887,"activeCount":101},[],{"trials":889,"activeCount":115,"soonestReadout":894},[890,901],{"nctId":891,"briefTitle":892,"status":107,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":899},"NCT04278898","Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose",[90],"2028-07-31","2029-01-31","2021-02-12",24,[27],[900],"N-Acetylcysteine",{"nctId":902,"briefTitle":903,"status":160,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":910},"NCT00809094","NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients",[90],"2011-02","2008-11",70,[909],"Cystic Fibrosis",[882],{"trials":912,"activeCount":115,"soonestReadout":894},[913],{"nctId":914,"briefTitle":915,"status":259,"phases":916,"primaryCompletion":894,"completion":895,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT05494398","Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label",[90,91],"2024-03-12",144,[27],[882],{"trials":922,"activeCount":101},[],{"trials":924,"activeCount":101},[],{"intervention":926,"totalTrials":152,"cells":927},"Nebivolol",{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":945,"PHASE4":959,"NA":961},{"trials":929,"activeCount":101},[],{"trials":931,"activeCount":101},[],{"trials":933,"activeCount":101},[934],{"nctId":935,"briefTitle":936,"status":716,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":821,"conditions":941,"interventions":943},"NCT04130438","Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging",[90],"2022-03-11","2024-10-17","2020-10-15",[942],"Myocardial Bridging",[926,944],"Diltiazem",{"trials":946,"activeCount":115,"soonestReadout":177},[947],{"nctId":948,"briefTitle":949,"status":107,"phases":950,"primaryCompletion":177,"completion":177,"start":951,"enrollment":124,"conditions":952,"interventions":957},"NCT06424834","Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries",[90,91],"2024-10-10",[953,954,955,956],"Angina Pectoris","Microvascular Angina","Vasospastic Angina","Myocardial Bridge of Coronary Artery",[958,926],"Amlodipine",{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":101},[],{"intervention":964,"totalTrials":115,"cells":965},"Topical Ripasudil",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":985,"NA":987},{"trials":967,"activeCount":101},[],{"trials":969,"activeCount":101},[],{"trials":971,"activeCount":101},[],{"trials":973,"activeCount":115,"soonestReadout":978},[974],{"nctId":975,"briefTitle":976,"status":145,"phases":977,"primaryCompletion":978,"completion":979,"start":980,"enrollment":814,"conditions":981,"interventions":983},"NCT05289661","Descemet Endothelial Thickness Comparison Trial I",[91],"2026-11-30","2027-11-30","2022-07-15",[982],"Fuchs",[964,984],"Topical Placebo",{"trials":986,"activeCount":101},[],{"trials":988,"activeCount":101},[],{"intervention":984,"totalTrials":115,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":1003,"NA":1005},{"trials":992,"activeCount":101},[],{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":115,"soonestReadout":978},[999],{"nctId":975,"briefTitle":976,"status":145,"phases":1000,"primaryCompletion":978,"completion":979,"start":980,"enrollment":814,"conditions":1001,"interventions":1002},[91],[982],[964,984],{"trials":1004,"activeCount":101},[],{"trials":1006,"activeCount":101},[],{"intervention":1008,"totalTrials":115,"cells":1009},"N acetyl cysteine",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1026,"NA":1028},{"trials":1011,"activeCount":101},[],{"trials":1013,"activeCount":101},[],{"trials":1015,"activeCount":101},[],{"trials":1017,"activeCount":115,"soonestReadout":1022},[1018],{"nctId":1019,"briefTitle":1020,"status":107,"phases":1021,"primaryCompletion":1022,"completion":894,"start":1023,"enrollment":918,"conditions":1024,"interventions":1025},"NCT05664789","Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial",[90,91],"2028-01-31","2023-04-26",[27],[1008],{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":101},[],{"intervention":1031,"totalTrials":115,"cells":1032},"Intra-operative single intravenous(iv) dose of \"cephalexin\" 2 g or \"clindamycin\" 900 mg.",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1054,"NA":1056},{"trials":1034,"activeCount":101},[],{"trials":1036,"activeCount":101},[],{"trials":1038,"activeCount":101},[],{"trials":1040,"activeCount":115,"soonestReadout":1045},[1041],{"nctId":1042,"briefTitle":1043,"status":259,"phases":1044,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1052},"NCT04194216","Antibiotic Prophylaxis in Rhinoplasty",[91],"2026-12-20","2027-04-20","2020-05-20",864,[1050,1051],"Nasal Obstruction","Nasal Surgical Procedures",[1031,1053],"Intra-operative single dose (iv) of \"cephalexin\" 2 g or \"clindamycin\" 900 mg and postoperative oral dose of \"cephalexin\" 250mg (every 4 hours) or \"clindamycin\" 150mg(every 6 hours) for 3 days",{"trials":1055,"activeCount":101},[],{"trials":1057,"activeCount":101},[],{"intervention":1053,"totalTrials":115,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1072,"NA":1074},{"trials":1061,"activeCount":101},[],{"trials":1063,"activeCount":101},[],{"trials":1065,"activeCount":101},[],{"trials":1067,"activeCount":115,"soonestReadout":1045},[1068],{"nctId":1042,"briefTitle":1043,"status":259,"phases":1069,"primaryCompletion":1045,"completion":1046,"start":1047,"enrollment":1048,"conditions":1070,"interventions":1071},[91],[1050,1051],[1031,1053],{"trials":1073,"activeCount":101},[],{"trials":1075,"activeCount":101},[],{"intervention":1077,"totalTrials":115,"cells":1078},"Cilostazol 100 mg",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1103,"NA":1105},{"trials":1080,"activeCount":101},[],{"trials":1082,"activeCount":101},[],{"trials":1084,"activeCount":101},[],{"trials":1086,"activeCount":115,"soonestReadout":1091},[1087],{"nctId":1088,"briefTitle":1089,"status":242,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1102},"NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial",[91],"2031-07","2026-08",2000,[1095,1096,1097,1098,1099,1100,1101],"Stroke Recurrence","Myocardial Infarction","Vascular Death","Ischemic Stroke","TIA (Transient Ischemic Attack)","Stroke (CVA) or Transient Ischemic Attack","Recurrent Stroke",[1077],{"trials":1104,"activeCount":101},[],{"trials":1106,"activeCount":101},[],{"intervention":1108,"totalTrials":115,"cells":1109},"Ripasudil",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1129,"NA":1131},{"trials":1111,"activeCount":101},[],{"trials":1113,"activeCount":101},[],{"trials":1115,"activeCount":101},[],{"trials":1117,"activeCount":115,"soonestReadout":979},[1118],{"nctId":1119,"briefTitle":1120,"status":107,"phases":1121,"primaryCompletion":979,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1128},"NCT05275972","Descemet Endothelial Thickness Comparison Trial II",[91],"2028-11-30","2023-01-23",60,[982,1126,1127],"Fuchs Dystrophy","Fuchs' Endothelial Dystrophy",[1108],{"trials":1130,"activeCount":101},[],{"trials":1132,"activeCount":101},[],{"intervention":1134,"totalTrials":115,"cells":1135},"Standardized seizure protocol",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1156,"NA":1158},{"trials":1137,"activeCount":101},[],{"trials":1139,"activeCount":101},[],{"trials":1141,"activeCount":101},[],{"trials":1143,"activeCount":115,"soonestReadout":1148},[1144],{"nctId":1145,"briefTitle":1146,"status":107,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1154},"NCT05121324","Pediatric Dose Optimization for Seizures in Emergency Medical Services",[91],"2026-07-31","2026-09-30","2022-08-08",6700,[1153],"Seizures",[1134,1155],"Conventional seizure protocol",{"trials":1157,"activeCount":101},[],{"trials":1159,"activeCount":101},[],{"intervention":1155,"totalTrials":115,"cells":1161},{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1174,"NA":1176},{"trials":1163,"activeCount":101},[],{"trials":1165,"activeCount":101},[],{"trials":1167,"activeCount":101},[],{"trials":1169,"activeCount":115,"soonestReadout":1148},[1170],{"nctId":1145,"briefTitle":1146,"status":107,"phases":1171,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":1151,"conditions":1172,"interventions":1173},[91],[1153],[1134,1155],{"trials":1175,"activeCount":101},[],{"trials":1177,"activeCount":101},[],{"intervention":1179,"totalTrials":115,"cells":1180},"Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1200,"NA":1202},{"trials":1182,"activeCount":101},[],{"trials":1184,"activeCount":101},[],{"trials":1186,"activeCount":101},[],{"trials":1188,"activeCount":115,"soonestReadout":1193},[1189],{"nctId":1190,"briefTitle":1191,"status":242,"phases":1192,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1199},"NCT07337655","Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial",[90,91],"2030-09-30","2032-09-30","2026-10-01",670,[1198],"Pre-term Birth",[1179],{"trials":1201,"activeCount":101},[],{"trials":1203,"activeCount":101},[],{"intervention":1205,"totalTrials":115,"cells":1206},"Tizanidine",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1228,"NA":1230},{"trials":1208,"activeCount":101},[],{"trials":1210,"activeCount":101},[],{"trials":1212,"activeCount":101},[],{"trials":1214,"activeCount":115,"soonestReadout":1219},[1215],{"nctId":1216,"briefTitle":1217,"status":107,"phases":1218,"primaryCompletion":1219,"completion":1220,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1227},"NCT06027099","CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial",[91],"2028-01","2028-07","2024-12-05",375,[33,1224,1225,1226],"Back Pain","Neck Pain","Opioid Misuse",[1205],{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"intervention":958,"totalTrials":115,"cells":1233},{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1246,"NA":1248},{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"trials":1239,"activeCount":101},[],{"trials":1241,"activeCount":115,"soonestReadout":177},[1242],{"nctId":948,"briefTitle":949,"status":107,"phases":1243,"primaryCompletion":177,"completion":177,"start":951,"enrollment":124,"conditions":1244,"interventions":1245},[90,91],[953,954,955,956],[958,926],{"trials":1247,"activeCount":101},[],{"trials":1249,"activeCount":101},[],{"intervention":1251,"totalTrials":115,"cells":1252},"Dexmedetomidine (IV) 0.5 mcg\u002Fkg",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1259,"PHASE4":1271,"NA":1273},{"trials":1254,"activeCount":101},[],{"trials":1256,"activeCount":101},[],{"trials":1258,"activeCount":101},[],{"trials":1260,"activeCount":115,"soonestReadout":244},[1261],{"nctId":1262,"briefTitle":1263,"status":242,"phases":1264,"primaryCompletion":244,"completion":1220,"start":246,"enrollment":208,"conditions":1265,"interventions":1270},"NCT07537894","Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation",[90,91],[1266,1267,1268,1269],"Abortion","Stillbirth","PTSD (Childbirth-Related)","Grief (Traumatic Grief and Existential Grief)",[1251],{"trials":1272,"activeCount":101},[],{"trials":1274,"activeCount":101},[],{"intervention":1276,"totalTrials":334,"cells":1277},"Panitumumab-IRDye800",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":101},[],{"trials":1283,"activeCount":334,"soonestReadout":1288},[1284,1296,1308],{"nctId":1285,"briefTitle":1286,"status":107,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1294},"NCT03510208","Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery",[89,90],"2026-05","2018-05-16",46,[1292,1293],"Malignant Brain Neoplasm","Malignant Glioma",[1295,1276],"Panitumumab",{"nctId":1297,"briefTitle":1298,"status":107,"phases":1299,"primaryCompletion":461,"completion":461,"start":1300,"enrollment":232,"conditions":1301,"interventions":1307},"NCT03582124","Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery",[89,90],"2018-07-19",[1302,1303,1304,1305,1306],"Lung Carcinoma","Metastatic Malignant Neoplasm in the Lung","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[1276],{"nctId":1309,"briefTitle":1310,"status":107,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1317},"NCT04085887","Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures",[89,90],"2028-12","2026-04",12,[1316],"Brain Tumor",[1276],{"trials":1319,"activeCount":101},[],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"intervention":67,"totalTrials":334,"cells":1325},{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1327,"activeCount":101},[],{"trials":1329,"activeCount":101},[],{"trials":1331,"activeCount":152,"soonestReadout":66},[1332,1345,1352],{"nctId":1333,"briefTitle":1334,"status":145,"phases":1335,"primaryCompletion":798,"completion":1336,"start":1337,"enrollment":684,"conditions":1338,"interventions":1343},"NCT04788043","Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma",[90],"2027-10","2022-06-21",[1339,1340,1341,1342],"Hodgkin Lymphoma","Classic Hodgkin Lymphoma","Relapsed Classical Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma",[1344,67],"Magrolimab",{"nctId":64,"briefTitle":65,"status":145,"phases":1346,"primaryCompletion":66,"completion":1347,"start":1348,"enrollment":1314,"conditions":1349,"interventions":1351},[90],"2026-09-01","2022-02-15",[1350],"Thyroid Cancer",[67],{"nctId":1353,"briefTitle":1354,"status":716,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":115,"conditions":1359,"interventions":1361},"NCT03988647","Palliative RT & Anti-PD-1\u002FPD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma",[90],"2020-11-16","2021-01-20","2019-07-24",[1360],"Merkel Cell Carcinoma",[67],{"trials":1363,"activeCount":101},[],{"trials":1365,"activeCount":101},[],{"trials":1367,"activeCount":101},[],{"intervention":1295,"totalTrials":152,"cells":1369},{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1374,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1371,"activeCount":101},[],{"trials":1373,"activeCount":101},[],{"trials":1375,"activeCount":152,"soonestReadout":1288},[1376,1380],{"nctId":1285,"briefTitle":1286,"status":107,"phases":1377,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1290,"conditions":1378,"interventions":1379},[89,90],[1292,1293],[1295,1276],{"nctId":1381,"briefTitle":1382,"status":242,"phases":1383,"primaryCompletion":434,"completion":434,"start":147,"enrollment":1124,"conditions":1384,"interventions":1386},"NCT05423197","89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET\u002FCT in HNSCC",[90],[1385],"Head-and-neck Squamous Cell Carcinoma",[1387,1295],"89Zr-panitumumab IV",{"trials":1389,"activeCount":101},[],{"trials":1391,"activeCount":101},[],{"trials":1393,"activeCount":101},[],{"intervention":704,"totalTrials":759,"cells":1395},{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1413,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1397,"activeCount":101},[],{"trials":1399,"activeCount":115,"soonestReadout":894},[1400],{"nctId":1401,"briefTitle":1402,"status":107,"phases":1403,"primaryCompletion":894,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1410},"NCT04196413","GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)",[89],"2043-07-31","2020-06-04",97,[1408,1409],"Glioma of Spinal Cord","Glioma of Brainstem",[1411,1412,730,704],"GD2 CAR T cells","Fludarabine",{"trials":1414,"activeCount":115,"soonestReadout":1446},[1415,1419,1429,1442,1457],{"nctId":693,"briefTitle":694,"status":160,"phases":1416,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":1417,"interventions":1418},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"nctId":1420,"briefTitle":1421,"status":160,"phases":1422,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":613,"conditions":1425,"interventions":1427},"NCT00003716","Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy",[90],"2007-01","1998-03",[1426],"Lymphoma",[1428],"rituximab",{"nctId":1430,"briefTitle":1431,"status":716,"phases":1432,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":1436,"interventions":1437},"NCT00481832","Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma",[90],"2014-10-27","2017-03-30",50,[722],[730,1438,727,708,1439,706,729,704,1440,1441],"BCNU","Antithymocyte globulin","CD34+ Cells","Solu-Medrol",{"nctId":1443,"briefTitle":1444,"status":242,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1452},"NCT06986382","Phase 1b\u002F2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell\u002FCD19+ B-cell Depletion for Patients With Monogenic and\u002For Early-onset Medically Refractory Crohn Disease",[89,90],"2037-07","2040-07","2025-07",14,[1451],"Crohn Disease",[1453,1454,1455,1456,766,704],"Prednisone\u002FMethylprenisolone","Palifermin","ATG","Clofarabine",{"nctId":714,"briefTitle":715,"status":716,"phases":1458,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":1459,"interventions":1460},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[1467,1476,1494],{"nctId":1468,"briefTitle":1469,"status":716,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":1472,"enrollment":115,"conditions":1473,"interventions":1475},"NCT01144754","Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +\u002F- XRT",[],"2012-04","2009-02",[1426,1474],"Non-Hodgkin's Lymphoma",[704],{"nctId":1477,"briefTitle":1478,"status":160,"phases":1479,"primaryCompletion":1480,"completion":220,"start":1481,"enrollment":1482,"conditions":1483,"interventions":1492},"NCT00398372","Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",[93],"2007-06","2000-11",500,[722,1484,1485,1486,1487,1488,1489,1490,1491],"Lymphomas: Non-Hodgkin","Lymphomas: Non-Hodgkin Cutaneous Lymphoma","Lymphomas: Non-Hodgkin Diffuse Large B-Cell","Lymphomas: Non-Hodgkin Follicular \u002F Indolent B-Cell","Lymphomas: Non-Hodgkin Mantle Cell","Lymphomas: Non-Hodgkin Marginal Zone","Lymphomas: Non-Hodgkin Peripheral T-Cell","Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia",[704,1493],"Epratuzumab",{"nctId":1495,"briefTitle":1496,"status":160,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":860,"conditions":1501,"interventions":1503},"NCT00350545","A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease",[93],"2012-05","2014-10","2006-08",[1502],"Graft vs Host Disease",[704,1504,1505,1506],"Prednisone","Cyclosporine A","tacrolimus",{"intervention":766,"totalTrials":821,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1534,"PHASE3":1553,"PHASE4":1555,"NA":1557},{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":115,"soonestReadout":1517},[1513],{"nctId":1514,"briefTitle":1515,"status":145,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":1519,"interventions":1526},"NCT05088356","Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w\u002FT-Cell Depleted Graft",[89],"2028-05","2021-09-07",[1520,1521,1522,1523,1524,1525],"Allogeneic Hematopoietic Cell Transplantation (HCT)","Advanced Hematologic Malignancies","Acute Leukemia","Chronic Myelogenous Leukemia","Myelodysplastic Syndromes","Myeloproliferative Disorders",[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],"Purified regulatory T-cells (Treg) plus CD34+ HSPC","Tacrolimus","Plerixafor","Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent","Thiotepa","Ruxolitinib","Sirolimus",{"trials":1535,"activeCount":115,"soonestReadout":1446},[1536,1540,1549],{"nctId":1443,"briefTitle":1444,"status":242,"phases":1537,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1538,"interventions":1539},[89,90],[1451],[1453,1454,1455,1456,766,704],{"nctId":1541,"briefTitle":1542,"status":160,"phases":1543,"primaryCompletion":1544,"completion":1545,"start":1500,"enrollment":1546,"conditions":1547,"interventions":1548},"NCT00349778","High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma",[90],"2009-04","2010-04",102,[763],[730,727,766,726,708],{"nctId":753,"briefTitle":754,"status":160,"phases":1550,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":1551,"interventions":1552},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":1554,"activeCount":101},[],{"trials":1556,"activeCount":101},[],{"trials":1558,"activeCount":101},[1559],{"nctId":1560,"briefTitle":1561,"status":160,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1544,"enrollment":613,"conditions":1565,"interventions":1567},"NCT00890552","A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis",[93],"2012-08","2012-10",[740,1566],"Amyloidosis",[1568,766,1569],"Lenalidomide","Dexamethasone",{"intervention":1571,"totalTrials":152,"cells":1572},"Suvorexant",{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1588,"PHASE4":1590,"NA":1603},{"trials":1574,"activeCount":101},[],{"trials":1576,"activeCount":101},[],{"trials":1578,"activeCount":115,"soonestReadout":1583},[1579],{"nctId":1580,"briefTitle":1581,"status":107,"phases":1582,"primaryCompletion":1583,"completion":1583,"start":1584,"enrollment":37,"conditions":1585,"interventions":1587},"NCT05546554","Trial of Suvorexant for Sleep in Children With Autism",[90],"2028-02-28","2023-08-09",[1586,27],"Autism",[1571],{"trials":1589,"activeCount":101},[],{"trials":1591,"activeCount":101},[1592],{"nctId":1593,"briefTitle":1594,"status":160,"phases":1595,"primaryCompletion":1596,"completion":1596,"start":1597,"enrollment":1598,"conditions":1599,"interventions":1602},"NCT02527564","Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder",[92],"2021-03-01","2015-09",61,[1600,1601],"Insomnia","Bipolar Disorder",[1571],{"trials":1604,"activeCount":101},[],{"intervention":1606,"totalTrials":152,"cells":1607},"Placebos",{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1624,"PHASE4":1626,"NA":1639},{"trials":1609,"activeCount":101},[],{"trials":1611,"activeCount":101},[],{"trials":1613,"activeCount":115,"soonestReadout":1618},[1614],{"nctId":1615,"briefTitle":1616,"status":107,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1435,"conditions":1620,"interventions":1622},"NCT03552705","The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients",[90],"2027-01-14","2019-08-01",[1621],"Anterior Cruciate Ligament Reconstruction",[1623,1606],"Tranexamic Acid",{"trials":1625,"activeCount":101},[],{"trials":1627,"activeCount":101},[1628],{"nctId":1629,"briefTitle":1630,"status":160,"phases":1631,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1637},"NCT02988908","Memory and Mental Health in Aging",[92],"2007-09","2000-04",198,[1636],"Memory",[1638,1606],"Donepezil",{"trials":1640,"activeCount":101},[],{"intervention":1642,"totalTrials":152,"cells":1643},"Guanfacine",{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1648,"PHASE3":1661,"PHASE4":1663,"NA":1675},{"trials":1645,"activeCount":101},[],{"trials":1647,"activeCount":101},[],{"trials":1649,"activeCount":115,"soonestReadout":1654},[1650],{"nctId":1651,"briefTitle":1652,"status":107,"phases":1653,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1657,"conditions":1658,"interventions":1659},"NCT06408246","ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression",[90],"2028-10-01","2029-02-01","2026-03-03",162,[21],[1642,1660],"Sertraline",{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":101},[1665],{"nctId":1666,"briefTitle":1667,"status":160,"phases":1668,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT04181736","The BIomarker Guided (BIG) Study for Depression",[92],"2024-01-17","2024-02-12","2022-09-14",28,[167],[1642],{"trials":1676,"activeCount":101},[],{"intervention":1678,"totalTrials":97,"cells":1679},"Gemcitabine",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1681,"activeCount":101},[],{"trials":1683,"activeCount":101},[],{"trials":1685,"activeCount":115,"soonestReadout":1288},[1686,1702,1726,1738,1749,1761,1773],{"nctId":1687,"briefTitle":1688,"status":716,"phases":1689,"primaryCompletion":1471,"completion":1690,"start":231,"enrollment":152,"conditions":1691,"interventions":1697},"NCT01151761","Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation",[90],"2012-07",[1692,1693,1694,1695,1696],"Cholangiocarcinoma","Hepatobiliary Neoplasm","Liver Cancer","Bile Duct Cancer","Cancer of Gallbladder",[1678,1698,1699,1700,1701],"Cisplatin","Carboplatin","Capecitabine","5FU",{"nctId":1703,"briefTitle":1704,"status":716,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":1708,"interventions":1721},"NCT03912818","Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer",[90],"2022-08-11","2019-04-10",[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],"Bladder Adenocarcinoma","Bladder Mixed Adenocarcinoma","Bladder Squamous Cell Carcinoma","Bladder Urothelial Carcinoma","Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant","Infiltrating Bladder Urothelial Carcinoma With Giant Cells","Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation","Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation","Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant","Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant","Infiltrating Bladder Urothelial Carcinoma, Nested Variant","Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant",[1699,1698,1722,1723,1678,1724,1725],"Doxorubicin","Durvalumab","Methotrexate","Vinblastine",{"nctId":1727,"briefTitle":1728,"status":160,"phases":1729,"primaryCompletion":1730,"completion":876,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1736},"NCT00388349","Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease",[90],"2008-03","2001-09",146,[1734,1735,1426],"Hodgkin Disease","Hodgkin's Lymphoma",[1678,1737,726,727,730],"Vinorelbine",{"nctId":1739,"briefTitle":1740,"status":716,"phases":1741,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":1745,"interventions":1746},"NCT00225173","Combination Chemotherapy +\u002F- Radiation in High Risk Hodgkin's Disease",[90],"2005-09","2006-09","2001-10",[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],"Vincristine","Bleomycin",{"nctId":1750,"briefTitle":1751,"status":160,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1759},"NCT00323869","Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer",[90],"2013-10","2006-06",48,[1757,1758],"Lung Cancer","Non-small Cell Lung Cancer (NSCLC)",[1760,1678,1699],"Bevacizumab",{"nctId":1762,"briefTitle":1763,"status":145,"phases":1764,"primaryCompletion":1288,"completion":1288,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1770},"NCT04727242","CytoreductiveSurgery & HIPEC w\u002FGemcitabine+Chemotherapy w\u002FDacarbazine in Uterine Leiomyosarcoma",[90],"2021-01-28",17,[1768,1769],"LMS - Leiomyosarcoma","Uterine Leiomyosarcoma",[1678,1771,1772],"Dacarbazine","Gadolinium",{"nctId":1774,"briefTitle":1775,"status":160,"phases":1776,"primaryCompletion":1753,"completion":1777,"start":1778,"enrollment":1779,"conditions":1780,"interventions":1782},"NCT01146054","Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma",[90],"2015-10","2009-10",59,[1781],"Pancreatic Cancer",[1678,1783],"Fludeoxyglucose",{"trials":1785,"activeCount":101},[],{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":101},[],{"intervention":1700,"totalTrials":97,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1819,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":101},[1796,1805],{"nctId":1797,"briefTitle":1798,"status":716,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":836,"conditions":1802,"interventions":1803},"NCT00473005","Phase I Oral mTOR Inhibitor RAD001 in Combo w\u002F Capecitabine for Metastatic Breast",[89],"2011-12","2007-08",[15],[1700,1804],"RAD001",{"nctId":1806,"briefTitle":1807,"status":716,"phases":1808,"primaryCompletion":1809,"completion":1809,"start":1754,"enrollment":1810,"conditions":1811,"interventions":1816},"NCT00368329","Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer",[89],"2009-03",4,[1812,1813,1814,1815],"Esophageal Neoplasms","Carcinoma, Squamous Cell","Adenocarcinoma","Esophageal Cancer",[1700,1817,1818,1699],"[18-F] Fluorodeoxyglucose","5-Fluorouracil",{"trials":1820,"activeCount":115,"soonestReadout":246},[1821,1825,1839,1849,1857],{"nctId":1687,"briefTitle":1688,"status":716,"phases":1822,"primaryCompletion":1471,"completion":1690,"start":231,"enrollment":152,"conditions":1823,"interventions":1824},[90],[1692,1693,1694,1695,1696],[1678,1698,1699,1700,1701],{"nctId":1826,"briefTitle":1827,"status":160,"phases":1828,"primaryCompletion":1829,"completion":1829,"start":1472,"enrollment":222,"conditions":1830,"interventions":1835},"NCT00780494","Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma",[90],"2017-12-31",[1831,1832,1833,1834],"Stomach Cancer","Gastric (Stomach) Cancer","Neoplasm of Cardioesophageal Junction","Gastrointestinal Stromal Tumor (GIST)",[1836,1837,1838],"bevacizumab","carboplatin","capecitabine",{"nctId":1840,"briefTitle":1841,"status":716,"phases":1842,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":152,"conditions":1845,"interventions":1848},"NCT01823679","Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin",[90],"2014-05","2013-03",[1846,1847],"Squamous Cell Carcinoma of the Skin","Recurrent Skin Cancer",[1700],{"nctId":1850,"briefTitle":1851,"status":107,"phases":1852,"primaryCompletion":246,"completion":1091,"start":1853,"enrollment":179,"conditions":1854,"interventions":1856},"NCT04768426","Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer",[90],"2021-02-03",[1855,15],"Triple Negative Breast Cancer",[1700],{"nctId":1858,"briefTitle":1859,"status":160,"phases":1860,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":232,"conditions":1864,"interventions":1866},"NCT00226980","A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma",[90],"2005-07","2006-07","2002-10",[1865],"Kidney Neoplasms",[1867,1700],"Thalidomide",{"trials":1869,"activeCount":101},[],{"trials":1871,"activeCount":101},[],{"trials":1873,"activeCount":101},[],{"intervention":711,"totalTrials":1810,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1877,"activeCount":101},[],{"trials":1879,"activeCount":101},[],{"trials":1881,"activeCount":115,"soonestReadout":1894},[1882,1886,1890,1897],{"nctId":693,"briefTitle":694,"status":160,"phases":1883,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":1884,"interventions":1885},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"nctId":714,"briefTitle":715,"status":716,"phases":1887,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":1888,"interventions":1889},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":1891,"briefTitle":1892,"status":107,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1584,"enrollment":37,"conditions":1895,"interventions":1896},"NCT05501678","Trial of Diphenhydramine for Sleep in Children With Autism",[90],"2027-12-31",[1586,27],[711],{"nctId":753,"briefTitle":754,"status":160,"phases":1898,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":1899,"interventions":1900},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":1902,"activeCount":101},[],{"trials":1904,"activeCount":101},[],{"trials":1906,"activeCount":101},[],{"intervention":1908,"totalTrials":334,"cells":1909},"Ipilimumab",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1957,"PHASE3":1980,"PHASE4":1982,"NA":1984},{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[1914],{"nctId":1915,"briefTitle":1916,"status":716,"phases":1917,"primaryCompletion":1918,"completion":1919,"start":1920,"enrollment":334,"conditions":1921,"interventions":1956},"NCT01769222","Ipilimumab and Local Radiation for Selected Solid Tumors",[89],"2014-11","2015-06","2013-02",[1922,1923,1924,1925,1926,1927,1928,1929,1930,1931,1932,1933,1934,1935,1936,1937,1938,1939,1940,1941,1942,1943,1944,1945,1946,1947,1948,1949,1950,1951,1952,1953,1954,1955],"Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Colon Cancer","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Melanoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Rectal Cancer","Recurrent Small Lymphocytic Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","T-cell Large Granular Lymphocyte Leukemia","Testicular Lymphoma","Waldenström Macroglobulinemia",[1908],{"trials":1958,"activeCount":115,"soonestReadout":176},[1959,1970],{"nctId":1960,"briefTitle":1961,"status":107,"phases":1962,"primaryCompletion":176,"completion":1963,"start":1964,"enrollment":1124,"conditions":1965,"interventions":1968},"NCT06712927","Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases",[90],"2030-02","2025-08-06",[1966,1967],"Melanoma","Brain Metastases",[1908,1969],"Nivolumab + Relatlimab FDC",{"nctId":1971,"briefTitle":1972,"status":160,"phases":1973,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":1977,"conditions":1978,"interventions":1979},"NCT01449279","Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy",[90],"2015-12-31","2016-12-01","2011-10",22,[1966],[1908],{"trials":1981,"activeCount":101},[],{"trials":1983,"activeCount":101},[],{"trials":1985,"activeCount":101},[],{"intervention":1987,"totalTrials":334,"cells":1988},"Cytarabine",{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":2021,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[1993],{"nctId":1994,"briefTitle":1995,"status":716,"phases":1996,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":1766,"conditions":2000,"interventions":2016},"NCT01904643","Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2015-05-13","2015-07-18","2014-02",[2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Recurrent Adult Acute Myeloid Leukemia",[2017,2018,2019,2020],"lenalidomide","mitoxantrone hydrochloride","etoposide","cytarabine",{"trials":2022,"activeCount":115,"soonestReadout":1336},[2023,2035],{"nctId":2024,"briefTitle":2025,"status":107,"phases":2026,"primaryCompletion":1336,"completion":2027,"start":2028,"enrollment":111,"conditions":2029,"interventions":2032},"NCT06561152","Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML",[89,90],"2028-10","2025-02-10",[2030,2031],"Refractory Acute Myeloid Leukemia","Relapsed Acute Myeloid Leukemia",[2033,2034,1987],"Tagraxofusp","Cladribine",{"nctId":2036,"briefTitle":2037,"status":160,"phases":2038,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":2041,"interventions":2046},"NCT01769209","Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",[90],"2016-11-25","2017-07-04",[2042,2043,2044,2045],"B-cell Adult Acute Lymphoblastic Leukemia (ALL)","Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)","Recurrent Adult Acute Lymphoblastic Leukemia (ALL)","T-cell Adult Acute Lymphoblastic Leukemia (ALL)",[2047,2048,2049,2050,1569,1987,1724],"Bortezomib","Doxorubicin hydrochloride","PEG-Asparaginase","Vincristine sulfate",{"trials":2052,"activeCount":101},[],{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"intervention":2058,"totalTrials":152,"cells":2059},"Nitrous Oxide",{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2061,"activeCount":101},[],{"trials":2063,"activeCount":101},[],{"trials":2065,"activeCount":115,"soonestReadout":461},[2066,2076],{"nctId":2067,"briefTitle":2068,"status":160,"phases":2069,"primaryCompletion":2070,"completion":2071,"start":2072,"enrollment":334,"conditions":2073,"interventions":2075},"NCT03375294","Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)",[90],"2019-07-31","2020-04-05","2018-04-01",[2074],"Post Traumatic Stress Disorder",[2058],{"nctId":2077,"briefTitle":2078,"status":107,"phases":2079,"primaryCompletion":461,"completion":1336,"start":2080,"enrollment":165,"conditions":2081,"interventions":2082},"NCT03826693","Efficacy of Nitrous Oxide in OCD: Pilot Study",[90],"2021-04-17",[126],[2058,2083],"Nitrogen",{"trials":2085,"activeCount":101},[],{"trials":2087,"activeCount":101},[],{"trials":2089,"activeCount":101},[],{"intervention":2091,"totalTrials":152,"cells":2092},"Heparin",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2106,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2094,"activeCount":101},[],{"trials":2096,"activeCount":101},[2097],{"nctId":2098,"briefTitle":2099,"status":160,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":897,"conditions":2103,"interventions":2105},"NCT02687256","Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set",[89],"2017-11","2016-03",[2104],"Type 1 Diabetes",[2091],{"trials":2107,"activeCount":115,"soonestReadout":611},[2108],{"nctId":2109,"briefTitle":2110,"status":107,"phases":2111,"primaryCompletion":611,"completion":2112,"start":2113,"enrollment":1435,"conditions":2114,"interventions":2119},"NCT06080074","Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System",[90],"2029-09","2025-04-15",[2115,2116,2117,2118],"Heart Failure","Cardiogenic Shock","Congenital Heart Disease","Cardiomyopathies",[2091,2120],"Bivalirudin",{"trials":2122,"activeCount":101},[],{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":101},[],{"intervention":1723,"totalTrials":152,"cells":2128},{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2130,"activeCount":101},[],{"trials":2132,"activeCount":101},[],{"trials":2134,"activeCount":115,"soonestReadout":2143},[2135,2139],{"nctId":1703,"briefTitle":1704,"status":716,"phases":2136,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":2137,"interventions":2138},[90],[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],[1699,1698,1722,1723,1678,1724,1725],{"nctId":2140,"briefTitle":2141,"status":107,"phases":2142,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":2145,"conditions":2146,"interventions":2151},"NCT04585477","Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)",[90],"2026-12-30","2021-04-08",80,[2147,2148,2149,2150],"Non-small Cell Lung Cancer","Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II","Non-small Cell Lung Cancer Stage III",[1723,2152],"Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy",{"trials":2154,"activeCount":101},[],{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":101},[],{"intervention":2160,"totalTrials":152,"cells":2161},"Vehicle",{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2163,"activeCount":101},[],{"trials":2165,"activeCount":101},[],{"trials":2167,"activeCount":115,"soonestReadout":2184},[2168,2180],{"nctId":2169,"briefTitle":2170,"status":160,"phases":2171,"primaryCompletion":2172,"completion":207,"start":2173,"enrollment":684,"conditions":2174,"interventions":2178},"NCT02960997","Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study",[90],"2018-12-14","2016-05",[2175,2176,2177],"Epidermolysis Bullosa Simplex","Epidermolysis Bullosa Simplex Kobner","Weber-Cockayne Syndrome",[2179,2160],"Sirolimus, 2%",{"nctId":2181,"briefTitle":2182,"status":145,"phases":2183,"primaryCompletion":2184,"completion":147,"start":2185,"enrollment":836,"conditions":2186,"interventions":2188},"NCT05891795","Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy",[89,90],"2026-01-31","2024-07-22",[2187],"Acne Vulgaris",[2189,2160],"Clascoterone 1% Top Cream",{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[],{"intervention":2197,"totalTrials":152,"cells":2198},"Hematopoietic Cell Transplantation",{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2211,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2200,"activeCount":101},[],{"trials":2202,"activeCount":101},[2203],{"nctId":2204,"briefTitle":2205,"status":716,"phases":2206,"primaryCompletion":1777,"completion":1777,"start":2207,"enrollment":115,"conditions":2208,"interventions":2210},"NCT00325741","Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus",[89],"2004-06",[2209],"Lupus Erythematosus, Systemic",[2197],{"trials":2212,"activeCount":115,"soonestReadout":246},[2213],{"nctId":2214,"briefTitle":2215,"status":145,"phases":2216,"primaryCompletion":246,"completion":246,"start":2217,"enrollment":2218,"conditions":2219,"interventions":2221},"NCT00319657","Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs",[89,90],"2004-07",15,[2220],"Immune Tolerance",[2222],"Hematopoietic cell transplantation",{"trials":2224,"activeCount":101},[],{"trials":2226,"activeCount":101},[],{"trials":2228,"activeCount":101},[],{"intervention":2230,"totalTrials":115,"cells":2231},"EYED-002 Low Dose",{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2236,"PHASE3":2253,"PHASE4":2255,"NA":2257},{"trials":2233,"activeCount":101},[],{"trials":2235,"activeCount":101},[],{"trials":2237,"activeCount":115,"soonestReadout":2027},[2238],{"nctId":2239,"briefTitle":2240,"status":242,"phases":2241,"primaryCompletion":2027,"completion":2242,"start":147,"enrollment":274,"conditions":2243,"interventions":2249},"NCT07619482","Topical Insulin for Glaucoma (TING2)",[89,90],"2029-10",[2244,2245,2246,2247,2248],"Open Angle Glaucoma","Primary Open Angle Glaucoma","Low Tension Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[2230,2250,2251,2252],"EYED-002 High Dose","EYED-002","Vehicle Placebo",{"trials":2254,"activeCount":101},[],{"trials":2256,"activeCount":101},[],{"trials":2258,"activeCount":101},[],{"intervention":2250,"totalTrials":115,"cells":2260},{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2262,"activeCount":101},[],{"trials":2264,"activeCount":101},[],{"trials":2266,"activeCount":115,"soonestReadout":2027},[2267],{"nctId":2239,"briefTitle":2240,"status":242,"phases":2268,"primaryCompletion":2027,"completion":2242,"start":147,"enrollment":274,"conditions":2269,"interventions":2270},[89,90],[2244,2245,2246,2247,2248],[2230,2250,2251,2252],{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":101},[],{"trials":2276,"activeCount":101},[],{"intervention":2251,"totalTrials":115,"cells":2278},{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2280,"activeCount":101},[],{"trials":2282,"activeCount":101},[],{"trials":2284,"activeCount":115,"soonestReadout":2027},[2285],{"nctId":2239,"briefTitle":2240,"status":242,"phases":2286,"primaryCompletion":2027,"completion":2242,"start":147,"enrollment":274,"conditions":2287,"interventions":2288},[89,90],[2244,2245,2246,2247,2248],[2230,2250,2251,2252],{"trials":2290,"activeCount":101},[],{"trials":2292,"activeCount":101},[],{"trials":2294,"activeCount":101},[],{"intervention":2252,"totalTrials":115,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2301,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2298,"activeCount":101},[],{"trials":2300,"activeCount":101},[],{"trials":2302,"activeCount":115,"soonestReadout":2027},[2303],{"nctId":2239,"briefTitle":2240,"status":242,"phases":2304,"primaryCompletion":2027,"completion":2242,"start":147,"enrollment":274,"conditions":2305,"interventions":2306},[89,90],[2244,2245,2246,2247,2248],[2230,2250,2251,2252],{"trials":2308,"activeCount":101},[],{"trials":2310,"activeCount":101},[],{"trials":2312,"activeCount":101},[],{"intervention":2314,"totalTrials":115,"cells":2315},"Fluoxetine",{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2317,"activeCount":101},[],{"trials":2319,"activeCount":101},[],{"trials":2321,"activeCount":115,"soonestReadout":2326},[2322],{"nctId":2323,"briefTitle":2324,"status":107,"phases":2325,"primaryCompletion":2326,"completion":2327,"start":2328,"enrollment":1124,"conditions":2329,"interventions":2333},"NCT04899687","Study of Dextromethorphan in OCD and Related Disorders",[90],"2027-04-01","2028-12-01","2022-01-20",[126,2330,2331,2332],"Illness Anxiety Disorder","Body Dysmorphic Disorders","Somatic Symptom Disorder",[2314,2334],"Dextromethorphan",{"trials":2336,"activeCount":101},[],{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[],{"intervention":2334,"totalTrials":115,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":115,"soonestReadout":2326},[2349],{"nctId":2323,"briefTitle":2324,"status":107,"phases":2350,"primaryCompletion":2326,"completion":2327,"start":2328,"enrollment":1124,"conditions":2351,"interventions":2352},[90],[126,2330,2331,2332],[2314,2334],{"trials":2354,"activeCount":101},[],{"trials":2356,"activeCount":101},[],{"trials":2358,"activeCount":101},[],{"intervention":2360,"totalTrials":115,"cells":2361},"Tiprelestat",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2363,"activeCount":101},[],{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":115,"soonestReadout":1963},[2368],{"nctId":2369,"briefTitle":2370,"status":242,"phases":2371,"primaryCompletion":1963,"completion":2372,"start":246,"enrollment":274,"conditions":2373,"interventions":2375},"NCT07601295","Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)",[90],"2030-03",[2374],"Pulmonary Arterial Hypertension (PAH)",[2360,2360],{"trials":2377,"activeCount":101},[],{"trials":2379,"activeCount":101},[],{"trials":2381,"activeCount":101},[],{"intervention":72,"totalTrials":115,"cells":2383},{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2398,"PHASE4":2400,"NA":2402},{"trials":2385,"activeCount":101},[],{"trials":2387,"activeCount":101},[],{"trials":2389,"activeCount":115,"soonestReadout":71},[2390],{"nctId":69,"briefTitle":70,"status":145,"phases":2391,"primaryCompletion":71,"completion":434,"start":2392,"enrollment":2393,"conditions":2394,"interventions":2397},[90],"2022-08-16",21,[1967,15,1757,2395,2396],"Leptomeningeal Disease","LMD",[72],{"trials":2399,"activeCount":101},[],{"trials":2401,"activeCount":101},[],{"trials":2403,"activeCount":101},[],{"intervention":2405,"totalTrials":115,"cells":2406},"Amino Acids",{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2411,"PHASE3":2421,"PHASE4":2423,"NA":2425},{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[],{"trials":2412,"activeCount":115,"soonestReadout":176},[2413],{"nctId":2414,"briefTitle":2415,"status":242,"phases":2416,"primaryCompletion":176,"completion":176,"start":2417,"enrollment":232,"conditions":2418,"interventions":2420},"NCT07001098","Amino Acids for Cardiac Surgery Associated AKI",[90],"2025-09",[2419],"Acute Kidney Injury",[2405],{"trials":2422,"activeCount":101},[],{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[],{"intervention":2428,"totalTrials":115,"cells":2429},"Esomeprazole",{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2434,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2431,"activeCount":101},[],{"trials":2433,"activeCount":101},[],{"trials":2435,"activeCount":115,"soonestReadout":1312},[2436],{"nctId":2437,"briefTitle":2438,"status":107,"phases":2439,"primaryCompletion":1312,"completion":1312,"start":2440,"enrollment":613,"conditions":2441,"interventions":2442},"NCT03866668","A Study of Esomeprazole in Children With Autism",[90],"2019-05-29",[1586,27],[2428],{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[],{"trials":2448,"activeCount":101},[],{"intervention":2450,"totalTrials":115,"cells":2451},"Baricitinib (LY3009104) 4 mg",{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2453,"activeCount":101},[],{"trials":2455,"activeCount":101},[],{"trials":2457,"activeCount":115,"soonestReadout":2462},[2458],{"nctId":2459,"briefTitle":2460,"status":242,"phases":2461,"primaryCompletion":2462,"completion":2327,"start":2463,"enrollment":247,"conditions":2464,"interventions":2466},"NCT06868381","A Trial of Baricitinib in Patients With Cardiac Sarcoidosis",[90],"2028-07-01","2026-04-01",[2465],"Cardiac Sarcoidosis",[2450],{"trials":2468,"activeCount":101},[],{"trials":2470,"activeCount":101},[],{"trials":2472,"activeCount":101},[],{"intervention":128,"totalTrials":115,"cells":2474},{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2476,"activeCount":101},[],{"trials":2478,"activeCount":101},[],{"trials":2480,"activeCount":115,"soonestReadout":122},[2481],{"nctId":119,"briefTitle":120,"status":107,"phases":2482,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":2483,"interventions":2484},[90],[126],[96,128],{"trials":2486,"activeCount":101},[],{"trials":2488,"activeCount":101},[],{"trials":2490,"activeCount":101},[],{"intervention":2492,"totalTrials":115,"cells":2493},"Efgartigimod",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2495,"activeCount":101},[],{"trials":2497,"activeCount":101},[],{"trials":2499,"activeCount":115,"soonestReadout":2504},[2500],{"nctId":2501,"briefTitle":2502,"status":107,"phases":2503,"primaryCompletion":2504,"completion":2505,"start":2506,"enrollment":821,"conditions":2507,"interventions":2509},"NCT07025330","A Study of Efgartigimod in Patients With IgG4-Related Disease",[90],"2028-03-01","2028-06-01","2025-11-12",[2508],"IgG4-related Disease",[2492],{"trials":2511,"activeCount":101},[],{"trials":2513,"activeCount":101},[],{"trials":2515,"activeCount":101},[],{"intervention":2517,"totalTrials":115,"cells":2518},"Pramipexole Immediate Release",{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2520,"activeCount":101},[],{"trials":2522,"activeCount":101},[],{"trials":2524,"activeCount":115,"soonestReadout":2529},[2525],{"nctId":2526,"briefTitle":2527,"status":107,"phases":2528,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":1124,"conditions":2531,"interventions":2533},"NCT07022405","Stratified Pharmacological Approaches for Regulating Circuit-Level Effects",[90],"2030-08","2026-01-23",[2532],"Depression - Major Depressive Disorder",[2517],{"trials":2535,"activeCount":101},[],{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[],{"intervention":2541,"totalTrials":115,"cells":2542},"Exparel",{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2544,"activeCount":101},[],{"trials":2546,"activeCount":101},[],{"trials":2548,"activeCount":115,"soonestReadout":379},[2549],{"nctId":2550,"briefTitle":2551,"status":107,"phases":2552,"primaryCompletion":379,"completion":2553,"start":2554,"enrollment":2218,"conditions":2555,"interventions":2562},"NCT04930887","Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain",[90],"2030-06","2023-02-01",[2556,2557,2558,2559,2560,2561],"Craniofacial Pain","Migraine","Cluster Headache","Trigeminal Autonomic Cephalgia","Sphenopalatine Ganglion Neuralgia","Paroxysmal Hemicrania",[2541,2563],"Saline",{"trials":2565,"activeCount":101},[],{"trials":2567,"activeCount":101},[],{"trials":2569,"activeCount":101},[],{"intervention":2571,"totalTrials":115,"cells":2572},"NSAID",{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2574,"activeCount":101},[],{"trials":2576,"activeCount":101},[],{"trials":2578,"activeCount":115,"soonestReadout":2583},[2579],{"nctId":2580,"briefTitle":2581,"status":107,"phases":2582,"primaryCompletion":2583,"completion":245,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2588},"NCT04676802","Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone",[90],"2027-02","2021-12-27",121,[354,2587],"Osteoarthritis Thumb",[2571,2589],"Opioid",{"trials":2591,"activeCount":101},[],{"trials":2593,"activeCount":101},[],{"trials":2595,"activeCount":101},[],{"intervention":2589,"totalTrials":115,"cells":2597},{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2599,"activeCount":101},[],{"trials":2601,"activeCount":101},[],{"trials":2603,"activeCount":115,"soonestReadout":2583},[2604],{"nctId":2580,"briefTitle":2581,"status":107,"phases":2605,"primaryCompletion":2583,"completion":245,"start":2584,"enrollment":2585,"conditions":2606,"interventions":2607},[90],[354,2587],[2571,2589],{"trials":2609,"activeCount":101},[],{"trials":2611,"activeCount":101},[],{"trials":2613,"activeCount":101},[],{"intervention":82,"totalTrials":115,"cells":2615},{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2629,"PHASE4":2631,"NA":2633},{"trials":2617,"activeCount":101},[],{"trials":2619,"activeCount":101},[],{"trials":2621,"activeCount":115,"soonestReadout":81},[2622],{"nctId":79,"briefTitle":80,"status":145,"phases":2623,"primaryCompletion":81,"completion":2624,"start":2625,"enrollment":232,"conditions":2626,"interventions":2628},[90],"2026-08-15","2021-05-15",[2627],"Glaucoma",[82],{"trials":2630,"activeCount":101},[],{"trials":2632,"activeCount":101},[],{"trials":2634,"activeCount":101},[],{"intervention":2636,"totalTrials":115,"cells":2637},"Bumetanide",{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2642,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2639,"activeCount":101},[],{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":115,"soonestReadout":2648},[2644],{"nctId":2645,"briefTitle":2646,"status":107,"phases":2647,"primaryCompletion":2648,"completion":2648,"start":2649,"enrollment":179,"conditions":2650,"interventions":2652},"NCT06052163","Bumetanide in Patients With Alzheimer's Disease",[90],"2026-12-15","2023-04-10",[2651],"Alzheimer Disease",[2636],{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":101},[],{"intervention":1660,"totalTrials":115,"cells":2660},{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2662,"activeCount":101},[],{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":115,"soonestReadout":1654},[2667],{"nctId":1651,"briefTitle":1652,"status":107,"phases":2668,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":1657,"conditions":2669,"interventions":2670},[90],[21],[1642,1660],{"trials":2672,"activeCount":101},[],{"trials":2674,"activeCount":101},[],{"trials":2676,"activeCount":101},[],{"intervention":1453,"totalTrials":115,"cells":2678},{"EARLY_PHASE1":2679,"PHASE1":2681,"PHASE2":2683,"PHASE3":2689,"PHASE4":2691,"NA":2693},{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":115,"soonestReadout":1446},[2685],{"nctId":1443,"briefTitle":1444,"status":242,"phases":2686,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":2687,"interventions":2688},[89,90],[1451],[1453,1454,1455,1456,766,704],{"trials":2690,"activeCount":101},[],{"trials":2692,"activeCount":101},[],{"trials":2694,"activeCount":101},[],{"intervention":1454,"totalTrials":115,"cells":2696},{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2707,"PHASE4":2709,"NA":2711},{"trials":2698,"activeCount":101},[],{"trials":2700,"activeCount":101},[],{"trials":2702,"activeCount":115,"soonestReadout":1446},[2703],{"nctId":1443,"briefTitle":1444,"status":242,"phases":2704,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":2705,"interventions":2706},[89,90],[1451],[1453,1454,1455,1456,766,704],{"trials":2708,"activeCount":101},[],{"trials":2710,"activeCount":101},[],{"trials":2712,"activeCount":101},[],{"intervention":1455,"totalTrials":115,"cells":2714},{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2725,"PHASE4":2727,"NA":2729},{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":115,"soonestReadout":1446},[2721],{"nctId":1443,"briefTitle":1444,"status":242,"phases":2722,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":2723,"interventions":2724},[89,90],[1451],[1453,1454,1455,1456,766,704],{"trials":2726,"activeCount":101},[],{"trials":2728,"activeCount":101},[],{"trials":2730,"activeCount":101},[],{"intervention":1456,"totalTrials":115,"cells":2732},{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2734,"activeCount":101},[],{"trials":2736,"activeCount":101},[],{"trials":2738,"activeCount":115,"soonestReadout":1446},[2739],{"nctId":1443,"briefTitle":1444,"status":242,"phases":2740,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":2741,"interventions":2742},[89,90],[1451],[1453,1454,1455,1456,766,704],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[],{"trials":2748,"activeCount":101},[],{"intervention":1344,"totalTrials":115,"cells":2750},{"EARLY_PHASE1":2751,"PHASE1":2753,"PHASE2":2755,"PHASE3":2761,"PHASE4":2763,"NA":2765},{"trials":2752,"activeCount":101},[],{"trials":2754,"activeCount":101},[],{"trials":2756,"activeCount":115,"soonestReadout":798},[2757],{"nctId":1333,"briefTitle":1334,"status":145,"phases":2758,"primaryCompletion":798,"completion":1336,"start":1337,"enrollment":684,"conditions":2759,"interventions":2760},[90],[1339,1340,1341,1342],[1344,67],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"trials":2766,"activeCount":101},[],{"intervention":251,"totalTrials":115,"cells":2768},{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2779,"PHASE4":2781,"NA":2783},{"trials":2770,"activeCount":101},[],{"trials":2772,"activeCount":101},[],{"trials":2774,"activeCount":115,"soonestReadout":244},[2775],{"nctId":240,"briefTitle":241,"status":242,"phases":2776,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":2777,"interventions":2778},[90],[249],[251,196],{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[],{"intervention":1969,"totalTrials":115,"cells":2786},{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2797,"PHASE4":2799,"NA":2801},{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[],{"trials":2792,"activeCount":115,"soonestReadout":176},[2793],{"nctId":1960,"briefTitle":1961,"status":107,"phases":2794,"primaryCompletion":176,"completion":1963,"start":1964,"enrollment":1124,"conditions":2795,"interventions":2796},[90],[1966,1967],[1908,1969],{"trials":2798,"activeCount":101},[],{"trials":2800,"activeCount":101},[],{"trials":2802,"activeCount":101},[],{"intervention":2804,"totalTrials":115,"cells":2805},"Toripalimab",{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2807,"activeCount":101},[],{"trials":2809,"activeCount":101},[],{"trials":2811,"activeCount":115,"soonestReadout":2816},[2812],{"nctId":2813,"briefTitle":2814,"status":107,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":897,"conditions":2818,"interventions":2820},"NCT06592599","Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)",[90],"2029-01","2024-09-03",[2819],"Nasopharyngeal Carcinoma",[2804],{"trials":2822,"activeCount":101},[],{"trials":2824,"activeCount":101},[],{"trials":2826,"activeCount":101},[],{"intervention":2828,"totalTrials":115,"cells":2829},"Talquetamab",{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"trials":2835,"activeCount":115,"soonestReadout":147},[2836],{"nctId":2837,"briefTitle":2838,"status":107,"phases":2839,"primaryCompletion":147,"completion":147,"start":2840,"enrollment":111,"conditions":2841,"interventions":2843},"NCT06461988","Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma",[90],"2025-06-05",[763,2842],"Post Stem Cell Transplant",[2828,2844],"Talquetamab and Lenalidomide",{"trials":2846,"activeCount":101},[],{"trials":2848,"activeCount":101},[],{"trials":2850,"activeCount":101},[],{"intervention":2844,"totalTrials":115,"cells":2852},{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2863,"PHASE4":2865,"NA":2867},{"trials":2854,"activeCount":101},[],{"trials":2856,"activeCount":101},[],{"trials":2858,"activeCount":115,"soonestReadout":147},[2859],{"nctId":2837,"briefTitle":2838,"status":107,"phases":2860,"primaryCompletion":147,"completion":147,"start":2840,"enrollment":111,"conditions":2861,"interventions":2862},[90],[763,2842],[2828,2844],{"trials":2864,"activeCount":101},[],{"trials":2866,"activeCount":101},[],{"trials":2868,"activeCount":101},[],{"intervention":2870,"totalTrials":115,"cells":2871},"Cabergoline",{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2885,"PHASE4":2887,"NA":2889},{"trials":2873,"activeCount":101},[],{"trials":2875,"activeCount":101},[],{"trials":2877,"activeCount":115,"soonestReadout":799},[2878],{"nctId":2879,"briefTitle":2880,"status":242,"phases":2881,"primaryCompletion":799,"completion":244,"start":246,"enrollment":699,"conditions":2882,"interventions":2884},"NCT06909123","A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss",[90],[2883],"Lactation Suppressed",[2870],{"trials":2886,"activeCount":101},[],{"trials":2888,"activeCount":101},[],{"trials":2890,"activeCount":101},[],{"intervention":2892,"totalTrials":115,"cells":2893},"Mogamulizumab",{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2895,"activeCount":101},[],{"trials":2897,"activeCount":101},[],{"trials":2899,"activeCount":115,"soonestReadout":177},[2900],{"nctId":2901,"briefTitle":2902,"status":107,"phases":2903,"primaryCompletion":177,"completion":177,"start":2904,"enrollment":232,"conditions":2905,"interventions":2908},"NCT04256018","Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome",[90],"2020-03-30",[2906,2907],"Sezary Syndrome","Mycosis Fungoides",[2892],{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[],{"trials":2914,"activeCount":101},[],{"intervention":1623,"totalTrials":115,"cells":2916},{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2927,"PHASE4":2929,"NA":2931},{"trials":2918,"activeCount":101},[],{"trials":2920,"activeCount":101},[],{"trials":2922,"activeCount":115,"soonestReadout":1618},[2923],{"nctId":1615,"briefTitle":1616,"status":107,"phases":2924,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1435,"conditions":2925,"interventions":2926},[90],[1621],[1623,1606],{"trials":2928,"activeCount":101},[],{"trials":2930,"activeCount":101},[],{"trials":2932,"activeCount":101},[],{"intervention":2152,"totalTrials":115,"cells":2934},{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2945,"PHASE4":2947,"NA":2949},{"trials":2936,"activeCount":101},[],{"trials":2938,"activeCount":101},[],{"trials":2940,"activeCount":115,"soonestReadout":2143},[2941],{"nctId":2140,"briefTitle":2141,"status":107,"phases":2942,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":2145,"conditions":2943,"interventions":2944},[90],[2147,2148,2149,2150],[1723,2152],{"trials":2946,"activeCount":101},[],{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[],{"intervention":2033,"totalTrials":115,"cells":2952},{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2954,"activeCount":101},[],{"trials":2956,"activeCount":101},[],{"trials":2958,"activeCount":115,"soonestReadout":1336},[2959],{"nctId":2024,"briefTitle":2025,"status":107,"phases":2960,"primaryCompletion":1336,"completion":2027,"start":2028,"enrollment":111,"conditions":2961,"interventions":2962},[89,90],[2030,2031],[2033,2034,1987],{"trials":2964,"activeCount":101},[],{"trials":2966,"activeCount":101},[],{"trials":2968,"activeCount":101},[],{"intervention":2034,"totalTrials":115,"cells":2970},{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2981,"PHASE4":2983,"NA":2985},{"trials":2972,"activeCount":101},[],{"trials":2974,"activeCount":101},[],{"trials":2976,"activeCount":115,"soonestReadout":1336},[2977],{"nctId":2024,"briefTitle":2025,"status":107,"phases":2978,"primaryCompletion":1336,"completion":2027,"start":2028,"enrollment":111,"conditions":2979,"interventions":2980},[89,90],[2030,2031],[2033,2034,1987],{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"intervention":2083,"totalTrials":115,"cells":2988},{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":2993,"PHASE3":2999,"PHASE4":3001,"NA":3003},{"trials":2990,"activeCount":101},[],{"trials":2992,"activeCount":101},[],{"trials":2994,"activeCount":115,"soonestReadout":461},[2995],{"nctId":2077,"briefTitle":2078,"status":107,"phases":2996,"primaryCompletion":461,"completion":1336,"start":2080,"enrollment":165,"conditions":2997,"interventions":2998},[90],[126],[2058,2083],{"trials":3000,"activeCount":101},[],{"trials":3002,"activeCount":101},[],{"trials":3004,"activeCount":101},[],{"intervention":3006,"totalTrials":115,"cells":3007},"VK-2019",{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":115,"soonestReadout":3018},[3014],{"nctId":3015,"briefTitle":3016,"status":145,"phases":3017,"primaryCompletion":3018,"completion":3019,"start":3020,"enrollment":191,"conditions":3021,"interventions":3024},"NCT04925544","Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies",[90],"2026-06-17","2027-06-17","2022-01-25",[3022,3023],"Nasopharyngeal Cancer","Epstein-Barr Virus Related Carcinoma",[3006],{"trials":3026,"activeCount":101},[],{"trials":3028,"activeCount":101},[],{"trials":3030,"activeCount":101},[],{"intervention":1387,"totalTrials":115,"cells":3032},{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3043,"PHASE4":3045,"NA":3047},{"trials":3034,"activeCount":101},[],{"trials":3036,"activeCount":101},[],{"trials":3038,"activeCount":115,"soonestReadout":434},[3039],{"nctId":1381,"briefTitle":1382,"status":242,"phases":3040,"primaryCompletion":434,"completion":434,"start":147,"enrollment":1124,"conditions":3041,"interventions":3042},[90],[1385],[1387,1295],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":101},[],{"intervention":3050,"totalTrials":115,"cells":3051},"Tofacitinib 10 MG [Xeljanz]",{"EARLY_PHASE1":3052,"PHASE1":3054,"PHASE2":3056,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3053,"activeCount":101},[],{"trials":3055,"activeCount":101},[],{"trials":3057,"activeCount":115,"soonestReadout":3062},[3058],{"nctId":3059,"briefTitle":3060,"status":107,"phases":3061,"primaryCompletion":3062,"completion":978,"start":3063,"enrollment":907,"conditions":3064,"interventions":3066},"NCT03681275","Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction",[90],"2025-11-30","2019-09-03",[3065],"Diaphragm Injury",[3050],{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[],{"trials":3072,"activeCount":101},[],{"intervention":3074,"totalTrials":115,"cells":3075},"BVEC",{"EARLY_PHASE1":3076,"PHASE1":3078,"PHASE2":3080,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3077,"activeCount":101},[],{"trials":3079,"activeCount":101},[],{"trials":3081,"activeCount":115,"soonestReadout":2583},[3082],{"nctId":3083,"briefTitle":3084,"status":107,"phases":3085,"primaryCompletion":2583,"completion":2583,"start":3086,"enrollment":737,"conditions":3087,"interventions":3089},"NCT06731933","Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin",[90],"2025-03-28",[3088],"Squamous Cell Carcinoma",[3074],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"trials":3095,"activeCount":101},[],{"intervention":86,"totalTrials":115,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3109,"PHASE4":3111,"NA":3113},{"trials":3099,"activeCount":101},[],{"trials":3101,"activeCount":101},[],{"trials":3103,"activeCount":115,"soonestReadout":81},[3104],{"nctId":84,"briefTitle":85,"status":145,"phases":3105,"primaryCompletion":81,"completion":2624,"start":148,"enrollment":3106,"conditions":3107,"interventions":3108},[90],54,[2627],[86],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"intervention":3116,"totalTrials":115,"cells":3117},"Dipyridamole 75 MG",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3134,"PHASE4":3136,"NA":3138},{"trials":3119,"activeCount":101},[],{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":115,"soonestReadout":3128},[3124],{"nctId":3125,"briefTitle":3126,"status":242,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":274,"conditions":3130,"interventions":3133},"NCT06824454","Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients",[90],"2026-03","2025-03",[3131,3132],"Hypophosphatemia","Kidney Transplantation",[3116],{"trials":3135,"activeCount":101},[],{"trials":3137,"activeCount":101},[],{"trials":3139,"activeCount":101},[],{"intervention":3141,"totalTrials":115,"cells":3142},"TS1-ASO",{"EARLY_PHASE1":3143,"PHASE1":3145,"PHASE2":3147,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3144,"activeCount":101},[],{"trials":3146,"activeCount":101},[],{"trials":3148,"activeCount":115,"soonestReadout":380},[3149],{"nctId":3150,"briefTitle":3151,"status":242,"phases":3152,"primaryCompletion":380,"completion":3153,"start":461,"enrollment":821,"conditions":3154,"interventions":3156},"NCT07600658","A Phase I\u002FII, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome",[89,90],"2030-12",[3155],"CACNA1C",[3141],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[],{"intervention":2189,"totalTrials":115,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3166,"activeCount":101},[],{"trials":3168,"activeCount":101},[],{"trials":3170,"activeCount":115,"soonestReadout":2184},[3171],{"nctId":2181,"briefTitle":2182,"status":145,"phases":3172,"primaryCompletion":2184,"completion":147,"start":2185,"enrollment":836,"conditions":3173,"interventions":3174},[89,90],[2187],[2189,2160],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[],{"trials":3180,"activeCount":101},[],{"intervention":3182,"totalTrials":115,"cells":3183},"Zolpidem",{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3188,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3185,"activeCount":101},[],{"trials":3187,"activeCount":101},[],{"trials":3189,"activeCount":115,"soonestReadout":3194},[3190],{"nctId":3191,"briefTitle":3192,"status":107,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":1584,"enrollment":37,"conditions":3195,"interventions":3196},"NCT05540574","Trial of Zolpidem for Sleep in Children With Autism",[90],"2028-04-30",[1586,27],[3182],{"trials":3198,"activeCount":101},[],{"trials":3200,"activeCount":101},[],{"trials":3202,"activeCount":101},[],{"intervention":2120,"totalTrials":115,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":101},[],{"trials":3208,"activeCount":101},[],{"trials":3210,"activeCount":115,"soonestReadout":611},[3211],{"nctId":2109,"briefTitle":2110,"status":107,"phases":3212,"primaryCompletion":611,"completion":2112,"start":2113,"enrollment":1435,"conditions":3213,"interventions":3214},[90],[2115,2116,2117,2118],[2091,2120],{"trials":3216,"activeCount":101},[],{"trials":3218,"activeCount":101},[],{"trials":3220,"activeCount":101},[],{"intervention":1771,"totalTrials":115,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":101},[],{"trials":3226,"activeCount":101},[],{"trials":3228,"activeCount":115,"soonestReadout":1288},[3229],{"nctId":1762,"briefTitle":1763,"status":145,"phases":3230,"primaryCompletion":1288,"completion":1288,"start":1765,"enrollment":1766,"conditions":3231,"interventions":3232},[90],[1768,1769],[1678,1771,1772],{"trials":3234,"activeCount":101},[],{"trials":3236,"activeCount":101},[],{"trials":3238,"activeCount":101},[],{"intervention":3240,"totalTrials":115,"cells":3241},"Extended-release sodium oxybate",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3258,"PHASE4":3260,"NA":3262},{"trials":3243,"activeCount":101},[],{"trials":3245,"activeCount":101},[],{"trials":3247,"activeCount":115,"soonestReadout":3252},[3248],{"nctId":3249,"briefTitle":3250,"status":107,"phases":3251,"primaryCompletion":3252,"completion":244,"start":3253,"enrollment":699,"conditions":3254,"interventions":3256},"NCT06809803","Extended-release Sodium Oxybate in Children",[90],"2027-06","2025-10-27",[3255],"Narcolepsy Type 1 (NT 1)",[3240,3257],"Non-extended-release oxybates",{"trials":3259,"activeCount":101},[],{"trials":3261,"activeCount":101},[],{"trials":3263,"activeCount":101},[],{"intervention":3257,"totalTrials":115,"cells":3265},{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3267,"activeCount":101},[],{"trials":3269,"activeCount":101},[],{"trials":3271,"activeCount":115,"soonestReadout":3252},[3272],{"nctId":3249,"briefTitle":3250,"status":107,"phases":3273,"primaryCompletion":3252,"completion":244,"start":3253,"enrollment":699,"conditions":3274,"interventions":3275},[90],[3255],[3240,3257],{"trials":3277,"activeCount":101},[],{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[],{"intervention":2563,"totalTrials":197,"cells":3283},{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3294,"PHASE4":3307,"NA":3342},{"trials":3285,"activeCount":101},[],{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":115,"soonestReadout":379},[3290],{"nctId":2550,"briefTitle":2551,"status":107,"phases":3291,"primaryCompletion":379,"completion":2553,"start":2554,"enrollment":2218,"conditions":3292,"interventions":3293},[90],[2556,2557,2558,2559,2560,2561],[2541,2563],{"trials":3295,"activeCount":101},[3296],{"nctId":3297,"briefTitle":3298,"status":160,"phases":3299,"primaryCompletion":3300,"completion":3300,"start":3301,"enrollment":3302,"conditions":3303,"interventions":3305},"NCT04355767","Convalescent Plasma in Outpatients With COVID-19",[91],"2021-03-29","2020-08-11",511,[3304],"Covid19",[3306,2563],"Convalescent Plasma",{"trials":3308,"activeCount":101},[3309,3319,3331],{"nctId":3310,"briefTitle":3311,"status":716,"phases":3312,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":115,"conditions":3315,"interventions":3317},"NCT04140396","Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia",[92],"2020-11-09","2020-02-10",[3316],"Rib Fractures",[2563,3318],"Lidocaine",{"nctId":3320,"briefTitle":3321,"status":132,"phases":3322,"primaryCompletion":3323,"completion":3324,"start":3325,"enrollment":101,"conditions":3326,"interventions":3330},"NCT03571919","Lidocaine Infusions for Rib Fractures",[92],"2019-06-01","2019-07-01","2018-06-15",[3327,3328,3329],"Rib Fracture Multiple","Trauma Chest","Pain, Acute",[3318,2563],{"nctId":3332,"briefTitle":3333,"status":160,"phases":3334,"primaryCompletion":3335,"completion":3335,"start":3336,"enrollment":179,"conditions":3337,"interventions":3339},"NCT05867342","Effects of Adrenaline Infiltration on Surgical Field of View in Endoscopic Sinus Surgery",[92],"2018-08-22","2017-05-12",[3338],"Intraoperative Bleeding",[3340,3341,2563],"Epinephrin","1% lidocaine with epinephrin 1:100,000",{"trials":3343,"activeCount":101},[3344],{"nctId":3345,"briefTitle":3346,"status":716,"phases":3347,"primaryCompletion":834,"completion":834,"start":3348,"enrollment":821,"conditions":3349,"interventions":3350},"NCT00822926","Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial",[93],"2009-01",[24],[3351,2563],"Botulinum Toxin Type A",{"intervention":1772,"totalTrials":334,"cells":3353},{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3370,"PHASE3":3376,"PHASE4":3378,"NA":3380},{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[3358],{"nctId":3359,"briefTitle":3360,"status":160,"phases":3361,"primaryCompletion":3362,"completion":3363,"start":3364,"enrollment":1314,"conditions":3365,"interventions":3368},"NCT04474353","Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma",[89],"2024-11-14","2025-09-02","2021-05-21",[3366,3367],"Glioblastoma","Newly Diagnosed Glioblastoma",[1772,3369],"Temozolomide",{"trials":3371,"activeCount":115,"soonestReadout":1288},[3372],{"nctId":1762,"briefTitle":1763,"status":145,"phases":3373,"primaryCompletion":1288,"completion":1288,"start":1765,"enrollment":1766,"conditions":3374,"interventions":3375},[90],[1768,1769],[1678,1771,1772],{"trials":3377,"activeCount":101},[],{"trials":3379,"activeCount":101},[],{"trials":3381,"activeCount":101},[3382],{"nctId":3383,"briefTitle":3384,"status":3385,"phases":3386,"conditions":3387,"interventions":3389},"NCT04809584","18F-DCFPyL PET\u002FMRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer","APPROVED_FOR_MARKETING",[],[3388],"Prostate Cancer",[3390,1772],"F18-DCFPyL",{"intervention":140,"totalTrials":334,"cells":3392},{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3407,"PHASE4":3409,"NA":3411},{"trials":3394,"activeCount":101},[],{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":115,"soonestReadout":147},[3399,3403],{"nctId":130,"briefTitle":131,"status":132,"phases":3400,"primaryCompletion":134,"completion":135,"start":136,"enrollment":101,"conditions":3401,"interventions":3402},[90],[138],[96,140,141],{"nctId":143,"briefTitle":144,"status":145,"phases":3404,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":3405,"interventions":3406},[90],[126],[96,140],{"trials":3408,"activeCount":101},[],{"trials":3410,"activeCount":101},[],{"trials":3412,"activeCount":101},[3413],{"nctId":268,"briefTitle":269,"status":160,"phases":3414,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":3415,"interventions":3416},[],[276],[278,196,140],{"intervention":730,"totalTrials":2218,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3496,"PHASE3":3546,"PHASE4":3548,"NA":3550},{"trials":3420,"activeCount":101},[],{"trials":3422,"activeCount":821,"soonestReadout":47},[3423,3427,3440,3449,3460,3474,3492],{"nctId":1401,"briefTitle":1402,"status":107,"phases":3424,"primaryCompletion":894,"completion":1404,"start":1405,"enrollment":1406,"conditions":3425,"interventions":3426},[89],[1408,1409],[1411,1412,730,704],{"nctId":45,"briefTitle":46,"status":145,"phases":3428,"primaryCompletion":47,"completion":3429,"start":3430,"enrollment":3431,"conditions":3432,"interventions":3437},[89],"2035-09-01","2017-09-01",56,[3433,3434,3435,3436],"B Acute Lymphoblastic Leukemia","CD19 Positive","Minimal Residual Disease","Philadelphia Chromosome Positive",[48,730,3438,3439],"Fludarabine Phosphate","NKTR-255",{"nctId":55,"briefTitle":56,"status":145,"phases":3441,"primaryCompletion":57,"completion":3442,"start":3443,"enrollment":28,"conditions":3444,"interventions":3448},[89],"2035-08-01","2017-10-20",[3433,3434,3435,3436,3445,3446,3447],"Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia",[48,730,3438],{"nctId":3450,"briefTitle":3451,"status":716,"phases":3452,"primaryCompletion":2102,"start":1843,"enrollment":152,"conditions":3453,"interventions":3457},"NCT01943188","Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer",[89],[3454,3455,3456],"Clear Cell Renal Cell Carcinoma","Recurrent Renal Cell Cancer","Stage IV Renal Cell Cancer",[3458,3459],"cyclophosphamide","therapeutic autologous lymphocytes",{"nctId":3461,"briefTitle":3462,"status":160,"phases":3463,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":1810,"conditions":3467,"interventions":3472},"NCT02512926","Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children",[89],"2021-08-28","2023-11-07","2016-02-16",[3468,3469,3470,3471],"Relapsed Solid Tumors","Refractory Solid Tumors","Relapsed Leukemia","Refractory Leukemia",[3473,730,727],"Carfilzomib",{"nctId":3475,"briefTitle":3476,"status":107,"phases":3477,"primaryCompletion":245,"completion":245,"start":3478,"enrollment":836,"conditions":3479,"interventions":3490},"NCT07087002","GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults",[89],"2025-08-28",[3480,3481,3482,3483,3484,3485,3486,3487,3488,3489],"Medulloblastoma","Central Nervous System Embryonal Tumor","Refractory Medulloblastoma","Recurrent Medulloblastoma","Pediatric Brain Tumor","Embryonal Tumor With Multilayered Rosettes (ETMR)","Pineoblastoma","Atypical Teratoid\u002FRhabdoid Tumor (ATRT) of the CNS","CNS Neuroblastoma","FOXR2-activated",[3491,1412,730],"GPC2-CAR T cells",{"nctId":1514,"briefTitle":1515,"status":145,"phases":3493,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":3494,"interventions":3495},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":3497,"activeCount":101},[3498,3510,3514,3518,3522,3526,3538,3542],{"nctId":3499,"briefTitle":3500,"status":716,"phases":3501,"primaryCompletion":3502,"completion":3503,"start":1500,"enrollment":334,"conditions":3504,"interventions":3508},"NCT01220297","Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT",[90],"2010-08","2011-08",[3505,3506,740,3507,1339],"Hematologic Diseases","Acute-graft-versus-host Disease","Non-Hodgkin Lymphoma (NHL)",[1533,729,726,727,730,3509],"FTBI",{"nctId":1430,"briefTitle":1431,"status":716,"phases":3511,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":3512,"interventions":3513},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"nctId":1727,"briefTitle":1728,"status":160,"phases":3515,"primaryCompletion":1730,"completion":876,"start":1731,"enrollment":1732,"conditions":3516,"interventions":3517},[90],[1734,1735,1426],[1678,1737,726,727,730],{"nctId":714,"briefTitle":715,"status":716,"phases":3519,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":3520,"interventions":3521},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":1739,"briefTitle":1740,"status":716,"phases":3523,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":3524,"interventions":3525},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"nctId":3527,"briefTitle":3528,"status":160,"phases":3529,"primaryCompletion":3530,"completion":3531,"start":3532,"enrollment":3533,"conditions":3534,"interventions":3537},"NCT00026208","Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma",[90],"2013-04-26","2017-02-13","2001-06",76,[3535,1426,1734,3536],"Lymphoma, Hodgkin Disease","Lymphoma: Hodgkin",[1747,730,1722,1504,1748,727],{"nctId":1541,"briefTitle":1542,"status":160,"phases":3539,"primaryCompletion":1544,"completion":1545,"start":1500,"enrollment":1546,"conditions":3540,"interventions":3541},[90],[763],[730,727,766,726,708],{"nctId":753,"briefTitle":754,"status":160,"phases":3543,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":3544,"interventions":3545},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":3547,"activeCount":101},[],{"trials":3549,"activeCount":101},[],{"trials":3551,"activeCount":101},[],{"intervention":1412,"totalTrials":334,"cells":3553},{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3570,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3555,"activeCount":101},[],{"trials":3557,"activeCount":334,"soonestReadout":245},[3558,3562,3566],{"nctId":1401,"briefTitle":1402,"status":107,"phases":3559,"primaryCompletion":894,"completion":1404,"start":1405,"enrollment":1406,"conditions":3560,"interventions":3561},[89],[1408,1409],[1411,1412,730,704],{"nctId":3475,"briefTitle":3476,"status":107,"phases":3563,"primaryCompletion":245,"completion":245,"start":3478,"enrollment":836,"conditions":3564,"interventions":3565},[89],[3480,3481,3482,3483,3484,3485,3486,3487,3488,3489],[3491,1412,730],{"nctId":1514,"briefTitle":1515,"status":145,"phases":3567,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":3568,"interventions":3569},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":3571,"activeCount":101},[],{"trials":3573,"activeCount":101},[],{"trials":3575,"activeCount":101},[],{"trials":3577,"activeCount":101},[],{"intervention":3579,"totalTrials":152,"cells":3580},"B7-H3CART",{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3601,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3582,"activeCount":101},[],{"trials":3584,"activeCount":152,"soonestReadout":246},[3585,3593],{"nctId":3586,"briefTitle":3587,"status":107,"phases":3588,"primaryCompletion":1092,"completion":1092,"start":3589,"enrollment":25,"conditions":3590,"interventions":3592},"NCT05474378","B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme",[89],"2022-07-12",[3591],"Brain and Nervous System",[3579],{"nctId":3594,"briefTitle":3595,"status":107,"phases":3596,"primaryCompletion":246,"completion":246,"start":3597,"enrollment":1755,"conditions":3598,"interventions":3600},"NCT06646627","Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors",[89],"2024-11-11",[3599],"Ovarian Cancer",[3579],{"trials":3602,"activeCount":101},[],{"trials":3604,"activeCount":101},[],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[],{"intervention":48,"totalTrials":152,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3623,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3612,"activeCount":101},[],{"trials":3614,"activeCount":152,"soonestReadout":47},[3615,3619],{"nctId":45,"briefTitle":46,"status":145,"phases":3616,"primaryCompletion":47,"completion":3429,"start":3430,"enrollment":3431,"conditions":3617,"interventions":3618},[89],[3433,3434,3435,3436],[48,730,3438,3439],{"nctId":55,"briefTitle":56,"status":145,"phases":3620,"primaryCompletion":57,"completion":3442,"start":3443,"enrollment":28,"conditions":3621,"interventions":3622},[89],[3433,3434,3435,3436,3445,3446,3447],[48,730,3438],{"trials":3624,"activeCount":101},[],{"trials":3626,"activeCount":101},[],{"trials":3628,"activeCount":101},[],{"trials":3630,"activeCount":101},[],{"intervention":3438,"totalTrials":152,"cells":3632},{"EARLY_PHASE1":3633,"PHASE1":3635,"PHASE2":3645,"PHASE3":3647,"PHASE4":3649,"NA":3651},{"trials":3634,"activeCount":101},[],{"trials":3636,"activeCount":152,"soonestReadout":47},[3637,3641],{"nctId":45,"briefTitle":46,"status":145,"phases":3638,"primaryCompletion":47,"completion":3429,"start":3430,"enrollment":3431,"conditions":3639,"interventions":3640},[89],[3433,3434,3435,3436],[48,730,3438,3439],{"nctId":55,"briefTitle":56,"status":145,"phases":3642,"primaryCompletion":57,"completion":3442,"start":3443,"enrollment":28,"conditions":3643,"interventions":3644},[89],[3433,3434,3435,3436,3445,3446,3447],[48,730,3438],{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"intervention":3654,"totalTrials":152,"cells":3655},"CD22CART",{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3686,"PHASE3":3688,"PHASE4":3690,"NA":3692},{"trials":3657,"activeCount":101},[],{"trials":3659,"activeCount":152,"soonestReadout":246},[3660,3677],{"nctId":3661,"briefTitle":3662,"status":107,"phases":3663,"primaryCompletion":3664,"completion":3664,"start":3665,"enrollment":3666,"conditions":3667,"interventions":3676},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[89],"2031-04","2024-03-29",148,[3668,3669,3670,3671,3672,3673,3674,3675],"Follicular Lymphoma","Mantle Cell Lymphoma","Hairy Cell Leukemia","Lymphoplasmacytic Lymphoma","Burkitt Lymphoma","Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia","Large B-cell Lymphoma",[3654],{"nctId":3678,"briefTitle":3679,"status":107,"phases":3680,"primaryCompletion":246,"completion":246,"start":3681,"enrollment":111,"conditions":3682,"interventions":3684},"NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",[89],"2024-05-13",[740,3683],"Acute Lymphoblastic Leukemia",[3654,3685],"Tisagenlecleucel",{"trials":3687,"activeCount":101},[],{"trials":3689,"activeCount":101},[],{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[],{"intervention":1528,"totalTrials":821,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3717,"PHASE3":3735,"PHASE4":3737,"NA":3748},{"trials":3697,"activeCount":101},[],{"trials":3699,"activeCount":152,"soonestReadout":3704},[3700,3713],{"nctId":3701,"briefTitle":3702,"status":242,"phases":3703,"primaryCompletion":3704,"completion":3704,"start":147,"enrollment":1435,"conditions":3705,"interventions":3712},"NCT07302776","TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT",[89],"2028-02",[3706,3707,3708,1524,3709,3710,3711],"GVHD","Hematopoietic Cell Transplantation (HCT)","Acute Myeloid Leukemia (AML)","Myelofibrosis (MF)","Chronic Myeloid Leukemia (CML)","Chronic Myelomonocytic Leukemia (CMML)",[1528],{"nctId":1514,"briefTitle":1515,"status":145,"phases":3714,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":3715,"interventions":3716},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":3718,"activeCount":101},[3719],{"nctId":3720,"briefTitle":3721,"status":160,"phases":3722,"primaryCompletion":3723,"completion":3724,"start":3725,"enrollment":1977,"conditions":3726,"interventions":3734},"NCT03734601","Total Body Irradiation +\u002F- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation",[90],"2019-12-26","2020-11-17","2018-11-05",[3727,1524,3728,3729,3730,3731,3732,1339,3733],"Acute Myeloid Leukemia","Myeloproliferative Disorder","Chronic Lymphocytic Leukemia","B-cell Lymphoma","T-cell Lymphoma","Non Hodgkin Lymphoma","Chronic Myelomonocytic Leukemia",[728,1528,729],{"trials":3736,"activeCount":101},[],{"trials":3738,"activeCount":101},[3739],{"nctId":3740,"briefTitle":3741,"status":160,"phases":3742,"primaryCompletion":1499,"completion":1499,"start":698,"enrollment":34,"conditions":3743,"interventions":3746},"NCT00296296","Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)",[92],[3744,399,3745],"Kidney Transplant","Diabetic Nephropathy",[3747,1528],"Cyclosporin",{"trials":3749,"activeCount":101},[3750],{"nctId":1495,"briefTitle":1496,"status":160,"phases":3751,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":860,"conditions":3752,"interventions":3753},[93],[1502],[704,1504,1505,1506],{"intervention":729,"totalTrials":759,"cells":3755},{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3788,"PHASE3":3819,"PHASE4":3831,"NA":3833},{"trials":3757,"activeCount":101},[],{"trials":3759,"activeCount":115,"soonestReadout":1517},[3760,3784],{"nctId":3761,"briefTitle":3762,"status":716,"phases":3763,"primaryCompletion":3764,"completion":3765,"start":3766,"enrollment":115,"conditions":3767,"interventions":3783},"NCT02728700","Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT",[89],"2017-04","2018-07","2016-02",[3768,3769,3770,3771,3772,3773,3774,3775,3776,3445,2015,3777,3446,3778,3779,3780,3781,3782],"Adult Hodgkin Lymphoma","Adult Myelodysplastic Syndrome","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Childhood Hodgkin Lymphoma","Childhood Myelodysplastic Syndrome","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Myelofibrosis","Primary Myelofibrosis","Recurrent Adult Non-Hodgkin Lymphoma","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Non-Hodgkin Lymphoma","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Non-Hodgkin Lymphoma",[749,1533],{"nctId":1514,"briefTitle":1515,"status":145,"phases":3785,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":3786,"interventions":3787},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":3789,"activeCount":101},[3790,3794,3798,3802,3811,3815],{"nctId":3499,"briefTitle":3500,"status":716,"phases":3791,"primaryCompletion":3502,"completion":3503,"start":1500,"enrollment":334,"conditions":3792,"interventions":3793},[90],[3505,3506,740,3507,1339],[1533,729,726,727,730,3509],{"nctId":1430,"briefTitle":1431,"status":716,"phases":3795,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":3796,"interventions":3797},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"nctId":714,"briefTitle":715,"status":716,"phases":3799,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":3800,"interventions":3801},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":3803,"briefTitle":3804,"status":160,"phases":3805,"primaryCompletion":756,"completion":3806,"start":3807,"enrollment":3808,"conditions":3809,"interventions":3810},"NCT00185640","Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies",[90],"2016-01","2003-03",303,[739,740],[706,728,729,708],{"nctId":733,"briefTitle":734,"status":160,"phases":3812,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":3813,"interventions":3814},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"nctId":3720,"briefTitle":3721,"status":160,"phases":3816,"primaryCompletion":3723,"completion":3724,"start":3725,"enrollment":1977,"conditions":3817,"interventions":3818},[90],[3727,1524,3728,3729,3730,3731,3732,1339,3733],[728,1528,729],{"trials":3820,"activeCount":101},[3821],{"nctId":3822,"briefTitle":3823,"status":716,"phases":3824,"primaryCompletion":1974,"completion":1974,"start":1801,"enrollment":3825,"conditions":3826,"interventions":3828},"NCT00568633","Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML",[91],58,[3827,740,3708],"Leukemia, Myeloid",[728,706,729,3829,3830],"Methylprednisolone sodium succinate","Best standard care",{"trials":3832,"activeCount":101},[],{"trials":3834,"activeCount":101},[],{"intervention":3836,"totalTrials":152,"cells":3837},"Micro Fragmented Adipose Tissue",{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3852,"PHASE3":3854,"PHASE4":3865,"NA":3867},{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":115,"soonestReadout":1894},[3842],{"nctId":3843,"briefTitle":3844,"status":107,"phases":3845,"primaryCompletion":1894,"completion":1894,"start":3846,"enrollment":1755,"conditions":3847,"interventions":3850},"NCT04929951","The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis",[89],"2022-07-28",[3848,3849],"Osteoarthritis Shoulder","Shoulder Pain",[3836,3851],"Corticosteroid",{"trials":3853,"activeCount":101},[],{"trials":3855,"activeCount":101},[3856],{"nctId":3857,"briefTitle":3858,"status":160,"phases":3859,"primaryCompletion":3860,"completion":3860,"start":2072,"enrollment":179,"conditions":3861,"interventions":3864},"NCT03467919","The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis",[91],"2024-10-29",[3862,3863],"Osteoarthritis, Knee","Knee Pain",[3836,3851],{"trials":3866,"activeCount":101},[],{"trials":3868,"activeCount":101},[],{"intervention":3851,"totalTrials":152,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3879,"PHASE3":3881,"PHASE4":3887,"NA":3889},{"trials":3872,"activeCount":101},[],{"trials":3874,"activeCount":115,"soonestReadout":1894},[3875],{"nctId":3843,"briefTitle":3844,"status":107,"phases":3876,"primaryCompletion":1894,"completion":1894,"start":3846,"enrollment":1755,"conditions":3877,"interventions":3878},[89],[3848,3849],[3836,3851],{"trials":3880,"activeCount":101},[],{"trials":3882,"activeCount":101},[3883],{"nctId":3857,"briefTitle":3858,"status":160,"phases":3884,"primaryCompletion":3860,"completion":3860,"start":2072,"enrollment":179,"conditions":3885,"interventions":3886},[91],[3862,3863],[3836,3851],{"trials":3888,"activeCount":101},[],{"trials":3890,"activeCount":101},[],{"intervention":1698,"totalTrials":97,"cells":3892},{"EARLY_PHASE1":3893,"PHASE1":3895,"PHASE2":3917,"PHASE3":3967,"PHASE4":3969,"NA":3971},{"trials":3894,"activeCount":101},[],{"trials":3896,"activeCount":115,"soonestReadout":3901},[3897,3908],{"nctId":3898,"briefTitle":3899,"status":107,"phases":3900,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":179,"conditions":3904,"interventions":3906},"NCT04392622","d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC",[89],"2027-08-15","2028-05-15","2021-02-15",[3905],"Xerostomia",[3907,1698],"D-Limonene Gelcaps",{"nctId":3909,"briefTitle":3910,"status":160,"phases":3911,"primaryCompletion":1862,"start":3912,"enrollment":247,"conditions":3913,"interventions":3915},"NCT00185835","Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck",[89],"2002-06",[3914,1813],"Head and Neck Cancer",[3916,1698],"ZD-1839",{"trials":3918,"activeCount":101},[3919,3923,3927,3939,3957],{"nctId":1687,"briefTitle":1688,"status":716,"phases":3920,"primaryCompletion":1471,"completion":1690,"start":231,"enrollment":152,"conditions":3921,"interventions":3922},[90],[1692,1693,1694,1695,1696],[1678,1698,1699,1700,1701],{"nctId":1703,"briefTitle":1704,"status":716,"phases":3924,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":3925,"interventions":3926},[90],[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],[1699,1698,1722,1723,1678,1724,1725],{"nctId":3928,"briefTitle":3929,"status":160,"phases":3930,"primaryCompletion":3931,"completion":698,"start":3932,"enrollment":3933,"conditions":3934,"interventions":3936},"NCT00002774","Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[90],"2000-06","1996-06",63,[3935],"Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)",[3937,1698,3938],"Tirapazamine","5-fluorouracil",{"nctId":3940,"briefTitle":3941,"status":160,"phases":3942,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":37,"conditions":3946,"interventions":3953},"NCT00896181","Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)",[90],"2020-01-03","2020-12","2008-12-10",[3947,3948,3949,3950,3951,3952],"Stage II Lymphoepithelioma of the Nasopharynx","Stage II Squamous Cell Carcinoma of the Nasopharynx","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx",[3954,3955,1837,3956],"docetaxel","cisplatin","fluorouracil",{"nctId":3958,"briefTitle":3959,"status":160,"phases":3960,"primaryCompletion":3961,"completion":3962,"start":1976,"enrollment":791,"conditions":3963,"interventions":3964},"NCT01437449","Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[90],"2018-09-11","2019-08",[3914],[3965,1698,3966,1699],"Docetaxel","Cetuximab",{"trials":3968,"activeCount":101},[],{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"intervention":1533,"totalTrials":197,"cells":3974},{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3987,"PHASE3":4022,"PHASE4":4024,"NA":4026},{"trials":3976,"activeCount":101},[],{"trials":3978,"activeCount":115,"soonestReadout":1517},[3979,3983],{"nctId":3761,"briefTitle":3762,"status":716,"phases":3980,"primaryCompletion":3764,"completion":3765,"start":3766,"enrollment":115,"conditions":3981,"interventions":3982},[89],[3768,3769,3770,3771,3772,3773,3774,3775,3776,3445,2015,3777,3446,3778,3779,3780,3781,3782],[749,1533],{"nctId":1514,"briefTitle":1515,"status":145,"phases":3984,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":3985,"interventions":3986},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":3988,"activeCount":101},[3989,3993,4005,4012],{"nctId":3499,"briefTitle":3500,"status":716,"phases":3990,"primaryCompletion":3502,"completion":3503,"start":1500,"enrollment":334,"conditions":3991,"interventions":3992},[90],[3505,3506,740,3507,1339],[1533,729,726,727,730,3509],{"nctId":3994,"briefTitle":3995,"status":160,"phases":3996,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":3998,"interventions":4000},"NCT00350181","Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT",[90],11,[740,722,3505,3999],"Acute GVHD",[1533,4001,1438,4002,4003,3509,4004],"MMF","VP-16","CY","BU",{"nctId":4006,"briefTitle":4007,"status":160,"phases":4008,"primaryCompletion":696,"completion":1563,"start":4009,"enrollment":699,"conditions":4010,"interventions":4011},"NCT00388362","Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease",[90],"2005-11",[1502],[1533,1504],{"nctId":4013,"briefTitle":4014,"status":132,"phases":4015,"primaryCompletion":379,"completion":379,"start":4016,"enrollment":101,"conditions":4017,"interventions":4021},"NCT06080165","Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations",[89,90],"2024-07",[4018,4019,4020],"PTEN Gene Mutation","PTEN Hamartoma Tumor Syndrome","PTEN Hamartoma Syndrome",[1533],{"trials":4023,"activeCount":101},[],{"trials":4025,"activeCount":101},[],{"trials":4027,"activeCount":101},[],{"intervention":4029,"totalTrials":152,"cells":4030},"Vinpocetine",{"EARLY_PHASE1":4031,"PHASE1":4033,"PHASE2":4044,"PHASE3":4054,"PHASE4":4056,"NA":4058},{"trials":4032,"activeCount":101},[],{"trials":4034,"activeCount":115,"soonestReadout":4039},[4035],{"nctId":4036,"briefTitle":4037,"status":242,"phases":4038,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":111,"conditions":4041,"interventions":4043},"NCT06635746","Dose Escalation Study of Vinpocetine in Healthy Volunteers",[89],"2026-06-01","2025-06-01",[4042],"Fetal Alcohol Spectrum Disorders",[4029],{"trials":4045,"activeCount":101},[4046],{"nctId":4047,"briefTitle":4048,"status":4049,"phases":4050,"primaryCompletion":177,"completion":177,"start":4051,"enrollment":232,"conditions":4052,"interventions":4053},"NCT02011971","Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy","SUSPENDED",[89,90],"2012-02",[113],[4029],{"trials":4055,"activeCount":101},[],{"trials":4057,"activeCount":101},[],{"trials":4059,"activeCount":101},[],{"intervention":4061,"totalTrials":152,"cells":4062},"Sarilumab",{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4075,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4064,"activeCount":101},[],{"trials":4066,"activeCount":115,"soonestReadout":1517},[4067],{"nctId":4068,"briefTitle":4069,"status":242,"phases":4070,"primaryCompletion":1517,"completion":1517,"start":1288,"enrollment":247,"conditions":4071,"interventions":4073},"NCT07484113","IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD",[89],[4072],"cGVHD",[4074,4061],"Belumosudil",{"trials":4076,"activeCount":101},[4077],{"nctId":4078,"briefTitle":4079,"status":160,"phases":4080,"primaryCompletion":4081,"completion":4082,"start":3063,"enrollment":737,"conditions":4083,"interventions":4085},"NCT04008069","Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis",[90],"2022-07-26","2022-09-09",[4084],"Sarcoidosis",[4061],{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"trials":4091,"activeCount":101},[],{"intervention":4093,"totalTrials":334,"cells":4094},"[18F]FTC-146",{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4142},{"trials":4096,"activeCount":101},[],{"trials":4098,"activeCount":115,"soonestReadout":4115},[4099,4111,4121],{"nctId":4100,"briefTitle":4101,"status":160,"phases":4102,"primaryCompletion":4103,"completion":4104,"start":4105,"enrollment":821,"conditions":4106,"interventions":4110},"NCT04435821","PET\u002FMRI in the Diagnosis of Pediatric Chronic Pain",[89],"2022-12-31","2024-10-31","2020-11-19",[33,4107,4108,4109],"Pediatric Disorder","Neuropathic Pain","Nociceptive Pain",[4093],{"nctId":4112,"briefTitle":4113,"status":242,"phases":4114,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":436,"conditions":4117,"interventions":4120},"NCT06599151","PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin",[89],"2030-10-01","2024-10-01",[4118,4108,4109,4119],"Nerve Pain","MIxed Pain (Nociceptive and Neuropathic)",[4093],{"nctId":4122,"briefTitle":4123,"status":4124,"phases":4125,"primaryCompletion":4126,"completion":4126,"start":4127,"enrollment":4128,"conditions":4129,"interventions":4135},"NCT03556137","PET\u002FMRI in the Diagnosis of Chronic Pain","UNKNOWN",[89],"2024-12-31","2018-07-16",190,[4108,4109,4130,4131,4132,4133,4134],"Mixed Pain (Nociceptive and Neuropathic)","Spinal Pain","Radiculopathy","Myelopathy","Neurogenic Claudication",[4093],{"trials":4137,"activeCount":101},[],{"trials":4139,"activeCount":101},[],{"trials":4141,"activeCount":101},[],{"trials":4143,"activeCount":101},[],{"intervention":4145,"totalTrials":115,"cells":4146},"KYV-101 anti-CD19 CAR-T cell therapy",{"EARLY_PHASE1":4147,"PHASE1":4149,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4148,"activeCount":101},[],{"trials":4150,"activeCount":115,"soonestReadout":3252},[4151],{"nctId":4152,"briefTitle":4153,"status":107,"phases":4154,"primaryCompletion":3252,"completion":3252,"start":4155,"enrollment":1314,"conditions":4156,"interventions":4160},"NCT06138132","A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",[89],"2024-04-10",[4157,4158,4159],"Multiple Sclerosis","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Secondary Progressive",[4145,4161],"Standard lymphodepletion regimen",{"trials":4163,"activeCount":101},[],{"trials":4165,"activeCount":101},[],{"trials":4167,"activeCount":101},[],{"trials":4169,"activeCount":101},[],{"intervention":4161,"totalTrials":115,"cells":4171},{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4180,"PHASE3":4182,"PHASE4":4184,"NA":4186},{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":115,"soonestReadout":3252},[4176],{"nctId":4152,"briefTitle":4153,"status":107,"phases":4177,"primaryCompletion":3252,"completion":3252,"start":4155,"enrollment":1314,"conditions":4178,"interventions":4179},[89],[4157,4158,4159],[4145,4161],{"trials":4181,"activeCount":101},[],{"trials":4183,"activeCount":101},[],{"trials":4185,"activeCount":101},[],{"trials":4187,"activeCount":101},[],{"intervention":3907,"totalTrials":115,"cells":4189},{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4198,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4191,"activeCount":101},[],{"trials":4193,"activeCount":115,"soonestReadout":3901},[4194],{"nctId":3898,"briefTitle":3899,"status":107,"phases":4195,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":179,"conditions":4196,"interventions":4197},[89],[3905],[3907,1698],{"trials":4199,"activeCount":101},[],{"trials":4201,"activeCount":101},[],{"trials":4203,"activeCount":101},[],{"trials":4205,"activeCount":101},[],{"intervention":1411,"totalTrials":115,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4216,"PHASE3":4218,"PHASE4":4220,"NA":4222},{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":115,"soonestReadout":894},[4212],{"nctId":1401,"briefTitle":1402,"status":107,"phases":4213,"primaryCompletion":894,"completion":1404,"start":1405,"enrollment":1406,"conditions":4214,"interventions":4215},[89],[1408,1409],[1411,1412,730,704],{"trials":4217,"activeCount":101},[],{"trials":4219,"activeCount":101},[],{"trials":4221,"activeCount":101},[],{"trials":4223,"activeCount":101},[],{"intervention":4225,"totalTrials":115,"cells":4226},"Niclosamide",{"EARLY_PHASE1":4227,"PHASE1":4229,"PHASE2":4238,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4228,"activeCount":101},[],{"trials":4230,"activeCount":115,"soonestReadout":246},[4231],{"nctId":4232,"briefTitle":4233,"status":107,"phases":4234,"primaryCompletion":246,"completion":177,"start":4235,"enrollment":737,"conditions":4236,"interventions":4237},"NCT05188170","Niclosamide in Pediatric Patients With Relapsed and Refractory AML",[89],"2022-11-21",[3708],[4225],{"trials":4239,"activeCount":101},[],{"trials":4241,"activeCount":101},[],{"trials":4243,"activeCount":101},[],{"trials":4245,"activeCount":101},[],{"intervention":62,"totalTrials":115,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4259,"PHASE3":4261,"PHASE4":4263,"NA":4265},{"trials":4249,"activeCount":101},[],{"trials":4251,"activeCount":115,"soonestReadout":61},[4252],{"nctId":59,"briefTitle":60,"status":242,"phases":4253,"primaryCompletion":61,"completion":1517,"start":4254,"enrollment":897,"conditions":4255,"interventions":4257},[89],"2023-10-01",[4256],"Islet Transplantation",[62,4258],"Infusion of concomitant Donor Derived Vertebral Bone Marrow",{"trials":4260,"activeCount":101},[],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[],{"intervention":4258,"totalTrials":115,"cells":4268},{"EARLY_PHASE1":4269,"PHASE1":4271,"PHASE2":4277,"PHASE3":4279,"PHASE4":4281,"NA":4283},{"trials":4270,"activeCount":101},[],{"trials":4272,"activeCount":115,"soonestReadout":61},[4273],{"nctId":59,"briefTitle":60,"status":242,"phases":4274,"primaryCompletion":61,"completion":1517,"start":4254,"enrollment":897,"conditions":4275,"interventions":4276},[89],[4256],[62,4258],{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"trials":4282,"activeCount":101},[],{"trials":4284,"activeCount":101},[],{"intervention":4286,"totalTrials":115,"cells":4287},"ORCA-T",{"EARLY_PHASE1":4288,"PHASE1":4290,"PHASE2":4301,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4289,"activeCount":101},[],{"trials":4291,"activeCount":115,"soonestReadout":1288},[4292],{"nctId":4293,"briefTitle":4294,"status":107,"phases":4295,"primaryCompletion":1288,"completion":177,"start":4296,"enrollment":897,"conditions":4297,"interventions":4300},"NCT06551584","Phase I Trial for Patients w\u002F Advanced Hematologic Malignancies Undergoing Allogeneic HCT",[89],"2025-12-01",[3727,4298,4299,1524],"Acute Lymphoid Leukemia","Mixed Phenotype Acute Leukemia",[4286],{"trials":4302,"activeCount":101},[],{"trials":4304,"activeCount":101},[],{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"intervention":3439,"totalTrials":115,"cells":4310},{"EARLY_PHASE1":4311,"PHASE1":4313,"PHASE2":4319,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4312,"activeCount":101},[],{"trials":4314,"activeCount":115,"soonestReadout":47},[4315],{"nctId":45,"briefTitle":46,"status":145,"phases":4316,"primaryCompletion":47,"completion":3429,"start":3430,"enrollment":3431,"conditions":4317,"interventions":4318},[89],[3433,3434,3435,3436],[48,730,3438,3439],{"trials":4320,"activeCount":101},[],{"trials":4322,"activeCount":101},[],{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[],{"intervention":4328,"totalTrials":115,"cells":4329},"Dasatinib",{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4342,"PHASE3":4344,"PHASE4":4346,"NA":4348},{"trials":4331,"activeCount":101},[],{"trials":4333,"activeCount":115,"soonestReadout":3252},[4334],{"nctId":4335,"briefTitle":4336,"status":145,"phases":4337,"primaryCompletion":3252,"completion":3252,"start":4338,"enrollment":684,"conditions":4339,"interventions":4341},"NCT05993949","Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia",[89],"2023-10-02",[4340],"Lymphoblastic Leukemia",[4328],{"trials":4343,"activeCount":101},[],{"trials":4345,"activeCount":101},[],{"trials":4347,"activeCount":101},[],{"trials":4349,"activeCount":101},[],{"intervention":4351,"totalTrials":115,"cells":4352},"Insulin, 4 units",{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4370,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4354,"activeCount":101},[],{"trials":4356,"activeCount":115,"soonestReadout":205},[4357],{"nctId":4358,"briefTitle":4359,"status":107,"phases":4360,"primaryCompletion":205,"completion":205,"start":4361,"enrollment":4362,"conditions":4363,"interventions":4364},"NCT05206877","Topical Insulin for Glaucoma",[89],"2022-04-01",52,[2627],[4351,4365,4366,4367,4368,4369],"Insulin, 20 units","insulin, 4 units twice daily","insulin, 20 units twice daily","insulin, 4 units three times daily","insulin, 20 units three times daily",{"trials":4371,"activeCount":101},[],{"trials":4373,"activeCount":101},[],{"trials":4375,"activeCount":101},[],{"trials":4377,"activeCount":101},[],{"intervention":4365,"totalTrials":115,"cells":4379},{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4388,"PHASE3":4390,"PHASE4":4392,"NA":4394},{"trials":4381,"activeCount":101},[],{"trials":4383,"activeCount":115,"soonestReadout":205},[4384],{"nctId":4358,"briefTitle":4359,"status":107,"phases":4385,"primaryCompletion":205,"completion":205,"start":4361,"enrollment":4362,"conditions":4386,"interventions":4387},[89],[2627],[4351,4365,4366,4367,4368,4369],{"trials":4389,"activeCount":101},[],{"trials":4391,"activeCount":101},[],{"trials":4393,"activeCount":101},[],{"trials":4395,"activeCount":101},[],{"intervention":4366,"totalTrials":115,"cells":4397},{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4406,"PHASE3":4408,"PHASE4":4410,"NA":4412},{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":115,"soonestReadout":205},[4402],{"nctId":4358,"briefTitle":4359,"status":107,"phases":4403,"primaryCompletion":205,"completion":205,"start":4361,"enrollment":4362,"conditions":4404,"interventions":4405},[89],[2627],[4351,4365,4366,4367,4368,4369],{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[],{"intervention":4367,"totalTrials":115,"cells":4415},{"EARLY_PHASE1":4416,"PHASE1":4418,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4430},{"trials":4417,"activeCount":101},[],{"trials":4419,"activeCount":115,"soonestReadout":205},[4420],{"nctId":4358,"briefTitle":4359,"status":107,"phases":4421,"primaryCompletion":205,"completion":205,"start":4361,"enrollment":4362,"conditions":4422,"interventions":4423},[89],[2627],[4351,4365,4366,4367,4368,4369],{"trials":4425,"activeCount":101},[],{"trials":4427,"activeCount":101},[],{"trials":4429,"activeCount":101},[],{"trials":4431,"activeCount":101},[],{"intervention":4368,"totalTrials":115,"cells":4433},{"EARLY_PHASE1":4434,"PHASE1":4436,"PHASE2":4442,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4435,"activeCount":101},[],{"trials":4437,"activeCount":115,"soonestReadout":205},[4438],{"nctId":4358,"briefTitle":4359,"status":107,"phases":4439,"primaryCompletion":205,"completion":205,"start":4361,"enrollment":4362,"conditions":4440,"interventions":4441},[89],[2627],[4351,4365,4366,4367,4368,4369],{"trials":4443,"activeCount":101},[],{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":101},[],{"intervention":4369,"totalTrials":115,"cells":4451},{"EARLY_PHASE1":4452,"PHASE1":4454,"PHASE2":4460,"PHASE3":4462,"PHASE4":4464,"NA":4466},{"trials":4453,"activeCount":101},[],{"trials":4455,"activeCount":115,"soonestReadout":205},[4456],{"nctId":4358,"briefTitle":4359,"status":107,"phases":4457,"primaryCompletion":205,"completion":205,"start":4361,"enrollment":4362,"conditions":4458,"interventions":4459},[89],[2627],[4351,4365,4366,4367,4368,4369],{"trials":4461,"activeCount":101},[],{"trials":4463,"activeCount":101},[],{"trials":4465,"activeCount":101},[],{"trials":4467,"activeCount":101},[],{"intervention":4469,"totalTrials":115,"cells":4470},"Combined Deceased Donor Kidney and Hematopoietic Cell Transplants",{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4483,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":115,"soonestReadout":612},[4475],{"nctId":4476,"briefTitle":4477,"status":259,"phases":4478,"primaryCompletion":612,"completion":4479,"start":4480,"enrollment":232,"conditions":4481,"interventions":4482},"NCT04571203","Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment",[89],"2029-10-01","2022-05-06",[2220],[4469],{"trials":4484,"activeCount":101},[],{"trials":4486,"activeCount":101},[],{"trials":4488,"activeCount":101},[],{"trials":4490,"activeCount":101},[],{"intervention":4492,"totalTrials":115,"cells":4493},"B7-H3CART Dose",{"EARLY_PHASE1":4494,"PHASE1":4496,"PHASE2":4510,"PHASE3":4512,"PHASE4":4514,"NA":4516},{"trials":4495,"activeCount":101},[],{"trials":4497,"activeCount":115,"soonestReadout":4502},[4498],{"nctId":4499,"briefTitle":4500,"status":107,"phases":4501,"primaryCompletion":4502,"completion":4502,"start":4503,"enrollment":4504,"conditions":4505,"interventions":4509},"NCT06500819","Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed\u002FRefractory Solid Tumors",[89],"2029-07","2024-07-11",41,[4506,4507,4508],"Neuroblastoma","Sarcoma","Osteosarcoma",[4492],{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":101},[],{"trials":4517,"activeCount":101},[],{"intervention":4519,"totalTrials":115,"cells":4520},"Rapcabtagene autoleucel",{"EARLY_PHASE1":4521,"PHASE1":4523,"PHASE2":4533,"PHASE3":4535,"PHASE4":4537,"NA":4539},{"trials":4522,"activeCount":101},[],{"trials":4524,"activeCount":115,"soonestReadout":4529},[4525],{"nctId":4526,"briefTitle":4527,"status":242,"phases":4528,"primaryCompletion":4529,"completion":4529,"start":1288,"enrollment":111,"conditions":4530,"interventions":4532},"NCT07443137","CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)",[89],"2028-08",[4531],"Large-cell Lymphoma",[4519],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[],{"intervention":3685,"totalTrials":115,"cells":4542},{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4551,"PHASE3":4553,"PHASE4":4555,"NA":4557},{"trials":4544,"activeCount":101},[],{"trials":4546,"activeCount":115,"soonestReadout":246},[4547],{"nctId":3678,"briefTitle":3679,"status":107,"phases":4548,"primaryCompletion":246,"completion":246,"start":3681,"enrollment":111,"conditions":4549,"interventions":4550},[89],[740,3683],[3654,3685],{"trials":4552,"activeCount":101},[],{"trials":4554,"activeCount":101},[],{"trials":4556,"activeCount":101},[],{"trials":4558,"activeCount":101},[],{"intervention":4560,"totalTrials":115,"cells":4561},"Orca-Q",{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4575,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4563,"activeCount":101},[],{"trials":4565,"activeCount":115,"soonestReadout":4570},[4566],{"nctId":4567,"briefTitle":4568,"status":242,"phases":4569,"primaryCompletion":4570,"completion":4570,"start":3129,"enrollment":247,"conditions":4571,"interventions":4573},"NCT06900192","A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis",[89],"2029-08",[4572,4157,4158,4159],"Primary Progressive Multiple Sclerosis",[4560,4574],"myeloablative regimen",{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":101},[],{"trials":4582,"activeCount":101},[],{"intervention":4574,"totalTrials":115,"cells":4584},{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4586,"activeCount":101},[],{"trials":4588,"activeCount":115,"soonestReadout":4570},[4589],{"nctId":4567,"briefTitle":4568,"status":242,"phases":4590,"primaryCompletion":4570,"completion":4570,"start":3129,"enrollment":247,"conditions":4591,"interventions":4592},[89],[4572,4157,4158,4159],[4560,4574],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[],{"intervention":4602,"totalTrials":115,"cells":4603},"Lutathera",{"EARLY_PHASE1":4604,"PHASE1":4606,"PHASE2":4617,"PHASE3":4619,"PHASE4":4621,"NA":4623},{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":115,"soonestReadout":246},[4608],{"nctId":4609,"briefTitle":4610,"status":107,"phases":4611,"primaryCompletion":246,"completion":611,"start":4612,"enrollment":247,"conditions":4613,"interventions":4615},"NCT04609592","Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",[89],"2021-03-17",[4614],"Gastroenteropancreatic Neuroendocrine Tumor",[4602,4616],"Gallium 68 Dotatate",{"trials":4618,"activeCount":101},[],{"trials":4620,"activeCount":101},[],{"trials":4622,"activeCount":101},[],{"trials":4624,"activeCount":101},[],{"intervention":4616,"totalTrials":115,"cells":4626},{"EARLY_PHASE1":4627,"PHASE1":4629,"PHASE2":4635,"PHASE3":4637,"PHASE4":4639,"NA":4641},{"trials":4628,"activeCount":101},[],{"trials":4630,"activeCount":115,"soonestReadout":246},[4631],{"nctId":4609,"briefTitle":4610,"status":107,"phases":4632,"primaryCompletion":246,"completion":611,"start":4612,"enrollment":247,"conditions":4633,"interventions":4634},[89],[4614],[4602,4616],{"trials":4636,"activeCount":101},[],{"trials":4638,"activeCount":101},[],{"trials":4640,"activeCount":101},[],{"trials":4642,"activeCount":101},[],{"intervention":4644,"totalTrials":115,"cells":4645},"Propofol - Emergence-from-LOR Protocol",{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4660,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4647,"activeCount":101},[],{"trials":4649,"activeCount":115,"soonestReadout":4654},[4650],{"nctId":4651,"briefTitle":4652,"status":259,"phases":4653,"primaryCompletion":4654,"completion":4654,"start":4655,"enrollment":2218,"conditions":4656,"interventions":4658},"NCT07198711","Induction of Dreaming With EEG and Anesthesia in Healthy Adults",[89],"2026-05-31","2025-05-20",[4657],"Healthy Volunteers",[4644,4659],"Propofol - Light Sedation Protocol",{"trials":4661,"activeCount":101},[],{"trials":4663,"activeCount":101},[],{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":101},[],{"intervention":4659,"totalTrials":115,"cells":4669},{"EARLY_PHASE1":4670,"PHASE1":4672,"PHASE2":4678,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4671,"activeCount":101},[],{"trials":4673,"activeCount":115,"soonestReadout":4654},[4674],{"nctId":4651,"briefTitle":4652,"status":259,"phases":4675,"primaryCompletion":4654,"completion":4654,"start":4655,"enrollment":2218,"conditions":4676,"interventions":4677},[89],[4657],[4644,4659],{"trials":4679,"activeCount":101},[],{"trials":4681,"activeCount":101},[],{"trials":4683,"activeCount":101},[],{"trials":4685,"activeCount":101},[],{"intervention":4687,"totalTrials":115,"cells":4688},"KYV-101",{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4690,"activeCount":101},[],{"trials":4692,"activeCount":115,"soonestReadout":4697},[4693],{"nctId":4694,"briefTitle":4695,"status":107,"phases":4696,"primaryCompletion":4697,"completion":4698,"start":4699,"enrollment":2393,"conditions":4700,"interventions":4702},"NCT06298019","Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis",[89],"2027-04","2039-04","2024-08-02",[4701],"Dermatomyositis",[4687],{"trials":4704,"activeCount":101},[],{"trials":4706,"activeCount":101},[],{"trials":4708,"activeCount":101},[],{"trials":4710,"activeCount":101},[],{"intervention":4712,"totalTrials":115,"cells":4713},"Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4727,"PHASE3":4729,"PHASE4":4731,"NA":4733},{"trials":4715,"activeCount":101},[],{"trials":4717,"activeCount":115,"soonestReadout":1288},[4718],{"nctId":4719,"briefTitle":4720,"status":145,"phases":4721,"primaryCompletion":1288,"completion":1288,"start":4722,"enrollment":1977,"conditions":4723,"interventions":4725},"NCT05507827","Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19\u002FCD22-CAR TCells in B-Cell ALL",[89],"2022-08-18",[4724],"Lymphoid Leukemia",[4712,4726],"Treg CD34+HSPC",{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[],{"trials":4732,"activeCount":101},[],{"trials":4734,"activeCount":101},[],{"intervention":4726,"totalTrials":115,"cells":4736},{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":115,"soonestReadout":1288},[4741],{"nctId":4719,"briefTitle":4720,"status":145,"phases":4742,"primaryCompletion":1288,"completion":1288,"start":4722,"enrollment":1977,"conditions":4743,"interventions":4744},[89],[4724],[4712,4726],{"trials":4746,"activeCount":101},[],{"trials":4748,"activeCount":101},[],{"trials":4750,"activeCount":101},[],{"trials":4752,"activeCount":101},[],{"intervention":4754,"totalTrials":115,"cells":4755},"Axicabtagene Ciloleucel",{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4769,"PHASE3":4771,"PHASE4":4773,"NA":4775},{"trials":4757,"activeCount":101},[],{"trials":4759,"activeCount":115,"soonestReadout":4764},[4760],{"nctId":4761,"briefTitle":4762,"status":107,"phases":4763,"primaryCompletion":4764,"completion":4764,"start":4765,"enrollment":111,"conditions":4766,"interventions":4768},"NCT05794958","Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and\u002For Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel",[89],"2038-04-01","2023-05-23",[4767,3675],"Non-Hodgkin Lymphoma",[4754],{"trials":4770,"activeCount":101},[],{"trials":4772,"activeCount":101},[],{"trials":4774,"activeCount":101},[],{"trials":4776,"activeCount":101},[],{"intervention":3491,"totalTrials":115,"cells":4778},{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4787,"PHASE3":4789,"PHASE4":4791,"NA":4793},{"trials":4780,"activeCount":101},[],{"trials":4782,"activeCount":115,"soonestReadout":245},[4783],{"nctId":3475,"briefTitle":3476,"status":107,"phases":4784,"primaryCompletion":245,"completion":245,"start":3478,"enrollment":836,"conditions":4785,"interventions":4786},[89],[3480,3481,3482,3483,3484,3485,3486,3487,3488,3489],[3491,1412,730],{"trials":4788,"activeCount":101},[],{"trials":4790,"activeCount":101},[],{"trials":4792,"activeCount":101},[],{"trials":4794,"activeCount":101},[],{"intervention":4074,"totalTrials":115,"cells":4796},{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4805,"PHASE3":4807,"PHASE4":4809,"NA":4811},{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":115,"soonestReadout":1517},[4801],{"nctId":4068,"briefTitle":4069,"status":242,"phases":4802,"primaryCompletion":1517,"completion":1517,"start":1288,"enrollment":247,"conditions":4803,"interventions":4804},[89],[4072],[4074,4061],{"trials":4806,"activeCount":101},[],{"trials":4808,"activeCount":101},[],{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[],{"intervention":1527,"totalTrials":115,"cells":4814},{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4823,"PHASE3":4825,"PHASE4":4827,"NA":4829},{"trials":4816,"activeCount":101},[],{"trials":4818,"activeCount":115,"soonestReadout":1517},[4819],{"nctId":1514,"briefTitle":1515,"status":145,"phases":4820,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":4821,"interventions":4822},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"trials":4828,"activeCount":101},[],{"trials":4830,"activeCount":101},[],{"intervention":1529,"totalTrials":115,"cells":4832},{"EARLY_PHASE1":4833,"PHASE1":4835,"PHASE2":4841,"PHASE3":4843,"PHASE4":4845,"NA":4847},{"trials":4834,"activeCount":101},[],{"trials":4836,"activeCount":115,"soonestReadout":1517},[4837],{"nctId":1514,"briefTitle":1515,"status":145,"phases":4838,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":4839,"interventions":4840},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":101},[],{"trials":4846,"activeCount":101},[],{"trials":4848,"activeCount":101},[],{"intervention":1530,"totalTrials":115,"cells":4850},{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4859,"PHASE3":4861,"PHASE4":4863,"NA":4865},{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":115,"soonestReadout":1517},[4855],{"nctId":1514,"briefTitle":1515,"status":145,"phases":4856,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":4857,"interventions":4858},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":101},[],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[],{"intervention":1531,"totalTrials":115,"cells":4868},{"EARLY_PHASE1":4869,"PHASE1":4871,"PHASE2":4877,"PHASE3":4879,"PHASE4":4881,"NA":4883},{"trials":4870,"activeCount":101},[],{"trials":4872,"activeCount":115,"soonestReadout":1517},[4873],{"nctId":1514,"briefTitle":1515,"status":145,"phases":4874,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":4875,"interventions":4876},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":4878,"activeCount":101},[],{"trials":4880,"activeCount":101},[],{"trials":4882,"activeCount":101},[],{"trials":4884,"activeCount":101},[],{"intervention":1532,"totalTrials":115,"cells":4886},{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4895,"PHASE3":4897,"PHASE4":4899,"NA":4901},{"trials":4888,"activeCount":101},[],{"trials":4890,"activeCount":115,"soonestReadout":1517},[4891],{"nctId":1514,"briefTitle":1515,"status":145,"phases":4892,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":382,"conditions":4893,"interventions":4894},[89],[1520,1521,1522,1523,1524,1525],[1527,1412,766,1528,730,1529,1530,1531,749,1532,1533],{"trials":4896,"activeCount":101},[],{"trials":4898,"activeCount":101},[],{"trials":4900,"activeCount":101},[],{"trials":4902,"activeCount":101},[],{"intervention":4904,"totalTrials":115,"cells":4905},"Diluted Humalog U-200 Insulin",{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4921,"PHASE3":4923,"PHASE4":4925,"NA":4927},{"trials":4907,"activeCount":101},[],{"trials":4909,"activeCount":115,"soonestReadout":246},[4910],{"nctId":4911,"briefTitle":4912,"status":107,"phases":4913,"primaryCompletion":246,"completion":798,"start":4914,"enrollment":111,"conditions":4915,"interventions":4918},"NCT07090824","Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes",[89],"2025-10-28",[4916,4917],"Diabetes Mellitus, Type 1","Type 1 Diabetes Mellitus",[4904,4919,4920],"Diluted U-500 Humulin Insulin","Lyumjev U-100 Insulin",{"trials":4922,"activeCount":101},[],{"trials":4924,"activeCount":101},[],{"trials":4926,"activeCount":101},[],{"trials":4928,"activeCount":101},[],{"intervention":4919,"totalTrials":115,"cells":4930},{"EARLY_PHASE1":4931,"PHASE1":4933,"PHASE2":4939,"PHASE3":4941,"PHASE4":4943,"NA":4945},{"trials":4932,"activeCount":101},[],{"trials":4934,"activeCount":115,"soonestReadout":246},[4935],{"nctId":4911,"briefTitle":4912,"status":107,"phases":4936,"primaryCompletion":246,"completion":798,"start":4914,"enrollment":111,"conditions":4937,"interventions":4938},[89],[4916,4917],[4904,4919,4920],{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[],{"trials":4944,"activeCount":101},[],{"trials":4946,"activeCount":101},[],{"intervention":4920,"totalTrials":115,"cells":4948},{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4957,"PHASE3":4959,"PHASE4":4961,"NA":4963},{"trials":4950,"activeCount":101},[],{"trials":4952,"activeCount":115,"soonestReadout":246},[4953],{"nctId":4911,"briefTitle":4912,"status":107,"phases":4954,"primaryCompletion":246,"completion":798,"start":4914,"enrollment":111,"conditions":4955,"interventions":4956},[89],[4916,4917],[4904,4919,4920],{"trials":4958,"activeCount":101},[],{"trials":4960,"activeCount":101},[],{"trials":4962,"activeCount":101},[],{"trials":4964,"activeCount":101},[],{"intervention":4966,"totalTrials":152,"cells":4967},"Ketamine Hydrochloride",{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4981,"PHASE3":4983,"PHASE4":4985,"NA":4987},{"trials":4969,"activeCount":101},[],{"trials":4971,"activeCount":115,"soonestReadout":4976},[4972],{"nctId":4973,"briefTitle":4974,"status":107,"phases":4975,"primaryCompletion":4976,"completion":4976,"start":4977,"enrollment":149,"conditions":4978,"interventions":4980},"NCT05962424","HNC: Human Neural Circuits Electrophysiology During Cognition",[89],"2030-09-01","2023-10-05",[4979],"Psychiatric Disorder",[4966],{"trials":4982,"activeCount":101},[],{"trials":4984,"activeCount":101},[],{"trials":4986,"activeCount":101},[],{"trials":4988,"activeCount":101},[4989],{"nctId":4990,"briefTitle":4991,"status":160,"phases":4992,"primaryCompletion":3348,"completion":3348,"start":4993,"enrollment":2393,"conditions":4994,"interventions":4996},"NCT00553839","Pharmacokinetics of Ketamine in Infants and Children",[93],"2007-07",[4995],"The Pk of IV Ketamine in Children With Heart Disease",[4997],"ketamine hydrochloride",{"intervention":4999,"totalTrials":152,"cells":5000},"Rosuvastatin",{"EARLY_PHASE1":5001,"PHASE1":5023,"PHASE2":5025,"PHASE3":5027,"PHASE4":5029,"NA":5031},{"trials":5002,"activeCount":152,"soonestReadout":5017},[5003,5013],{"nctId":5004,"briefTitle":5005,"status":107,"phases":5006,"primaryCompletion":5007,"completion":5008,"start":5009,"enrollment":111,"conditions":5010,"interventions":5012},"NCT06538649","Effect of Statins on Crohn's Disease",[88],"2027-10-31","2028-10-31","2024-12-12",[5011,1451],"Crohn's Ileocolitis",[4999],{"nctId":5014,"briefTitle":5015,"status":107,"phases":5016,"primaryCompletion":5017,"completion":1894,"start":5018,"enrollment":2218,"conditions":5019,"interventions":5022},"NCT05912387","Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study",[88],"2027-05-31","2023-05-31",[5020,5021],"Primary Sclerosing Cholangitis","Inflammatory Bowel Diseases",[4999],{"trials":5024,"activeCount":101},[],{"trials":5026,"activeCount":101},[],{"trials":5028,"activeCount":101},[],{"trials":5030,"activeCount":101},[],{"trials":5032,"activeCount":101},[],{"intervention":212,"totalTrials":115,"cells":5034},{"EARLY_PHASE1":5035,"PHASE1":5041,"PHASE2":5043,"PHASE3":5045,"PHASE4":5047,"NA":5049},{"trials":5036,"activeCount":115,"soonestReadout":205},[5037],{"nctId":202,"briefTitle":203,"status":107,"phases":5038,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":5039,"interventions":5040},[88],[210],[196,212],{"trials":5042,"activeCount":101},[],{"trials":5044,"activeCount":101},[],{"trials":5046,"activeCount":101},[],{"trials":5048,"activeCount":101},[],{"trials":5050,"activeCount":101},[],{"intervention":5052,"totalTrials":115,"cells":5053},"Anselamimab",{"EARLY_PHASE1":5054,"PHASE1":5063,"PHASE2":5065,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5055,"activeCount":115,"soonestReadout":1220},[5056],{"nctId":5057,"briefTitle":5058,"status":242,"phases":5059,"primaryCompletion":1220,"completion":1220,"start":246,"enrollment":821,"conditions":5060,"interventions":5062},"NCT07615270","A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement",[88],[5061],"AL Amyloidosis",[5052],{"trials":5064,"activeCount":101},[],{"trials":5066,"activeCount":101},[],{"trials":5068,"activeCount":101},[],{"trials":5070,"activeCount":101},[],{"trials":5072,"activeCount":101},[],{"intervention":5074,"totalTrials":115,"cells":5075},"Cannabigerol",{"EARLY_PHASE1":5076,"PHASE1":5085,"PHASE2":5087,"PHASE3":5089,"PHASE4":5091,"NA":5093},{"trials":5077,"activeCount":115,"soonestReadout":1517},[5078],{"nctId":5079,"briefTitle":5080,"status":242,"phases":5081,"primaryCompletion":1517,"completion":1517,"start":244,"enrollment":111,"conditions":5082,"interventions":5084},"NCT07577999","The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy",[88],[5083],"Non-metastatic Bladder Cancer",[5074],{"trials":5086,"activeCount":101},[],{"trials":5088,"activeCount":101},[],{"trials":5090,"activeCount":101},[],{"trials":5092,"activeCount":101},[],{"trials":5094,"activeCount":101},[],{"intervention":5096,"totalTrials":115,"cells":5097},"MITI-001 administration",{"EARLY_PHASE1":5098,"PHASE1":5109,"PHASE2":5111,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5099,"activeCount":115,"soonestReadout":1312},[5100],{"nctId":5101,"briefTitle":5102,"status":242,"phases":5103,"primaryCompletion":1312,"completion":3153,"start":5104,"enrollment":191,"conditions":5105,"interventions":5108},"NCT07238790","Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea",[88],"2025-12",[5106,5107],"IBS (Irritable Bowel Syndrome)","Diarrhea",[5096],{"trials":5110,"activeCount":101},[],{"trials":5112,"activeCount":101},[],{"trials":5114,"activeCount":101},[],{"trials":5116,"activeCount":101},[],{"trials":5118,"activeCount":101},[],{"intervention":5120,"totalTrials":115,"cells":5121},"Amisulpride",{"EARLY_PHASE1":5122,"PHASE1":5134,"PHASE2":5136,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5123,"activeCount":115,"soonestReadout":5128},[5124],{"nctId":5125,"briefTitle":5126,"status":242,"phases":5127,"primaryCompletion":5128,"completion":5129,"start":5130,"enrollment":208,"conditions":5131,"interventions":5133},"NCT07348172","Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings",[88],"2027-03-31","2028-03-31","2026-03-01",[5132],"Drug Liking",[5120],{"trials":5135,"activeCount":101},[],{"trials":5137,"activeCount":101},[],{"trials":5139,"activeCount":101},[],{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":101},[],{"intervention":5145,"totalTrials":115,"cells":5146},"Droperidol",{"EARLY_PHASE1":5147,"PHASE1":5159,"PHASE2":5161,"PHASE3":5163,"PHASE4":5165,"NA":5167},{"trials":5148,"activeCount":115,"soonestReadout":5153},[5149],{"nctId":5150,"briefTitle":5151,"status":259,"phases":5152,"primaryCompletion":5153,"completion":5154,"start":5155,"enrollment":5156,"conditions":5157,"interventions":5158},"NCT07015528","Assessment of Drug Liking In Peri-procedural Clinical Settings",[88],"2026-08-31","2027-08-31","2025-09-30",130,[5132],[5145],{"trials":5160,"activeCount":101},[],{"trials":5162,"activeCount":101},[],{"trials":5164,"activeCount":101},[],{"trials":5166,"activeCount":101},[],{"trials":5168,"activeCount":101},[],{"intervention":77,"totalTrials":115,"cells":5170},{"EARLY_PHASE1":5171,"PHASE1":5181,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5189},{"trials":5172,"activeCount":115,"soonestReadout":76},[5173],{"nctId":74,"briefTitle":75,"status":242,"phases":5174,"primaryCompletion":76,"completion":329,"start":5175,"enrollment":1124,"conditions":5176,"interventions":5180},[88],"2025-01",[5177,5178,5179],"Pregnancy","Pharmacokinetics","Postpartum Hemorrhage",[77],{"trials":5182,"activeCount":101},[],{"trials":5184,"activeCount":101},[],{"trials":5186,"activeCount":101},[],{"trials":5188,"activeCount":101},[],{"trials":5190,"activeCount":101},[],{"intervention":5192,"totalTrials":152,"cells":5193},"Platelet rich plasma",{"EARLY_PHASE1":5194,"PHASE1":5205,"PHASE2":5207,"PHASE3":5209,"PHASE4":5211,"NA":5213},{"trials":5195,"activeCount":101},[5196],{"nctId":5197,"briefTitle":5198,"status":160,"phases":5199,"primaryCompletion":5200,"completion":5200,"start":5201,"enrollment":1435,"conditions":5202,"interventions":5204},"NCT03379649","Platelet Rich Plasma for Patients With Recurrent Implantation Failure",[88],"2023-12-20","2019-01-16",[5203],"Infertility",[5192],{"trials":5206,"activeCount":101},[],{"trials":5208,"activeCount":101},[],{"trials":5210,"activeCount":101},[],{"trials":5212,"activeCount":101},[],{"trials":5214,"activeCount":115,"soonestReadout":205},[5215],{"nctId":5216,"briefTitle":5217,"status":107,"phases":5218,"primaryCompletion":205,"completion":205,"start":5219,"enrollment":247,"conditions":5220,"interventions":5224},"NCT05479474","Platelet Rich Plasma Testis Treatment for Infertile Men",[93],"2023-01-18",[5221,5222,5223],"Male Infertility","Nonobstructive Azoospermia","Azoospermia",[5192],{"intervention":53,"totalTrials":115,"cells":5226},{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5233,"PHASE4":5235,"NA":5237},{"trials":5228,"activeCount":101},[],{"trials":5230,"activeCount":101},[],{"trials":5232,"activeCount":101},[],{"trials":5234,"activeCount":101},[],{"trials":5236,"activeCount":101},[],{"trials":5238,"activeCount":115,"soonestReadout":52},[5239],{"nctId":50,"briefTitle":51,"status":145,"phases":5240,"primaryCompletion":52,"completion":52,"start":5241,"enrollment":232,"conditions":5242,"interventions":5245},[],"2021-11-15",[5243,5244],"Blast or Combat Exposure","Head Injury Trauma",[53],{"intervention":5247,"totalTrials":115,"cells":5248},"iSWAB-DNA",{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5255,"PHASE4":5257,"NA":5259},{"trials":5250,"activeCount":101},[],{"trials":5252,"activeCount":101},[],{"trials":5254,"activeCount":101},[],{"trials":5256,"activeCount":101},[],{"trials":5258,"activeCount":101},[],{"trials":5260,"activeCount":115,"soonestReadout":5265},[5261],{"nctId":5262,"briefTitle":5263,"status":107,"phases":5264,"primaryCompletion":5265,"completion":5265,"start":5266,"enrollment":5267,"conditions":5268,"interventions":5273},"NCT05701111","Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress",[93],"2027-05","2024-02-23",80800,[2074,5269,5270,5271,5272],"Complex Posttraumatic Stress Disorder","Stress","Burn Out","Mental Health Issue",[5247],{"intervention":5275,"totalTrials":115,"cells":5276},"Flu shot",{"EARLY_PHASE1":5277,"PHASE1":5279,"PHASE2":5281,"PHASE3":5283,"PHASE4":5285,"NA":5287},{"trials":5278,"activeCount":101},[],{"trials":5280,"activeCount":101},[],{"trials":5282,"activeCount":101},[],{"trials":5284,"activeCount":101},[],{"trials":5286,"activeCount":101},[],{"trials":5288,"activeCount":115,"soonestReadout":5293},[5289],{"nctId":5290,"briefTitle":5291,"status":107,"phases":5292,"primaryCompletion":5293,"completion":5293,"start":5294,"enrollment":5295,"conditions":5296,"interventions":5300},"NCT04579588","Understanding Immunity to the Flu Vaccine in COVID-19 Patients",[],"2028-04","2020-10-29",230,[5297,5298,5299],"Corona Virus Infection","Flu Vaccine","Immunity",[5275],{"intervention":43,"totalTrials":115,"cells":5302},{"EARLY_PHASE1":5303,"PHASE1":5305,"PHASE2":5307,"PHASE3":5309,"PHASE4":5311,"NA":5313},{"trials":5304,"activeCount":101},[],{"trials":5306,"activeCount":101},[],{"trials":5308,"activeCount":101},[],{"trials":5310,"activeCount":101},[],{"trials":5312,"activeCount":101},[],{"trials":5314,"activeCount":115,"soonestReadout":42},[5315],{"nctId":40,"briefTitle":41,"status":145,"phases":5316,"primaryCompletion":42,"completion":5317,"start":5318,"enrollment":1732,"conditions":5319,"interventions":5325},[93],"2026-05-17","2015-01-13",[5320,5321,5322,5323,5324],"Prostate Adenocarcinoma","Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer",[43,5326,5327,5328,5329],"Leuprolide Acetate","Goserelin Acetate","Triptorelin Pamoate","Degarelix",{"intervention":5326,"totalTrials":115,"cells":5331},{"EARLY_PHASE1":5332,"PHASE1":5334,"PHASE2":5336,"PHASE3":5338,"PHASE4":5340,"NA":5342},{"trials":5333,"activeCount":101},[],{"trials":5335,"activeCount":101},[],{"trials":5337,"activeCount":101},[],{"trials":5339,"activeCount":101},[],{"trials":5341,"activeCount":101},[],{"trials":5343,"activeCount":115,"soonestReadout":42},[5344],{"nctId":40,"briefTitle":41,"status":145,"phases":5345,"primaryCompletion":42,"completion":5317,"start":5318,"enrollment":1732,"conditions":5346,"interventions":5347},[93],[5320,5321,5322,5323,5324],[43,5326,5327,5328,5329],{"intervention":5327,"totalTrials":115,"cells":5349},{"EARLY_PHASE1":5350,"PHASE1":5352,"PHASE2":5354,"PHASE3":5356,"PHASE4":5358,"NA":5360},{"trials":5351,"activeCount":101},[],{"trials":5353,"activeCount":101},[],{"trials":5355,"activeCount":101},[],{"trials":5357,"activeCount":101},[],{"trials":5359,"activeCount":101},[],{"trials":5361,"activeCount":115,"soonestReadout":42},[5362],{"nctId":40,"briefTitle":41,"status":145,"phases":5363,"primaryCompletion":42,"completion":5317,"start":5318,"enrollment":1732,"conditions":5364,"interventions":5365},[93],[5320,5321,5322,5323,5324],[43,5326,5327,5328,5329],{"intervention":5328,"totalTrials":115,"cells":5367},{"EARLY_PHASE1":5368,"PHASE1":5370,"PHASE2":5372,"PHASE3":5374,"PHASE4":5376,"NA":5378},{"trials":5369,"activeCount":101},[],{"trials":5371,"activeCount":101},[],{"trials":5373,"activeCount":101},[],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[],{"trials":5379,"activeCount":115,"soonestReadout":42},[5380],{"nctId":40,"briefTitle":41,"status":145,"phases":5381,"primaryCompletion":42,"completion":5317,"start":5318,"enrollment":1732,"conditions":5382,"interventions":5383},[93],[5320,5321,5322,5323,5324],[43,5326,5327,5328,5329],{"intervention":5329,"totalTrials":115,"cells":5385},{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[],{"trials":5395,"activeCount":101},[],{"trials":5397,"activeCount":115,"soonestReadout":42},[5398],{"nctId":40,"briefTitle":41,"status":145,"phases":5399,"primaryCompletion":42,"completion":5317,"start":5318,"enrollment":1732,"conditions":5400,"interventions":5401},[93],[5320,5321,5322,5323,5324],[43,5326,5327,5328,5329],{"intervention":5403,"totalTrials":115,"cells":5404},"Neurocognition Interventions",{"EARLY_PHASE1":5405,"PHASE1":5407,"PHASE2":5409,"PHASE3":5411,"PHASE4":5413,"NA":5415},{"trials":5406,"activeCount":101},[],{"trials":5408,"activeCount":101},[],{"trials":5410,"activeCount":101},[],{"trials":5412,"activeCount":101},[],{"trials":5414,"activeCount":101},[],{"trials":5416,"activeCount":115,"soonestReadout":5421},[5417],{"nctId":5418,"briefTitle":5419,"status":145,"phases":5420,"primaryCompletion":5421,"completion":5421,"start":5422,"enrollment":5423,"conditions":5424,"interventions":5431},"NCT03839784","Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient",[],"2030-08-30","2020-09-01",250,[5425,5426,5427,5428,5429,5430],"Cognitive Decline","Cognitive Change","Cognitive Impairment","Postoperative Delirium","Anesthesia; Reaction","Anesthesia; Adverse Effect",[5403],{"intervention":5433,"totalTrials":115,"cells":5434},"LDN",{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5439,"PHASE3":5441,"PHASE4":5443,"NA":5445},{"trials":5436,"activeCount":101},[],{"trials":5438,"activeCount":101},[],{"trials":5440,"activeCount":101},[],{"trials":5442,"activeCount":101},[],{"trials":5444,"activeCount":101},[],{"trials":5446,"activeCount":115,"soonestReadout":244},[5447],{"nctId":5448,"briefTitle":5449,"status":107,"phases":5450,"primaryCompletion":244,"completion":244,"start":1919,"enrollment":149,"conditions":5451,"interventions":5453},"NCT02502162","Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome",[93],[5452],"Complex Regional Pain Syndrome",[5433],{"intervention":5455,"totalTrials":115,"cells":5456},"Ropivacaine 0.2%",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5467},{"trials":5458,"activeCount":101},[],{"trials":5460,"activeCount":101},[],{"trials":5462,"activeCount":101},[],{"trials":5464,"activeCount":101},[],{"trials":5466,"activeCount":101},[],{"trials":5468,"activeCount":115,"soonestReadout":177},[5469],{"nctId":5470,"briefTitle":5471,"status":242,"phases":5472,"primaryCompletion":177,"completion":177,"start":5104,"enrollment":5473,"conditions":5474,"interventions":5476},"NCT06964347","Combined Local Anesthetic Blockade and Neuromodulation vs Local Anesthetic Blockade Only for Analgesia After Below-knee Amputation: RCT",[93],62,[5475],"Amputation",[5455],{"intervention":5478,"totalTrials":115,"cells":5479},"mutation analysis",{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5486,"PHASE4":5488,"NA":5490},{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[],{"trials":5489,"activeCount":101},[],{"trials":5491,"activeCount":115,"soonestReadout":177},[5492],{"nctId":5493,"briefTitle":5494,"status":107,"phases":5495,"primaryCompletion":177,"completion":177,"start":5496,"enrollment":208,"conditions":5497,"interventions":5499},"NCT02215928","Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors",[],"2014-07-28",[5498],"Unspecified Adult Solid Tumor, Protocol Specific",[5478],{"intervention":5501,"totalTrials":759,"cells":5502},"Fluzone®",{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5517,"PHASE3":5519,"PHASE4":5521,"NA":5586},{"trials":5504,"activeCount":101},[],{"trials":5506,"activeCount":101},[5507],{"nctId":5508,"briefTitle":5509,"status":160,"phases":5510,"primaryCompletion":5511,"completion":5511,"start":5512,"enrollment":2145,"conditions":5513,"interventions":5515},"NCT03453801","The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection",[89],"2019-01-14","2014-09-30",[5514,193],"Influenza",[5501,5516],"FluMist®",{"trials":5518,"activeCount":101},[],{"trials":5520,"activeCount":101},[],{"trials":5522,"activeCount":101},[5523,5531,5538,5546,5553,5562,5571,5578],{"nctId":5524,"briefTitle":5525,"status":160,"phases":5526,"primaryCompletion":1800,"completion":5527,"start":876,"enrollment":1977,"conditions":5528,"interventions":5530},"NCT01831934","Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)",[92],"2012-03",[5529],"MELAS Syndrome",[5501],{"nctId":5532,"briefTitle":5533,"status":160,"phases":5534,"primaryCompletion":1920,"completion":1920,"start":5535,"enrollment":191,"conditions":5536,"interventions":5537},"NCT03023553","The Human Mucosal Immune Responses to Influenza Virus (SLVP026)",[92],"2012-12",[5514],[5501,5516],{"nctId":5539,"briefTitle":5540,"status":160,"phases":5541,"primaryCompletion":5542,"completion":5542,"start":220,"enrollment":5543,"conditions":5544,"interventions":5545},"NCT01987349","T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009",[92],"2010-01",72,[5514],[5501,5516],{"nctId":5547,"briefTitle":5548,"status":716,"phases":5549,"primaryCompletion":5550,"completion":5550,"start":1597,"enrollment":334,"conditions":5551,"interventions":5552},"NCT03023709","Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)",[92],"2015-12",[5514],[5501,5516],{"nctId":5554,"briefTitle":5555,"status":160,"phases":5556,"primaryCompletion":757,"completion":757,"start":3503,"enrollment":5557,"conditions":5558,"interventions":5559},"NCT02141581","Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)",[92],86,[5514],[5501,5560,5561],"Fluzone® Intradermal","2011-2012 FluMist®",{"nctId":5563,"briefTitle":5564,"status":160,"phases":5565,"primaryCompletion":5566,"completion":5566,"start":5567,"enrollment":5568,"conditions":5569,"interventions":5570},"NCT03028974","Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)",[92],"2017-11-20","2014-09-17",77,[5514],[5501,5516],{"nctId":5572,"briefTitle":5573,"status":160,"phases":5574,"primaryCompletion":231,"completion":231,"start":876,"enrollment":9,"conditions":5575,"interventions":5576},"NCT03022396","T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010",[92],[5514],[5577,5501],"High Dose Fluzone®",{"nctId":5579,"briefTitle":5580,"status":716,"phases":5581,"primaryCompletion":5582,"completion":5582,"start":5583,"enrollment":247,"conditions":5584,"interventions":5585},"NCT03028987","Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)",[92],"2015-11-18","2014-11-19",[5514],[5501,5516],{"trials":5587,"activeCount":101},[],{"intervention":5516,"totalTrials":97,"cells":5589},{"EARLY_PHASE1":5590,"PHASE1":5592,"PHASE2":5598,"PHASE3":5600,"PHASE4":5602,"NA":5631},{"trials":5591,"activeCount":101},[],{"trials":5593,"activeCount":101},[5594],{"nctId":5508,"briefTitle":5509,"status":160,"phases":5595,"primaryCompletion":5511,"completion":5511,"start":5512,"enrollment":2145,"conditions":5596,"interventions":5597},[89],[5514,193],[5501,5516],{"trials":5599,"activeCount":101},[],{"trials":5601,"activeCount":101},[],{"trials":5603,"activeCount":101},[5604,5611,5615,5619,5623,5627],{"nctId":5605,"briefTitle":5606,"status":160,"phases":5607,"primaryCompletion":5608,"completion":5608,"start":1564,"enrollment":836,"conditions":5609,"interventions":5610},"NCT03023683","Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)",[92],"2012-11",[5514],[5516],{"nctId":5532,"briefTitle":5533,"status":160,"phases":5612,"primaryCompletion":1920,"completion":1920,"start":5535,"enrollment":191,"conditions":5613,"interventions":5614},[92],[5514],[5501,5516],{"nctId":5539,"briefTitle":5540,"status":160,"phases":5616,"primaryCompletion":5542,"completion":5542,"start":220,"enrollment":5543,"conditions":5617,"interventions":5618},[92],[5514],[5501,5516],{"nctId":5547,"briefTitle":5548,"status":716,"phases":5620,"primaryCompletion":5550,"completion":5550,"start":1597,"enrollment":334,"conditions":5621,"interventions":5622},[92],[5514],[5501,5516],{"nctId":5563,"briefTitle":5564,"status":160,"phases":5624,"primaryCompletion":5566,"completion":5566,"start":5567,"enrollment":5568,"conditions":5625,"interventions":5626},[92],[5514],[5501,5516],{"nctId":5579,"briefTitle":5580,"status":716,"phases":5628,"primaryCompletion":5582,"completion":5582,"start":5583,"enrollment":247,"conditions":5629,"interventions":5630},[92],[5514],[5501,5516],{"trials":5632,"activeCount":101},[],{"intervention":5634,"totalTrials":334,"cells":5635},"Anastrozole",{"EARLY_PHASE1":5636,"PHASE1":5638,"PHASE2":5640,"PHASE3":5661,"PHASE4":5663,"NA":5676},{"trials":5637,"activeCount":101},[],{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":101},[5642,5652],{"nctId":5643,"briefTitle":5644,"status":160,"phases":5645,"primaryCompletion":5646,"completion":5647,"start":5648,"enrollment":222,"conditions":5649,"interventions":5650},"NCT00186121","Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women",[90],"2013-05","2013-06","2000-10",[15],[5634,5651],"Goserelin",{"nctId":5653,"briefTitle":5654,"status":716,"phases":5655,"primaryCompletion":5656,"completion":5656,"start":5657,"enrollment":115,"conditions":5658,"interventions":5659},"NCT00481845","Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer",[90],"2009-12","2008-01",[15],[5660,5634],"Vandetanib",{"trials":5662,"activeCount":101},[],{"trials":5664,"activeCount":101},[5665],{"nctId":5666,"briefTitle":5667,"status":160,"phases":5668,"primaryCompletion":5669,"completion":5669,"start":5670,"enrollment":5671,"conditions":5672,"interventions":5674},"NCT02137538","Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole",[92],"2018-06-05","2009-11-18",79,[5673],"Short Stature",[5675,5634],"Letrozole",{"trials":5677,"activeCount":101},[],{"intervention":5679,"totalTrials":152,"cells":5680},"Sodium Oxybate",{"EARLY_PHASE1":5681,"PHASE1":5683,"PHASE2":5685,"PHASE3":5697,"PHASE4":5699,"NA":5711},{"trials":5682,"activeCount":101},[],{"trials":5684,"activeCount":101},[],{"trials":5686,"activeCount":101},[5687],{"nctId":5688,"briefTitle":5689,"status":160,"phases":5690,"primaryCompletion":5656,"completion":5656,"start":5691,"enrollment":1755,"conditions":5692,"interventions":5694},"NCT00383643","Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.",[90],"2006-05",[5693],"Sleep Initiation and Maintenance Disorders",[5695,5696],"zolpidem tartrate","sodium oxybate",{"trials":5698,"activeCount":101},[],{"trials":5700,"activeCount":101},[5701],{"nctId":5702,"briefTitle":5703,"status":160,"phases":5704,"primaryCompletion":5705,"completion":5705,"start":5706,"enrollment":897,"conditions":5707,"interventions":5710},"NCT04006925","Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate",[92],"2022-02-01","2019-09-10",[5708,5709],"REM Sleep Behavior Disorder","Parkinson Disease",[5679],{"trials":5712,"activeCount":101},[],{"intervention":5714,"totalTrials":152,"cells":5715},"Bupivacaine",{"EARLY_PHASE1":5716,"PHASE1":5718,"PHASE2":5720,"PHASE3":5722,"PHASE4":5737,"NA":5747},{"trials":5717,"activeCount":101},[],{"trials":5719,"activeCount":101},[],{"trials":5721,"activeCount":101},[],{"trials":5723,"activeCount":101},[5724],{"nctId":5725,"briefTitle":5726,"status":160,"phases":5727,"primaryCompletion":5728,"completion":5729,"start":813,"enrollment":149,"conditions":5730,"interventions":5732},"NCT02601027","Transversus Abdominis Plane Block in Microsurgical Breast Recon w\u002FAbdominal Free Flap in Breast CA",[91],"2019-09-07","2021-06",[5731],"Breast - Female",[5714,5733,5734,5735,5736],"Acetominophen","Hydromorphone","Oxycodone","Ondansetron",{"trials":5738,"activeCount":101},[5739],{"nctId":5740,"briefTitle":5741,"status":716,"phases":5742,"primaryCompletion":5743,"completion":5743,"start":1777,"enrollment":31,"conditions":5744,"interventions":5745},"NCT02573597","PIEB vs CEI for Labor Analgesia: An MLAC Study",[92],"2018-05-22",[5177],[5714,5746],"Sufentanil",{"trials":5748,"activeCount":101},[],{"intervention":5750,"totalTrials":152,"cells":5751},"sugar pill",{"EARLY_PHASE1":5752,"PHASE1":5754,"PHASE2":5756,"PHASE3":5766,"PHASE4":5768,"NA":5774},{"trials":5753,"activeCount":101},[],{"trials":5755,"activeCount":101},[],{"trials":5757,"activeCount":101},[5758],{"nctId":5759,"briefTitle":5760,"status":160,"phases":5761,"primaryCompletion":834,"completion":834,"start":220,"enrollment":165,"conditions":5762,"interventions":5764},"NCT01120626","Randomized Controlled Study of Donepezil in Fragile X Syndrome",[90],[5763],"Fragile X Syndrome",[5765,5750],"donepezil",{"trials":5767,"activeCount":101},[],{"trials":5769,"activeCount":101},[5770],{"nctId":854,"briefTitle":855,"status":160,"phases":5771,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":5772,"interventions":5773},[92],[167,36],[404,863],{"trials":5775,"activeCount":101},[],{"intervention":5777,"totalTrials":152,"cells":5778},"TIV",{"EARLY_PHASE1":5779,"PHASE1":5781,"PHASE2":5783,"PHASE3":5785,"PHASE4":5787,"NA":5805},{"trials":5780,"activeCount":101},[],{"trials":5782,"activeCount":101},[],{"trials":5784,"activeCount":101},[],{"trials":5786,"activeCount":101},[],{"trials":5788,"activeCount":101},[5789,5797],{"nctId":5790,"briefTitle":5791,"status":160,"phases":5792,"primaryCompletion":1800,"completion":1800,"start":5793,"enrollment":3933,"conditions":5794,"interventions":5795},"NCT03022422","T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011",[92],"2011-09",[5514],[5777,5796],"High-Dose TIV",{"nctId":5798,"briefTitle":5799,"status":160,"phases":5800,"primaryCompletion":5801,"completion":5801,"start":1564,"enrollment":1977,"conditions":5802,"interventions":5803},"NCT03022435","T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012",[92],"2013-01",[5514],[5777,5796,5804],"LAIV",{"trials":5806,"activeCount":101},[],{"intervention":5796,"totalTrials":152,"cells":5808},{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5817,"NA":5827},{"trials":5810,"activeCount":101},[],{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[],{"trials":5818,"activeCount":101},[5819,5823],{"nctId":5790,"briefTitle":5791,"status":160,"phases":5820,"primaryCompletion":1800,"completion":1800,"start":5793,"enrollment":3933,"conditions":5821,"interventions":5822},[92],[5514],[5777,5796],{"nctId":5798,"briefTitle":5799,"status":160,"phases":5824,"primaryCompletion":5801,"completion":5801,"start":1564,"enrollment":1977,"conditions":5825,"interventions":5826},[92],[5514],[5777,5796,5804],{"trials":5828,"activeCount":101},[],{"intervention":5830,"totalTrials":152,"cells":5831},"FluMist",{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5836,"PHASE3":5838,"PHASE4":5840,"NA":5858},{"trials":5833,"activeCount":101},[],{"trials":5835,"activeCount":101},[],{"trials":5837,"activeCount":101},[],{"trials":5839,"activeCount":101},[],{"trials":5841,"activeCount":101},[5842,5850],{"nctId":5843,"briefTitle":5844,"status":132,"phases":5845,"primaryCompletion":5846,"completion":5846,"start":5847,"enrollment":101,"conditions":5848,"interventions":5849},"NCT03884296","Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood",[92],"2023-11-17","2019-04-15",[5514],[5830],{"nctId":5851,"briefTitle":5852,"status":160,"phases":5853,"primaryCompletion":1800,"completion":1800,"start":876,"enrollment":5854,"conditions":5855,"interventions":5856},"NCT03020498","B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)",[92],91,[5514],[5857,5830],"Fluzone",{"trials":5859,"activeCount":101},[],{"intervention":5861,"totalTrials":152,"cells":5862},"Quadrivalent inactivated influenza vaccine",{"EARLY_PHASE1":5863,"PHASE1":5865,"PHASE2":5875,"PHASE3":5877,"PHASE4":5879,"NA":5888},{"trials":5864,"activeCount":101},[],{"trials":5866,"activeCount":101},[5867],{"nctId":5868,"briefTitle":5869,"status":716,"phases":5870,"primaryCompletion":5871,"completion":5871,"start":5872,"enrollment":152,"conditions":5873,"interventions":5874},"NCT03888989","Response to Influenza Vaccine During Pregnancy",[89],"2023-12-31","2019-09-30",[5514],[5861],{"trials":5876,"activeCount":101},[],{"trials":5878,"activeCount":101},[],{"trials":5880,"activeCount":101},[5881],{"nctId":5882,"briefTitle":5883,"status":132,"phases":5884,"primaryCompletion":5846,"completion":5846,"start":5885,"enrollment":101,"conditions":5886,"interventions":5887},"NCT03898973","Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood",[92],"2019-04-11",[5514],[5861],{"trials":5889,"activeCount":101},[],{"intervention":5857,"totalTrials":152,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5898,"PHASE4":5900,"NA":5912},{"trials":5893,"activeCount":101},[],{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[],{"trials":5899,"activeCount":101},[],{"trials":5901,"activeCount":101},[5902,5908],{"nctId":5903,"briefTitle":5904,"status":160,"phases":5905,"primaryCompletion":834,"completion":834,"start":1753,"enrollment":684,"conditions":5906,"interventions":5907},"NCT03020537","B-cell Immunity to Influenza (SLVP017)- Year 5, 2013",[92],[5514],[5857],{"nctId":5851,"briefTitle":5852,"status":160,"phases":5909,"primaryCompletion":1800,"completion":1800,"start":876,"enrollment":5854,"conditions":5910,"interventions":5911},[92],[5514],[5857,5830],{"trials":5913,"activeCount":101},[],{"intervention":5915,"totalTrials":152,"cells":5916},"Varenicline",{"EARLY_PHASE1":5917,"PHASE1":5919,"PHASE2":5921,"PHASE3":5930,"PHASE4":5932,"NA":5944},{"trials":5918,"activeCount":101},[],{"trials":5920,"activeCount":101},[],{"trials":5922,"activeCount":101},[5923],{"nctId":5924,"briefTitle":5925,"status":160,"phases":5926,"primaryCompletion":1499,"completion":1499,"start":3503,"enrollment":1766,"conditions":5927,"interventions":5929},"NCT01413516","Varenicline In-Patient Study",[90],[5928],"Smoking Cessation",[5915],{"trials":5931,"activeCount":101},[],{"trials":5933,"activeCount":101},[5934],{"nctId":5935,"briefTitle":5936,"status":160,"phases":5937,"primaryCompletion":875,"completion":875,"start":5938,"enrollment":5939,"conditions":5940,"interventions":5941},"NCT01330043","Extended Treatment for Smoking Cessation",[92],"2010-03",223,[5928],[5942,5943,5915],"Bupropion","Nicotine patch",{"trials":5945,"activeCount":101},[],{"intervention":5947,"totalTrials":115,"cells":5948},"Omeprazole",{"EARLY_PHASE1":5949,"PHASE1":5951,"PHASE2":5953,"PHASE3":5955,"PHASE4":5957,"NA":5968},{"trials":5950,"activeCount":101},[],{"trials":5952,"activeCount":101},[],{"trials":5954,"activeCount":101},[],{"trials":5956,"activeCount":101},[],{"trials":5958,"activeCount":101},[5959],{"nctId":5960,"briefTitle":5961,"status":160,"phases":5962,"primaryCompletion":5963,"completion":5963,"start":5964,"enrollment":25,"conditions":5965,"interventions":5967},"NCT03327051","Gastric Acid Suppression and Probiotic Colonization",[92],"2018-12-30","2018-03-20",[5966],"Probiotics",[5947],{"trials":5969,"activeCount":101},[],{"intervention":5971,"totalTrials":115,"cells":5972},"gatifloxacin",{"EARLY_PHASE1":5973,"PHASE1":5975,"PHASE2":5977,"PHASE3":5979,"PHASE4":5981,"NA":5993},{"trials":5974,"activeCount":101},[],{"trials":5976,"activeCount":101},[],{"trials":5978,"activeCount":101},[],{"trials":5980,"activeCount":101},[],{"trials":5982,"activeCount":101},[5983],{"nctId":5984,"briefTitle":5985,"status":160,"phases":5986,"primaryCompletion":5656,"completion":5656,"start":5987,"enrollment":5988,"conditions":5989,"interventions":5992},"NCT00410891","Topical Antibiotics and Intravitreous Injections",[92],"2008-07",129,[5990,5991],"Intravitreous","Injections",[5971],{"trials":5994,"activeCount":101},[],{"intervention":5996,"totalTrials":115,"cells":5997},"Fluzone® standard IIV3",{"EARLY_PHASE1":5998,"PHASE1":6000,"PHASE2":6002,"PHASE3":6004,"PHASE4":6006,"NA":6017},{"trials":5999,"activeCount":101},[],{"trials":6001,"activeCount":101},[],{"trials":6003,"activeCount":101},[],{"trials":6005,"activeCount":101},[],{"trials":6007,"activeCount":101},[6008],{"nctId":6009,"briefTitle":6010,"status":160,"phases":6011,"primaryCompletion":6012,"completion":6012,"start":6013,"enrollment":111,"conditions":6014,"interventions":6015},"NCT03023176","T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013",[92],"2013-11","2013-09",[5514],[5996,6016],"Fluzone® standard IIV3 Pediatric Dose",{"trials":6018,"activeCount":101},[],{"intervention":6016,"totalTrials":115,"cells":6020},{"EARLY_PHASE1":6021,"PHASE1":6023,"PHASE2":6025,"PHASE3":6027,"PHASE4":6029,"NA":6035},{"trials":6022,"activeCount":101},[],{"trials":6024,"activeCount":101},[],{"trials":6026,"activeCount":101},[],{"trials":6028,"activeCount":101},[],{"trials":6030,"activeCount":101},[6031],{"nctId":6009,"briefTitle":6010,"status":160,"phases":6032,"primaryCompletion":6012,"completion":6012,"start":6013,"enrollment":111,"conditions":6033,"interventions":6034},[92],[5514],[5996,6016],{"trials":6036,"activeCount":101},[],{"intervention":6038,"totalTrials":115,"cells":6039},"Eslicarbazepine",{"EARLY_PHASE1":6040,"PHASE1":6042,"PHASE2":6044,"PHASE3":6046,"PHASE4":6048,"NA":6059},{"trials":6041,"activeCount":101},[],{"trials":6043,"activeCount":101},[],{"trials":6045,"activeCount":101},[],{"trials":6047,"activeCount":101},[],{"trials":6049,"activeCount":101},[6050],{"nctId":6051,"briefTitle":6052,"status":160,"phases":6053,"primaryCompletion":6054,"completion":6054,"start":6055,"enrollment":1290,"conditions":6056,"interventions":6057},"NCT02912364","Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults",[92],"2018-04-20","2016-07",[113],[6038,6058],"Carbamazepine",{"trials":6060,"activeCount":101},[],{"intervention":6058,"totalTrials":115,"cells":6062},{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6067,"PHASE3":6069,"PHASE4":6071,"NA":6077},{"trials":6064,"activeCount":101},[],{"trials":6066,"activeCount":101},[],{"trials":6068,"activeCount":101},[],{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[6073],{"nctId":6051,"briefTitle":6052,"status":160,"phases":6074,"primaryCompletion":6054,"completion":6054,"start":6055,"enrollment":1290,"conditions":6075,"interventions":6076},[92],[113],[6038,6058],{"trials":6078,"activeCount":101},[],{"intervention":6080,"totalTrials":115,"cells":6081},"Olanzapine\u002FZyprexa",{"EARLY_PHASE1":6082,"PHASE1":6084,"PHASE2":6086,"PHASE3":6088,"PHASE4":6090,"NA":6099},{"trials":6083,"activeCount":101},[],{"trials":6085,"activeCount":101},[],{"trials":6087,"activeCount":101},[],{"trials":6089,"activeCount":101},[],{"trials":6091,"activeCount":101},[6092],{"nctId":6093,"briefTitle":6094,"status":160,"phases":6095,"primaryCompletion":6096,"completion":6096,"start":1861,"enrollment":1435,"conditions":6097,"interventions":6098},"NCT00186017","Short Term Rescue Study of Olanzapine",[92],"2010-06",[1601],[6080],{"trials":6100,"activeCount":101},[],{"intervention":3747,"totalTrials":115,"cells":6102},{"EARLY_PHASE1":6103,"PHASE1":6105,"PHASE2":6107,"PHASE3":6109,"PHASE4":6111,"NA":6117},{"trials":6104,"activeCount":101},[],{"trials":6106,"activeCount":101},[],{"trials":6108,"activeCount":101},[],{"trials":6110,"activeCount":101},[],{"trials":6112,"activeCount":101},[6113],{"nctId":3740,"briefTitle":3741,"status":160,"phases":6114,"primaryCompletion":1499,"completion":1499,"start":698,"enrollment":34,"conditions":6115,"interventions":6116},[92],[3744,399,3745],[3747,1528],{"trials":6118,"activeCount":101},[],{"intervention":6120,"totalTrials":115,"cells":6121},"12 mL paracervical block",{"EARLY_PHASE1":6122,"PHASE1":6124,"PHASE2":6126,"PHASE3":6128,"PHASE4":6130,"NA":6141},{"trials":6123,"activeCount":101},[],{"trials":6125,"activeCount":101},[],{"trials":6127,"activeCount":101},[],{"trials":6129,"activeCount":101},[],{"trials":6131,"activeCount":101},[6132],{"nctId":6133,"briefTitle":6134,"status":160,"phases":6135,"primaryCompletion":940,"completion":940,"start":6136,"enrollment":6137,"conditions":6138,"interventions":6139},"NCT03356145","12 Versus 20 mL PCB for D&E Cervical Prep",[92],"2017-01-01",96,[24],[6120,6140],"20 mL paracervical block",{"trials":6142,"activeCount":101},[],{"intervention":6140,"totalTrials":115,"cells":6144},{"EARLY_PHASE1":6145,"PHASE1":6147,"PHASE2":6149,"PHASE3":6151,"PHASE4":6153,"NA":6159},{"trials":6146,"activeCount":101},[],{"trials":6148,"activeCount":101},[],{"trials":6150,"activeCount":101},[],{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[6155],{"nctId":6133,"briefTitle":6134,"status":160,"phases":6156,"primaryCompletion":940,"completion":940,"start":6136,"enrollment":6137,"conditions":6157,"interventions":6158},[92],[24],[6120,6140],{"trials":6160,"activeCount":101},[],{"intervention":6162,"totalTrials":115,"cells":6163},"Fibrinogen Concentrate",{"EARLY_PHASE1":6164,"PHASE1":6166,"PHASE2":6168,"PHASE3":6170,"PHASE4":6172,"NA":6182},{"trials":6165,"activeCount":101},[],{"trials":6167,"activeCount":101},[],{"trials":6169,"activeCount":101},[],{"trials":6171,"activeCount":101},[],{"trials":6173,"activeCount":101},[6174],{"nctId":6175,"briefTitle":6176,"status":160,"phases":6177,"primaryCompletion":6178,"completion":6178,"start":2102,"enrollment":1124,"conditions":6179,"interventions":6180},"NCT03014700","Fibrinogen Concentrate vs Cryoprecipitate",[92],"2018-04-25",[2117],[6162,6181],"Cryoprecipitate",{"trials":6183,"activeCount":101},[],{"intervention":6181,"totalTrials":115,"cells":6185},{"EARLY_PHASE1":6186,"PHASE1":6188,"PHASE2":6190,"PHASE3":6192,"PHASE4":6194,"NA":6200},{"trials":6187,"activeCount":101},[],{"trials":6189,"activeCount":101},[],{"trials":6191,"activeCount":101},[],{"trials":6193,"activeCount":101},[],{"trials":6195,"activeCount":101},[6196],{"nctId":6175,"briefTitle":6176,"status":160,"phases":6197,"primaryCompletion":6178,"completion":6178,"start":2102,"enrollment":1124,"conditions":6198,"interventions":6199},[92],[2117],[6162,6181],{"trials":6201,"activeCount":101},[],{"intervention":6203,"totalTrials":115,"cells":6204},"Retinol",{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6209,"PHASE3":6211,"PHASE4":6213,"NA":6224},{"trials":6206,"activeCount":101},[],{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[],{"trials":6214,"activeCount":101},[6215],{"nctId":6216,"briefTitle":6217,"status":160,"phases":6218,"primaryCompletion":6219,"completion":6219,"start":813,"enrollment":6220,"conditions":6221,"interventions":6223},"NCT02906566","Retinol on Human Skin Aging in East Asian Descent",[92],"2018-03-09",110,[6222],"Intrinsic Aging of Skin",[6203],{"trials":6225,"activeCount":101},[],{"intervention":6227,"totalTrials":115,"cells":6228},"8 weeks SOF\u002FLED",{"EARLY_PHASE1":6229,"PHASE1":6231,"PHASE2":6233,"PHASE3":6235,"PHASE4":6237,"NA":6248},{"trials":6230,"activeCount":101},[],{"trials":6232,"activeCount":101},[],{"trials":6234,"activeCount":101},[],{"trials":6236,"activeCount":101},[],{"trials":6238,"activeCount":101},[6239],{"nctId":6240,"briefTitle":6241,"status":160,"phases":6242,"primaryCompletion":6243,"completion":6243,"start":1919,"enrollment":1124,"conditions":6244,"interventions":6246},"NCT02480166","Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6",[92],"2016-10",[6245],"PT-NANBH",[6227,6247],"12 weeks SOF\u002FLED",{"trials":6249,"activeCount":101},[],{"intervention":6247,"totalTrials":115,"cells":6251},{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6256,"PHASE3":6258,"PHASE4":6260,"NA":6266},{"trials":6253,"activeCount":101},[],{"trials":6255,"activeCount":101},[],{"trials":6257,"activeCount":101},[],{"trials":6259,"activeCount":101},[],{"trials":6261,"activeCount":101},[6262],{"nctId":6240,"briefTitle":6241,"status":160,"phases":6263,"primaryCompletion":6243,"completion":6243,"start":1919,"enrollment":1124,"conditions":6264,"interventions":6265},[92],[6245],[6227,6247],{"trials":6267,"activeCount":101},[],{"intervention":6269,"totalTrials":115,"cells":6270},"Valproic Acid",{"EARLY_PHASE1":6271,"PHASE1":6273,"PHASE2":6275,"PHASE3":6277,"PHASE4":6279,"NA":6292},{"trials":6272,"activeCount":101},[],{"trials":6274,"activeCount":101},[],{"trials":6276,"activeCount":101},[],{"trials":6278,"activeCount":101},[],{"trials":6280,"activeCount":101},[6281],{"nctId":6282,"briefTitle":6283,"status":716,"phases":6284,"primaryCompletion":6285,"completion":6285,"start":6286,"enrollment":334,"conditions":6287,"interventions":6290},"NCT02343575","Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU",[92],"2018-01","2015-01",[6288,6289],"Hyperactive Delirium","Mixed Delirium",[6269,6291],"Haloperidol",{"trials":6293,"activeCount":101},[],{"intervention":6291,"totalTrials":115,"cells":6295},{"EARLY_PHASE1":6296,"PHASE1":6298,"PHASE2":6300,"PHASE3":6302,"PHASE4":6304,"NA":6310},{"trials":6297,"activeCount":101},[],{"trials":6299,"activeCount":101},[],{"trials":6301,"activeCount":101},[],{"trials":6303,"activeCount":101},[],{"trials":6305,"activeCount":101},[6306],{"nctId":6282,"briefTitle":6283,"status":716,"phases":6307,"primaryCompletion":6285,"completion":6285,"start":6286,"enrollment":334,"conditions":6308,"interventions":6309},[92],[6288,6289],[6269,6291],{"trials":6311,"activeCount":101},[],{"intervention":6313,"totalTrials":115,"cells":6314},"H.P. Acthar Gel",{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6321,"PHASE4":6323,"NA":6332},{"trials":6316,"activeCount":101},[],{"trials":6318,"activeCount":101},[],{"trials":6320,"activeCount":101},[],{"trials":6322,"activeCount":101},[],{"trials":6324,"activeCount":101},[6325],{"nctId":6326,"briefTitle":6327,"status":160,"phases":6328,"primaryCompletion":857,"completion":857,"start":220,"enrollment":2218,"conditions":6329,"interventions":6331},"NCT01155141","Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH",[92],[6330],"Kidney Diseases",[6313],{"trials":6333,"activeCount":101},[],{"intervention":6335,"totalTrials":115,"cells":6336},"Epsilonaminocaproic acid",{"EARLY_PHASE1":6337,"PHASE1":6339,"PHASE2":6341,"PHASE3":6343,"PHASE4":6345,"NA":6355},{"trials":6338,"activeCount":101},[],{"trials":6340,"activeCount":101},[],{"trials":6342,"activeCount":101},[],{"trials":6344,"activeCount":101},[],{"trials":6346,"activeCount":101},[6347],{"nctId":6348,"briefTitle":6349,"status":160,"phases":6350,"primaryCompletion":1999,"completion":1999,"start":6351,"enrollment":179,"conditions":6352,"interventions":6354},"NCT01981863","Fibrinolysis Before Cardiopulmonary Bypass?",[92],"2013-07",[6353],"Pathologic Fibrinolysis",[6335],{"trials":6356,"activeCount":101},[],{"intervention":6358,"totalTrials":115,"cells":6359},"Zymar",{"EARLY_PHASE1":6360,"PHASE1":6362,"PHASE2":6364,"PHASE3":6366,"PHASE4":6368,"NA":6377},{"trials":6361,"activeCount":101},[],{"trials":6363,"activeCount":101},[],{"trials":6365,"activeCount":101},[],{"trials":6367,"activeCount":101},[],{"trials":6369,"activeCount":101},[6370],{"nctId":6371,"briefTitle":6372,"status":160,"phases":6373,"primaryCompletion":697,"completion":697,"start":1423,"enrollment":1124,"conditions":6374,"interventions":6376},"NCT00350363","One Hour Preoperative Gatifloxacin",[92],[6375],"Ophthalmic Surgery",[6358],{"trials":6378,"activeCount":101},[],{"intervention":6380,"totalTrials":115,"cells":6381},"Quetiapine\u002FSeroquel",{"EARLY_PHASE1":6382,"PHASE1":6384,"PHASE2":6386,"PHASE3":6388,"PHASE4":6390,"NA":6400},{"trials":6383,"activeCount":101},[],{"trials":6385,"activeCount":101},[],{"trials":6387,"activeCount":101},[],{"trials":6389,"activeCount":101},[],{"trials":6391,"activeCount":101},[6392],{"nctId":6393,"briefTitle":6394,"status":160,"phases":6395,"primaryCompletion":3503,"completion":3503,"start":6396,"enrollment":19,"conditions":6397,"interventions":6399},"NCT00186043","Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II",[92],"2008-08",[6398],"Bipolar II Disorder",[6380],{"trials":6401,"activeCount":101},[],{"intervention":6403,"totalTrials":115,"cells":6404},"Loop Diuretics vs. loop + thiazide diuretics",{"EARLY_PHASE1":6405,"PHASE1":6407,"PHASE2":6409,"PHASE3":6411,"PHASE4":6413,"NA":6424},{"trials":6406,"activeCount":101},[],{"trials":6408,"activeCount":101},[],{"trials":6410,"activeCount":101},[],{"trials":6412,"activeCount":101},[],{"trials":6414,"activeCount":101},[6415],{"nctId":6416,"briefTitle":6417,"status":132,"phases":6418,"primaryCompletion":6419,"completion":6420,"start":6421,"enrollment":101,"conditions":6422,"interventions":6423},"NCT03999216","Comparing Diuretic Strategies in Hospitalized Heart Failure",[92],"2024-01","2024-06","2023-07",[2115],[6403],{"trials":6425,"activeCount":101},[],{"intervention":6427,"totalTrials":115,"cells":6428},"Bupivacaine Block",{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6435,"PHASE4":6437,"NA":6445},{"trials":6430,"activeCount":101},[],{"trials":6432,"activeCount":101},[],{"trials":6434,"activeCount":101},[],{"trials":6436,"activeCount":101},[],{"trials":6438,"activeCount":101},[6439],{"nctId":6440,"briefTitle":6441,"status":160,"phases":6442,"primaryCompletion":5938,"completion":3502,"start":1801,"enrollment":3431,"conditions":6443,"interventions":6444},"NCT00927888","Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery",[92],[354],[6427],{"trials":6446,"activeCount":101},[],{"intervention":6448,"totalTrials":115,"cells":6449},"treprostinil inhalations",{"EARLY_PHASE1":6450,"PHASE1":6452,"PHASE2":6454,"PHASE3":6456,"PHASE4":6458,"NA":6468},{"trials":6451,"activeCount":101},[],{"trials":6453,"activeCount":101},[],{"trials":6455,"activeCount":101},[],{"trials":6457,"activeCount":101},[],{"trials":6459,"activeCount":101},[6460],{"nctId":6461,"briefTitle":6462,"status":160,"phases":6463,"primaryCompletion":6464,"completion":6464,"start":835,"enrollment":2393,"conditions":6465,"interventions":6466},"NCT01305252","A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).",[92],"2014-09",[846],[6448,6467],"tadalafil",{"trials":6469,"activeCount":101},[],{"intervention":6467,"totalTrials":115,"cells":6471},{"EARLY_PHASE1":6472,"PHASE1":6474,"PHASE2":6476,"PHASE3":6478,"PHASE4":6480,"NA":6486},{"trials":6473,"activeCount":101},[],{"trials":6475,"activeCount":101},[],{"trials":6477,"activeCount":101},[],{"trials":6479,"activeCount":101},[],{"trials":6481,"activeCount":101},[6482],{"nctId":6461,"briefTitle":6462,"status":160,"phases":6483,"primaryCompletion":6464,"completion":6464,"start":835,"enrollment":2393,"conditions":6484,"interventions":6485},[92],[846],[6448,6467],{"trials":6487,"activeCount":101},[],{"intervention":5804,"totalTrials":115,"cells":6489},{"EARLY_PHASE1":6490,"PHASE1":6492,"PHASE2":6494,"PHASE3":6496,"PHASE4":6498,"NA":6504},{"trials":6491,"activeCount":101},[],{"trials":6493,"activeCount":101},[],{"trials":6495,"activeCount":101},[],{"trials":6497,"activeCount":101},[],{"trials":6499,"activeCount":101},[6500],{"nctId":5798,"briefTitle":5799,"status":160,"phases":6501,"primaryCompletion":5801,"completion":5801,"start":1564,"enrollment":1977,"conditions":6502,"interventions":6503},[92],[5514],[5777,5796,5804],{"trials":6505,"activeCount":101},[],{"intervention":6507,"totalTrials":115,"cells":6508},"Plant Sterol",{"EARLY_PHASE1":6509,"PHASE1":6511,"PHASE2":6513,"PHASE3":6515,"PHASE4":6517,"NA":6528},{"trials":6510,"activeCount":101},[],{"trials":6512,"activeCount":101},[],{"trials":6514,"activeCount":101},[],{"trials":6516,"activeCount":101},[],{"trials":6518,"activeCount":101},[6519],{"nctId":6520,"briefTitle":6521,"status":160,"phases":6522,"primaryCompletion":6523,"completion":6523,"start":6524,"enrollment":1435,"conditions":6525,"interventions":6527},"NCT04030247","Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients",[92],"2021-03-31","2020-01-06",[6526],"Cardiovascular Risk Factor",[6507],{"trials":6529,"activeCount":101},[],{"intervention":6531,"totalTrials":115,"cells":6532},"Topiramate",{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6539,"PHASE4":6541,"NA":6551},{"trials":6534,"activeCount":101},[],{"trials":6536,"activeCount":101},[],{"trials":6538,"activeCount":101},[],{"trials":6540,"activeCount":101},[],{"trials":6542,"activeCount":101},[6543],{"nctId":6544,"briefTitle":6545,"status":160,"phases":6546,"primaryCompletion":874,"completion":874,"start":1801,"enrollment":1314,"conditions":6547,"interventions":6550},"NCT00572117","Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder",[92],[1601,6548,6549],"Alcoholism","Alcohol Dependence",[6531],{"trials":6552,"activeCount":101},[],{"intervention":5675,"totalTrials":115,"cells":6554},{"EARLY_PHASE1":6555,"PHASE1":6557,"PHASE2":6559,"PHASE3":6561,"PHASE4":6563,"NA":6569},{"trials":6556,"activeCount":101},[],{"trials":6558,"activeCount":101},[],{"trials":6560,"activeCount":101},[],{"trials":6562,"activeCount":101},[],{"trials":6564,"activeCount":101},[6565],{"nctId":5666,"briefTitle":5667,"status":160,"phases":6566,"primaryCompletion":5669,"completion":5669,"start":5670,"enrollment":5671,"conditions":6567,"interventions":6568},[92],[5673],[5675,5634],{"trials":6570,"activeCount":101},[],{"intervention":6572,"totalTrials":115,"cells":6573},"2008-2009 FluMist LAIV",{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6580,"PHASE4":6582,"NA":6590},{"trials":6575,"activeCount":101},[],{"trials":6577,"activeCount":101},[],{"trials":6579,"activeCount":101},[],{"trials":6581,"activeCount":101},[],{"trials":6583,"activeCount":101},[6584],{"nctId":6585,"briefTitle":6586,"status":716,"phases":6587,"primaryCompletion":3348,"completion":3348,"start":906,"enrollment":197,"conditions":6588,"interventions":6589},"NCT03020472","Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age",[92],[5514],[6572],{"trials":6591,"activeCount":101},[],{"intervention":6593,"totalTrials":115,"cells":6594},"Ferumoxytol-enhanced magnetic resonance imaging",{"EARLY_PHASE1":6595,"PHASE1":6597,"PHASE2":6599,"PHASE3":6601,"PHASE4":6603,"NA":6614},{"trials":6596,"activeCount":101},[],{"trials":6598,"activeCount":101},[],{"trials":6600,"activeCount":101},[],{"trials":6602,"activeCount":101},[],{"trials":6604,"activeCount":101},[6605],{"nctId":6606,"briefTitle":6607,"status":160,"phases":6608,"primaryCompletion":6609,"completion":6609,"start":6610,"enrollment":1449,"conditions":6611,"interventions":6613},"NCT02893293","Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI",[92],"2023-10-31","2015-05",[6612],"Osteonecrosis",[6593],{"trials":6615,"activeCount":101},[],{"intervention":6617,"totalTrials":115,"cells":6618},"Cefazolin 25 mg\u002Fkg body weight and Vancomycin hydrochloride",{"EARLY_PHASE1":6619,"PHASE1":6621,"PHASE2":6623,"PHASE3":6625,"PHASE4":6627,"NA":6639},{"trials":6620,"activeCount":101},[],{"trials":6622,"activeCount":101},[],{"trials":6624,"activeCount":101},[],{"trials":6626,"activeCount":101},[],{"trials":6628,"activeCount":101},[6629],{"nctId":6630,"briefTitle":6631,"status":160,"phases":6632,"primaryCompletion":757,"completion":757,"start":4051,"enrollment":6633,"conditions":6634,"interventions":6637},"NCT01619982","Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients",[92],32,[6635,6636],"Congenital Heart Diseases","Aortic Valve Disorder",[6617,6638],"Cefazolin 30 mg\u002Fkg body weight",{"trials":6640,"activeCount":101},[],{"intervention":6638,"totalTrials":115,"cells":6642},{"EARLY_PHASE1":6643,"PHASE1":6645,"PHASE2":6647,"PHASE3":6649,"PHASE4":6651,"NA":6657},{"trials":6644,"activeCount":101},[],{"trials":6646,"activeCount":101},[],{"trials":6648,"activeCount":101},[],{"trials":6650,"activeCount":101},[],{"trials":6652,"activeCount":101},[6653],{"nctId":6630,"briefTitle":6631,"status":160,"phases":6654,"primaryCompletion":757,"completion":757,"start":4051,"enrollment":6633,"conditions":6655,"interventions":6656},[92],[6635,6636],[6617,6638],{"trials":6658,"activeCount":101},[],{"intervention":6660,"totalTrials":115,"cells":6661},"Fiasp",{"EARLY_PHASE1":6662,"PHASE1":6664,"PHASE2":6666,"PHASE3":6668,"PHASE4":6670,"NA":6681},{"trials":6663,"activeCount":101},[],{"trials":6665,"activeCount":101},[],{"trials":6667,"activeCount":101},[],{"trials":6669,"activeCount":101},[],{"trials":6671,"activeCount":101},[6672],{"nctId":6673,"briefTitle":6674,"status":160,"phases":6675,"primaryCompletion":6676,"completion":6676,"start":6677,"enrollment":791,"conditions":6678,"interventions":6679},"NCT03554486","Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy",[92],"2019-03-30","2018-07-23",[4916],[6660,6680],"Novolog",{"trials":6682,"activeCount":101},[],{"intervention":6680,"totalTrials":115,"cells":6684},{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6691,"PHASE4":6693,"NA":6699},{"trials":6686,"activeCount":101},[],{"trials":6688,"activeCount":101},[],{"trials":6690,"activeCount":101},[],{"trials":6692,"activeCount":101},[],{"trials":6694,"activeCount":101},[6695],{"nctId":6673,"briefTitle":6674,"status":160,"phases":6696,"primaryCompletion":6676,"completion":6676,"start":6677,"enrollment":791,"conditions":6697,"interventions":6698},[92],[4916],[6660,6680],{"trials":6700,"activeCount":101},[],{"intervention":6702,"totalTrials":115,"cells":6703},"Depakote ER",{"EARLY_PHASE1":6704,"PHASE1":6706,"PHASE2":6708,"PHASE3":6710,"PHASE4":6712,"NA":6721},{"trials":6705,"activeCount":101},[],{"trials":6707,"activeCount":101},[],{"trials":6709,"activeCount":101},[],{"trials":6711,"activeCount":101},[],{"trials":6713,"activeCount":101},[6714],{"nctId":6715,"briefTitle":6716,"status":160,"phases":6717,"primaryCompletion":3348,"completion":3348,"start":271,"enrollment":1672,"conditions":6718,"interventions":6720},"NCT00186186","Depakote ER in Bipolar Depression",[92],[6719],"Depression, Bipolar",[6702],{"trials":6722,"activeCount":101},[],{"intervention":5746,"totalTrials":115,"cells":6724},{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6729,"PHASE3":6731,"PHASE4":6733,"NA":6739},{"trials":6726,"activeCount":101},[],{"trials":6728,"activeCount":101},[],{"trials":6730,"activeCount":101},[],{"trials":6732,"activeCount":101},[],{"trials":6734,"activeCount":101},[6735],{"nctId":5740,"briefTitle":5741,"status":716,"phases":6736,"primaryCompletion":5743,"completion":5743,"start":1777,"enrollment":31,"conditions":6737,"interventions":6738},[92],[5177],[5714,5746],{"trials":6740,"activeCount":101},[],{"intervention":6742,"totalTrials":115,"cells":6743},"Simeprevir",{"EARLY_PHASE1":6744,"PHASE1":6746,"PHASE2":6748,"PHASE3":6750,"PHASE4":6752,"NA":6761},{"trials":6745,"activeCount":101},[],{"trials":6747,"activeCount":101},[],{"trials":6749,"activeCount":101},[],{"trials":6751,"activeCount":101},[],{"trials":6753,"activeCount":101},[6754],{"nctId":6755,"briefTitle":6756,"status":132,"phases":6757,"primaryCompletion":3806,"completion":3806,"start":1597,"enrollment":101,"conditions":6758,"interventions":6759},"NCT02485080","Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1",[92],[6245],[6742,6760],"Sofosbuvir",{"trials":6762,"activeCount":101},[],{"intervention":6760,"totalTrials":115,"cells":6764},{"EARLY_PHASE1":6765,"PHASE1":6767,"PHASE2":6769,"PHASE3":6771,"PHASE4":6773,"NA":6779},{"trials":6766,"activeCount":101},[],{"trials":6768,"activeCount":101},[],{"trials":6770,"activeCount":101},[],{"trials":6772,"activeCount":101},[],{"trials":6774,"activeCount":101},[6775],{"nctId":6755,"briefTitle":6756,"status":132,"phases":6776,"primaryCompletion":3806,"completion":3806,"start":1597,"enrollment":101,"conditions":6777,"interventions":6778},[92],[6245],[6742,6760],{"trials":6780,"activeCount":101},[],{"intervention":6782,"totalTrials":115,"cells":6783},"Prostaglandin Analog",{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6790,"PHASE4":6792,"NA":6804},{"trials":6785,"activeCount":101},[],{"trials":6787,"activeCount":101},[],{"trials":6789,"activeCount":101},[],{"trials":6791,"activeCount":101},[],{"trials":6793,"activeCount":101},[6794],{"nctId":6795,"briefTitle":6796,"status":132,"phases":6797,"primaryCompletion":6798,"completion":6798,"start":858,"enrollment":101,"conditions":6799,"interventions":6802},"NCT01927406","The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.",[92],"2016-12",[6800,6801,2627],"Thyroid Eye Disease","Ocular Hypertension",[6782,6803],"Timolol",{"trials":6805,"activeCount":101},[],{"intervention":6803,"totalTrials":115,"cells":6807},{"EARLY_PHASE1":6808,"PHASE1":6810,"PHASE2":6812,"PHASE3":6814,"PHASE4":6816,"NA":6822},{"trials":6809,"activeCount":101},[],{"trials":6811,"activeCount":101},[],{"trials":6813,"activeCount":101},[],{"trials":6815,"activeCount":101},[],{"trials":6817,"activeCount":101},[6818],{"nctId":6795,"briefTitle":6796,"status":132,"phases":6819,"primaryCompletion":6798,"completion":6798,"start":858,"enrollment":101,"conditions":6820,"interventions":6821},[92],[6800,6801,2627],[6782,6803],{"trials":6823,"activeCount":101},[],{"intervention":6825,"totalTrials":115,"cells":6826},"Zostavax™",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6833,"PHASE4":6835,"NA":6844},{"trials":6828,"activeCount":101},[],{"trials":6830,"activeCount":101},[],{"trials":6832,"activeCount":101},[],{"trials":6834,"activeCount":101},[],{"trials":6836,"activeCount":101},[6837],{"nctId":6838,"briefTitle":6839,"status":160,"phases":6840,"primaryCompletion":1800,"completion":1800,"start":876,"enrollment":3106,"conditions":6841,"interventions":6843},"NCT01911065","T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020",[92],[6842],"Herpes Zoster",[6825],{"trials":6845,"activeCount":101},[],{"intervention":6847,"totalTrials":115,"cells":6848},"bupropion and smoking cessation behavioral intervention",{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6855,"PHASE4":6857,"NA":6866},{"trials":6850,"activeCount":101},[],{"trials":6852,"activeCount":101},[],{"trials":6854,"activeCount":101},[],{"trials":6856,"activeCount":101},[],{"trials":6858,"activeCount":101},[6859],{"nctId":6860,"briefTitle":6861,"status":160,"phases":6862,"primaryCompletion":1632,"completion":1632,"start":2207,"enrollment":111,"conditions":6863,"interventions":6865},"NCT00186446","Treatment of Nicotine Dependence and Acute Depression",[92],[167,6864],"Nicotine Dependence",[6847],{"trials":6867,"activeCount":101},[],{"intervention":6869,"totalTrials":115,"cells":6870},"Tenofovir Alafenamide",{"EARLY_PHASE1":6871,"PHASE1":6873,"PHASE2":6875,"PHASE3":6877,"PHASE4":6879,"NA":6891},{"trials":6872,"activeCount":101},[],{"trials":6874,"activeCount":101},[],{"trials":6876,"activeCount":101},[],{"trials":6878,"activeCount":101},[],{"trials":6880,"activeCount":101},[6881],{"nctId":6882,"briefTitle":6883,"status":160,"phases":6884,"primaryCompletion":6885,"completion":6885,"start":6886,"enrollment":6887,"conditions":6888,"interventions":6890},"NCT03471624","Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)",[92],"2022-04-19","2018-05-01",270,[6889],"Hepatitis B, Chronic",[6869],{"trials":6892,"activeCount":101},[],{"intervention":6894,"totalTrials":115,"cells":6895},"Ziprasidone\u002FGeodon",{"EARLY_PHASE1":6896,"PHASE1":6898,"PHASE2":6900,"PHASE3":6902,"PHASE4":6904,"NA":6912},{"trials":6897,"activeCount":101},[],{"trials":6899,"activeCount":101},[],{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[],{"trials":6905,"activeCount":101},[6906],{"nctId":6907,"briefTitle":6908,"status":160,"phases":6909,"primaryCompletion":5656,"completion":5656,"start":1423,"enrollment":613,"conditions":6910,"interventions":6911},"NCT00472641","Geodon in Weight Loss Study for Bipolar Disorders",[92],[1601],[6894],{"trials":6913,"activeCount":101},[],{"intervention":6915,"totalTrials":115,"cells":6916},"Lemborexant",{"EARLY_PHASE1":6917,"PHASE1":6919,"PHASE2":6921,"PHASE3":6923,"PHASE4":6925,"NA":6936},{"trials":6918,"activeCount":101},[],{"trials":6920,"activeCount":101},[],{"trials":6922,"activeCount":101},[],{"trials":6924,"activeCount":101},[],{"trials":6926,"activeCount":101},[6927],{"nctId":6928,"briefTitle":6929,"status":160,"phases":6930,"primaryCompletion":6931,"completion":6931,"start":5705,"enrollment":6932,"conditions":6933,"interventions":6935},"NCT05463861","Lemborexant in Delayed Sleep Phase Syndrome",[92],"2026-01-21",71,[6934],"Delayed Sleep Phase Syndrome",[6915],{"trials":6937,"activeCount":101},[],{"intervention":6939,"totalTrials":115,"cells":6940},"2011-2012 Fluzone IIV3",{"EARLY_PHASE1":6941,"PHASE1":6943,"PHASE2":6945,"PHASE3":6947,"PHASE4":6949,"NA":6957},{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"trials":6946,"activeCount":101},[],{"trials":6948,"activeCount":101},[],{"trials":6950,"activeCount":101},[6951],{"nctId":6952,"briefTitle":6953,"status":160,"phases":6954,"primaryCompletion":5535,"completion":5535,"start":1498,"enrollment":247,"conditions":6955,"interventions":6956},"NCT02987374","Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization",[92],[5514],[6939],{"trials":6958,"activeCount":101},[],{"intervention":6960,"totalTrials":115,"cells":6961},"Triamcinolone Acetonide",{"EARLY_PHASE1":6962,"PHASE1":6964,"PHASE2":6966,"PHASE3":6968,"PHASE4":6970,"NA":6982},{"trials":6963,"activeCount":101},[],{"trials":6965,"activeCount":101},[],{"trials":6967,"activeCount":101},[],{"trials":6969,"activeCount":101},[],{"trials":6971,"activeCount":101},[6972],{"nctId":6973,"briefTitle":6974,"status":160,"phases":6975,"primaryCompletion":6976,"completion":6976,"start":6977,"enrollment":6978,"conditions":6979,"interventions":6980},"NCT02877485","The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation",[92],"2019-08-15","2016-08",42,[1050],[6960,6981],"Ayr saline nasal mist",{"trials":6983,"activeCount":101},[],{"intervention":6981,"totalTrials":115,"cells":6985},{"EARLY_PHASE1":6986,"PHASE1":6988,"PHASE2":6990,"PHASE3":6992,"PHASE4":6994,"NA":7000},{"trials":6987,"activeCount":101},[],{"trials":6989,"activeCount":101},[],{"trials":6991,"activeCount":101},[],{"trials":6993,"activeCount":101},[],{"trials":6995,"activeCount":101},[6996],{"nctId":6973,"briefTitle":6974,"status":160,"phases":6997,"primaryCompletion":6976,"completion":6976,"start":6977,"enrollment":6978,"conditions":6998,"interventions":6999},[92],[1050],[6960,6981],{"trials":7001,"activeCount":101},[],{"intervention":7003,"totalTrials":115,"cells":7004},"Cystoscopic injection of Botox into the urinary bladder",{"EARLY_PHASE1":7005,"PHASE1":7007,"PHASE2":7009,"PHASE3":7011,"PHASE4":7013,"NA":7027},{"trials":7006,"activeCount":101},[],{"trials":7008,"activeCount":101},[],{"trials":7010,"activeCount":101},[],{"trials":7012,"activeCount":101},[],{"trials":7014,"activeCount":101},[7015],{"nctId":7016,"briefTitle":7017,"status":160,"phases":7018,"primaryCompletion":7019,"completion":7020,"start":1472,"enrollment":111,"conditions":7021,"interventions":7026},"NCT01421719","Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease",[92],"2011-05","2011-07",[7022,7023,7024,7025],"Parkinson's Disease","Neurogenic Bladder","Urinary Incontinence","Clostridium Botulinum Toxin Adverse Reaction",[7003],{"trials":7028,"activeCount":101},[],{"intervention":7030,"totalTrials":115,"cells":7031},"Atorvastatin",{"EARLY_PHASE1":7032,"PHASE1":7034,"PHASE2":7036,"PHASE3":7038,"PHASE4":7040,"NA":7052},{"trials":7033,"activeCount":101},[],{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[],{"trials":7039,"activeCount":101},[],{"trials":7041,"activeCount":101},[7042],{"nctId":7043,"briefTitle":7044,"status":160,"phases":7045,"primaryCompletion":7046,"completion":7047,"start":6610,"enrollment":7048,"conditions":7049,"interventions":7051},"NCT02437084","Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling",[92],"2020-02","2020-04",115,[7050,36,401],"Hyperlipidemia",[7030],{"trials":7053,"activeCount":101},[],{"intervention":7055,"totalTrials":115,"cells":7056},"Tranexamic Acid 1,000 Mg\u002F10 mL",{"EARLY_PHASE1":7057,"PHASE1":7059,"PHASE2":7061,"PHASE3":7063,"PHASE4":7065,"NA":7079},{"trials":7058,"activeCount":101},[],{"trials":7060,"activeCount":101},[],{"trials":7062,"activeCount":101},[],{"trials":7064,"activeCount":101},[],{"trials":7066,"activeCount":101},[7067],{"nctId":7068,"briefTitle":7069,"status":160,"phases":7070,"primaryCompletion":7071,"completion":7071,"start":7072,"enrollment":179,"conditions":7073,"interventions":7078},"NCT04754230","Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery",[92],"2022-02-20","2021-06-17",[7074,1050,7075,7076,7077],"Chronic Sinusitis","Turbinate; Hypertrophy Mucous Membrane","Deviated Nasal Septum - Congenital","Deviated Nasal Septum Acquired",[7055],{"trials":7080,"activeCount":101},[],{"intervention":7082,"totalTrials":115,"cells":7083},"Desipramine",{"EARLY_PHASE1":7084,"PHASE1":7086,"PHASE2":7088,"PHASE3":7090,"PHASE4":7092,"NA":7104},{"trials":7085,"activeCount":101},[],{"trials":7087,"activeCount":101},[],{"trials":7089,"activeCount":101},[],{"trials":7091,"activeCount":101},[],{"trials":7093,"activeCount":101},[7094],{"nctId":7095,"briefTitle":7096,"status":160,"phases":7097,"primaryCompletion":7098,"completion":7099,"start":7100,"enrollment":5557,"conditions":7101,"interventions":7102},"NCT03548454","Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization",[92],"2023-12-24","2024-06-26","2018-09-20",[33],[7103,7082],"Duloxetine",{"trials":7105,"activeCount":101},[],{"intervention":7107,"totalTrials":115,"cells":7108},"5% inhaled nitrous oxide",{"EARLY_PHASE1":7109,"PHASE1":7111,"PHASE2":7113,"PHASE3":7115,"PHASE4":7117,"NA":7130},{"trials":7110,"activeCount":101},[],{"trials":7112,"activeCount":101},[],{"trials":7114,"activeCount":101},[],{"trials":7116,"activeCount":101},[],{"trials":7118,"activeCount":101},[7119],{"nctId":7120,"briefTitle":7121,"status":132,"phases":7122,"primaryCompletion":7123,"completion":7123,"start":7124,"enrollment":101,"conditions":7125,"interventions":7128},"NCT05396144","Can Nitrous Oxide (Laughing Gas) be Used as a Sedative for GI Endoscopy Procedures?",[92],"2025-08-31","2024-05-01",[7126,7127],"Endoscopy","Colonoscopy",[7107,7129],"50% inhaled nitrous oxide",{"trials":7131,"activeCount":101},[],{"intervention":7129,"totalTrials":115,"cells":7133},{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7140,"PHASE4":7142,"NA":7148},{"trials":7135,"activeCount":101},[],{"trials":7137,"activeCount":101},[],{"trials":7139,"activeCount":101},[],{"trials":7141,"activeCount":101},[],{"trials":7143,"activeCount":101},[7144],{"nctId":7120,"briefTitle":7121,"status":132,"phases":7145,"primaryCompletion":7123,"completion":7123,"start":7124,"enrollment":101,"conditions":7146,"interventions":7147},[92],[7126,7127],[7107,7129],{"trials":7149,"activeCount":101},[],{"intervention":7151,"totalTrials":115,"cells":7152},"Trivalent, inactivated influenza vaccine",{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7174},{"trials":7154,"activeCount":101},[],{"trials":7156,"activeCount":101},[],{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[],{"trials":7162,"activeCount":101},[7163],{"nctId":7164,"briefTitle":7165,"status":160,"phases":7166,"primaryCompletion":5550,"completion":7167,"start":7168,"enrollment":7169,"conditions":7170,"interventions":7171},"NCT01827462","Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)",[92],"2017-03","2007-10",136,[5514],[7151,7172,7173],"Quadrivalent, inactivated influenza vaccine","High-Dose Trivalent, inactivated influenza vaccine",{"trials":7175,"activeCount":101},[],{"intervention":7172,"totalTrials":115,"cells":7177},{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7192},{"trials":7179,"activeCount":101},[],{"trials":7181,"activeCount":101},[],{"trials":7183,"activeCount":101},[],{"trials":7185,"activeCount":101},[],{"trials":7187,"activeCount":101},[7188],{"nctId":7164,"briefTitle":7165,"status":160,"phases":7189,"primaryCompletion":5550,"completion":7167,"start":7168,"enrollment":7169,"conditions":7190,"interventions":7191},[92],[5514],[7151,7172,7173],{"trials":7193,"activeCount":101},[],{"intervention":7173,"totalTrials":115,"cells":7195},{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7200,"PHASE3":7202,"PHASE4":7204,"NA":7210},{"trials":7197,"activeCount":101},[],{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"trials":7205,"activeCount":101},[7206],{"nctId":7164,"briefTitle":7165,"status":160,"phases":7207,"primaryCompletion":5550,"completion":7167,"start":7168,"enrollment":7169,"conditions":7208,"interventions":7209},[92],[5514],[7151,7172,7173],{"trials":7211,"activeCount":101},[],{"intervention":7213,"totalTrials":115,"cells":7214},"Fluzone® 2009-2010 Formula",{"EARLY_PHASE1":7215,"PHASE1":7217,"PHASE2":7219,"PHASE3":7221,"PHASE4":7223,"NA":7233},{"trials":7216,"activeCount":101},[],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[],{"trials":7222,"activeCount":101},[],{"trials":7224,"activeCount":101},[7225],{"nctId":7226,"briefTitle":7227,"status":160,"phases":7228,"primaryCompletion":5656,"completion":5656,"start":219,"enrollment":7229,"conditions":7230,"interventions":7231},"NCT02133781","B-cell Immunity to Influenza (SLVP017)- Year 1, 2009",[92],51,[5514],[7213,7232],"FluMist® 2009-2010 Formula",{"trials":7234,"activeCount":101},[],{"intervention":7232,"totalTrials":115,"cells":7236},{"EARLY_PHASE1":7237,"PHASE1":7239,"PHASE2":7241,"PHASE3":7243,"PHASE4":7245,"NA":7251},{"trials":7238,"activeCount":101},[],{"trials":7240,"activeCount":101},[],{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[],{"trials":7246,"activeCount":101},[7247],{"nctId":7226,"briefTitle":7227,"status":160,"phases":7248,"primaryCompletion":5656,"completion":5656,"start":219,"enrollment":7229,"conditions":7249,"interventions":7250},[92],[5514],[7213,7232],{"trials":7252,"activeCount":101},[],{"intervention":7254,"totalTrials":115,"cells":7255},"Fluzone® 2012-2013 Formula NDC No 498281-012-50",{"EARLY_PHASE1":7256,"PHASE1":7258,"PHASE2":7260,"PHASE3":7262,"PHASE4":7264,"NA":7274},{"trials":7257,"activeCount":101},[],{"trials":7259,"activeCount":101},[],{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"trials":7265,"activeCount":101},[7266],{"nctId":7267,"briefTitle":7268,"status":160,"phases":7269,"primaryCompletion":5535,"completion":5535,"start":1564,"enrollment":7270,"conditions":7271,"interventions":7273},"NCT02134184","The Influence of Chronic CMV Infection on Influenza Vaccine Responses",[92],78,[7272,5514],"Cytomegalovirus Infections",[7254],{"trials":7275,"activeCount":101},[],{"intervention":7277,"totalTrials":115,"cells":7278},"Tissue sealant",{"EARLY_PHASE1":7279,"PHASE1":7281,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7297},{"trials":7280,"activeCount":101},[],{"trials":7282,"activeCount":101},[],{"trials":7284,"activeCount":101},[],{"trials":7286,"activeCount":101},[],{"trials":7288,"activeCount":101},[7289],{"nctId":7290,"briefTitle":7291,"status":160,"phases":7292,"primaryCompletion":812,"completion":812,"start":7293,"enrollment":152,"conditions":7294,"interventions":7296},"NCT02952365","Tissue Sealant Use in LASIK Enhancement Surgery",[92],"2016-10-01",[7295],"Epithelial Ingrowth",[7277],{"trials":7298,"activeCount":101},[],{"intervention":7300,"totalTrials":115,"cells":7301},"Fosaprepitant 150 mg",{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7306,"PHASE3":7308,"PHASE4":7310,"NA":7321},{"trials":7303,"activeCount":101},[],{"trials":7305,"activeCount":101},[],{"trials":7307,"activeCount":101},[],{"trials":7309,"activeCount":101},[],{"trials":7311,"activeCount":101},[7312],{"nctId":7313,"briefTitle":7314,"status":160,"phases":7315,"primaryCompletion":7316,"completion":7316,"start":7317,"enrollment":3997,"conditions":7318,"interventions":7320},"NCT03197064","Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia",[92],"2020-01-31","2018-01-01",[7319],"Postoperative Nausea",[7300],{"trials":7322,"activeCount":101},[],{"intervention":7324,"totalTrials":115,"cells":7325},"Pharmacotherapy",{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7330,"PHASE3":7332,"PHASE4":7334,"NA":7344},{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[],{"trials":7331,"activeCount":101},[],{"trials":7333,"activeCount":101},[],{"trials":7335,"activeCount":101},[7336],{"nctId":7337,"briefTitle":7338,"status":160,"phases":7339,"primaryCompletion":7340,"completion":7340,"start":219,"enrollment":699,"conditions":7341,"interventions":7343},"NCT00991081","Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.",[92],"2011-03",[7342],"Smoking",[7324],{"trials":7345,"activeCount":101},[],{"intervention":7347,"totalTrials":115,"cells":7348},"Nitric Oxide",{"EARLY_PHASE1":7349,"PHASE1":7351,"PHASE2":7353,"PHASE3":7355,"PHASE4":7357,"NA":7366},{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[],{"trials":7356,"activeCount":101},[],{"trials":7358,"activeCount":101},[7359],{"nctId":7360,"briefTitle":7361,"status":160,"phases":7362,"primaryCompletion":1753,"completion":1753,"start":1564,"enrollment":1449,"conditions":7363,"interventions":7364},"NCT01717209","Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement",[92],[2115],[7347,7365],"Prostacyclin",{"trials":7367,"activeCount":101},[],{"intervention":7365,"totalTrials":115,"cells":7369},{"EARLY_PHASE1":7370,"PHASE1":7372,"PHASE2":7374,"PHASE3":7376,"PHASE4":7378,"NA":7384},{"trials":7371,"activeCount":101},[],{"trials":7373,"activeCount":101},[],{"trials":7375,"activeCount":101},[],{"trials":7377,"activeCount":101},[],{"trials":7379,"activeCount":101},[7380],{"nctId":7360,"briefTitle":7361,"status":160,"phases":7381,"primaryCompletion":1753,"completion":1753,"start":1564,"enrollment":1449,"conditions":7382,"interventions":7383},[92],[2115],[7347,7365],{"trials":7385,"activeCount":101},[],{"intervention":7387,"totalTrials":115,"cells":7388},"Prednisolone 1%",{"EARLY_PHASE1":7389,"PHASE1":7391,"PHASE2":7393,"PHASE3":7395,"PHASE4":7397,"NA":7407},{"trials":7390,"activeCount":101},[],{"trials":7392,"activeCount":101},[],{"trials":7394,"activeCount":101},[],{"trials":7396,"activeCount":101},[],{"trials":7398,"activeCount":101},[7399],{"nctId":7400,"briefTitle":7401,"status":160,"phases":7402,"primaryCompletion":1597,"completion":1597,"start":220,"enrollment":1406,"conditions":7403,"interventions":7404},"NCT00981435","Steroids After Laser Trabeculoplasty for Glaucoma",[92],[2627],[7387,7405,7406],"Ketorolac","Artificial Tears",{"trials":7408,"activeCount":101},[],{"intervention":7405,"totalTrials":115,"cells":7410},{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7415,"PHASE3":7417,"PHASE4":7419,"NA":7425},{"trials":7412,"activeCount":101},[],{"trials":7414,"activeCount":101},[],{"trials":7416,"activeCount":101},[],{"trials":7418,"activeCount":101},[],{"trials":7420,"activeCount":101},[7421],{"nctId":7400,"briefTitle":7401,"status":160,"phases":7422,"primaryCompletion":1597,"completion":1597,"start":220,"enrollment":1406,"conditions":7423,"interventions":7424},[92],[2627],[7387,7405,7406],{"trials":7426,"activeCount":101},[],{"intervention":7406,"totalTrials":115,"cells":7428},{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7435,"PHASE4":7437,"NA":7443},{"trials":7430,"activeCount":101},[],{"trials":7432,"activeCount":101},[],{"trials":7434,"activeCount":101},[],{"trials":7436,"activeCount":101},[],{"trials":7438,"activeCount":101},[7439],{"nctId":7400,"briefTitle":7401,"status":160,"phases":7440,"primaryCompletion":1597,"completion":1597,"start":220,"enrollment":1406,"conditions":7441,"interventions":7442},[92],[2627],[7387,7405,7406],{"trials":7444,"activeCount":101},[],{"intervention":5560,"totalTrials":115,"cells":7446},{"EARLY_PHASE1":7447,"PHASE1":7449,"PHASE2":7451,"PHASE3":7453,"PHASE4":7455,"NA":7461},{"trials":7448,"activeCount":101},[],{"trials":7450,"activeCount":101},[],{"trials":7452,"activeCount":101},[],{"trials":7454,"activeCount":101},[],{"trials":7456,"activeCount":101},[7457],{"nctId":5554,"briefTitle":5555,"status":160,"phases":7458,"primaryCompletion":757,"completion":757,"start":3503,"enrollment":5557,"conditions":7459,"interventions":7460},[92],[5514],[5501,5560,5561],{"trials":7462,"activeCount":101},[],{"intervention":5561,"totalTrials":115,"cells":7464},{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7471,"PHASE4":7473,"NA":7479},{"trials":7466,"activeCount":101},[],{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[],{"trials":7472,"activeCount":101},[],{"trials":7474,"activeCount":101},[7475],{"nctId":5554,"briefTitle":5555,"status":160,"phases":7476,"primaryCompletion":757,"completion":757,"start":3503,"enrollment":5557,"conditions":7477,"interventions":7478},[92],[5514],[5501,5560,5561],{"trials":7480,"activeCount":101},[],{"intervention":7482,"totalTrials":115,"cells":7483},"OxyCODONE 5 Mg (milligram) Oral",{"EARLY_PHASE1":7484,"PHASE1":7486,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7511},{"trials":7485,"activeCount":101},[],{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[7494],{"nctId":7495,"briefTitle":7496,"status":160,"phases":7497,"primaryCompletion":7498,"completion":7499,"start":7500,"enrollment":7501,"conditions":7502,"interventions":7508},"NCT03783702","Pain Control Following Sinus Surgery",[92],"2020-07-01","2020-12-30","2019-04-04",118,[7503,7504,7505,7506,7507,803,24],"Sinusitis","Opioid Use","Opioid Abuse","Narcotic Use","Otolaryngologic Disease",[7482,7509,7510],"Ibuprofen 600 Mg (milligram) Oral","Acetaminophen 650 MG (milligram) Oral",{"trials":7512,"activeCount":101},[],{"intervention":7509,"totalTrials":115,"cells":7514},{"EARLY_PHASE1":7515,"PHASE1":7517,"PHASE2":7519,"PHASE3":7521,"PHASE4":7523,"NA":7529},{"trials":7516,"activeCount":101},[],{"trials":7518,"activeCount":101},[],{"trials":7520,"activeCount":101},[],{"trials":7522,"activeCount":101},[],{"trials":7524,"activeCount":101},[7525],{"nctId":7495,"briefTitle":7496,"status":160,"phases":7526,"primaryCompletion":7498,"completion":7499,"start":7500,"enrollment":7501,"conditions":7527,"interventions":7528},[92],[7503,7504,7505,7506,7507,803,24],[7482,7509,7510],{"trials":7530,"activeCount":101},[],{"intervention":7510,"totalTrials":115,"cells":7532},{"EARLY_PHASE1":7533,"PHASE1":7535,"PHASE2":7537,"PHASE3":7539,"PHASE4":7541,"NA":7547},{"trials":7534,"activeCount":101},[],{"trials":7536,"activeCount":101},[],{"trials":7538,"activeCount":101},[],{"trials":7540,"activeCount":101},[],{"trials":7542,"activeCount":101},[7543],{"nctId":7495,"briefTitle":7496,"status":160,"phases":7544,"primaryCompletion":7498,"completion":7499,"start":7500,"enrollment":7501,"conditions":7545,"interventions":7546},[92],[7503,7504,7505,7506,7507,803,24],[7482,7509,7510],{"trials":7548,"activeCount":101},[],{"intervention":7550,"totalTrials":115,"cells":7551},"efavirenz or nevirapine",{"EARLY_PHASE1":7552,"PHASE1":7554,"PHASE2":7556,"PHASE3":7558,"PHASE4":7560,"NA":7570},{"trials":7553,"activeCount":101},[],{"trials":7555,"activeCount":101},[],{"trials":7557,"activeCount":101},[],{"trials":7559,"activeCount":101},[],{"trials":7561,"activeCount":101},[7562],{"nctId":7563,"briefTitle":7564,"status":716,"phases":7565,"primaryCompletion":1730,"completion":1730,"start":4993,"enrollment":821,"conditions":7566,"interventions":7569},"NCT00523458","A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV",[92],[7567,7568],"HIV Infections","Tuberculosis",[7550],{"trials":7571,"activeCount":101},[],{"intervention":7573,"totalTrials":115,"cells":7574},"Recombinant human growth hormone; pioglitazone",{"EARLY_PHASE1":7575,"PHASE1":7577,"PHASE2":7579,"PHASE3":7581,"PHASE4":7583,"NA":7594},{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"trials":7582,"activeCount":101},[],{"trials":7584,"activeCount":101},[7585],{"nctId":7586,"briefTitle":7587,"status":160,"phases":7588,"completion":7589,"start":3807,"enrollment":1124,"conditions":7590,"interventions":7593},"NCT00352287","Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults",[92],"2005-04",[18,7591,7592],"Metabolic Syndrome","Impaired Glucose Tolerance",[7573],{"trials":7595,"activeCount":101},[],{"intervention":5577,"totalTrials":115,"cells":7597},{"EARLY_PHASE1":7598,"PHASE1":7600,"PHASE2":7602,"PHASE3":7604,"PHASE4":7606,"NA":7612},{"trials":7599,"activeCount":101},[],{"trials":7601,"activeCount":101},[],{"trials":7603,"activeCount":101},[],{"trials":7605,"activeCount":101},[],{"trials":7607,"activeCount":101},[7608],{"nctId":5572,"briefTitle":5573,"status":160,"phases":7609,"primaryCompletion":231,"completion":231,"start":876,"enrollment":9,"conditions":7610,"interventions":7611},[92],[5514],[5577,5501],{"trials":7613,"activeCount":101},[],{"intervention":7615,"totalTrials":115,"cells":7616},"Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo",{"EARLY_PHASE1":7617,"PHASE1":7619,"PHASE2":7621,"PHASE3":7623,"PHASE4":7625,"NA":7636},{"trials":7618,"activeCount":101},[],{"trials":7620,"activeCount":101},[],{"trials":7622,"activeCount":101},[],{"trials":7624,"activeCount":101},[],{"trials":7626,"activeCount":101},[7627],{"nctId":7628,"briefTitle":7629,"status":160,"phases":7630,"completion":719,"start":7631,"enrollment":208,"conditions":7632,"interventions":7635},"NCT00186329","BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)",[92],"2004-03",[7633,7634],"Congestive Heart Failure Exacerbation","Renal Insufficiency",[7615],{"trials":7637,"activeCount":101},[],{"intervention":7639,"totalTrials":115,"cells":7640},"Phenylephrine",{"EARLY_PHASE1":7641,"PHASE1":7643,"PHASE2":7645,"PHASE3":7647,"PHASE4":7649,"NA":7661},{"trials":7642,"activeCount":101},[],{"trials":7644,"activeCount":101},[],{"trials":7646,"activeCount":101},[],{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[7651],{"nctId":7652,"briefTitle":7653,"status":160,"phases":7654,"primaryCompletion":858,"completion":858,"start":7655,"enrollment":2218,"conditions":7656,"interventions":7658},"NCT05439460","Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension",[92],"2012-01",[7657],"Pulmonary Arterial Hypertension",[7639,7659,7660],"Epinephrine","Arginine Vasopressin",{"trials":7662,"activeCount":101},[],{"intervention":7659,"totalTrials":115,"cells":7664},{"EARLY_PHASE1":7665,"PHASE1":7667,"PHASE2":7669,"PHASE3":7671,"PHASE4":7673,"NA":7679},{"trials":7666,"activeCount":101},[],{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[7675],{"nctId":7652,"briefTitle":7653,"status":160,"phases":7676,"primaryCompletion":858,"completion":858,"start":7655,"enrollment":2218,"conditions":7677,"interventions":7678},[92],[7657],[7639,7659,7660],{"trials":7680,"activeCount":101},[],{"intervention":7660,"totalTrials":115,"cells":7682},{"EARLY_PHASE1":7683,"PHASE1":7685,"PHASE2":7687,"PHASE3":7689,"PHASE4":7691,"NA":7697},{"trials":7684,"activeCount":101},[],{"trials":7686,"activeCount":101},[],{"trials":7688,"activeCount":101},[],{"trials":7690,"activeCount":101},[],{"trials":7692,"activeCount":101},[7693],{"nctId":7652,"briefTitle":7653,"status":160,"phases":7694,"primaryCompletion":858,"completion":858,"start":7655,"enrollment":2218,"conditions":7695,"interventions":7696},[92],[7657],[7639,7659,7660],{"trials":7698,"activeCount":101},[],{"intervention":7700,"totalTrials":115,"cells":7701},"Triamcinolone or Betamethasone",{"EARLY_PHASE1":7702,"PHASE1":7704,"PHASE2":7706,"PHASE3":7708,"PHASE4":7710,"NA":7722},{"trials":7703,"activeCount":101},[],{"trials":7705,"activeCount":101},[],{"trials":7707,"activeCount":101},[],{"trials":7709,"activeCount":101},[],{"trials":7711,"activeCount":101},[7712],{"nctId":7713,"briefTitle":7714,"status":716,"phases":7715,"primaryCompletion":7716,"completion":7716,"start":5422,"enrollment":7717,"conditions":7718,"interventions":7721},"NCT04278833","Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions",[92],"2021-05-28",165,[779,7719,7720],"Tendinopathy","Impingement Shoulder",[7700,1569],{"trials":7723,"activeCount":101},[],{"intervention":3340,"totalTrials":115,"cells":7725},{"EARLY_PHASE1":7726,"PHASE1":7728,"PHASE2":7730,"PHASE3":7732,"PHASE4":7734,"NA":7740},{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[],{"trials":7731,"activeCount":101},[],{"trials":7733,"activeCount":101},[],{"trials":7735,"activeCount":101},[7736],{"nctId":3332,"briefTitle":3333,"status":160,"phases":7737,"primaryCompletion":3335,"completion":3335,"start":3336,"enrollment":179,"conditions":7738,"interventions":7739},[92],[3338],[3340,3341,2563],{"trials":7741,"activeCount":101},[],{"intervention":3341,"totalTrials":115,"cells":7743},{"EARLY_PHASE1":7744,"PHASE1":7746,"PHASE2":7748,"PHASE3":7750,"PHASE4":7752,"NA":7758},{"trials":7745,"activeCount":101},[],{"trials":7747,"activeCount":101},[],{"trials":7749,"activeCount":101},[],{"trials":7751,"activeCount":101},[],{"trials":7753,"activeCount":101},[7754],{"nctId":3332,"briefTitle":3333,"status":160,"phases":7755,"primaryCompletion":3335,"completion":3335,"start":3336,"enrollment":179,"conditions":7756,"interventions":7757},[92],[3338],[3340,3341,2563],{"trials":7759,"activeCount":101},[],{"intervention":5942,"totalTrials":115,"cells":7761},{"EARLY_PHASE1":7762,"PHASE1":7764,"PHASE2":7766,"PHASE3":7768,"PHASE4":7770,"NA":7776},{"trials":7763,"activeCount":101},[],{"trials":7765,"activeCount":101},[],{"trials":7767,"activeCount":101},[],{"trials":7769,"activeCount":101},[],{"trials":7771,"activeCount":101},[7772],{"nctId":5935,"briefTitle":5936,"status":160,"phases":7773,"primaryCompletion":875,"completion":875,"start":5938,"enrollment":5939,"conditions":7774,"interventions":7775},[92],[5928],[5942,5943,5915],{"trials":7777,"activeCount":101},[],{"intervention":5943,"totalTrials":115,"cells":7779},{"EARLY_PHASE1":7780,"PHASE1":7782,"PHASE2":7784,"PHASE3":7786,"PHASE4":7788,"NA":7794},{"trials":7781,"activeCount":101},[],{"trials":7783,"activeCount":101},[],{"trials":7785,"activeCount":101},[],{"trials":7787,"activeCount":101},[],{"trials":7789,"activeCount":101},[7790],{"nctId":5935,"briefTitle":5936,"status":160,"phases":7791,"primaryCompletion":875,"completion":875,"start":5938,"enrollment":5939,"conditions":7792,"interventions":7793},[92],[5928],[5942,5943,5915],{"trials":7795,"activeCount":101},[],{"intervention":706,"totalTrials":684,"cells":7797},{"EARLY_PHASE1":7798,"PHASE1":7800,"PHASE2":7802,"PHASE3":7843,"PHASE4":7849,"NA":7851},{"trials":7799,"activeCount":101},[],{"trials":7801,"activeCount":101},[],{"trials":7803,"activeCount":101},[7804,7808,7812,7816,7831,7835,7839],{"nctId":693,"briefTitle":694,"status":160,"phases":7805,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":7806,"interventions":7807},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"nctId":1430,"briefTitle":1431,"status":716,"phases":7809,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":7810,"interventions":7811},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"nctId":714,"briefTitle":715,"status":716,"phases":7813,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":7814,"interventions":7815},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":7817,"briefTitle":7818,"status":160,"phases":7819,"primaryCompletion":7820,"completion":7821,"start":758,"enrollment":7822,"conditions":7823,"interventions":7828},"NCT00896493","Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w\u002F Cutaneous T Cell Lymphoma",[90],"2021-11-06","2022-12",38,[7824,2906,7825,7826,722,7827],"Mycoses","Lymphoma, T-Cell, Cutaneous","Bone Marrow Transplant Failure","Cutaneous T-cell Lymphoma",[7829,7830],"anti-thymocyte globulin","cyclosporine",{"nctId":3803,"briefTitle":3804,"status":160,"phases":7832,"primaryCompletion":756,"completion":3806,"start":3807,"enrollment":3808,"conditions":7833,"interventions":7834},[90],[739,740],[706,728,729,708],{"nctId":733,"briefTitle":734,"status":160,"phases":7836,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":7837,"interventions":7838},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"nctId":753,"briefTitle":754,"status":160,"phases":7840,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":7841,"interventions":7842},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":7844,"activeCount":101},[7845],{"nctId":3822,"briefTitle":3823,"status":716,"phases":7846,"primaryCompletion":1974,"completion":1974,"start":1801,"enrollment":3825,"conditions":7847,"interventions":7848},[91],[3827,740,3708],[728,706,729,3829,3830],{"trials":7850,"activeCount":101},[],{"trials":7852,"activeCount":101},[],{"intervention":728,"totalTrials":197,"cells":7854},{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7881,"PHASE4":7887,"NA":7889},{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[7861,7865,7869,7873,7877],{"nctId":714,"briefTitle":715,"status":716,"phases":7862,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":7863,"interventions":7864},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":7817,"briefTitle":7818,"status":160,"phases":7866,"primaryCompletion":7820,"completion":7821,"start":758,"enrollment":7822,"conditions":7867,"interventions":7868},[90],[7824,2906,7825,7826,722,7827],[7829,7830],{"nctId":3803,"briefTitle":3804,"status":160,"phases":7870,"primaryCompletion":756,"completion":3806,"start":3807,"enrollment":3808,"conditions":7871,"interventions":7872},[90],[739,740],[706,728,729,708],{"nctId":733,"briefTitle":734,"status":160,"phases":7874,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":7875,"interventions":7876},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"nctId":3720,"briefTitle":3721,"status":160,"phases":7878,"primaryCompletion":3723,"completion":3724,"start":3725,"enrollment":1977,"conditions":7879,"interventions":7880},[90],[3727,1524,3728,3729,3730,3731,3732,1339,3733],[728,1528,729],{"trials":7882,"activeCount":101},[7883],{"nctId":3822,"briefTitle":3823,"status":716,"phases":7884,"primaryCompletion":1974,"completion":1974,"start":1801,"enrollment":3825,"conditions":7885,"interventions":7886},[91],[3827,740,3708],[728,706,729,3829,3830],{"trials":7888,"activeCount":101},[],{"trials":7890,"activeCount":101},[],{"intervention":7892,"totalTrials":334,"cells":7893},"Oxaliplatin",{"EARLY_PHASE1":7894,"PHASE1":7896,"PHASE2":7898,"PHASE3":7923,"PHASE4":7936,"NA":7938},{"trials":7895,"activeCount":101},[],{"trials":7897,"activeCount":101},[],{"trials":7899,"activeCount":101},[7900,7910],{"nctId":7901,"briefTitle":7902,"status":160,"phases":7903,"primaryCompletion":7904,"completion":7904,"start":7905,"enrollment":247,"conditions":7906,"interventions":7908},"NCT00186277","Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer",[90],"2006-12","2003-12",[7907],"Bladder Cancer",[7892,7909],"Taxotere",{"nctId":7911,"briefTitle":7912,"status":160,"phases":7913,"completion":7914,"start":7915,"conditions":7916,"interventions":7918},"NCT00025142","Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer",[90],"2006-11","2001-07",[7917],"Colorectal Cancer",[7919,3956,7920,7921,7922],"FOLFOX regimen","gefitinib","leucovorin calcium","oxaliplatin",{"trials":7924,"activeCount":101},[7925],{"nctId":7926,"briefTitle":7927,"status":160,"phases":7928,"primaryCompletion":7929,"completion":7930,"start":7931,"enrollment":791,"conditions":7932,"interventions":7933},"NCT01926197","Phase 3 Study of FOLFIRINOX (mFFX) +\u002F- SBRT in Locally Advanced Pancreatic Cancer",[91],"2021-09-30","2022-09-30","2013-08-14",[1781],[7892,7934,7935,1701],"Irinotecan","Leucovorin",{"trials":7937,"activeCount":101},[],{"trials":7939,"activeCount":101},[],{"intervention":7941,"totalTrials":334,"cells":7942},"Calcium chloride",{"EARLY_PHASE1":7943,"PHASE1":7958,"PHASE2":7960,"PHASE3":7975,"PHASE4":7987,"NA":7989},{"trials":7944,"activeCount":101},[7945],{"nctId":7946,"briefTitle":7947,"status":160,"phases":7948,"primaryCompletion":7949,"completion":7949,"start":7950,"enrollment":7951,"conditions":7952,"interventions":7956},"NCT05973747","Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients",[88],"2023-12-15","2023-08-19",34,[5179,7953,7954,7955],"Pregnancy Related","Hypocalcemia","Parturition Complication",[7957,7941],"Calcium Gluconate",{"trials":7959,"activeCount":101},[],{"trials":7961,"activeCount":101},[7962],{"nctId":7963,"briefTitle":7964,"status":160,"phases":7965,"primaryCompletion":7966,"completion":7967,"start":7968,"enrollment":179,"conditions":7969,"interventions":7973},"NCT03867383","Calcium Chloride for Prevention of Uterine Atony During Cesarean",[89,90],"2021-07-30","2021-08-15","2019-03-15",[7970,7971,7972],"Uterine Atony","Uterine Atony With Hemorrhage","Cesarean Section Complications",[7974],"Calcium Chloride",{"trials":7976,"activeCount":101},[7977],{"nctId":7978,"briefTitle":7979,"status":160,"phases":7980,"primaryCompletion":7981,"completion":7982,"start":7983,"enrollment":149,"conditions":7984,"interventions":7985},"NCT05027048","Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery",[91],"2023-03-29","2023-04-03","2022-04-04",[7970,7971,5179,7972],[7941,7986],"Saline placebo",{"trials":7988,"activeCount":101},[],{"trials":7990,"activeCount":101},[],{"intervention":1701,"totalTrials":152,"cells":7992},{"EARLY_PHASE1":7993,"PHASE1":7995,"PHASE2":7997,"PHASE3":8003,"PHASE4":8009,"NA":8011},{"trials":7994,"activeCount":101},[],{"trials":7996,"activeCount":101},[],{"trials":7998,"activeCount":101},[7999],{"nctId":1687,"briefTitle":1688,"status":716,"phases":8000,"primaryCompletion":1471,"completion":1690,"start":231,"enrollment":152,"conditions":8001,"interventions":8002},[90],[1692,1693,1694,1695,1696],[1678,1698,1699,1700,1701],{"trials":8004,"activeCount":101},[8005],{"nctId":7926,"briefTitle":7927,"status":160,"phases":8006,"primaryCompletion":7929,"completion":7930,"start":7931,"enrollment":791,"conditions":8007,"interventions":8008},[91],[1781],[7892,7934,7935,1701],{"trials":8010,"activeCount":101},[],{"trials":8012,"activeCount":101},[],{"intervention":8014,"totalTrials":152,"cells":8015},"Acetazolamide",{"EARLY_PHASE1":8016,"PHASE1":8018,"PHASE2":8030,"PHASE3":8032,"PHASE4":8043,"NA":8045},{"trials":8017,"activeCount":101},[],{"trials":8019,"activeCount":101},[8020],{"nctId":8021,"briefTitle":8022,"status":160,"phases":8023,"primaryCompletion":8024,"completion":8024,"start":8025,"enrollment":8026,"conditions":8027,"interventions":8029},"NCT03424226","Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages",[89],"2018-09-30","2018-08-04",105,[8028],"Acute Mountain Sickness",[8014],{"trials":8031,"activeCount":101},[],{"trials":8033,"activeCount":101},[8034],{"nctId":8035,"briefTitle":8036,"status":160,"phases":8037,"primaryCompletion":8038,"completion":8038,"start":6977,"enrollment":8039,"conditions":8040,"interventions":8041},"NCT02604173","Altitude Sickness Prevention and Efficacy of Comparative Treatments",[91],"2016-09",103,[8028],[8042,8014],"Budesonide",{"trials":8044,"activeCount":101},[],{"trials":8046,"activeCount":101},[],{"intervention":7934,"totalTrials":152,"cells":8048},{"EARLY_PHASE1":8049,"PHASE1":8051,"PHASE2":8053,"PHASE3":8065,"PHASE4":8071,"NA":8073},{"trials":8050,"activeCount":101},[],{"trials":8052,"activeCount":101},[],{"trials":8054,"activeCount":101},[8055],{"nctId":8056,"briefTitle":8057,"status":716,"phases":8058,"primaryCompletion":874,"completion":874,"start":7019,"enrollment":334,"conditions":8059,"interventions":8062},"NCT01313884","Cyclophosphamide, Doxorubicin, Vincristine w\u002F Irinotecan and Temozolomide in Ewings Sarcoma",[90],[8060,8061],"Bone Cancer","Ewing's Sarcoma",[7934,1747,3369,1722,8063,8064],"Cytoxan","Pegfilgrastim",{"trials":8066,"activeCount":101},[8067],{"nctId":7926,"briefTitle":7927,"status":160,"phases":8068,"primaryCompletion":7929,"completion":7930,"start":7931,"enrollment":791,"conditions":8069,"interventions":8070},[91],[1781],[7892,7934,7935,1701],{"trials":8072,"activeCount":101},[],{"trials":8074,"activeCount":101},[],{"intervention":8076,"totalTrials":152,"cells":8077},"liraglutide",{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8091,"PHASE3":8093,"PHASE4":8104,"NA":8106},{"trials":8079,"activeCount":101},[],{"trials":8081,"activeCount":101},[8082],{"nctId":8083,"briefTitle":8084,"status":160,"phases":8085,"primaryCompletion":8086,"completion":8086,"start":833,"enrollment":4504,"conditions":8087,"interventions":8089},"NCT02140983","Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes",[89],"2017-02",[36,8088],"Dementia",[8090],"Liraglutide",{"trials":8092,"activeCount":101},[],{"trials":8094,"activeCount":101},[8095],{"nctId":8096,"briefTitle":8097,"status":160,"phases":8098,"primaryCompletion":5535,"completion":5535,"start":5656,"enrollment":8099,"conditions":8100,"interventions":8103},"NCT01784965","Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.",[91],69,[8101,8102],"Pre-diabetes","Older Adults",[8076],{"trials":8105,"activeCount":101},[],{"trials":8107,"activeCount":101},[],{"intervention":8109,"totalTrials":152,"cells":8110},"Dakin's solution",{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8115,"PHASE3":8125,"PHASE4":8137,"NA":8139},{"trials":8112,"activeCount":101},[],{"trials":8114,"activeCount":101},[],{"trials":8116,"activeCount":101},[8117],{"nctId":8118,"briefTitle":8119,"status":160,"phases":8120,"primaryCompletion":8121,"completion":8121,"start":874,"enrollment":111,"conditions":8122,"interventions":8124},"NCT02203565","Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy",[90],"2016-07-07",[15,8123],"Skin Reactions Secondary to Radiation Therapy",[8109],{"trials":8126,"activeCount":101},[8127],{"nctId":8128,"briefTitle":8129,"status":160,"phases":8130,"primaryCompletion":8131,"completion":8131,"start":6610,"enrollment":8132,"conditions":8133,"interventions":8136},"NCT02369835","Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy",[91],"2018-07-18",132,[8134,8135],"Head and Neck Carcinoma","Radiation-Induced Dermatitis",[8109],{"trials":8138,"activeCount":101},[],{"trials":8140,"activeCount":101},[],{"intervention":8142,"totalTrials":115,"cells":8143},"embolic agent",{"EARLY_PHASE1":8144,"PHASE1":8146,"PHASE2":8148,"PHASE3":8150,"PHASE4":8163,"NA":8165},{"trials":8145,"activeCount":101},[],{"trials":8147,"activeCount":101},[],{"trials":8149,"activeCount":101},[],{"trials":8151,"activeCount":101},[8152],{"nctId":8153,"briefTitle":8154,"status":716,"phases":8155,"primaryCompletion":4103,"completion":4103,"start":8156,"enrollment":191,"conditions":8157,"interventions":8161},"NCT02762266","Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization",[91],"2016-02-27",[8158,8159,8160],"Child-Pugh Class A","Child-Pugh Class B","Recurrent Hepatocellular Carcinoma",[8142,8162],"lipiodol",{"trials":8164,"activeCount":101},[],{"trials":8166,"activeCount":101},[],{"intervention":8162,"totalTrials":115,"cells":8168},{"EARLY_PHASE1":8169,"PHASE1":8171,"PHASE2":8173,"PHASE3":8175,"PHASE4":8181,"NA":8183},{"trials":8170,"activeCount":101},[],{"trials":8172,"activeCount":101},[],{"trials":8174,"activeCount":101},[],{"trials":8176,"activeCount":101},[8177],{"nctId":8153,"briefTitle":8154,"status":716,"phases":8178,"primaryCompletion":4103,"completion":4103,"start":8156,"enrollment":191,"conditions":8179,"interventions":8180},[91],[8158,8159,8160],[8142,8162],{"trials":8182,"activeCount":101},[],{"trials":8184,"activeCount":101},[],{"intervention":8186,"totalTrials":115,"cells":8187},"Augmentin",{"EARLY_PHASE1":8188,"PHASE1":8190,"PHASE2":8192,"PHASE3":8194,"PHASE4":8207,"NA":8209},{"trials":8189,"activeCount":101},[],{"trials":8191,"activeCount":101},[],{"trials":8193,"activeCount":101},[],{"trials":8195,"activeCount":101},[8196],{"nctId":8197,"briefTitle":8198,"status":160,"phases":8199,"completion":4009,"start":8200,"enrollment":8201,"conditions":8202,"interventions":8206},"NCT00185939","The Use of Prophylactic Antibiotics In the Management of Dog Bites",[90,91],"2003-08",125,[8203,8204,8205],"Bite","Wound","Infection",[8186],{"trials":8208,"activeCount":101},[],{"trials":8210,"activeCount":101},[],{"intervention":8212,"totalTrials":115,"cells":8213},"Misoprostol 400mcg buccal",{"EARLY_PHASE1":8214,"PHASE1":8216,"PHASE2":8218,"PHASE3":8220,"PHASE4":8232,"NA":8234},{"trials":8215,"activeCount":101},[],{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[],{"trials":8221,"activeCount":101},[8222],{"nctId":8223,"briefTitle":8224,"status":716,"phases":8225,"primaryCompletion":8226,"completion":8226,"start":8227,"enrollment":97,"conditions":8228,"interventions":8231},"NCT06078501","MisOpRostol Effect on Second Trimester Abortion Blood Loss",[91],"2024-07-12","2024-02-08",[8229,8230],"Blood Loss, Surgical","Second Trimester Abortion",[8212],{"trials":8233,"activeCount":101},[],{"trials":8235,"activeCount":101},[],{"intervention":8237,"totalTrials":115,"cells":8238},"vaginal 2% Xylocaine",{"EARLY_PHASE1":8239,"PHASE1":8241,"PHASE2":8243,"PHASE3":8245,"PHASE4":8257,"NA":8259},{"trials":8240,"activeCount":101},[],{"trials":8242,"activeCount":101},[],{"trials":8244,"activeCount":101},[],{"trials":8246,"activeCount":101},[8247],{"nctId":8248,"briefTitle":8249,"status":160,"phases":8250,"primaryCompletion":3806,"completion":3806,"start":8251,"enrollment":8252,"conditions":8253,"interventions":8255},"NCT02447029","Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial",[91],"2015-04",142,[8254],"Pregnancy, Unwanted",[8237,8256],"standard lidocaine paracervical block",{"trials":8258,"activeCount":101},[],{"trials":8260,"activeCount":101},[],{"intervention":8256,"totalTrials":115,"cells":8262},{"EARLY_PHASE1":8263,"PHASE1":8265,"PHASE2":8267,"PHASE3":8269,"PHASE4":8275,"NA":8277},{"trials":8264,"activeCount":101},[],{"trials":8266,"activeCount":101},[],{"trials":8268,"activeCount":101},[],{"trials":8270,"activeCount":101},[8271],{"nctId":8248,"briefTitle":8249,"status":160,"phases":8272,"primaryCompletion":3806,"completion":3806,"start":8251,"enrollment":8252,"conditions":8273,"interventions":8274},[91],[8254],[8237,8256],{"trials":8276,"activeCount":101},[],{"trials":8278,"activeCount":101},[],{"intervention":5733,"totalTrials":115,"cells":8280},{"EARLY_PHASE1":8281,"PHASE1":8283,"PHASE2":8285,"PHASE3":8287,"PHASE4":8293,"NA":8295},{"trials":8282,"activeCount":101},[],{"trials":8284,"activeCount":101},[],{"trials":8286,"activeCount":101},[],{"trials":8288,"activeCount":101},[8289],{"nctId":5725,"briefTitle":5726,"status":160,"phases":8290,"primaryCompletion":5728,"completion":5729,"start":813,"enrollment":149,"conditions":8291,"interventions":8292},[91],[5731],[5714,5733,5734,5735,5736],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[],{"intervention":5734,"totalTrials":115,"cells":8298},{"EARLY_PHASE1":8299,"PHASE1":8301,"PHASE2":8303,"PHASE3":8305,"PHASE4":8311,"NA":8313},{"trials":8300,"activeCount":101},[],{"trials":8302,"activeCount":101},[],{"trials":8304,"activeCount":101},[],{"trials":8306,"activeCount":101},[8307],{"nctId":5725,"briefTitle":5726,"status":160,"phases":8308,"primaryCompletion":5728,"completion":5729,"start":813,"enrollment":149,"conditions":8309,"interventions":8310},[91],[5731],[5714,5733,5734,5735,5736],{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[],{"intervention":5735,"totalTrials":115,"cells":8316},{"EARLY_PHASE1":8317,"PHASE1":8319,"PHASE2":8321,"PHASE3":8323,"PHASE4":8329,"NA":8331},{"trials":8318,"activeCount":101},[],{"trials":8320,"activeCount":101},[],{"trials":8322,"activeCount":101},[],{"trials":8324,"activeCount":101},[8325],{"nctId":5725,"briefTitle":5726,"status":160,"phases":8326,"primaryCompletion":5728,"completion":5729,"start":813,"enrollment":149,"conditions":8327,"interventions":8328},[91],[5731],[5714,5733,5734,5735,5736],{"trials":8330,"activeCount":101},[],{"trials":8332,"activeCount":101},[],{"intervention":8334,"totalTrials":115,"cells":8335},"Modafinil",{"EARLY_PHASE1":8336,"PHASE1":8338,"PHASE2":8340,"PHASE3":8342,"PHASE4":8352,"NA":8354},{"trials":8337,"activeCount":101},[],{"trials":8339,"activeCount":101},[],{"trials":8341,"activeCount":101},[],{"trials":8343,"activeCount":101},[8344],{"nctId":8345,"briefTitle":8346,"status":132,"phases":8347,"primaryCompletion":188,"completion":8348,"start":8349,"enrollment":101,"conditions":8350,"interventions":8351},"NCT04317001","Treatment for Cognitive Impairment in Depression",[91],"2024-11-30","2018-12-01",[167],[8334],{"trials":8353,"activeCount":101},[],{"trials":8355,"activeCount":101},[],{"intervention":8357,"totalTrials":115,"cells":8358},"Antidepressant",{"EARLY_PHASE1":8359,"PHASE1":8361,"PHASE2":8363,"PHASE3":8365,"PHASE4":8374,"NA":8376},{"trials":8360,"activeCount":101},[],{"trials":8362,"activeCount":101},[],{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[8367],{"nctId":8368,"briefTitle":8369,"status":160,"phases":8370,"primaryCompletion":1919,"completion":1919,"start":8371,"enrollment":124,"conditions":8372,"interventions":8373},"NCT00767624","TRIAD - Treatment of Insomnia and Depression",[90,91],"2008-12",[5693,21],[8357],{"trials":8375,"activeCount":101},[],{"trials":8377,"activeCount":101},[],{"intervention":7986,"totalTrials":115,"cells":8379},{"EARLY_PHASE1":8380,"PHASE1":8382,"PHASE2":8384,"PHASE3":8386,"PHASE4":8392,"NA":8394},{"trials":8381,"activeCount":101},[],{"trials":8383,"activeCount":101},[],{"trials":8385,"activeCount":101},[],{"trials":8387,"activeCount":101},[8388],{"nctId":7978,"briefTitle":7979,"status":160,"phases":8389,"primaryCompletion":7981,"completion":7982,"start":7983,"enrollment":149,"conditions":8390,"interventions":8391},[91],[7970,7971,5179,7972],[7941,7986],{"trials":8393,"activeCount":101},[],{"trials":8395,"activeCount":101},[],{"intervention":3829,"totalTrials":115,"cells":8397},{"EARLY_PHASE1":8398,"PHASE1":8400,"PHASE2":8402,"PHASE3":8404,"PHASE4":8410,"NA":8412},{"trials":8399,"activeCount":101},[],{"trials":8401,"activeCount":101},[],{"trials":8403,"activeCount":101},[],{"trials":8405,"activeCount":101},[8406],{"nctId":3822,"briefTitle":3823,"status":716,"phases":8407,"primaryCompletion":1974,"completion":1974,"start":1801,"enrollment":3825,"conditions":8408,"interventions":8409},[91],[3827,740,3708],[728,706,729,3829,3830],{"trials":8411,"activeCount":101},[],{"trials":8413,"activeCount":101},[],{"intervention":3830,"totalTrials":115,"cells":8415},{"EARLY_PHASE1":8416,"PHASE1":8418,"PHASE2":8420,"PHASE3":8422,"PHASE4":8428,"NA":8430},{"trials":8417,"activeCount":101},[],{"trials":8419,"activeCount":101},[],{"trials":8421,"activeCount":101},[],{"trials":8423,"activeCount":101},[8424],{"nctId":3822,"briefTitle":3823,"status":716,"phases":8425,"primaryCompletion":1974,"completion":1974,"start":1801,"enrollment":3825,"conditions":8426,"interventions":8427},[91],[3827,740,3708],[728,706,729,3829,3830],{"trials":8429,"activeCount":101},[],{"trials":8431,"activeCount":101},[],{"intervention":8433,"totalTrials":115,"cells":8434},"Lithium",{"EARLY_PHASE1":8435,"PHASE1":8437,"PHASE2":8439,"PHASE3":8441,"PHASE4":8451,"NA":8453},{"trials":8436,"activeCount":101},[],{"trials":8438,"activeCount":101},[],{"trials":8440,"activeCount":101},[],{"trials":8442,"activeCount":101},[8443],{"nctId":8444,"briefTitle":8445,"status":160,"phases":8446,"primaryCompletion":7168,"completion":7168,"start":8447,"enrollment":1546,"conditions":8448,"interventions":8449},"NCT00074776","Acute Treatment of Bipolar II Depression",[91],"2003-05",[1601],[8433,8450],"Lamotrigine",{"trials":8452,"activeCount":101},[],{"trials":8454,"activeCount":101},[],{"intervention":8450,"totalTrials":115,"cells":8456},{"EARLY_PHASE1":8457,"PHASE1":8459,"PHASE2":8461,"PHASE3":8463,"PHASE4":8469,"NA":8471},{"trials":8458,"activeCount":101},[],{"trials":8460,"activeCount":101},[],{"trials":8462,"activeCount":101},[],{"trials":8464,"activeCount":101},[8465],{"nctId":8444,"briefTitle":8445,"status":160,"phases":8466,"primaryCompletion":7168,"completion":7168,"start":8447,"enrollment":1546,"conditions":8467,"interventions":8468},[91],[1601],[8433,8450],{"trials":8470,"activeCount":101},[],{"trials":8472,"activeCount":101},[],{"intervention":7935,"totalTrials":115,"cells":8474},{"EARLY_PHASE1":8475,"PHASE1":8477,"PHASE2":8479,"PHASE3":8481,"PHASE4":8487,"NA":8489},{"trials":8476,"activeCount":101},[],{"trials":8478,"activeCount":101},[],{"trials":8480,"activeCount":101},[],{"trials":8482,"activeCount":101},[8483],{"nctId":7926,"briefTitle":7927,"status":160,"phases":8484,"primaryCompletion":7929,"completion":7930,"start":7931,"enrollment":791,"conditions":8485,"interventions":8486},[91],[1781],[7892,7934,7935,1701],{"trials":8488,"activeCount":101},[],{"trials":8490,"activeCount":101},[],{"intervention":8492,"totalTrials":115,"cells":8493},"Lidocaine-Prilocaine Cream",{"EARLY_PHASE1":8494,"PHASE1":8496,"PHASE2":8498,"PHASE3":8500,"PHASE4":8509,"NA":8511},{"trials":8495,"activeCount":101},[],{"trials":8497,"activeCount":101},[],{"trials":8499,"activeCount":101},[],{"trials":8501,"activeCount":101},[8502],{"nctId":8503,"briefTitle":8504,"status":132,"phases":8505,"primaryCompletion":7821,"completion":7821,"start":3944,"enrollment":101,"conditions":8506,"interventions":8507},"NCT03508804","Lidocaine-Prilocaine Cream in Conjunction With Paracervical Block for Pain With Abortion",[91],[24],[8492,8508],"1% Lidocaine Paracervical Block",{"trials":8510,"activeCount":101},[],{"trials":8512,"activeCount":101},[],{"intervention":8508,"totalTrials":115,"cells":8514},{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8521,"PHASE4":8527,"NA":8529},{"trials":8516,"activeCount":101},[],{"trials":8518,"activeCount":101},[],{"trials":8520,"activeCount":101},[],{"trials":8522,"activeCount":101},[8523],{"nctId":8503,"briefTitle":8504,"status":132,"phases":8524,"primaryCompletion":7821,"completion":7821,"start":3944,"enrollment":101,"conditions":8525,"interventions":8526},[91],[24],[8492,8508],{"trials":8528,"activeCount":101},[],{"trials":8530,"activeCount":101},[],{"intervention":8532,"totalTrials":115,"cells":8533},"Vaginal 2% Lidocaine",{"EARLY_PHASE1":8534,"PHASE1":8536,"PHASE2":8538,"PHASE3":8540,"PHASE4":8553,"NA":8555},{"trials":8535,"activeCount":101},[],{"trials":8537,"activeCount":101},[],{"trials":8539,"activeCount":101},[],{"trials":8541,"activeCount":101},[8542],{"nctId":8543,"briefTitle":8544,"status":160,"phases":8545,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":8548,"conditions":8549,"interventions":8551},"NCT02738203","Self-Administered Lidocaine Gel for Pain Management With IUD Insertion",[91],"2017-10-19","2016-06-01",220,[8550],"IUD Insertion",[8532,8552],"Surgical Lubricant Jelly",{"trials":8554,"activeCount":101},[],{"trials":8556,"activeCount":101},[],{"intervention":8552,"totalTrials":115,"cells":8558},{"EARLY_PHASE1":8559,"PHASE1":8561,"PHASE2":8563,"PHASE3":8565,"PHASE4":8571,"NA":8573},{"trials":8560,"activeCount":101},[],{"trials":8562,"activeCount":101},[],{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[8567],{"nctId":8543,"briefTitle":8544,"status":160,"phases":8568,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":8548,"conditions":8569,"interventions":8570},[91],[8550],[8532,8552],{"trials":8572,"activeCount":101},[],{"trials":8574,"activeCount":101},[],{"intervention":8576,"totalTrials":115,"cells":8577},"Enoxaparin",{"EARLY_PHASE1":8578,"PHASE1":8580,"PHASE2":8582,"PHASE3":8584,"PHASE4":8593,"NA":8595},{"trials":8579,"activeCount":101},[],{"trials":8581,"activeCount":101},[],{"trials":8583,"activeCount":101},[],{"trials":8585,"activeCount":101},[8586],{"nctId":8587,"briefTitle":8588,"status":160,"phases":8589,"primaryCompletion":3503,"completion":1499,"start":758,"enrollment":3997,"conditions":8590,"interventions":8592},"NCT00878826","Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.",[90,91],[8591],"Venous Thrombosis",[8576],{"trials":8594,"activeCount":101},[],{"trials":8596,"activeCount":101},[],{"intervention":8042,"totalTrials":115,"cells":8598},{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8605,"PHASE4":8611,"NA":8613},{"trials":8600,"activeCount":101},[],{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":101},[8607],{"nctId":8035,"briefTitle":8036,"status":160,"phases":8608,"primaryCompletion":8038,"completion":8038,"start":6977,"enrollment":8039,"conditions":8609,"interventions":8610},[91],[8028],[8042,8014],{"trials":8612,"activeCount":101},[],{"trials":8614,"activeCount":101},[],{"intervention":8616,"totalTrials":115,"cells":8617},"Unasyn",{"EARLY_PHASE1":8618,"PHASE1":8620,"PHASE2":8622,"PHASE3":8624,"PHASE4":8635,"NA":8637},{"trials":8619,"activeCount":101},[],{"trials":8621,"activeCount":101},[],{"trials":8623,"activeCount":101},[],{"trials":8625,"activeCount":101},[8626],{"nctId":8627,"briefTitle":8628,"status":160,"phases":8629,"primaryCompletion":8630,"completion":8630,"start":758,"enrollment":297,"conditions":8631,"interventions":8633},"NCT00879190","Ampicillin \u002F Sulbactam vs. Ampicillin \u002F Gentamicin for Treatment of Chorioamnionitis",[90,91],"2012-06",[8632],"Chorioamnionitis",[8616,8634],"Ampicillin\u002Fgentamicin",{"trials":8636,"activeCount":101},[],{"trials":8638,"activeCount":101},[],{"intervention":8634,"totalTrials":115,"cells":8640},{"EARLY_PHASE1":8641,"PHASE1":8643,"PHASE2":8645,"PHASE3":8647,"PHASE4":8653,"NA":8655},{"trials":8642,"activeCount":101},[],{"trials":8644,"activeCount":101},[],{"trials":8646,"activeCount":101},[],{"trials":8648,"activeCount":101},[8649],{"nctId":8627,"briefTitle":8628,"status":160,"phases":8650,"primaryCompletion":8630,"completion":8630,"start":758,"enrollment":297,"conditions":8651,"interventions":8652},[90,91],[8632],[8616,8634],{"trials":8654,"activeCount":101},[],{"trials":8656,"activeCount":101},[],{"intervention":8658,"totalTrials":115,"cells":8659},"Lidocaine Gel",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8664,"PHASE3":8666,"PHASE4":8676,"NA":8678},{"trials":8661,"activeCount":101},[],{"trials":8663,"activeCount":101},[],{"trials":8665,"activeCount":101},[],{"trials":8667,"activeCount":101},[8668],{"nctId":8669,"briefTitle":8670,"status":160,"phases":8671,"primaryCompletion":3764,"completion":3764,"start":6055,"enrollment":5543,"conditions":8672,"interventions":8674},"NCT02852434","Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation",[91],[8673],"Pain Management, Cervical Preparation",[8658,8675],"Lidocaine Paracervical Block",{"trials":8677,"activeCount":101},[],{"trials":8679,"activeCount":101},[],{"intervention":8675,"totalTrials":115,"cells":8681},{"EARLY_PHASE1":8682,"PHASE1":8684,"PHASE2":8686,"PHASE3":8688,"PHASE4":8694,"NA":8696},{"trials":8683,"activeCount":101},[],{"trials":8685,"activeCount":101},[],{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[8690],{"nctId":8669,"briefTitle":8670,"status":160,"phases":8691,"primaryCompletion":3764,"completion":3764,"start":6055,"enrollment":5543,"conditions":8692,"interventions":8693},[91],[8673],[8658,8675],{"trials":8695,"activeCount":101},[],{"trials":8697,"activeCount":101},[],{"intervention":8699,"totalTrials":115,"cells":8700},"Human Growth Hormone",{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8705,"PHASE3":8707,"PHASE4":8718,"NA":8720},{"trials":8702,"activeCount":101},[],{"trials":8704,"activeCount":101},[],{"trials":8706,"activeCount":101},[],{"trials":8708,"activeCount":101},[8709],{"nctId":8710,"briefTitle":8711,"status":160,"phases":8712,"primaryCompletion":8713,"completion":8713,"start":8714,"enrollment":3997,"conditions":8715,"interventions":8717},"NCT01007071","Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency",[91],"2012-12-12","2009-11-01",[8716],"Hypopituitarism",[8699],{"trials":8719,"activeCount":101},[],{"trials":8721,"activeCount":101},[],{"intervention":8723,"totalTrials":115,"cells":8724},"Etonogestrel-Immediate",{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8729,"PHASE3":8731,"PHASE4":8746,"NA":8748},{"trials":8726,"activeCount":101},[],{"trials":8728,"activeCount":101},[],{"trials":8730,"activeCount":101},[],{"trials":8732,"activeCount":101},[8733],{"nctId":8734,"briefTitle":8735,"status":160,"phases":8736,"primaryCompletion":8737,"completion":8738,"start":8739,"enrollment":8740,"conditions":8741,"interventions":8744},"NCT02866643","Labor and Delivery Implant Insertion: A Randomized Controlled Trial",[91],"2019-09-06","2021-07-31","2016-10-28",95,[8742,8743],"Postpartum Contraception","Family Planning",[8723,8745],"Etonogestrel-Delayed",{"trials":8747,"activeCount":101},[],{"trials":8749,"activeCount":101},[],{"intervention":8745,"totalTrials":115,"cells":8751},{"EARLY_PHASE1":8752,"PHASE1":8754,"PHASE2":8756,"PHASE3":8758,"PHASE4":8764,"NA":8766},{"trials":8753,"activeCount":101},[],{"trials":8755,"activeCount":101},[],{"trials":8757,"activeCount":101},[],{"trials":8759,"activeCount":101},[8760],{"nctId":8734,"briefTitle":8735,"status":160,"phases":8761,"primaryCompletion":8737,"completion":8738,"start":8739,"enrollment":8740,"conditions":8762,"interventions":8763},[91],[8742,8743],[8723,8745],{"trials":8765,"activeCount":101},[],{"trials":8767,"activeCount":101},[],{"intervention":8769,"totalTrials":115,"cells":8770},"ursodiol",{"EARLY_PHASE1":8771,"PHASE1":8773,"PHASE2":8775,"PHASE3":8777,"PHASE4":8789,"NA":8791},{"trials":8772,"activeCount":101},[],{"trials":8774,"activeCount":101},[],{"trials":8776,"activeCount":101},[],{"trials":8778,"activeCount":101},[8779],{"nctId":8780,"briefTitle":8781,"status":716,"phases":8782,"primaryCompletion":8783,"completion":8783,"start":8784,"enrollment":152,"conditions":8785,"interventions":8788},"NCT03724175","The Role of Secondary Bile Acids in Intestinal Inflammation",[90,91],"2026-03-02","2019-08-26",[8786,8787],"Ulcerative Colitis","Pouchitis",[8769],{"trials":8790,"activeCount":101},[],{"trials":8792,"activeCount":101},[],{"intervention":8794,"totalTrials":115,"cells":8795},"Vasopressin (USP) Injectable Solution [Vasostrict]",{"EARLY_PHASE1":8796,"PHASE1":8798,"PHASE2":8800,"PHASE3":8802,"PHASE4":8814,"NA":8816},{"trials":8797,"activeCount":101},[],{"trials":8799,"activeCount":101},[],{"trials":8801,"activeCount":101},[],{"trials":8803,"activeCount":101},[8804],{"nctId":8805,"briefTitle":8806,"status":160,"phases":8807,"primaryCompletion":8808,"completion":8808,"start":8809,"enrollment":8810,"conditions":8811,"interventions":8813},"NCT03204786","Intranasal Vasopressin Treatment in Children With Autism",[90,91],"2024-03-18","2018-02-20",157,[1586,27,8812],"ASD",[8794],{"trials":8815,"activeCount":101},[],{"trials":8817,"activeCount":101},[],{"intervention":781,"totalTrials":115,"cells":8819},{"EARLY_PHASE1":8820,"PHASE1":8822,"PHASE2":8824,"PHASE3":8826,"PHASE4":8832,"NA":8834},{"trials":8821,"activeCount":101},[],{"trials":8823,"activeCount":101},[],{"trials":8825,"activeCount":101},[],{"trials":8827,"activeCount":101},[8828],{"nctId":772,"briefTitle":773,"status":160,"phases":8829,"completion":775,"start":776,"enrollment":777,"conditions":8830,"interventions":8831},[91],[779],[781,683],{"trials":8833,"activeCount":101},[],{"trials":8835,"activeCount":101},[],{"intervention":8837,"totalTrials":115,"cells":8838},"Darunavir\u002FCobicistat",{"EARLY_PHASE1":8839,"PHASE1":8841,"PHASE2":8843,"PHASE3":8845,"PHASE4":8855,"NA":8857},{"trials":8840,"activeCount":101},[],{"trials":8842,"activeCount":101},[],{"trials":8844,"activeCount":101},[],{"trials":8846,"activeCount":101},[8847],{"nctId":8848,"briefTitle":8849,"status":132,"phases":8850,"primaryCompletion":148,"completion":148,"start":2173,"enrollment":101,"conditions":8851,"interventions":8853},"NCT02499978","Darunavir\u002FCobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity",[90,91],[8852],"HIV\u002FAIDS",[8837,8854],"Dolutegravir",{"trials":8856,"activeCount":101},[],{"trials":8858,"activeCount":101},[],{"intervention":8854,"totalTrials":115,"cells":8860},{"EARLY_PHASE1":8861,"PHASE1":8863,"PHASE2":8865,"PHASE3":8867,"PHASE4":8873,"NA":8875},{"trials":8862,"activeCount":101},[],{"trials":8864,"activeCount":101},[],{"trials":8866,"activeCount":101},[],{"trials":8868,"activeCount":101},[8869],{"nctId":8848,"briefTitle":8849,"status":132,"phases":8870,"primaryCompletion":148,"completion":148,"start":2173,"enrollment":101,"conditions":8871,"interventions":8872},[90,91],[8852],[8837,8854],{"trials":8874,"activeCount":101},[],{"trials":8876,"activeCount":101},[],{"intervention":8878,"totalTrials":115,"cells":8879},"Buprenorphine",{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8884,"PHASE3":8886,"PHASE4":8896,"NA":8898},{"trials":8881,"activeCount":101},[],{"trials":8883,"activeCount":101},[],{"trials":8885,"activeCount":101},[],{"trials":8887,"activeCount":101},[8888],{"nctId":8889,"briefTitle":8890,"status":160,"phases":8891,"primaryCompletion":8892,"completion":8892,"start":8893,"enrollment":1435,"conditions":8894,"interventions":8895},"NCT04116528","Opiate Suicide Study in Patients With Major Depression",[91],"2025-04-28","2020-08-01",[167],[8878],{"trials":8897,"activeCount":101},[],{"trials":8899,"activeCount":101},[],{"intervention":8901,"totalTrials":115,"cells":8902},"Inhaled budesonide and formoterol",{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8907,"PHASE3":8909,"PHASE4":8925,"NA":8927},{"trials":8904,"activeCount":101},[],{"trials":8906,"activeCount":101},[],{"trials":8908,"activeCount":101},[],{"trials":8910,"activeCount":101},[8911],{"nctId":8912,"briefTitle":8913,"status":716,"phases":8914,"primaryCompletion":8915,"completion":8915,"start":8916,"enrollment":8917,"conditions":8918,"interventions":8923},"NCT04193878","ARrest RESpiraTory Failure From PNEUMONIA",[91],"2025-07-22","2020-06-01",465,[8919,8920,8921,8922],"Pneumonia","Hypoxemia","Acute Respiratory Failure","COVID-19 Pneumonia",[8901,8924],"Inhaled placebo",{"trials":8926,"activeCount":101},[],{"trials":8928,"activeCount":101},[],{"intervention":8924,"totalTrials":115,"cells":8930},{"EARLY_PHASE1":8931,"PHASE1":8933,"PHASE2":8935,"PHASE3":8937,"PHASE4":8943,"NA":8945},{"trials":8932,"activeCount":101},[],{"trials":8934,"activeCount":101},[],{"trials":8936,"activeCount":101},[],{"trials":8938,"activeCount":101},[8939],{"nctId":8912,"briefTitle":8913,"status":716,"phases":8940,"primaryCompletion":8915,"completion":8915,"start":8916,"enrollment":8917,"conditions":8941,"interventions":8942},[91],[8919,8920,8921,8922],[8901,8924],{"trials":8944,"activeCount":101},[],{"trials":8946,"activeCount":101},[],{"intervention":8948,"totalTrials":115,"cells":8949},"Amifostine",{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8954,"PHASE3":8956,"PHASE4":8964,"NA":8966},{"trials":8951,"activeCount":101},[],{"trials":8953,"activeCount":101},[],{"trials":8955,"activeCount":101},[],{"trials":8957,"activeCount":101},[8958],{"nctId":8959,"briefTitle":8960,"status":716,"phases":8961,"primaryCompletion":857,"completion":6286,"start":844,"enrollment":1766,"conditions":8962,"interventions":8963},"NCT01364259","A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia",[91],[659],[8948],{"trials":8965,"activeCount":101},[],{"trials":8967,"activeCount":101},[],{"intervention":8969,"totalTrials":115,"cells":8970},"Rituximab for transplant rejection",{"EARLY_PHASE1":8971,"PHASE1":8973,"PHASE2":8975,"PHASE3":8977,"PHASE4":8985,"NA":8987},{"trials":8972,"activeCount":101},[],{"trials":8974,"activeCount":101},[],{"trials":8976,"activeCount":101},[],{"trials":8978,"activeCount":101},[8979],{"nctId":8980,"briefTitle":8981,"status":160,"phases":8982,"completion":1801,"start":698,"enrollment":111,"conditions":8983,"interventions":8984},"NCT00697996","Rituximab for Pediatric Renal Transplant Rejection",[90,91],[3132],[8969],{"trials":8986,"activeCount":101},[],{"trials":8988,"activeCount":101},[],{"intervention":8990,"totalTrials":115,"cells":8991},"Isotonic saline",{"EARLY_PHASE1":8992,"PHASE1":8994,"PHASE2":8996,"PHASE3":8998,"PHASE4":9010,"NA":9012},{"trials":8993,"activeCount":101},[],{"trials":8995,"activeCount":101},[],{"trials":8997,"activeCount":101},[],{"trials":8999,"activeCount":101},[9000],{"nctId":9001,"briefTitle":9002,"status":132,"phases":9003,"primaryCompletion":9004,"completion":9004,"start":7498,"enrollment":101,"conditions":9005,"interventions":9007},"NCT04242368","Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis",[90,91],"2021-07-01",[9006],"Chronic Rhinosinusitis (Diagnosis)",[8990,9008,9009],"Hypertonic Nasal Wash","Fluticasone Propionate",{"trials":9011,"activeCount":101},[],{"trials":9013,"activeCount":101},[],{"intervention":9008,"totalTrials":115,"cells":9015},{"EARLY_PHASE1":9016,"PHASE1":9018,"PHASE2":9020,"PHASE3":9022,"PHASE4":9028,"NA":9030},{"trials":9017,"activeCount":101},[],{"trials":9019,"activeCount":101},[],{"trials":9021,"activeCount":101},[],{"trials":9023,"activeCount":101},[9024],{"nctId":9001,"briefTitle":9002,"status":132,"phases":9025,"primaryCompletion":9004,"completion":9004,"start":7498,"enrollment":101,"conditions":9026,"interventions":9027},[90,91],[9006],[8990,9008,9009],{"trials":9029,"activeCount":101},[],{"trials":9031,"activeCount":101},[],{"intervention":9009,"totalTrials":115,"cells":9033},{"EARLY_PHASE1":9034,"PHASE1":9036,"PHASE2":9038,"PHASE3":9040,"PHASE4":9046,"NA":9048},{"trials":9035,"activeCount":101},[],{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[],{"trials":9041,"activeCount":101},[9042],{"nctId":9001,"briefTitle":9002,"status":132,"phases":9043,"primaryCompletion":9004,"completion":9004,"start":7498,"enrollment":101,"conditions":9044,"interventions":9045},[90,91],[9006],[8990,9008,9009],{"trials":9047,"activeCount":101},[],{"trials":9049,"activeCount":101},[],{"intervention":9051,"totalTrials":115,"cells":9052},"Oral Vancomycin",{"EARLY_PHASE1":9053,"PHASE1":9055,"PHASE2":9057,"PHASE3":9059,"PHASE4":9068,"NA":9070},{"trials":9054,"activeCount":101},[],{"trials":9056,"activeCount":101},[],{"trials":9058,"activeCount":101},[],{"trials":9060,"activeCount":101},[9061],{"nctId":9062,"briefTitle":9063,"status":160,"phases":9064,"primaryCompletion":9065,"completion":9065,"start":7655,"enrollment":7951,"conditions":9066,"interventions":9067},"NCT01802073","Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects",[91],"2015-08",[5020],[9051],{"trials":9069,"activeCount":101},[],{"trials":9071,"activeCount":101},[],{"intervention":9073,"totalTrials":115,"cells":9074},"Progesterone",{"EARLY_PHASE1":9075,"PHASE1":9077,"PHASE2":9079,"PHASE3":9081,"PHASE4":9091,"NA":9093},{"trials":9076,"activeCount":101},[],{"trials":9078,"activeCount":101},[],{"trials":9080,"activeCount":101},[],{"trials":9082,"activeCount":101},[9083],{"nctId":9084,"briefTitle":9085,"status":716,"phases":9086,"primaryCompletion":1920,"completion":875,"start":1778,"enrollment":97,"conditions":9087,"interventions":9089},"NCT00946088","Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial",[90,91],[9088],"Pregnancy Complications",[9073,9090],"Polyethylene glycol&hydrogenated vegetable oil.",{"trials":9092,"activeCount":101},[],{"trials":9094,"activeCount":101},[],{"intervention":9090,"totalTrials":115,"cells":9096},{"EARLY_PHASE1":9097,"PHASE1":9099,"PHASE2":9101,"PHASE3":9103,"PHASE4":9109,"NA":9111},{"trials":9098,"activeCount":101},[],{"trials":9100,"activeCount":101},[],{"trials":9102,"activeCount":101},[],{"trials":9104,"activeCount":101},[9105],{"nctId":9084,"briefTitle":9085,"status":716,"phases":9106,"primaryCompletion":1920,"completion":875,"start":1778,"enrollment":97,"conditions":9107,"interventions":9108},[90,91],[9088],[9073,9090],{"trials":9110,"activeCount":101},[],{"trials":9112,"activeCount":101},[],{"intervention":9114,"totalTrials":115,"cells":9115},"Ferumoxytol Injection [Feraheme]",{"EARLY_PHASE1":9116,"PHASE1":9118,"PHASE2":9120,"PHASE3":9122,"PHASE4":9134,"NA":9136},{"trials":9117,"activeCount":101},[],{"trials":9119,"activeCount":101},[],{"trials":9121,"activeCount":101},[],{"trials":9123,"activeCount":101},[9124],{"nctId":9125,"briefTitle":9126,"status":160,"phases":9127,"primaryCompletion":189,"completion":189,"start":9128,"enrollment":9129,"conditions":9130,"interventions":9132},"NCT04253626","Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia",[91],"2021-01-21",83,[7953,9131],"Anemia, Iron Deficiency",[9114,9133],"Ferrous Sulfate",{"trials":9135,"activeCount":101},[],{"trials":9137,"activeCount":101},[],{"intervention":9133,"totalTrials":115,"cells":9139},{"EARLY_PHASE1":9140,"PHASE1":9142,"PHASE2":9144,"PHASE3":9146,"PHASE4":9152,"NA":9154},{"trials":9141,"activeCount":101},[],{"trials":9143,"activeCount":101},[],{"trials":9145,"activeCount":101},[],{"trials":9147,"activeCount":101},[9148],{"nctId":9125,"briefTitle":9126,"status":160,"phases":9149,"primaryCompletion":189,"completion":189,"start":9128,"enrollment":9129,"conditions":9150,"interventions":9151},[91],[7953,9131],[9114,9133],{"trials":9153,"activeCount":101},[],{"trials":9155,"activeCount":101},[],{"intervention":3306,"totalTrials":115,"cells":9157},{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9162,"PHASE3":9164,"PHASE4":9170,"NA":9172},{"trials":9159,"activeCount":101},[],{"trials":9161,"activeCount":101},[],{"trials":9163,"activeCount":101},[],{"trials":9165,"activeCount":101},[9166],{"nctId":3297,"briefTitle":3298,"status":160,"phases":9167,"primaryCompletion":3300,"completion":3300,"start":3301,"enrollment":3302,"conditions":9168,"interventions":9169},[91],[3304],[3306,2563],{"trials":9171,"activeCount":101},[],{"trials":9173,"activeCount":101},[],{"intervention":9175,"totalTrials":115,"cells":9176},"Extended treatment",{"EARLY_PHASE1":9177,"PHASE1":9179,"PHASE2":9181,"PHASE3":9183,"PHASE4":9193,"NA":9195},{"trials":9178,"activeCount":101},[],{"trials":9180,"activeCount":101},[],{"trials":9182,"activeCount":101},[],{"trials":9184,"activeCount":101},[9185],{"nctId":9186,"briefTitle":9187,"status":160,"phases":9188,"primaryCompletion":9189,"completion":7020,"start":1743,"enrollment":9190,"conditions":9191,"interventions":9192},"NCT00459953","Extended Cessation Treatment for Teen Smokers",[90,91],"2011-06",141,[6864],[9175],{"trials":9194,"activeCount":101},[],{"trials":9196,"activeCount":101},[],{"intervention":9198,"totalTrials":115,"cells":9199},"Atazanavir",{"EARLY_PHASE1":9200,"PHASE1":9202,"PHASE2":9204,"PHASE3":9206,"PHASE4":9215,"NA":9217},{"trials":9201,"activeCount":101},[],{"trials":9203,"activeCount":101},[],{"trials":9205,"activeCount":101},[],{"trials":9207,"activeCount":101},[9208],{"nctId":9209,"briefTitle":9210,"status":160,"phases":9211,"primaryCompletion":9212,"completion":1809,"start":271,"enrollment":1124,"conditions":9213,"interventions":9214},"NCT00160329","Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia",[91],"2007-04",[7050,7567],[9198],{"trials":9216,"activeCount":101},[],{"trials":9218,"activeCount":101},[],{"intervention":727,"totalTrials":3997,"cells":9220},{"EARLY_PHASE1":9221,"PHASE1":9223,"PHASE2":9233,"PHASE3":9286,"PHASE4":9288,"NA":9290},{"trials":9222,"activeCount":101},[],{"trials":9224,"activeCount":101},[9225,9229],{"nctId":1994,"briefTitle":1995,"status":716,"phases":9226,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":1766,"conditions":9227,"interventions":9228},[89],[2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015],[2017,2018,2019,2020],{"nctId":3461,"briefTitle":3462,"status":160,"phases":9230,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":1810,"conditions":9231,"interventions":9232},[89],[3468,3469,3470,3471],[3473,730,727],{"trials":9234,"activeCount":101},[9235,9239,9253,9257,9266,9270,9274,9278,9282],{"nctId":3499,"briefTitle":3500,"status":716,"phases":9236,"primaryCompletion":3502,"completion":3503,"start":1500,"enrollment":334,"conditions":9237,"interventions":9238},[90],[3505,3506,740,3507,1339],[1533,729,726,727,730,3509],{"nctId":9240,"briefTitle":9241,"status":160,"phases":9242,"completion":1731,"start":9243,"conditions":9244,"interventions":9245},"NCT00002714","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease",[90],"1995-04",[1426],[9246,9247,9248,2019,9249,9250,9251,9252],"bleomycin sulfate","Stanford V regimen","doxorubicin hydrochloride","mechlorethamine hydrochloride","prednisone","vinblastine sulfate","vincristine sulfate",{"nctId":1430,"briefTitle":1431,"status":716,"phases":9254,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":9255,"interventions":9256},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"nctId":9258,"briefTitle":9259,"status":160,"phases":9260,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":9262,"interventions":9263},"NCT00002715","Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma",[90],"1989-04",[1426],[9264,9247,2048,727,9265,1504,1725,2050],"Bleomycin sulfate","Mechlorethamine hydrochloride",{"nctId":1727,"briefTitle":1728,"status":160,"phases":9267,"primaryCompletion":1730,"completion":876,"start":1731,"enrollment":1732,"conditions":9268,"interventions":9269},[90],[1734,1735,1426],[1678,1737,726,727,730],{"nctId":714,"briefTitle":715,"status":716,"phases":9271,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":9272,"interventions":9273},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":1739,"briefTitle":1740,"status":716,"phases":9275,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":9276,"interventions":9277},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"nctId":3527,"briefTitle":3528,"status":160,"phases":9279,"primaryCompletion":3530,"completion":3531,"start":3532,"enrollment":3533,"conditions":9280,"interventions":9281},[90],[3535,1426,1734,3536],[1747,730,1722,1504,1748,727],{"nctId":1541,"briefTitle":1542,"status":160,"phases":9283,"primaryCompletion":1544,"completion":1545,"start":1500,"enrollment":1546,"conditions":9284,"interventions":9285},[90],[763],[730,727,766,726,708],{"trials":9287,"activeCount":101},[],{"trials":9289,"activeCount":101},[],{"trials":9291,"activeCount":101},[],{"intervention":1699,"totalTrials":684,"cells":9293},{"EARLY_PHASE1":9294,"PHASE1":9296,"PHASE2":9302,"PHASE3":9335,"PHASE4":9337,"NA":9339},{"trials":9295,"activeCount":101},[],{"trials":9297,"activeCount":101},[9298],{"nctId":1806,"briefTitle":1807,"status":716,"phases":9299,"primaryCompletion":1809,"completion":1809,"start":1754,"enrollment":1810,"conditions":9300,"interventions":9301},[89],[1812,1813,1814,1815],[1700,1817,1818,1699],{"trials":9303,"activeCount":101},[9304,9308,9312,9316,9320,9324,9328],{"nctId":1687,"briefTitle":1688,"status":716,"phases":9305,"primaryCompletion":1471,"completion":1690,"start":231,"enrollment":152,"conditions":9306,"interventions":9307},[90],[1692,1693,1694,1695,1696],[1678,1698,1699,1700,1701],{"nctId":1826,"briefTitle":1827,"status":160,"phases":9309,"primaryCompletion":1829,"completion":1829,"start":1472,"enrollment":222,"conditions":9310,"interventions":9311},[90],[1831,1832,1833,1834],[1836,1837,1838],{"nctId":1703,"briefTitle":1704,"status":716,"phases":9313,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":9314,"interventions":9315},[90],[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],[1699,1698,1722,1723,1678,1724,1725],{"nctId":1750,"briefTitle":1751,"status":160,"phases":9317,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":9318,"interventions":9319},[90],[1757,1758],[1760,1678,1699],{"nctId":3940,"briefTitle":3941,"status":160,"phases":9321,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":37,"conditions":9322,"interventions":9323},[90],[3947,3948,3949,3950,3951,3952],[3954,3955,1837,3956],{"nctId":3958,"briefTitle":3959,"status":160,"phases":9325,"primaryCompletion":3961,"completion":3962,"start":1976,"enrollment":791,"conditions":9326,"interventions":9327},[90],[3914],[3965,1698,3966,1699],{"nctId":9329,"briefTitle":9330,"status":716,"phases":9331,"primaryCompletion":220,"completion":1918,"start":3807,"enrollment":191,"conditions":9332,"interventions":9334},"NCT00238615","Phase II Docetaxel \u002F Carboplatin \u002F XRT + Surgical Resection in Stage III NSCLC",[90],[1757,9333],"Carcinoma, Non-Small-Cell Lung",[3965,1699],{"trials":9336,"activeCount":101},[],{"trials":9338,"activeCount":101},[],{"trials":9340,"activeCount":101},[],{"intervention":708,"totalTrials":197,"cells":9342},{"EARLY_PHASE1":9343,"PHASE1":9345,"PHASE2":9347,"PHASE3":9373,"PHASE4":9375,"NA":9377},{"trials":9344,"activeCount":101},[],{"trials":9346,"activeCount":101},[],{"trials":9348,"activeCount":101},[9349,9353,9357,9361,9365,9369],{"nctId":693,"briefTitle":694,"status":160,"phases":9350,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":9351,"interventions":9352},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"nctId":1430,"briefTitle":1431,"status":716,"phases":9354,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":9355,"interventions":9356},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"nctId":714,"briefTitle":715,"status":716,"phases":9358,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":9359,"interventions":9360},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":3803,"briefTitle":3804,"status":160,"phases":9362,"primaryCompletion":756,"completion":3806,"start":3807,"enrollment":3808,"conditions":9363,"interventions":9364},[90],[739,740],[706,728,729,708],{"nctId":1541,"briefTitle":1542,"status":160,"phases":9366,"primaryCompletion":1544,"completion":1545,"start":1500,"enrollment":1546,"conditions":9367,"interventions":9368},[90],[763],[730,727,766,726,708],{"nctId":753,"briefTitle":754,"status":160,"phases":9370,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":9371,"interventions":9372},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":9374,"activeCount":101},[],{"trials":9376,"activeCount":101},[],{"trials":9378,"activeCount":101},[],{"intervention":726,"totalTrials":1810,"cells":9380},{"EARLY_PHASE1":9381,"PHASE1":9383,"PHASE2":9385,"PHASE3":9403,"PHASE4":9405,"NA":9407},{"trials":9382,"activeCount":101},[],{"trials":9384,"activeCount":101},[],{"trials":9386,"activeCount":101},[9387,9391,9395,9399],{"nctId":3499,"briefTitle":3500,"status":716,"phases":9388,"primaryCompletion":3502,"completion":3503,"start":1500,"enrollment":334,"conditions":9389,"interventions":9390},[90],[3505,3506,740,3507,1339],[1533,729,726,727,730,3509],{"nctId":1727,"briefTitle":1728,"status":160,"phases":9392,"primaryCompletion":1730,"completion":876,"start":1731,"enrollment":1732,"conditions":9393,"interventions":9394},[90],[1734,1735,1426],[1678,1737,726,727,730],{"nctId":714,"briefTitle":715,"status":716,"phases":9396,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":9397,"interventions":9398},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":1541,"briefTitle":1542,"status":160,"phases":9400,"primaryCompletion":1544,"completion":1545,"start":1500,"enrollment":1546,"conditions":9401,"interventions":9402},[90],[763],[730,727,766,726,708],{"trials":9404,"activeCount":101},[],{"trials":9406,"activeCount":101},[],{"trials":9408,"activeCount":101},[],{"intervention":1724,"totalTrials":1810,"cells":9410},{"EARLY_PHASE1":9411,"PHASE1":9413,"PHASE2":9425,"PHASE3":9448,"PHASE4":9450,"NA":9452},{"trials":9412,"activeCount":101},[],{"trials":9414,"activeCount":101},[9415],{"nctId":9416,"briefTitle":9417,"status":132,"phases":9418,"primaryCompletion":9419,"completion":9420,"start":9421,"enrollment":101,"conditions":9422,"interventions":9424},"NCT04830878","Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients",[89],"2023-04","2024-04","2021-04",[9423],"Proliferative Vitreoretinopathy",[1724],{"trials":9426,"activeCount":101},[9427,9440,9444],{"nctId":9428,"briefTitle":9429,"status":160,"phases":9430,"primaryCompletion":9431,"completion":9431,"start":9432,"enrollment":1977,"conditions":9433,"interventions":9438},"NCT03520842","Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer",[90],"2022-06-15","2018-08-14",[9434,9435,9436,9437],"KRAS Gene Mutation","Metastatic Malignant Neoplasm in the Brain","Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer AJCC v7",[1724,9439],"Regorafenib",{"nctId":1703,"briefTitle":1704,"status":716,"phases":9441,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":9442,"interventions":9443},[90],[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],[1699,1698,1722,1723,1678,1724,1725],{"nctId":2036,"briefTitle":2037,"status":160,"phases":9445,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":9446,"interventions":9447},[90],[2042,2043,2044,2045],[2047,2048,2049,2050,1569,1987,1724],{"trials":9449,"activeCount":101},[],{"trials":9451,"activeCount":101},[],{"trials":9453,"activeCount":101},[],{"intervention":1722,"totalTrials":1810,"cells":9455},{"EARLY_PHASE1":9456,"PHASE1":9458,"PHASE2":9460,"PHASE3":9478,"PHASE4":9480,"NA":9482},{"trials":9457,"activeCount":101},[],{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[9462,9466,9470,9474],{"nctId":1703,"briefTitle":1704,"status":716,"phases":9463,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":9464,"interventions":9465},[90],[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],[1699,1698,1722,1723,1678,1724,1725],{"nctId":8056,"briefTitle":8057,"status":716,"phases":9467,"primaryCompletion":874,"completion":874,"start":7019,"enrollment":334,"conditions":9468,"interventions":9469},[90],[8060,8061],[7934,1747,3369,1722,8063,8064],{"nctId":1739,"briefTitle":1740,"status":716,"phases":9471,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":9472,"interventions":9473},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"nctId":3527,"briefTitle":3528,"status":160,"phases":9475,"primaryCompletion":3530,"completion":3531,"start":3532,"enrollment":3533,"conditions":9476,"interventions":9477},[90],[3535,1426,1734,3536],[1747,730,1722,1504,1748,727],{"trials":9479,"activeCount":101},[],{"trials":9481,"activeCount":101},[],{"trials":9483,"activeCount":101},[],{"intervention":3369,"totalTrials":1810,"cells":9485},{"EARLY_PHASE1":9486,"PHASE1":9488,"PHASE2":9494,"PHASE3":9517,"PHASE4":9519,"NA":9521},{"trials":9487,"activeCount":101},[],{"trials":9489,"activeCount":101},[9490],{"nctId":3359,"briefTitle":3360,"status":160,"phases":9491,"primaryCompletion":3362,"completion":3363,"start":3364,"enrollment":1314,"conditions":9492,"interventions":9493},[89],[3366,3367],[1772,3369],{"trials":9495,"activeCount":101},[9496,9500,9510],{"nctId":8056,"briefTitle":8057,"status":716,"phases":9497,"primaryCompletion":874,"completion":874,"start":7019,"enrollment":334,"conditions":9498,"interventions":9499},[90],[8060,8061],[7934,1747,3369,1722,8063,8064],{"nctId":9501,"briefTitle":9502,"status":160,"phases":9503,"primaryCompletion":9504,"completion":9505,"start":1545,"enrollment":232,"conditions":9506,"interventions":9509},"NCT01120639","Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform",[89,90],"2016-11","2020-11-15",[3366,9507,9508],"Cancer of Brain and Nervous System","Glioblastoma Multiforme",[3369],{"nctId":9511,"briefTitle":9512,"status":716,"phases":9513,"primaryCompletion":1919,"completion":1919,"start":5527,"enrollment":334,"conditions":9514,"interventions":9516},"NCT01857752","Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala",[90],[9515],"Retinoblastoma",[3369],{"trials":9518,"activeCount":101},[],{"trials":9520,"activeCount":101},[],{"trials":9522,"activeCount":101},[],{"intervention":9524,"totalTrials":1810,"cells":9525},"Omalizumab",{"EARLY_PHASE1":9526,"PHASE1":9540,"PHASE2":9557,"PHASE3":9572,"PHASE4":9574,"NA":9576},{"trials":9527,"activeCount":101},[9528],{"nctId":9529,"briefTitle":9530,"status":716,"phases":9531,"primaryCompletion":9532,"completion":9532,"start":9533,"enrollment":191,"conditions":9534,"interventions":9537},"NCT04943744","Gastrointestinal STRING Test With Oral Immunotherapy",[88],"2024-05-17","2021-05-17",[9535,9536],"Eosinophilic Disorder","Food Allergy",[9538,9539],"omalizumab","dupliumab",{"trials":9541,"activeCount":101},[9542,9549],{"nctId":9543,"briefTitle":9544,"status":160,"phases":9545,"primaryCompletion":756,"completion":5550,"start":859,"enrollment":222,"conditions":9546,"interventions":9548},"NCT01510626","Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center",[89],[9547],"Immune System Diseases",[9524],{"nctId":9550,"briefTitle":9551,"status":160,"phases":9552,"primaryCompletion":7904,"completion":7904,"start":9553,"enrollment":684,"conditions":9554,"interventions":9556},"NCT01678092","Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis",[89],"2004-05",[9555],"Atopic Dermatitis",[9538],{"trials":9558,"activeCount":101},[9559],{"nctId":9560,"briefTitle":9561,"status":160,"phases":9562,"primaryCompletion":2113,"completion":9563,"start":9564,"enrollment":5156,"conditions":9565,"interventions":9570},"NCT03679676","Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)",[90],"2025-05-02","2020-02-05",[9566,9536,9567,9568,9569],"Hypersensitivity","Hypersensitivity, Food","Peanut Hypersensitivity","Peanut Allergy",[9524,9571],"Dupilumab",{"trials":9573,"activeCount":101},[],{"trials":9575,"activeCount":101},[],{"trials":9577,"activeCount":101},[],{"intervention":1725,"totalTrials":334,"cells":9579},{"EARLY_PHASE1":9580,"PHASE1":9582,"PHASE2":9584,"PHASE3":9598,"PHASE4":9600,"NA":9602},{"trials":9581,"activeCount":101},[],{"trials":9583,"activeCount":101},[],{"trials":9585,"activeCount":101},[9586,9590,9594],{"nctId":1703,"briefTitle":1704,"status":716,"phases":9587,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":97,"conditions":9588,"interventions":9589},[90],[1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720],[1699,1698,1722,1723,1678,1724,1725],{"nctId":9258,"briefTitle":9259,"status":160,"phases":9591,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":9592,"interventions":9593},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"nctId":1739,"briefTitle":1740,"status":716,"phases":9595,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":9596,"interventions":9597},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"trials":9599,"activeCount":101},[],{"trials":9601,"activeCount":101},[],{"trials":9603,"activeCount":101},[],{"intervention":1747,"totalTrials":334,"cells":9605},{"EARLY_PHASE1":9606,"PHASE1":9608,"PHASE2":9610,"PHASE3":9624,"PHASE4":9626,"NA":9628},{"trials":9607,"activeCount":101},[],{"trials":9609,"activeCount":101},[],{"trials":9611,"activeCount":101},[9612,9616,9620],{"nctId":8056,"briefTitle":8057,"status":716,"phases":9613,"primaryCompletion":874,"completion":874,"start":7019,"enrollment":334,"conditions":9614,"interventions":9615},[90],[8060,8061],[7934,1747,3369,1722,8063,8064],{"nctId":1739,"briefTitle":1740,"status":716,"phases":9617,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":9618,"interventions":9619},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"nctId":3527,"briefTitle":3528,"status":160,"phases":9621,"primaryCompletion":3530,"completion":3531,"start":3532,"enrollment":3533,"conditions":9622,"interventions":9623},[90],[3535,1426,1734,3536],[1747,730,1722,1504,1748,727],{"trials":9625,"activeCount":101},[],{"trials":9627,"activeCount":101},[],{"trials":9629,"activeCount":101},[],{"intervention":2048,"totalTrials":334,"cells":9631},{"EARLY_PHASE1":9632,"PHASE1":9634,"PHASE2":9636,"PHASE3":9650,"PHASE4":9652,"NA":9654},{"trials":9633,"activeCount":101},[],{"trials":9635,"activeCount":101},[],{"trials":9637,"activeCount":101},[9638,9642,9646],{"nctId":9240,"briefTitle":9241,"status":160,"phases":9639,"completion":1731,"start":9243,"conditions":9640,"interventions":9641},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"nctId":9258,"briefTitle":9259,"status":160,"phases":9643,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":9644,"interventions":9645},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"nctId":2036,"briefTitle":2037,"status":160,"phases":9647,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":9648,"interventions":9649},[90],[2042,2043,2044,2045],[2047,2048,2049,2050,1569,1987,1724],{"trials":9651,"activeCount":101},[],{"trials":9653,"activeCount":101},[],{"trials":9655,"activeCount":101},[],{"intervention":2050,"totalTrials":334,"cells":9657},{"EARLY_PHASE1":9658,"PHASE1":9660,"PHASE2":9662,"PHASE3":9676,"PHASE4":9678,"NA":9680},{"trials":9659,"activeCount":101},[],{"trials":9661,"activeCount":101},[],{"trials":9663,"activeCount":101},[9664,9668,9672],{"nctId":9240,"briefTitle":9241,"status":160,"phases":9665,"completion":1731,"start":9243,"conditions":9666,"interventions":9667},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"nctId":9258,"briefTitle":9259,"status":160,"phases":9669,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":9670,"interventions":9671},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"nctId":2036,"briefTitle":2037,"status":160,"phases":9673,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":9674,"interventions":9675},[90],[2042,2043,2044,2045],[2047,2048,2049,2050,1569,1987,1724],{"trials":9677,"activeCount":101},[],{"trials":9679,"activeCount":101},[],{"trials":9681,"activeCount":101},[],{"intervention":9683,"totalTrials":334,"cells":9684},"arsenic trioxide",{"EARLY_PHASE1":9685,"PHASE1":9687,"PHASE2":9697,"PHASE3":9713,"PHASE4":9715,"NA":9717},{"trials":9686,"activeCount":101},[],{"trials":9688,"activeCount":101},[9689],{"nctId":9690,"briefTitle":9691,"status":160,"phases":9692,"primaryCompletion":5657,"completion":1544,"start":7905,"enrollment":1314,"conditions":9693,"interventions":9695},"NCT00185861","Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma",[89],[9694],"Brain Cancer",[9696],"Arsenic Trioxide",{"trials":9698,"activeCount":101},[9699,9705],{"nctId":9700,"briefTitle":9701,"status":132,"phases":9702,"primaryCompletion":6610,"start":5646,"enrollment":101,"conditions":9703,"interventions":9704},"NCT01835288","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],[2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015],[9683],{"nctId":9706,"briefTitle":9707,"status":160,"phases":9708,"primaryCompletion":6012,"completion":813,"start":9709,"enrollment":821,"conditions":9710,"interventions":9712},"NCT01791894","Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma",[89,90],"2013-04",[9711,1847],"Basal Cell Carcinoma of the Skin",[9683],{"trials":9714,"activeCount":101},[],{"trials":9716,"activeCount":101},[],{"trials":9718,"activeCount":101},[],{"intervention":710,"totalTrials":334,"cells":9720},{"EARLY_PHASE1":9721,"PHASE1":9723,"PHASE2":9725,"PHASE3":9739,"PHASE4":9741,"NA":9743},{"trials":9722,"activeCount":101},[],{"trials":9724,"activeCount":101},[],{"trials":9726,"activeCount":101},[9727,9731,9735],{"nctId":693,"briefTitle":694,"status":160,"phases":9728,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":9729,"interventions":9730},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"nctId":733,"briefTitle":734,"status":160,"phases":9732,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":9733,"interventions":9734},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"nctId":753,"briefTitle":754,"status":160,"phases":9736,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":9737,"interventions":9738},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":9740,"activeCount":101},[],{"trials":9742,"activeCount":101},[],{"trials":9744,"activeCount":101},[],{"intervention":9746,"totalTrials":334,"cells":9747},"Acebilustat",{"EARLY_PHASE1":9748,"PHASE1":9750,"PHASE2":9752,"PHASE3":9780,"PHASE4":9782,"NA":9784},{"trials":9749,"activeCount":101},[],{"trials":9751,"activeCount":101},[],{"trials":9753,"activeCount":101},[9754,9763,9772],{"nctId":9755,"briefTitle":9756,"status":160,"phases":9757,"primaryCompletion":9758,"completion":4296,"start":9759,"enrollment":179,"conditions":9760,"interventions":9762},"NCT05203835","A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema",[90],"2025-10-21","2022-07-27",[9761],"Lymphedema of Upper Arm",[9746],{"nctId":9764,"briefTitle":9765,"status":160,"phases":9766,"primaryCompletion":9767,"completion":9768,"start":9769,"enrollment":149,"conditions":9770,"interventions":9771},"NCT04662060","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol",[90],"2022-05-03","2023-02-02","2021-04-23",[3304],[9746],{"nctId":9773,"briefTitle":9774,"status":160,"phases":9775,"primaryCompletion":9767,"completion":9768,"start":9769,"enrollment":9776,"conditions":9777,"interventions":9778},"NCT04662086","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol",[90],122,[3304],[9746,9779],"Camostat",{"trials":9781,"activeCount":101},[],{"trials":9783,"activeCount":101},[],{"trials":9785,"activeCount":101},[],{"intervention":9787,"totalTrials":334,"cells":9788},"N-Acetyl Cysteine",{"EARLY_PHASE1":9789,"PHASE1":9791,"PHASE2":9793,"PHASE3":9820,"PHASE4":9822,"NA":9824},{"trials":9790,"activeCount":101},[],{"trials":9792,"activeCount":101},[],{"trials":9794,"activeCount":101},[9795,9804,9811],{"nctId":9796,"briefTitle":9797,"status":160,"phases":9798,"primaryCompletion":876,"completion":876,"start":9799,"enrollment":9800,"conditions":9801,"interventions":9803},"NCT00627705","A Study of N-Acetyl Cysteine in Children With Autism",[90],"2008-02",43,[9802],"Autistic Disorder",[9787],{"nctId":9805,"briefTitle":9806,"status":160,"phases":9807,"primaryCompletion":6096,"completion":6096,"start":9808,"enrollment":897,"conditions":9809,"interventions":9810},"NCT00676195","An Open-Label Study of N-Acetyl Cysteine in Children With Autism",[90],"2008-06",[9802],[9787],{"nctId":9812,"briefTitle":9813,"status":160,"phases":9814,"primaryCompletion":9815,"completion":9815,"start":9004,"enrollment":232,"conditions":9816,"interventions":9818},"NCT04732000","Oxidative Stress and Surgical Recovery",[90],"2023-03-01",[9817,354],"Surgical Recovery",[9819],"N-acetyl cysteine",{"trials":9821,"activeCount":101},[],{"trials":9823,"activeCount":101},[],{"trials":9825,"activeCount":101},[],{"intervention":731,"totalTrials":334,"cells":9827},{"EARLY_PHASE1":9828,"PHASE1":9830,"PHASE2":9852,"PHASE3":9858,"PHASE4":9860,"NA":9862},{"trials":9829,"activeCount":101},[],{"trials":9831,"activeCount":101},[9832,9842],{"nctId":9833,"briefTitle":9834,"status":132,"phases":9835,"primaryCompletion":2102,"start":9836,"enrollment":101,"conditions":9837,"interventions":9839},"NCT02087813","Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses",[89],"2014-03",[9838],"Neuromyelitis Optica",[9840,9841],"Alpha1-antitrypsin","methylprednisolone",{"nctId":9843,"briefTitle":9844,"status":160,"phases":9845,"primaryCompletion":9846,"completion":9847,"start":9848,"enrollment":334,"conditions":9849,"interventions":9851},"NCT05587673","High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)",[89],"2023-10-11","2024-10-11","2022-10-06",[5021,1451,8786,9850],"Indeterminate Colitis",[731],{"trials":9853,"activeCount":101},[9854],{"nctId":714,"briefTitle":715,"status":716,"phases":9855,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":9856,"interventions":9857},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"trials":9859,"activeCount":101},[],{"trials":9861,"activeCount":101},[],{"trials":9863,"activeCount":101},[],{"intervention":3965,"totalTrials":334,"cells":9865},{"EARLY_PHASE1":9866,"PHASE1":9868,"PHASE2":9870,"PHASE3":9884,"PHASE4":9886,"NA":9888},{"trials":9867,"activeCount":101},[],{"trials":9869,"activeCount":101},[],{"trials":9871,"activeCount":101},[9872,9876,9880],{"nctId":3940,"briefTitle":3941,"status":160,"phases":9873,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":37,"conditions":9874,"interventions":9875},[90],[3947,3948,3949,3950,3951,3952],[3954,3955,1837,3956],{"nctId":3958,"briefTitle":3959,"status":160,"phases":9877,"primaryCompletion":3961,"completion":3962,"start":1976,"enrollment":791,"conditions":9878,"interventions":9879},[90],[3914],[3965,1698,3966,1699],{"nctId":9329,"briefTitle":9330,"status":716,"phases":9881,"primaryCompletion":220,"completion":1918,"start":3807,"enrollment":191,"conditions":9882,"interventions":9883},[90],[1757,9333],[3965,1699],{"trials":9885,"activeCount":101},[],{"trials":9887,"activeCount":101},[],{"trials":9889,"activeCount":101},[],{"intervention":3509,"totalTrials":152,"cells":9891},{"EARLY_PHASE1":9892,"PHASE1":9894,"PHASE2":9896,"PHASE3":9906,"PHASE4":9908,"NA":9910},{"trials":9893,"activeCount":101},[],{"trials":9895,"activeCount":101},[],{"trials":9897,"activeCount":101},[9898,9902],{"nctId":3499,"briefTitle":3500,"status":716,"phases":9899,"primaryCompletion":3502,"completion":3503,"start":1500,"enrollment":334,"conditions":9900,"interventions":9901},[90],[3505,3506,740,3507,1339],[1533,729,726,727,730,3509],{"nctId":3994,"briefTitle":3995,"status":160,"phases":9903,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":9904,"interventions":9905},[90],[740,722,3505,3999],[1533,4001,1438,4002,4003,3509,4004],{"trials":9907,"activeCount":101},[],{"trials":9909,"activeCount":101},[],{"trials":9911,"activeCount":101},[],{"intervention":7909,"totalTrials":152,"cells":9913},{"EARLY_PHASE1":9914,"PHASE1":9916,"PHASE2":9918,"PHASE3":9932,"PHASE4":9934,"NA":9936},{"trials":9915,"activeCount":101},[],{"trials":9917,"activeCount":101},[],{"trials":9919,"activeCount":101},[9920,9924],{"nctId":7901,"briefTitle":7902,"status":160,"phases":9921,"primaryCompletion":7904,"completion":7904,"start":7905,"enrollment":247,"conditions":9922,"interventions":9923},[90],[7907],[7892,7909],{"nctId":9925,"briefTitle":9926,"status":160,"phases":9927,"primaryCompletion":9928,"completion":220,"start":9929,"enrollment":191,"conditions":9930,"interventions":9931},"NCT00186420","Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation",[90],"2006-01","2003-07",[3388],[7909],{"trials":9933,"activeCount":101},[],{"trials":9935,"activeCount":101},[],{"trials":9937,"activeCount":101},[],{"intervention":9939,"totalTrials":152,"cells":9940},"Cabergoline 1 MG",{"EARLY_PHASE1":9941,"PHASE1":9943,"PHASE2":9945,"PHASE3":9965,"PHASE4":9967,"NA":9969},{"trials":9942,"activeCount":101},[],{"trials":9944,"activeCount":101},[],{"trials":9946,"activeCount":101},[9947,9956],{"nctId":9948,"briefTitle":9949,"status":160,"phases":9950,"primaryCompletion":9951,"completion":9952,"start":9953,"enrollment":8099,"conditions":9954,"interventions":9955},"NCT06029673","Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss",[90],"2025-06-15","2025-07-01","2024-02-07",[2883],[9939],{"nctId":9957,"briefTitle":9958,"status":160,"phases":9959,"primaryCompletion":9960,"completion":9815,"start":9961,"enrollment":9962,"conditions":9963,"interventions":9964},"NCT04701333","Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss",[90],"2022-06-24","2021-04-01",73,[2883],[9939],{"trials":9966,"activeCount":101},[],{"trials":9968,"activeCount":101},[],{"trials":9970,"activeCount":101},[],{"intervention":9972,"totalTrials":152,"cells":9973},"Vorinostat",{"EARLY_PHASE1":9974,"PHASE1":9976,"PHASE2":9987,"PHASE3":9996,"PHASE4":9998,"NA":10000},{"trials":9975,"activeCount":101},[],{"trials":9977,"activeCount":101},[9978],{"nctId":9979,"briefTitle":9980,"status":160,"phases":9981,"primaryCompletion":874,"completion":9982,"start":9983,"enrollment":1766,"conditions":9984,"interventions":9986},"NCT00946673","Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer",[89],"2015-07","2009-06",[9694,9985,1757,9333],"Neoplasm Metastasis",[9972],{"trials":9988,"activeCount":101},[9989],{"nctId":9990,"briefTitle":9991,"status":716,"phases":9992,"primaryCompletion":833,"completion":1999,"start":697,"enrollment":1672,"conditions":9993,"interventions":9995},"NCT01187446","Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides",[89,90],[9994,7827],"Cutaneous Lymphoma",[9972],{"trials":9997,"activeCount":101},[],{"trials":9999,"activeCount":101},[],{"trials":10001,"activeCount":101},[],{"intervention":7919,"totalTrials":152,"cells":10003},{"EARLY_PHASE1":10004,"PHASE1":10006,"PHASE2":10008,"PHASE3":10024,"PHASE4":10026,"NA":10028},{"trials":10005,"activeCount":101},[],{"trials":10007,"activeCount":101},[],{"trials":10009,"activeCount":101},[10010,10020],{"nctId":10011,"briefTitle":10012,"status":160,"phases":10013,"primaryCompletion":1669,"completion":1669,"start":10014,"enrollment":7822,"conditions":10015,"interventions":10017},"NCT04380337","Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer",[90],"2020-05-21",[10016],"Rectal Cancer",[10018,7919,10019],"FOLFOXIRI","XELOX",{"nctId":7911,"briefTitle":7912,"status":160,"phases":10021,"completion":7914,"start":7915,"conditions":10022,"interventions":10023},[90],[7917],[7919,3956,7920,7921,7922],{"trials":10025,"activeCount":101},[],{"trials":10027,"activeCount":101},[],{"trials":10029,"activeCount":101},[],{"intervention":10031,"totalTrials":152,"cells":10032},"Pregnenolone",{"EARLY_PHASE1":10033,"PHASE1":10035,"PHASE2":10037,"PHASE3":10054,"PHASE4":10056,"NA":10058},{"trials":10034,"activeCount":101},[],{"trials":10036,"activeCount":101},[],{"trials":10038,"activeCount":101},[10039,10045],{"nctId":10040,"briefTitle":10041,"status":160,"phases":10042,"primaryCompletion":6013,"completion":6013,"start":7020,"enrollment":2218,"conditions":10043,"interventions":10044},"NCT01881737","A Study of Pregnenolone in the Treatment of Individuals With Autism",[90],[9802],[10031],{"nctId":10046,"briefTitle":10047,"status":160,"phases":10048,"primaryCompletion":10049,"completion":10050,"start":10051,"enrollment":179,"conditions":10052,"interventions":10053},"NCT02627508","Pilot Trial of Pregnenolone in Autism",[90],"2026-03-13","2026-03-17","2016-01-29",[27,1586],[10031],{"trials":10055,"activeCount":101},[],{"trials":10057,"activeCount":101},[],{"trials":10059,"activeCount":101},[],{"intervention":10061,"totalTrials":152,"cells":10062},"Hydroxyurea",{"EARLY_PHASE1":10063,"PHASE1":10065,"PHASE2":10067,"PHASE3":10082,"PHASE4":10084,"NA":10086},{"trials":10064,"activeCount":101},[],{"trials":10066,"activeCount":101},[],{"trials":10068,"activeCount":101},[10069,10076],{"nctId":10070,"briefTitle":10071,"status":160,"phases":10072,"primaryCompletion":4051,"completion":4051,"start":271,"enrollment":34,"conditions":10073,"interventions":10075},"NCT00568698","A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients",[89,90],[10074],"Muscular Atrophy, Spinal",[10061],{"nctId":10077,"briefTitle":10078,"status":160,"phases":10079,"primaryCompletion":5938,"completion":5938,"start":271,"enrollment":791,"conditions":10080,"interventions":10081},"NCT00568802","A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients",[89,90],[10074],[10061],{"trials":10083,"activeCount":101},[],{"trials":10085,"activeCount":101},[],{"trials":10087,"activeCount":101},[],{"intervention":1438,"totalTrials":152,"cells":10089},{"EARLY_PHASE1":10090,"PHASE1":10092,"PHASE2":10094,"PHASE3":10104,"PHASE4":10106,"NA":10108},{"trials":10091,"activeCount":101},[],{"trials":10093,"activeCount":101},[],{"trials":10095,"activeCount":101},[10096,10100],{"nctId":3994,"briefTitle":3995,"status":160,"phases":10097,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":10098,"interventions":10099},[90],[740,722,3505,3999],[1533,4001,1438,4002,4003,3509,4004],{"nctId":1430,"briefTitle":1431,"status":716,"phases":10101,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":10102,"interventions":10103},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"trials":10105,"activeCount":101},[],{"trials":10107,"activeCount":101},[],{"trials":10109,"activeCount":101},[],{"intervention":9246,"totalTrials":152,"cells":10111},{"EARLY_PHASE1":10112,"PHASE1":10114,"PHASE2":10116,"PHASE3":10126,"PHASE4":10128,"NA":10130},{"trials":10113,"activeCount":101},[],{"trials":10115,"activeCount":101},[],{"trials":10117,"activeCount":101},[10118,10122],{"nctId":9240,"briefTitle":9241,"status":160,"phases":10119,"completion":1731,"start":9243,"conditions":10120,"interventions":10121},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"nctId":9258,"briefTitle":9259,"status":160,"phases":10123,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":10124,"interventions":10125},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"trials":10127,"activeCount":101},[],{"trials":10129,"activeCount":101},[],{"trials":10131,"activeCount":101},[],{"intervention":9247,"totalTrials":152,"cells":10133},{"EARLY_PHASE1":10134,"PHASE1":10136,"PHASE2":10138,"PHASE3":10148,"PHASE4":10150,"NA":10152},{"trials":10135,"activeCount":101},[],{"trials":10137,"activeCount":101},[],{"trials":10139,"activeCount":101},[10140,10144],{"nctId":9240,"briefTitle":9241,"status":160,"phases":10141,"completion":1731,"start":9243,"conditions":10142,"interventions":10143},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"nctId":9258,"briefTitle":9259,"status":160,"phases":10145,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":10146,"interventions":10147},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"trials":10149,"activeCount":101},[],{"trials":10151,"activeCount":101},[],{"trials":10153,"activeCount":101},[],{"intervention":9249,"totalTrials":152,"cells":10155},{"EARLY_PHASE1":10156,"PHASE1":10158,"PHASE2":10160,"PHASE3":10170,"PHASE4":10172,"NA":10174},{"trials":10157,"activeCount":101},[],{"trials":10159,"activeCount":101},[],{"trials":10161,"activeCount":101},[10162,10166],{"nctId":9240,"briefTitle":9241,"status":160,"phases":10163,"completion":1731,"start":9243,"conditions":10164,"interventions":10165},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"nctId":9258,"briefTitle":9259,"status":160,"phases":10167,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":10168,"interventions":10169},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"trials":10171,"activeCount":101},[],{"trials":10173,"activeCount":101},[],{"trials":10175,"activeCount":101},[],{"intervention":10177,"totalTrials":152,"cells":10178},"Azacitidine",{"EARLY_PHASE1":10179,"PHASE1":10181,"PHASE2":10183,"PHASE3":10199,"PHASE4":10201,"NA":10203},{"trials":10180,"activeCount":101},[],{"trials":10182,"activeCount":101},[],{"trials":10184,"activeCount":101},[10185,10192],{"nctId":10186,"briefTitle":10187,"status":160,"phases":10188,"primaryCompletion":9189,"completion":8630,"start":1544,"enrollment":165,"conditions":10189,"interventions":10191},"NCT00890929","Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)",[89,90],[3708,10190],"Adult Acute Myeloblastic Leukemia",[1568,10177],{"nctId":10193,"briefTitle":10194,"status":716,"phases":10195,"primaryCompletion":9836,"completion":1843,"start":3503,"enrollment":28,"conditions":10196,"interventions":10198},"NCT01442714","Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS",[90],[740,3708,10197],"Myelodysplastic Syndromes (MDS)",[10177,1568],{"trials":10200,"activeCount":101},[],{"trials":10202,"activeCount":101},[],{"trials":10204,"activeCount":101},[],{"intervention":10206,"totalTrials":152,"cells":10207},"Trametinib",{"EARLY_PHASE1":10208,"PHASE1":10210,"PHASE2":10212,"PHASE3":10236,"PHASE4":10238,"NA":10240},{"trials":10209,"activeCount":101},[],{"trials":10211,"activeCount":101},[],{"trials":10213,"activeCount":101},[10214,10225],{"nctId":10215,"briefTitle":10216,"status":160,"phases":10217,"primaryCompletion":3725,"completion":10218,"start":10219,"enrollment":115,"conditions":10220,"interventions":10223},"NCT02367859","Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma",[90],"2019-06-26","2017-07-17",[10221,10222],"Ameloblastoma","BRAF Gene Mutation",[10224,10206],"Dabrafenib",{"nctId":10226,"briefTitle":10227,"status":160,"phases":10228,"primaryCompletion":10229,"completion":10230,"start":10231,"enrollment":613,"conditions":10232,"interventions":10235},"NCT04258046","Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation",[90],"2026-02-02","2026-02-18","2020-12-01",[10233,10234],"Venous Malformation","Arterial Disease",[10206],{"trials":10237,"activeCount":101},[],{"trials":10239,"activeCount":101},[],{"trials":10241,"activeCount":101},[],{"intervention":10243,"totalTrials":152,"cells":10244},"velcade",{"EARLY_PHASE1":10245,"PHASE1":10247,"PHASE2":10256,"PHASE3":10266,"PHASE4":10268,"NA":10270},{"trials":10246,"activeCount":101},[],{"trials":10248,"activeCount":101},[10249],{"nctId":10250,"briefTitle":10251,"status":160,"phases":10252,"primaryCompletion":1999,"start":3502,"enrollment":3997,"conditions":10253,"interventions":10254},"NCT01114282","Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed\u002FRefractory MM",[89],[763],[10243,10255],"Pralatrexate",{"trials":10257,"activeCount":101},[10258],{"nctId":10259,"briefTitle":10260,"status":132,"phases":10261,"primaryCompletion":7020,"completion":7020,"start":6096,"enrollment":101,"conditions":10262,"interventions":10264},"NCT01162031","Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia",[90],[740,10263],"Acute Lymphocytic Leukemia",[10265],"Velcade",{"trials":10267,"activeCount":101},[],{"trials":10269,"activeCount":101},[],{"trials":10271,"activeCount":101},[],{"intervention":3938,"totalTrials":152,"cells":10273},{"EARLY_PHASE1":10274,"PHASE1":10276,"PHASE2":10282,"PHASE3":10288,"PHASE4":10290,"NA":10292},{"trials":10275,"activeCount":101},[],{"trials":10277,"activeCount":101},[10278],{"nctId":1806,"briefTitle":1807,"status":716,"phases":10279,"primaryCompletion":1809,"completion":1809,"start":1754,"enrollment":1810,"conditions":10280,"interventions":10281},[89],[1812,1813,1814,1815],[1700,1817,1818,1699],{"trials":10283,"activeCount":101},[10284],{"nctId":3928,"briefTitle":3929,"status":160,"phases":10285,"primaryCompletion":3931,"completion":698,"start":3932,"enrollment":3933,"conditions":10286,"interventions":10287},[90],[3935],[3937,1698,3938],{"trials":10289,"activeCount":101},[],{"trials":10291,"activeCount":101},[],{"trials":10293,"activeCount":101},[],{"intervention":1737,"totalTrials":152,"cells":10295},{"EARLY_PHASE1":10296,"PHASE1":10298,"PHASE2":10300,"PHASE3":10310,"PHASE4":10312,"NA":10314},{"trials":10297,"activeCount":101},[],{"trials":10299,"activeCount":101},[],{"trials":10301,"activeCount":101},[10302,10306],{"nctId":1727,"briefTitle":1728,"status":160,"phases":10303,"primaryCompletion":1730,"completion":876,"start":1731,"enrollment":1732,"conditions":10304,"interventions":10305},[90],[1734,1735,1426],[1678,1737,726,727,730],{"nctId":1739,"briefTitle":1740,"status":716,"phases":10307,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":10308,"interventions":10309},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"trials":10311,"activeCount":101},[],{"trials":10313,"activeCount":101},[],{"trials":10315,"activeCount":101},[],{"intervention":9779,"totalTrials":152,"cells":10317},{"EARLY_PHASE1":10318,"PHASE1":10320,"PHASE2":10322,"PHASE3":10336,"PHASE4":10338,"NA":10340},{"trials":10319,"activeCount":101},[],{"trials":10321,"activeCount":101},[],{"trials":10323,"activeCount":101},[10324,10328],{"nctId":9773,"briefTitle":9774,"status":160,"phases":10325,"primaryCompletion":9767,"completion":9768,"start":9769,"enrollment":9776,"conditions":10326,"interventions":10327},[90],[3304],[9746,9779],{"nctId":10329,"briefTitle":10330,"status":716,"phases":10331,"primaryCompletion":10332,"completion":10333,"start":9769,"enrollment":152,"conditions":10334,"interventions":10335},"NCT04662073","COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol",[90],"2021-06-08","2022-03-04",[3304],[9779],{"trials":10337,"activeCount":101},[],{"trials":10339,"activeCount":101},[],{"trials":10341,"activeCount":101},[],{"intervention":3956,"totalTrials":152,"cells":10343},{"EARLY_PHASE1":10344,"PHASE1":10346,"PHASE2":10348,"PHASE3":10358,"PHASE4":10360,"NA":10362},{"trials":10345,"activeCount":101},[],{"trials":10347,"activeCount":101},[],{"trials":10349,"activeCount":101},[10350,10354],{"nctId":7911,"briefTitle":7912,"status":160,"phases":10351,"completion":7914,"start":7915,"conditions":10352,"interventions":10353},[90],[7917],[7919,3956,7920,7921,7922],{"nctId":3940,"briefTitle":3941,"status":160,"phases":10355,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":37,"conditions":10356,"interventions":10357},[90],[3947,3948,3949,3950,3951,3952],[3954,3955,1837,3956],{"trials":10359,"activeCount":101},[],{"trials":10361,"activeCount":101},[],{"trials":10363,"activeCount":101},[],{"intervention":1748,"totalTrials":152,"cells":10365},{"EARLY_PHASE1":10366,"PHASE1":10368,"PHASE2":10370,"PHASE3":10380,"PHASE4":10382,"NA":10384},{"trials":10367,"activeCount":101},[],{"trials":10369,"activeCount":101},[],{"trials":10371,"activeCount":101},[10372,10376],{"nctId":1739,"briefTitle":1740,"status":716,"phases":10373,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":10374,"interventions":10375},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"nctId":3527,"briefTitle":3528,"status":160,"phases":10377,"primaryCompletion":3530,"completion":3531,"start":3532,"enrollment":3533,"conditions":10378,"interventions":10379},[90],[3535,1426,1734,3536],[1747,730,1722,1504,1748,727],{"trials":10381,"activeCount":101},[],{"trials":10383,"activeCount":101},[],{"trials":10385,"activeCount":101},[],{"intervention":10387,"totalTrials":152,"cells":10388},"Vasopressin",{"EARLY_PHASE1":10389,"PHASE1":10400,"PHASE2":10402,"PHASE3":10413,"PHASE4":10415,"NA":10417},{"trials":10390,"activeCount":101},[10391],{"nctId":10392,"briefTitle":10393,"status":160,"phases":10394,"primaryCompletion":1348,"completion":1348,"start":10395,"enrollment":1672,"conditions":10396,"interventions":10399},"NCT04463394","The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology",[88],"2020-08-12",[10397,10398],"Hypotension","Fontan Physiology",[10387],{"trials":10401,"activeCount":101},[],{"trials":10403,"activeCount":101},[10404],{"nctId":10405,"briefTitle":10406,"status":160,"phases":10407,"primaryCompletion":10408,"completion":10408,"start":834,"enrollment":10409,"conditions":10410,"interventions":10412},"NCT01962870","The Role of Vasopressin in the Social Deficits of Autism",[90],"2017-05-30",68,[10411],"Autism Spectrum Disorders",[10387],{"trials":10414,"activeCount":101},[],{"trials":10416,"activeCount":101},[],{"trials":10418,"activeCount":101},[],{"intervention":10420,"totalTrials":152,"cells":10421},"Itraconazole",{"EARLY_PHASE1":10422,"PHASE1":10424,"PHASE2":10426,"PHASE3":10448,"PHASE4":10450,"NA":10452},{"trials":10423,"activeCount":101},[],{"trials":10425,"activeCount":101},[],{"trials":10427,"activeCount":101},[10428,10440],{"nctId":10429,"briefTitle":10430,"status":716,"phases":10431,"primaryCompletion":10432,"completion":10432,"start":876,"enrollment":1810,"conditions":10433,"interventions":10439},"NCT01450683","Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy",[90],"2011-04",[3388,10434,10435,10436,10437,10438],"Prostatic Neoplasms","Castrate-resistant Prostate Cancer (CRPC)","Androgen-insensitive Prostate Cancer","Hormone-refractory Prostate Cancer","Metastatic Disease",[10420],{"nctId":10441,"briefTitle":10442,"status":160,"phases":10443,"primaryCompletion":7340,"completion":4051,"start":1545,"enrollment":34,"conditions":10444,"interventions":10447},"NCT01108094","Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w\u002F Basal Cell Carcinomas",[90],[10445,10446],"Basal Cell Carcinoma (BCC)","Skin Cancer",[10420],{"trials":10449,"activeCount":101},[],{"trials":10451,"activeCount":101},[],{"trials":10453,"activeCount":101},[],{"intervention":10455,"totalTrials":152,"cells":10456},"Naltrexone",{"EARLY_PHASE1":10457,"PHASE1":10459,"PHASE2":10468,"PHASE3":10480,"PHASE4":10482,"NA":10484},{"trials":10458,"activeCount":101},[],{"trials":10460,"activeCount":101},[10461],{"nctId":10462,"briefTitle":10463,"status":160,"phases":10464,"primaryCompletion":10465,"completion":10465,"start":8038,"enrollment":737,"conditions":10466,"interventions":10467},"NCT02911597","Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)",[89],"2018-02",[21],[10455],{"trials":10469,"activeCount":101},[10470],{"nctId":10471,"briefTitle":10472,"status":4049,"phases":10473,"primaryCompletion":4016,"completion":10474,"start":10475,"enrollment":179,"conditions":10476,"interventions":10479},"NCT04450316","Low-dose Naltrexone for Bladder Pain Syndrome",[90],"2024-10","2020-10-08",[10477,10478],"Bladder Pain Syndrome","Interstitial Cystitis",[10455],{"trials":10481,"activeCount":101},[],{"trials":10483,"activeCount":101},[],{"trials":10485,"activeCount":101},[],{"intervention":10487,"totalTrials":115,"cells":10488},"Lidocaine IV",{"EARLY_PHASE1":10489,"PHASE1":10491,"PHASE2":10493,"PHASE3":10502,"PHASE4":10504,"NA":10506},{"trials":10490,"activeCount":101},[],{"trials":10492,"activeCount":101},[],{"trials":10494,"activeCount":101},[10495],{"nctId":10496,"briefTitle":10497,"status":132,"phases":10498,"primaryCompletion":1288,"completion":1288,"start":61,"enrollment":101,"conditions":10499,"interventions":10500},"NCT04707183","Comparison of Continuous Intravenous Lidocaine Infusion Versus ESP Block for Rib Fracture Analgesia",[90],[3316],[10487,10501],"2% Lidocaine via ESPB",{"trials":10503,"activeCount":101},[],{"trials":10505,"activeCount":101},[],{"trials":10507,"activeCount":101},[],{"intervention":10501,"totalTrials":115,"cells":10509},{"EARLY_PHASE1":10510,"PHASE1":10512,"PHASE2":10514,"PHASE3":10520,"PHASE4":10522,"NA":10524},{"trials":10511,"activeCount":101},[],{"trials":10513,"activeCount":101},[],{"trials":10515,"activeCount":101},[10516],{"nctId":10496,"briefTitle":10497,"status":132,"phases":10517,"primaryCompletion":1288,"completion":1288,"start":61,"enrollment":101,"conditions":10518,"interventions":10519},[90],[3316],[10487,10501],{"trials":10521,"activeCount":101},[],{"trials":10523,"activeCount":101},[],{"trials":10525,"activeCount":101},[],{"intervention":10527,"totalTrials":115,"cells":10528},"recombinant human hyaluronidase",{"EARLY_PHASE1":10529,"PHASE1":10531,"PHASE2":10533,"PHASE3":10543,"PHASE4":10545,"NA":10547},{"trials":10530,"activeCount":101},[],{"trials":10532,"activeCount":101},[],{"trials":10534,"activeCount":101},[10535],{"nctId":10536,"briefTitle":10537,"status":716,"phases":10538,"primaryCompletion":813,"completion":813,"start":834,"enrollment":334,"conditions":10539,"interventions":10542},"NCT01928030","Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer",[89,90],[10540,10541],"Lymphedema","Malignant Neoplasm",[10527],{"trials":10544,"activeCount":101},[],{"trials":10546,"activeCount":101},[],{"trials":10548,"activeCount":101},[],{"intervention":10550,"totalTrials":115,"cells":10551},"Favipiravir",{"EARLY_PHASE1":10552,"PHASE1":10554,"PHASE2":10556,"PHASE3":10569,"PHASE4":10571,"NA":10573},{"trials":10553,"activeCount":101},[],{"trials":10555,"activeCount":101},[],{"trials":10557,"activeCount":101},[10558],{"nctId":10559,"briefTitle":10560,"status":160,"phases":10561,"primaryCompletion":10562,"completion":10562,"start":10563,"enrollment":10564,"conditions":10565,"interventions":10568},"NCT04346628","Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19",[90],"2021-04-16","2020-07-12",149,[10566,10567],"Sars-CoV2","COVID-19",[10550],{"trials":10570,"activeCount":101},[],{"trials":10572,"activeCount":101},[],{"trials":10574,"activeCount":101},[],{"intervention":10576,"totalTrials":115,"cells":10577},"Camostat Mesilate",{"EARLY_PHASE1":10578,"PHASE1":10580,"PHASE2":10582,"PHASE3":10592,"PHASE4":10594,"NA":10596},{"trials":10579,"activeCount":101},[],{"trials":10581,"activeCount":101},[],{"trials":10583,"activeCount":101},[10584],{"nctId":10585,"briefTitle":10586,"status":160,"phases":10587,"primaryCompletion":2625,"completion":2625,"start":10588,"enrollment":10589,"conditions":10590,"interventions":10591},"NCT04524663","Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients",[90],"2020-12-19",49,[3304],[10576],{"trials":10593,"activeCount":101},[],{"trials":10595,"activeCount":101},[],{"trials":10597,"activeCount":101},[],{"intervention":944,"totalTrials":115,"cells":10599},{"EARLY_PHASE1":10600,"PHASE1":10602,"PHASE2":10604,"PHASE3":10610,"PHASE4":10612,"NA":10614},{"trials":10601,"activeCount":101},[],{"trials":10603,"activeCount":101},[],{"trials":10605,"activeCount":101},[10606],{"nctId":935,"briefTitle":936,"status":716,"phases":10607,"primaryCompletion":938,"completion":939,"start":940,"enrollment":821,"conditions":10608,"interventions":10609},[90],[942],[926,944],{"trials":10611,"activeCount":101},[],{"trials":10613,"activeCount":101},[],{"trials":10615,"activeCount":101},[],{"intervention":10617,"totalTrials":115,"cells":10618},"Fluorescein Sodium",{"EARLY_PHASE1":10619,"PHASE1":10621,"PHASE2":10623,"PHASE3":10639,"PHASE4":10641,"NA":10643},{"trials":10620,"activeCount":101},[],{"trials":10622,"activeCount":101},[],{"trials":10624,"activeCount":101},[10625],{"nctId":10626,"briefTitle":10627,"status":160,"phases":10628,"primaryCompletion":10629,"completion":10629,"start":10630,"enrollment":684,"conditions":10631,"interventions":10638},"NCT06054178","Identification of Nerves Using Fluorescein Sodium",[90],"2025-05-22","2024-11-07",[10632,10633,10634,10635,10636,10637],"Pleomorphic Adenoma of the Parotid","Warthin Tumor","Head and Neck Disorder","Head and Neck","Thyroid Disease","Thyroidectomy",[10617],{"trials":10640,"activeCount":101},[],{"trials":10642,"activeCount":101},[],{"trials":10644,"activeCount":101},[],{"intervention":10646,"totalTrials":115,"cells":10647},"pomalidomide (CC-4047",{"EARLY_PHASE1":10648,"PHASE1":10650,"PHASE2":10652,"PHASE3":10661,"PHASE4":10663,"NA":10665},{"trials":10649,"activeCount":101},[],{"trials":10651,"activeCount":101},[],{"trials":10653,"activeCount":101},[10654],{"nctId":10655,"briefTitle":10656,"status":132,"phases":10657,"primaryCompletion":6096,"completion":6096,"start":1545,"enrollment":101,"conditions":10658,"interventions":10660},"NCT01135199","Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis",[90],[10659],"Pulmonary Fibrosis",[10646],{"trials":10662,"activeCount":101},[],{"trials":10664,"activeCount":101},[],{"trials":10666,"activeCount":101},[],{"intervention":10668,"totalTrials":115,"cells":10669},"Indomethacin",{"EARLY_PHASE1":10670,"PHASE1":10672,"PHASE2":10674,"PHASE3":10685,"PHASE4":10687,"NA":10689},{"trials":10671,"activeCount":101},[],{"trials":10673,"activeCount":101},[],{"trials":10675,"activeCount":101},[10676],{"nctId":10677,"briefTitle":10678,"status":160,"phases":10679,"primaryCompletion":10680,"completion":10680,"start":9212,"enrollment":34,"conditions":10681,"interventions":10683},"NCT00486824","Indomethacin Versus Nifedipine for Preterm Labor Tocolysis",[89,90],"2012-12-08",[10682],"Obstetric Labor, Premature",[10668,10684],"Nifedipine",{"trials":10686,"activeCount":101},[],{"trials":10688,"activeCount":101},[],{"trials":10690,"activeCount":101},[],{"intervention":10692,"totalTrials":115,"cells":10693},"Hydroxychloroquine\u002FAtorvastatin",{"EARLY_PHASE1":10694,"PHASE1":10696,"PHASE2":10698,"PHASE3":10708,"PHASE4":10710,"NA":10712},{"trials":10695,"activeCount":101},[],{"trials":10697,"activeCount":101},[],{"trials":10699,"activeCount":101},[10700],{"nctId":10701,"briefTitle":10702,"status":160,"phases":10703,"primaryCompletion":10704,"completion":6243,"start":1498,"enrollment":2393,"conditions":10705,"interventions":10707},"NCT01645176","Hydroxychloroquine\u002FAtorvastatin in the Treatment of Osteoarthritis (OA) of the Knee",[90],"2016-04",[10706],"Osteoarthritis of the Knee",[10692],{"trials":10709,"activeCount":101},[],{"trials":10711,"activeCount":101},[],{"trials":10713,"activeCount":101},[],{"intervention":10715,"totalTrials":115,"cells":10716},"Fexofenadine",{"EARLY_PHASE1":10717,"PHASE1":10719,"PHASE2":10721,"PHASE3":10732,"PHASE4":10734,"NA":10736},{"trials":10718,"activeCount":101},[],{"trials":10720,"activeCount":101},[],{"trials":10722,"activeCount":101},[10723],{"nctId":10724,"briefTitle":10725,"status":716,"phases":10726,"primaryCompletion":10727,"completion":10727,"start":10728,"enrollment":3997,"conditions":10729,"interventions":10731},"NCT03425097","Fexofenadine Use in Gastroesophageal Reflux Symptoms",[90],"2019-01-08","2018-02-07",[10730],"Gastroesophageal Reflux",[10715],{"trials":10733,"activeCount":101},[],{"trials":10735,"activeCount":101},[],{"trials":10737,"activeCount":101},[],{"intervention":10739,"totalTrials":115,"cells":10740},"99mTc-methyl diphosphonate",{"EARLY_PHASE1":10741,"PHASE1":10743,"PHASE2":10745,"PHASE3":10762,"PHASE4":10764,"NA":10766},{"trials":10742,"activeCount":101},[],{"trials":10744,"activeCount":101},[],{"trials":10746,"activeCount":101},[10747],{"nctId":10748,"briefTitle":10749,"status":160,"phases":10750,"primaryCompletion":10751,"completion":10752,"start":9928,"enrollment":10753,"conditions":10754,"interventions":10756},"NCT00375830","Combined 18F-NaF\u002F18F-FDG PET\u002FMRI for Detection of Skeletal Metastases",[90],"2017-04-17","2019-03-14",114,[10755],"Cancer",[10739,10757,10758,10759,10760,10761],"18F-Fludeoxyglucose","18F-Sodium Fluoride","Gadopentetate dimeglumine","Gadofosveset","Gadobutrol",{"trials":10763,"activeCount":101},[],{"trials":10765,"activeCount":101},[],{"trials":10767,"activeCount":101},[],{"intervention":10757,"totalTrials":115,"cells":10769},{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10780,"PHASE4":10782,"NA":10784},{"trials":10771,"activeCount":101},[],{"trials":10773,"activeCount":101},[],{"trials":10775,"activeCount":101},[10776],{"nctId":10748,"briefTitle":10749,"status":160,"phases":10777,"primaryCompletion":10751,"completion":10752,"start":9928,"enrollment":10753,"conditions":10778,"interventions":10779},[90],[10755],[10739,10757,10758,10759,10760,10761],{"trials":10781,"activeCount":101},[],{"trials":10783,"activeCount":101},[],{"trials":10785,"activeCount":101},[],{"intervention":10758,"totalTrials":115,"cells":10787},{"EARLY_PHASE1":10788,"PHASE1":10790,"PHASE2":10792,"PHASE3":10798,"PHASE4":10800,"NA":10802},{"trials":10789,"activeCount":101},[],{"trials":10791,"activeCount":101},[],{"trials":10793,"activeCount":101},[10794],{"nctId":10748,"briefTitle":10749,"status":160,"phases":10795,"primaryCompletion":10751,"completion":10752,"start":9928,"enrollment":10753,"conditions":10796,"interventions":10797},[90],[10755],[10739,10757,10758,10759,10760,10761],{"trials":10799,"activeCount":101},[],{"trials":10801,"activeCount":101},[],{"trials":10803,"activeCount":101},[],{"intervention":10759,"totalTrials":115,"cells":10805},{"EARLY_PHASE1":10806,"PHASE1":10808,"PHASE2":10810,"PHASE3":10816,"PHASE4":10818,"NA":10820},{"trials":10807,"activeCount":101},[],{"trials":10809,"activeCount":101},[],{"trials":10811,"activeCount":101},[10812],{"nctId":10748,"briefTitle":10749,"status":160,"phases":10813,"primaryCompletion":10751,"completion":10752,"start":9928,"enrollment":10753,"conditions":10814,"interventions":10815},[90],[10755],[10739,10757,10758,10759,10760,10761],{"trials":10817,"activeCount":101},[],{"trials":10819,"activeCount":101},[],{"trials":10821,"activeCount":101},[],{"intervention":10760,"totalTrials":115,"cells":10823},{"EARLY_PHASE1":10824,"PHASE1":10826,"PHASE2":10828,"PHASE3":10834,"PHASE4":10836,"NA":10838},{"trials":10825,"activeCount":101},[],{"trials":10827,"activeCount":101},[],{"trials":10829,"activeCount":101},[10830],{"nctId":10748,"briefTitle":10749,"status":160,"phases":10831,"primaryCompletion":10751,"completion":10752,"start":9928,"enrollment":10753,"conditions":10832,"interventions":10833},[90],[10755],[10739,10757,10758,10759,10760,10761],{"trials":10835,"activeCount":101},[],{"trials":10837,"activeCount":101},[],{"trials":10839,"activeCount":101},[],{"intervention":10761,"totalTrials":115,"cells":10841},{"EARLY_PHASE1":10842,"PHASE1":10844,"PHASE2":10846,"PHASE3":10852,"PHASE4":10854,"NA":10856},{"trials":10843,"activeCount":101},[],{"trials":10845,"activeCount":101},[],{"trials":10847,"activeCount":101},[10848],{"nctId":10748,"briefTitle":10749,"status":160,"phases":10849,"primaryCompletion":10751,"completion":10752,"start":9928,"enrollment":10753,"conditions":10850,"interventions":10851},[90],[10755],[10739,10757,10758,10759,10760,10761],{"trials":10853,"activeCount":101},[],{"trials":10855,"activeCount":101},[],{"trials":10857,"activeCount":101},[],{"intervention":10859,"totalTrials":115,"cells":10860},"Mitoxantrone",{"EARLY_PHASE1":10861,"PHASE1":10863,"PHASE2":10865,"PHASE3":10874,"PHASE4":10876,"NA":10878},{"trials":10862,"activeCount":101},[],{"trials":10864,"activeCount":101},[],{"trials":10866,"activeCount":101},[10867],{"nctId":10868,"briefTitle":10869,"status":716,"phases":10870,"primaryCompletion":1778,"completion":5542,"start":1862,"enrollment":247,"conditions":10871,"interventions":10872},"NCT00477087","Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer",[90],[10434],[10859,10873],"GM-CSF",{"trials":10875,"activeCount":101},[],{"trials":10877,"activeCount":101},[],{"trials":10879,"activeCount":101},[],{"intervention":10873,"totalTrials":115,"cells":10881},{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10892,"PHASE4":10894,"NA":10896},{"trials":10883,"activeCount":101},[],{"trials":10885,"activeCount":101},[],{"trials":10887,"activeCount":101},[10888],{"nctId":10868,"briefTitle":10869,"status":716,"phases":10889,"primaryCompletion":1778,"completion":5542,"start":1862,"enrollment":247,"conditions":10890,"interventions":10891},[90],[10434],[10859,10873],{"trials":10893,"activeCount":101},[],{"trials":10895,"activeCount":101},[],{"trials":10897,"activeCount":101},[],{"intervention":10899,"totalTrials":115,"cells":10900},"oxytocin 24IU",{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10905,"PHASE3":10916,"PHASE4":10918,"NA":10920},{"trials":10902,"activeCount":101},[],{"trials":10904,"activeCount":101},[],{"trials":10906,"activeCount":101},[10907],{"nctId":10908,"briefTitle":10909,"status":160,"phases":10910,"primaryCompletion":10911,"completion":5542,"start":10912,"enrollment":247,"conditions":10913,"interventions":10914},"NCT01254045","Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome",[90],"2009-11","2007-02",[5763],[10899,10915],"oxytocin 48IU",{"trials":10917,"activeCount":101},[],{"trials":10919,"activeCount":101},[],{"trials":10921,"activeCount":101},[],{"intervention":10915,"totalTrials":115,"cells":10923},{"EARLY_PHASE1":10924,"PHASE1":10926,"PHASE2":10928,"PHASE3":10934,"PHASE4":10936,"NA":10938},{"trials":10925,"activeCount":101},[],{"trials":10927,"activeCount":101},[],{"trials":10929,"activeCount":101},[10930],{"nctId":10908,"briefTitle":10909,"status":160,"phases":10931,"primaryCompletion":10911,"completion":5542,"start":10912,"enrollment":247,"conditions":10932,"interventions":10933},[90],[5763],[10899,10915],{"trials":10935,"activeCount":101},[],{"trials":10937,"activeCount":101},[],{"trials":10939,"activeCount":101},[],{"intervention":10941,"totalTrials":115,"cells":10942},"Manganese-enhanced MRI contrast reagent",{"EARLY_PHASE1":10943,"PHASE1":10945,"PHASE2":10947,"PHASE3":10958,"PHASE4":10960,"NA":10962},{"trials":10944,"activeCount":101},[],{"trials":10946,"activeCount":101},[],{"trials":10948,"activeCount":101},[10949],{"nctId":10950,"briefTitle":10951,"status":160,"phases":10952,"primaryCompletion":10953,"completion":10953,"start":8251,"enrollment":28,"conditions":10954,"interventions":10956},"NCT02933034","Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury",[89,90],"2019-02-03",[10955],"ISCHEMIC CARDIOMYOPATHY",[10941,10957],"Gadolinium-enhanced MRI contrast reagent",{"trials":10959,"activeCount":101},[],{"trials":10961,"activeCount":101},[],{"trials":10963,"activeCount":101},[],{"intervention":10957,"totalTrials":115,"cells":10965},{"EARLY_PHASE1":10966,"PHASE1":10968,"PHASE2":10970,"PHASE3":10976,"PHASE4":10978,"NA":10980},{"trials":10967,"activeCount":101},[],{"trials":10969,"activeCount":101},[],{"trials":10971,"activeCount":101},[10972],{"nctId":10950,"briefTitle":10951,"status":160,"phases":10973,"primaryCompletion":10953,"completion":10953,"start":8251,"enrollment":28,"conditions":10974,"interventions":10975},[89,90],[10955],[10941,10957],{"trials":10977,"activeCount":101},[],{"trials":10979,"activeCount":101},[],{"trials":10981,"activeCount":101},[],{"intervention":10018,"totalTrials":115,"cells":10983},{"EARLY_PHASE1":10984,"PHASE1":10986,"PHASE2":10988,"PHASE3":10994,"PHASE4":10996,"NA":10998},{"trials":10985,"activeCount":101},[],{"trials":10987,"activeCount":101},[],{"trials":10989,"activeCount":101},[10990],{"nctId":10011,"briefTitle":10012,"status":160,"phases":10991,"primaryCompletion":1669,"completion":1669,"start":10014,"enrollment":7822,"conditions":10992,"interventions":10993},[90],[10016],[10018,7919,10019],{"trials":10995,"activeCount":101},[],{"trials":10997,"activeCount":101},[],{"trials":10999,"activeCount":101},[],{"intervention":10019,"totalTrials":115,"cells":11001},{"EARLY_PHASE1":11002,"PHASE1":11004,"PHASE2":11006,"PHASE3":11012,"PHASE4":11014,"NA":11016},{"trials":11003,"activeCount":101},[],{"trials":11005,"activeCount":101},[],{"trials":11007,"activeCount":101},[11008],{"nctId":10011,"briefTitle":10012,"status":160,"phases":11009,"primaryCompletion":1669,"completion":1669,"start":10014,"enrollment":7822,"conditions":11010,"interventions":11011},[90],[10016],[10018,7919,10019],{"trials":11013,"activeCount":101},[],{"trials":11015,"activeCount":101},[],{"trials":11017,"activeCount":101},[],{"intervention":11019,"totalTrials":115,"cells":11020},"Hymecromone",{"EARLY_PHASE1":11021,"PHASE1":11023,"PHASE2":11025,"PHASE3":11036,"PHASE4":11038,"NA":11040},{"trials":11022,"activeCount":101},[],{"trials":11024,"activeCount":101},[],{"trials":11026,"activeCount":101},[11027],{"nctId":11028,"briefTitle":11029,"status":160,"phases":11030,"primaryCompletion":11031,"completion":11032,"start":4361,"enrollment":1766,"conditions":11033,"interventions":11035},"NCT05128929","Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).",[90],"2023-09-21","2023-09-29",[11034],"Pulmonary Hypertension",[11019],{"trials":11037,"activeCount":101},[],{"trials":11039,"activeCount":101},[],{"trials":11041,"activeCount":101},[],{"intervention":9439,"totalTrials":115,"cells":11043},{"EARLY_PHASE1":11044,"PHASE1":11046,"PHASE2":11048,"PHASE3":11054,"PHASE4":11056,"NA":11058},{"trials":11045,"activeCount":101},[],{"trials":11047,"activeCount":101},[],{"trials":11049,"activeCount":101},[11050],{"nctId":9428,"briefTitle":9429,"status":160,"phases":11051,"primaryCompletion":9431,"completion":9431,"start":9432,"enrollment":1977,"conditions":11052,"interventions":11053},[90],[9434,9435,9436,9437],[1724,9439],{"trials":11055,"activeCount":101},[],{"trials":11057,"activeCount":101},[],{"trials":11059,"activeCount":101},[],{"intervention":11061,"totalTrials":115,"cells":11062},"Botulinum Toxin type B",{"EARLY_PHASE1":11063,"PHASE1":11065,"PHASE2":11067,"PHASE3":11078,"PHASE4":11080,"NA":11082},{"trials":11064,"activeCount":101},[],{"trials":11066,"activeCount":101},[],{"trials":11068,"activeCount":101},[11069],{"nctId":11070,"briefTitle":11071,"status":160,"phases":11072,"completion":11073,"start":11074,"enrollment":247,"conditions":11075,"interventions":11077},"NCT00238641","\"DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?\"",[89,90],"2005-05","2002-01",[11076],"Cerebral Palsy",[11061],{"trials":11079,"activeCount":101},[],{"trials":11081,"activeCount":101},[],{"trials":11083,"activeCount":101},[],{"intervention":11085,"totalTrials":115,"cells":11086},"Ga-68-DOTA-TATE",{"EARLY_PHASE1":11087,"PHASE1":11089,"PHASE2":11091,"PHASE3":11105,"PHASE4":11107,"NA":11109},{"trials":11088,"activeCount":101},[],{"trials":11090,"activeCount":101},[],{"trials":11092,"activeCount":101},[11093],{"nctId":11094,"briefTitle":11095,"status":160,"phases":11096,"primaryCompletion":11097,"completion":9564,"start":11098,"enrollment":22,"conditions":11099,"interventions":11103},"NCT03125629","Comparison of PET\u002FCT vs. PET\u002FMRI Using 2 Radiopharmaceuticals",[90],"2016-11-30","2014-05-27",[11100,11101,11102],"Cancer Diagnosis","Diagnostic Techniques and Procedures","Diagnostic Imaging",[11104,11085],"F-18 FDG",{"trials":11106,"activeCount":101},[],{"trials":11108,"activeCount":101},[],{"trials":11110,"activeCount":101},[],{"intervention":11112,"totalTrials":115,"cells":11113},"Imatinib mesylate",{"EARLY_PHASE1":11114,"PHASE1":11116,"PHASE2":11118,"PHASE3":11127,"PHASE4":11129,"NA":11131},{"trials":11115,"activeCount":101},[],{"trials":11117,"activeCount":101},[],{"trials":11119,"activeCount":101},[11120],{"nctId":11121,"briefTitle":11122,"status":160,"phases":11123,"primaryCompletion":876,"completion":876,"start":4993,"enrollment":759,"conditions":11124,"interventions":11126},"NCT00506831","Imatinib in Systemic Sclerosis",[89,90],[11125],"Scleroderma, Systemic",[11112],{"trials":11128,"activeCount":101},[],{"trials":11130,"activeCount":101},[],{"trials":11132,"activeCount":101},[],{"intervention":11134,"totalTrials":115,"cells":11135},"Oxytocin nasal spray",{"EARLY_PHASE1":11136,"PHASE1":11138,"PHASE2":11140,"PHASE3":11148,"PHASE4":11150,"NA":11152},{"trials":11137,"activeCount":101},[],{"trials":11139,"activeCount":101},[],{"trials":11141,"activeCount":101},[11142],{"nctId":11143,"briefTitle":11144,"status":160,"phases":11145,"primaryCompletion":2173,"completion":2173,"start":8630,"enrollment":3106,"conditions":11146,"interventions":11147},"NCT01624194","Intranasal Oxytocin Treatment for Social Deficits in Children With Autism",[90],[1586],[11134],{"trials":11149,"activeCount":101},[],{"trials":11151,"activeCount":101},[],{"trials":11153,"activeCount":101},[],{"intervention":11155,"totalTrials":115,"cells":11156},"Sildenafil 20 mg",{"EARLY_PHASE1":11157,"PHASE1":11159,"PHASE2":11161,"PHASE3":11173,"PHASE4":11175,"NA":11177},{"trials":11158,"activeCount":101},[],{"trials":11160,"activeCount":101},[],{"trials":11162,"activeCount":101},[11163],{"nctId":11164,"briefTitle":11165,"status":160,"phases":11166,"primaryCompletion":11167,"completion":11167,"start":11168,"enrollment":1977,"conditions":11169,"interventions":11172},"NCT02335242","Sildenafil for the Treatment of Lymphatic Malformations",[90],"2021-03-30","2015-05-23",[11170,11171],"Lymphatic Malformations","Lymphatic Diseases",[11155],{"trials":11174,"activeCount":101},[],{"trials":11176,"activeCount":101},[],{"trials":11178,"activeCount":101},[],{"intervention":11180,"totalTrials":115,"cells":11181},"Methadone",{"EARLY_PHASE1":11182,"PHASE1":11184,"PHASE2":11186,"PHASE3":11195,"PHASE4":11197,"NA":11199},{"trials":11183,"activeCount":101},[],{"trials":11185,"activeCount":101},[],{"trials":11187,"activeCount":101},[11188],{"nctId":11189,"briefTitle":11190,"status":160,"phases":11191,"primaryCompletion":8630,"completion":8630,"start":5938,"enrollment":11192,"conditions":11193,"interventions":11194},"NCT01094522","Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.",[89,90],47,[24],[11180,819],{"trials":11196,"activeCount":101},[],{"trials":11198,"activeCount":101},[],{"trials":11200,"activeCount":101},[],{"intervention":11202,"totalTrials":115,"cells":11203},"LY3361237",{"EARLY_PHASE1":11204,"PHASE1":11206,"PHASE2":11208,"PHASE3":11220,"PHASE4":11222,"NA":11224},{"trials":11205,"activeCount":101},[],{"trials":11207,"activeCount":101},[],{"trials":11209,"activeCount":101},[11210],{"nctId":11211,"briefTitle":11212,"status":132,"phases":11213,"primaryCompletion":11214,"completion":11215,"start":11216,"enrollment":101,"conditions":11217,"interventions":11219},"NCT05781451","Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome",[90],"2027-01-01","2028-01-01","2025-01-01",[11218],"Primary Sjogren's Syndrome",[11202],{"trials":11221,"activeCount":101},[],{"trials":11223,"activeCount":101},[],{"trials":11225,"activeCount":101},[],{"intervention":11227,"totalTrials":115,"cells":11228},"Rituximab 375 mg\u002Fm2",{"EARLY_PHASE1":11229,"PHASE1":11231,"PHASE2":11233,"PHASE3":11245,"PHASE4":11247,"NA":11249},{"trials":11230,"activeCount":101},[],{"trials":11232,"activeCount":101},[],{"trials":11234,"activeCount":101},[11235],{"nctId":11236,"briefTitle":11237,"status":160,"phases":11238,"primaryCompletion":3807,"completion":3807,"start":11239,"enrollment":222,"conditions":11240,"interventions":11244},"NCT00225212","Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma",[90],"1997-11",[1474,11241,3669,11242,11243,1426],"Diffuse Large Cell Lymphoma","Transformed Lymphoma","Other Subtypes of B-cell Lymphoma",[11227],{"trials":11246,"activeCount":101},[],{"trials":11248,"activeCount":101},[],{"trials":11250,"activeCount":101},[],{"intervention":11252,"totalTrials":115,"cells":11253},"Adalimumab",{"EARLY_PHASE1":11254,"PHASE1":11256,"PHASE2":11258,"PHASE3":11266,"PHASE4":11268,"NA":11270},{"trials":11255,"activeCount":101},[],{"trials":11257,"activeCount":101},[],{"trials":11259,"activeCount":101},[11260],{"nctId":11261,"briefTitle":11262,"status":160,"phases":11263,"completion":9928,"start":698,"enrollment":1314,"conditions":11264,"interventions":11265},"NCT00185562","A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis",[90],[779],[11252],{"trials":11267,"activeCount":101},[],{"trials":11269,"activeCount":101},[],{"trials":11271,"activeCount":101},[],{"intervention":11273,"totalTrials":115,"cells":11274},"Peginterferon Lambda-1a",{"EARLY_PHASE1":11275,"PHASE1":11277,"PHASE2":11279,"PHASE3":11290,"PHASE4":11292,"NA":11294},{"trials":11276,"activeCount":101},[],{"trials":11278,"activeCount":101},[],{"trials":11280,"activeCount":101},[11281],{"nctId":11282,"briefTitle":11283,"status":160,"phases":11284,"primaryCompletion":11285,"completion":11286,"start":11287,"enrollment":149,"conditions":11288,"interventions":11289},"NCT04331899","Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19",[90],"2020-08-14","2021-05-06","2020-04-25",[10567],[11273],{"trials":11291,"activeCount":101},[],{"trials":11293,"activeCount":101},[],{"trials":11295,"activeCount":101},[],{"intervention":4001,"totalTrials":115,"cells":11297},{"EARLY_PHASE1":11298,"PHASE1":11300,"PHASE2":11302,"PHASE3":11308,"PHASE4":11310,"NA":11312},{"trials":11299,"activeCount":101},[],{"trials":11301,"activeCount":101},[],{"trials":11303,"activeCount":101},[11304],{"nctId":3994,"briefTitle":3995,"status":160,"phases":11305,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":11306,"interventions":11307},[90],[740,722,3505,3999],[1533,4001,1438,4002,4003,3509,4004],{"trials":11309,"activeCount":101},[],{"trials":11311,"activeCount":101},[],{"trials":11313,"activeCount":101},[],{"intervention":4002,"totalTrials":115,"cells":11315},{"EARLY_PHASE1":11316,"PHASE1":11318,"PHASE2":11320,"PHASE3":11326,"PHASE4":11328,"NA":11330},{"trials":11317,"activeCount":101},[],{"trials":11319,"activeCount":101},[],{"trials":11321,"activeCount":101},[11322],{"nctId":3994,"briefTitle":3995,"status":160,"phases":11323,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":11324,"interventions":11325},[90],[740,722,3505,3999],[1533,4001,1438,4002,4003,3509,4004],{"trials":11327,"activeCount":101},[],{"trials":11329,"activeCount":101},[],{"trials":11331,"activeCount":101},[],{"intervention":4003,"totalTrials":115,"cells":11333},{"EARLY_PHASE1":11334,"PHASE1":11336,"PHASE2":11338,"PHASE3":11344,"PHASE4":11346,"NA":11348},{"trials":11335,"activeCount":101},[],{"trials":11337,"activeCount":101},[],{"trials":11339,"activeCount":101},[11340],{"nctId":3994,"briefTitle":3995,"status":160,"phases":11341,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":11342,"interventions":11343},[90],[740,722,3505,3999],[1533,4001,1438,4002,4003,3509,4004],{"trials":11345,"activeCount":101},[],{"trials":11347,"activeCount":101},[],{"trials":11349,"activeCount":101},[],{"intervention":4004,"totalTrials":115,"cells":11351},{"EARLY_PHASE1":11352,"PHASE1":11354,"PHASE2":11356,"PHASE3":11362,"PHASE4":11364,"NA":11366},{"trials":11353,"activeCount":101},[],{"trials":11355,"activeCount":101},[],{"trials":11357,"activeCount":101},[11358],{"nctId":3994,"briefTitle":3995,"status":160,"phases":11359,"primaryCompletion":1801,"completion":1545,"start":1500,"enrollment":3997,"conditions":11360,"interventions":11361},[90],[740,722,3505,3999],[1533,4001,1438,4002,4003,3509,4004],{"trials":11363,"activeCount":101},[],{"trials":11365,"activeCount":101},[],{"trials":11367,"activeCount":101},[],{"intervention":11369,"totalTrials":115,"cells":11370},"Armodafinil",{"EARLY_PHASE1":11371,"PHASE1":11373,"PHASE2":11375,"PHASE3":11384,"PHASE4":11386,"NA":11388},{"trials":11372,"activeCount":101},[],{"trials":11374,"activeCount":101},[],{"trials":11376,"activeCount":101},[11377],{"nctId":11378,"briefTitle":11379,"status":160,"phases":11380,"primaryCompletion":6055,"completion":6055,"start":231,"enrollment":907,"conditions":11381,"interventions":11383},"NCT01011218","Management of Insomnia in Breast Cancer Patients",[90],[1600,11382],"Fatigue",[11369],{"trials":11385,"activeCount":101},[],{"trials":11387,"activeCount":101},[],{"trials":11389,"activeCount":101},[],{"intervention":2179,"totalTrials":115,"cells":11391},{"EARLY_PHASE1":11392,"PHASE1":11394,"PHASE2":11396,"PHASE3":11402,"PHASE4":11404,"NA":11406},{"trials":11393,"activeCount":101},[],{"trials":11395,"activeCount":101},[],{"trials":11397,"activeCount":101},[11398],{"nctId":2169,"briefTitle":2170,"status":160,"phases":11399,"primaryCompletion":2172,"completion":207,"start":2173,"enrollment":684,"conditions":11400,"interventions":11401},[90],[2175,2176,2177],[2179,2160],{"trials":11403,"activeCount":101},[],{"trials":11405,"activeCount":101},[],{"trials":11407,"activeCount":101},[],{"intervention":11409,"totalTrials":115,"cells":11410},"18F-Fluoromisonidazole",{"EARLY_PHASE1":11411,"PHASE1":11413,"PHASE2":11415,"PHASE3":11428,"PHASE4":11430,"NA":11432},{"trials":11412,"activeCount":101},[],{"trials":11414,"activeCount":101},[],{"trials":11416,"activeCount":101},[11417],{"nctId":11418,"briefTitle":11419,"status":160,"phases":11420,"primaryCompletion":11421,"completion":11422,"start":11423,"enrollment":821,"conditions":11424,"interventions":11427},"NCT02695628","[18F]FMISO PET\u002FCT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer",[90],"2018-04-30","2018-10-31","2016-09-13",[11425,11426],"Adult Liver Carcinoma","Liver Cirrhosis",[11409],{"trials":11429,"activeCount":101},[],{"trials":11431,"activeCount":101},[],{"trials":11433,"activeCount":101},[],{"intervention":11435,"totalTrials":115,"cells":11436},"Midostaurin",{"EARLY_PHASE1":11437,"PHASE1":11439,"PHASE2":11441,"PHASE3":11452,"PHASE4":11454,"NA":11456},{"trials":11438,"activeCount":101},[],{"trials":11440,"activeCount":101},[],{"trials":11442,"activeCount":101},[11443],{"nctId":11444,"briefTitle":11445,"status":132,"phases":11446,"primaryCompletion":11447,"completion":11447,"enrollment":101,"conditions":11448,"interventions":11451},"NCT02723435","Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant",[90],"2018-04",[11449,11450],"Acute Myeloid Leukemia With Gene Mutations","Adult Acute Myeloid Leukemia in Remission",[11435],{"trials":11453,"activeCount":101},[],{"trials":11455,"activeCount":101},[],{"trials":11457,"activeCount":101},[],{"intervention":11459,"totalTrials":115,"cells":11460},"Selegiline",{"EARLY_PHASE1":11461,"PHASE1":11463,"PHASE2":11465,"PHASE3":11475,"PHASE4":11477,"NA":11479},{"trials":11462,"activeCount":101},[],{"trials":11464,"activeCount":101},[],{"trials":11466,"activeCount":101},[11467],{"nctId":11468,"briefTitle":11469,"status":160,"phases":11470,"primaryCompletion":6396,"completion":7020,"start":1861,"enrollment":11471,"conditions":11472,"interventions":11474},"NCT01330030","Selegiline Patch for Treatment of Nicotine Dependence",[90],243,[11473],"Tobacco Use Disorder",[11459],{"trials":11476,"activeCount":101},[],{"trials":11478,"activeCount":101},[],{"trials":11480,"activeCount":101},[],{"intervention":11482,"totalTrials":115,"cells":11483},"Bexarotene",{"EARLY_PHASE1":11484,"PHASE1":11486,"PHASE2":11488,"PHASE3":11498,"PHASE4":11500,"NA":11502},{"trials":11485,"activeCount":101},[],{"trials":11487,"activeCount":101},[],{"trials":11489,"activeCount":101},[11490],{"nctId":11491,"briefTitle":11492,"status":160,"phases":11493,"primaryCompletion":7589,"completion":11494,"start":272,"enrollment":1314,"conditions":11495,"interventions":11496},"NCT00238628","A Phase I\u002FII Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer",[89,90],"2005-12",[1757],[11482,11497],"Iressa",{"trials":11499,"activeCount":101},[],{"trials":11501,"activeCount":101},[],{"trials":11503,"activeCount":101},[],{"intervention":11497,"totalTrials":115,"cells":11505},{"EARLY_PHASE1":11506,"PHASE1":11508,"PHASE2":11510,"PHASE3":11516,"PHASE4":11518,"NA":11520},{"trials":11507,"activeCount":101},[],{"trials":11509,"activeCount":101},[],{"trials":11511,"activeCount":101},[11512],{"nctId":11491,"briefTitle":11492,"status":160,"phases":11513,"primaryCompletion":7589,"completion":11494,"start":272,"enrollment":1314,"conditions":11514,"interventions":11515},[89,90],[1757],[11482,11497],{"trials":11517,"activeCount":101},[],{"trials":11519,"activeCount":101},[],{"trials":11521,"activeCount":101},[],{"intervention":8063,"totalTrials":115,"cells":11523},{"EARLY_PHASE1":11524,"PHASE1":11526,"PHASE2":11528,"PHASE3":11534,"PHASE4":11536,"NA":11538},{"trials":11525,"activeCount":101},[],{"trials":11527,"activeCount":101},[],{"trials":11529,"activeCount":101},[11530],{"nctId":8056,"briefTitle":8057,"status":716,"phases":11531,"primaryCompletion":874,"completion":874,"start":7019,"enrollment":334,"conditions":11532,"interventions":11533},[90],[8060,8061],[7934,1747,3369,1722,8063,8064],{"trials":11535,"activeCount":101},[],{"trials":11537,"activeCount":101},[],{"trials":11539,"activeCount":101},[],{"intervention":8064,"totalTrials":115,"cells":11541},{"EARLY_PHASE1":11542,"PHASE1":11544,"PHASE2":11546,"PHASE3":11552,"PHASE4":11554,"NA":11556},{"trials":11543,"activeCount":101},[],{"trials":11545,"activeCount":101},[],{"trials":11547,"activeCount":101},[11548],{"nctId":8056,"briefTitle":8057,"status":716,"phases":11549,"primaryCompletion":874,"completion":874,"start":7019,"enrollment":334,"conditions":11550,"interventions":11551},[90],[8060,8061],[7934,1747,3369,1722,8063,8064],{"trials":11553,"activeCount":101},[],{"trials":11555,"activeCount":101},[],{"trials":11557,"activeCount":101},[],{"intervention":9251,"totalTrials":115,"cells":11559},{"EARLY_PHASE1":11560,"PHASE1":11562,"PHASE2":11564,"PHASE3":11570,"PHASE4":11572,"NA":11574},{"trials":11561,"activeCount":101},[],{"trials":11563,"activeCount":101},[],{"trials":11565,"activeCount":101},[11566],{"nctId":9240,"briefTitle":9241,"status":160,"phases":11567,"completion":1731,"start":9243,"conditions":11568,"interventions":11569},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"trials":11571,"activeCount":101},[],{"trials":11573,"activeCount":101},[],{"trials":11575,"activeCount":101},[],{"intervention":11577,"totalTrials":115,"cells":11578},"RO4995819",{"EARLY_PHASE1":11579,"PHASE1":11581,"PHASE2":11583,"PHASE3":11592,"PHASE4":11594,"NA":11596},{"trials":11580,"activeCount":101},[],{"trials":11582,"activeCount":101},[],{"trials":11584,"activeCount":101},[11585],{"nctId":11586,"briefTitle":11587,"status":132,"phases":11588,"primaryCompletion":834,"completion":1843,"start":11589,"enrollment":101,"conditions":11590,"interventions":11591},"NCT01733654","Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w\u002FMajor Depressive Disorder",[90],"2012-09",[21,167],[11577],{"trials":11593,"activeCount":101},[],{"trials":11595,"activeCount":101},[],{"trials":11597,"activeCount":101},[],{"intervention":11599,"totalTrials":115,"cells":11600},"Oral treprostinil",{"EARLY_PHASE1":11601,"PHASE1":11603,"PHASE2":11605,"PHASE3":11616,"PHASE4":11618,"NA":11620},{"trials":11602,"activeCount":101},[],{"trials":11604,"activeCount":101},[],{"trials":11606,"activeCount":101},[11607],{"nctId":11608,"briefTitle":11609,"status":160,"phases":11610,"primaryCompletion":11611,"completion":11611,"start":6243,"enrollment":1314,"conditions":11612,"interventions":11615},"NCT02663895","Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis",[90],"2020-05-13",[11613,11614],"Systemic Sclerosis","Calcinosis",[11599],{"trials":11617,"activeCount":101},[],{"trials":11619,"activeCount":101},[],{"trials":11621,"activeCount":101},[],{"intervention":11623,"totalTrials":115,"cells":11624},"Angiotensin-",{"EARLY_PHASE1":11625,"PHASE1":11627,"PHASE2":11629,"PHASE3":11639,"PHASE4":11641,"NA":11643},{"trials":11626,"activeCount":101},[],{"trials":11628,"activeCount":101},[],{"trials":11630,"activeCount":101},[11631],{"nctId":11632,"briefTitle":11633,"status":132,"phases":11634,"primaryCompletion":11635,"completion":11635,"start":11636,"enrollment":101,"conditions":11637,"interventions":11638},"NCT04570501","Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients",[89,90],"2022-08","2022-02",[3304],[11623],{"trials":11640,"activeCount":101},[],{"trials":11642,"activeCount":101},[],{"trials":11644,"activeCount":101},[],{"intervention":705,"totalTrials":115,"cells":11646},{"EARLY_PHASE1":11647,"PHASE1":11649,"PHASE2":11651,"PHASE3":11657,"PHASE4":11659,"NA":11661},{"trials":11648,"activeCount":101},[],{"trials":11650,"activeCount":101},[],{"trials":11652,"activeCount":101},[11653],{"nctId":693,"briefTitle":694,"status":160,"phases":11654,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":11655,"interventions":11656},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"trials":11658,"activeCount":101},[],{"trials":11660,"activeCount":101},[],{"trials":11662,"activeCount":101},[],{"intervention":707,"totalTrials":115,"cells":11664},{"EARLY_PHASE1":11665,"PHASE1":11667,"PHASE2":11669,"PHASE3":11675,"PHASE4":11677,"NA":11679},{"trials":11666,"activeCount":101},[],{"trials":11668,"activeCount":101},[],{"trials":11670,"activeCount":101},[11671],{"nctId":693,"briefTitle":694,"status":160,"phases":11672,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":11673,"interventions":11674},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"trials":11676,"activeCount":101},[],{"trials":11678,"activeCount":101},[],{"trials":11680,"activeCount":101},[],{"intervention":709,"totalTrials":115,"cells":11682},{"EARLY_PHASE1":11683,"PHASE1":11685,"PHASE2":11687,"PHASE3":11693,"PHASE4":11695,"NA":11697},{"trials":11684,"activeCount":101},[],{"trials":11686,"activeCount":101},[],{"trials":11688,"activeCount":101},[11689],{"nctId":693,"briefTitle":694,"status":160,"phases":11690,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":11691,"interventions":11692},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"trials":11694,"activeCount":101},[],{"trials":11696,"activeCount":101},[],{"trials":11698,"activeCount":101},[],{"intervention":11700,"totalTrials":115,"cells":11701},"Paclitaxel",{"EARLY_PHASE1":11702,"PHASE1":11704,"PHASE2":11706,"PHASE3":11718,"PHASE4":11720,"NA":11722},{"trials":11703,"activeCount":101},[],{"trials":11705,"activeCount":101},[],{"trials":11707,"activeCount":101},[11708],{"nctId":11709,"briefTitle":11710,"status":716,"phases":11711,"primaryCompletion":2102,"completion":11712,"start":11713,"enrollment":836,"conditions":11714,"interventions":11717},"NCT01055028","Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma",[90],"2016-06-24","2010-02",[11715,11716],"Angiosarcomas","Soft Tissue Sarcoma",[1760,11700],{"trials":11719,"activeCount":101},[],{"trials":11721,"activeCount":101},[],{"trials":11723,"activeCount":101},[],{"intervention":10224,"totalTrials":115,"cells":11725},{"EARLY_PHASE1":11726,"PHASE1":11728,"PHASE2":11730,"PHASE3":11736,"PHASE4":11738,"NA":11740},{"trials":11727,"activeCount":101},[],{"trials":11729,"activeCount":101},[],{"trials":11731,"activeCount":101},[11732],{"nctId":10215,"briefTitle":10216,"status":160,"phases":11733,"primaryCompletion":3725,"completion":10218,"start":10219,"enrollment":115,"conditions":11734,"interventions":11735},[90],[10221,10222],[10224,10206],{"trials":11737,"activeCount":101},[],{"trials":11739,"activeCount":101},[],{"trials":11741,"activeCount":101},[],{"intervention":9571,"totalTrials":115,"cells":11743},{"EARLY_PHASE1":11744,"PHASE1":11746,"PHASE2":11748,"PHASE3":11754,"PHASE4":11756,"NA":11758},{"trials":11745,"activeCount":101},[],{"trials":11747,"activeCount":101},[],{"trials":11749,"activeCount":101},[11750],{"nctId":9560,"briefTitle":9561,"status":160,"phases":11751,"primaryCompletion":2113,"completion":9563,"start":9564,"enrollment":5156,"conditions":11752,"interventions":11753},[90],[9566,9536,9567,9568,9569],[9524,9571],{"trials":11755,"activeCount":101},[],{"trials":11757,"activeCount":101},[],{"trials":11759,"activeCount":101},[],{"intervention":11761,"totalTrials":115,"cells":11762},"LINjeta U-100 Insulin",{"EARLY_PHASE1":11763,"PHASE1":11765,"PHASE2":11767,"PHASE3":11777,"PHASE4":11779,"NA":11781},{"trials":11764,"activeCount":101},[],{"trials":11766,"activeCount":101},[],{"trials":11768,"activeCount":101},[11769],{"nctId":11770,"briefTitle":11771,"status":132,"phases":11772,"primaryCompletion":231,"completion":9189,"start":1545,"enrollment":101,"conditions":11773,"interventions":11775},"NCT01067118","A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.",[90],[11774],"Diabetes Mellitus",[11761,11776],"Humalog U-100",{"trials":11778,"activeCount":101},[],{"trials":11780,"activeCount":101},[],{"trials":11782,"activeCount":101},[],{"intervention":11776,"totalTrials":115,"cells":11784},{"EARLY_PHASE1":11785,"PHASE1":11787,"PHASE2":11789,"PHASE3":11795,"PHASE4":11797,"NA":11799},{"trials":11786,"activeCount":101},[],{"trials":11788,"activeCount":101},[],{"trials":11790,"activeCount":101},[11791],{"nctId":11770,"briefTitle":11771,"status":132,"phases":11792,"primaryCompletion":231,"completion":9189,"start":1545,"enrollment":101,"conditions":11793,"interventions":11794},[90],[11774],[11761,11776],{"trials":11796,"activeCount":101},[],{"trials":11798,"activeCount":101},[],{"trials":11800,"activeCount":101},[],{"intervention":11802,"totalTrials":115,"cells":11803},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":11804,"PHASE1":11806,"PHASE2":11808,"PHASE3":11819,"PHASE4":11821,"NA":11823},{"trials":11805,"activeCount":101},[],{"trials":11807,"activeCount":101},[],{"trials":11809,"activeCount":101},[11810],{"nctId":11811,"briefTitle":11812,"status":160,"phases":11813,"primaryCompletion":833,"completion":833,"start":1809,"enrollment":197,"conditions":11814,"interventions":11818},"NCT00957931","Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs",[90],[11815,11816,11817],"Sickle Cell Disease","Thalassemia","Diamond-Blackfan Anemia",[11802],{"trials":11820,"activeCount":101},[],{"trials":11822,"activeCount":101},[],{"trials":11824,"activeCount":101},[],{"intervention":11826,"totalTrials":115,"cells":11827},"Oral antibiotics and vaginal probiotics",{"EARLY_PHASE1":11828,"PHASE1":11830,"PHASE2":11832,"PHASE3":11843,"PHASE4":11845,"NA":11847},{"trials":11829,"activeCount":101},[],{"trials":11831,"activeCount":101},[],{"trials":11833,"activeCount":101},[11834],{"nctId":11835,"briefTitle":11836,"status":160,"phases":11837,"primaryCompletion":9004,"completion":9004,"start":11838,"enrollment":4504,"conditions":11839,"interventions":11842},"NCT03401918","Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility",[90],"2017-08-01",[11840,11841],"Recurrent Pregnancy Loss","Unexplained Infertility",[11826],{"trials":11844,"activeCount":101},[],{"trials":11846,"activeCount":101},[],{"trials":11848,"activeCount":101},[],{"intervention":5651,"totalTrials":115,"cells":11850},{"EARLY_PHASE1":11851,"PHASE1":11853,"PHASE2":11855,"PHASE3":11861,"PHASE4":11863,"NA":11865},{"trials":11852,"activeCount":101},[],{"trials":11854,"activeCount":101},[],{"trials":11856,"activeCount":101},[11857],{"nctId":5643,"briefTitle":5644,"status":160,"phases":11858,"primaryCompletion":5646,"completion":5647,"start":5648,"enrollment":222,"conditions":11859,"interventions":11860},[90],[15],[5634,5651],{"trials":11862,"activeCount":101},[],{"trials":11864,"activeCount":101},[],{"trials":11866,"activeCount":101},[],{"intervention":11868,"totalTrials":115,"cells":11869},"Peanut Protein 4,000mg",{"EARLY_PHASE1":11870,"PHASE1":11872,"PHASE2":11874,"PHASE3":11886,"PHASE4":11888,"NA":11890},{"trials":11871,"activeCount":101},[],{"trials":11873,"activeCount":101},[],{"trials":11875,"activeCount":101},[11876],{"nctId":11877,"briefTitle":11878,"status":160,"phases":11879,"primaryCompletion":11880,"completion":11881,"start":756,"enrollment":149,"conditions":11882,"interventions":11883},"NCT02103270","The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery",[90],"2018-07-25","2018-09-01",[9569],[11868,11884,11885],"Oat Flour","Peanut Protein 300 mg",{"trials":11887,"activeCount":101},[],{"trials":11889,"activeCount":101},[],{"trials":11891,"activeCount":101},[],{"intervention":11884,"totalTrials":115,"cells":11893},{"EARLY_PHASE1":11894,"PHASE1":11896,"PHASE2":11898,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11895,"activeCount":101},[],{"trials":11897,"activeCount":101},[],{"trials":11899,"activeCount":101},[11900],{"nctId":11877,"briefTitle":11878,"status":160,"phases":11901,"primaryCompletion":11880,"completion":11881,"start":756,"enrollment":149,"conditions":11902,"interventions":11903},[90],[9569],[11868,11884,11885],{"trials":11905,"activeCount":101},[],{"trials":11907,"activeCount":101},[],{"trials":11909,"activeCount":101},[],{"intervention":11885,"totalTrials":115,"cells":11911},{"EARLY_PHASE1":11912,"PHASE1":11914,"PHASE2":11916,"PHASE3":11922,"PHASE4":11924,"NA":11926},{"trials":11913,"activeCount":101},[],{"trials":11915,"activeCount":101},[],{"trials":11917,"activeCount":101},[11918],{"nctId":11877,"briefTitle":11878,"status":160,"phases":11919,"primaryCompletion":11880,"completion":11881,"start":756,"enrollment":149,"conditions":11920,"interventions":11921},[90],[9569],[11868,11884,11885],{"trials":11923,"activeCount":101},[],{"trials":11925,"activeCount":101},[],{"trials":11927,"activeCount":101},[],{"intervention":11929,"totalTrials":115,"cells":11930},"Norco 5Mg-325Mg",{"EARLY_PHASE1":11931,"PHASE1":11933,"PHASE2":11935,"PHASE3":11948,"PHASE4":11950,"NA":11952},{"trials":11932,"activeCount":101},[],{"trials":11934,"activeCount":101},[],{"trials":11936,"activeCount":101},[11937],{"nctId":11938,"briefTitle":11939,"status":160,"phases":11940,"primaryCompletion":3362,"completion":11941,"start":11942,"enrollment":11943,"conditions":11944,"interventions":11945},"NCT03584152","Postoperative Pain Management in Rhinoplasty",[90],"2025-07-17","2019-08-09",159,[354],[11929,11946,11947],"Tylenol 325Mg Caplet","Ibuprofen 200 mg",{"trials":11949,"activeCount":101},[],{"trials":11951,"activeCount":101},[],{"trials":11953,"activeCount":101},[],{"intervention":11946,"totalTrials":115,"cells":11955},{"EARLY_PHASE1":11956,"PHASE1":11958,"PHASE2":11960,"PHASE3":11966,"PHASE4":11968,"NA":11970},{"trials":11957,"activeCount":101},[],{"trials":11959,"activeCount":101},[],{"trials":11961,"activeCount":101},[11962],{"nctId":11938,"briefTitle":11939,"status":160,"phases":11963,"primaryCompletion":3362,"completion":11941,"start":11942,"enrollment":11943,"conditions":11964,"interventions":11965},[90],[354],[11929,11946,11947],{"trials":11967,"activeCount":101},[],{"trials":11969,"activeCount":101},[],{"trials":11971,"activeCount":101},[],{"intervention":11947,"totalTrials":115,"cells":11973},{"EARLY_PHASE1":11974,"PHASE1":11976,"PHASE2":11978,"PHASE3":11984,"PHASE4":11986,"NA":11988},{"trials":11975,"activeCount":101},[],{"trials":11977,"activeCount":101},[],{"trials":11979,"activeCount":101},[11980],{"nctId":11938,"briefTitle":11939,"status":160,"phases":11981,"primaryCompletion":3362,"completion":11941,"start":11942,"enrollment":11943,"conditions":11982,"interventions":11983},[90],[354],[11929,11946,11947],{"trials":11985,"activeCount":101},[],{"trials":11987,"activeCount":101},[],{"trials":11989,"activeCount":101},[],{"intervention":11991,"totalTrials":115,"cells":11992},"Idiotype-pulsed allogeneic dendritic cells",{"EARLY_PHASE1":11993,"PHASE1":11995,"PHASE2":11997,"PHASE3":12007,"PHASE4":12009,"NA":12011},{"trials":11994,"activeCount":101},[],{"trials":11996,"activeCount":101},[],{"trials":11998,"activeCount":101},[11999],{"nctId":12000,"briefTitle":12001,"status":160,"phases":12002,"primaryCompletion":12003,"completion":8371,"start":12004,"enrollment":232,"conditions":12005,"interventions":12006},"NCT00186316","Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells",[89,90],"2006-04","2003-04",[763],[11991],{"trials":12008,"activeCount":101},[],{"trials":12010,"activeCount":101},[],{"trials":12012,"activeCount":101},[],{"intervention":12014,"totalTrials":115,"cells":12015},"caffeine\u002Fpropranolol combination",{"EARLY_PHASE1":12016,"PHASE1":12018,"PHASE2":12020,"PHASE3":12029,"PHASE4":12031,"NA":12033},{"trials":12017,"activeCount":101},[],{"trials":12019,"activeCount":101},[],{"trials":12021,"activeCount":101},[12022],{"nctId":12023,"briefTitle":12024,"status":160,"phases":12025,"primaryCompletion":220,"completion":5656,"start":1423,"enrollment":1124,"conditions":12026,"interventions":12028},"NCT01080677","Caffeine\u002FPropranolol Intervention for Acute Migraine",[90],[12027],"Migraine Disorders",[12014],{"trials":12030,"activeCount":101},[],{"trials":12032,"activeCount":101},[],{"trials":12034,"activeCount":101},[],{"intervention":1439,"totalTrials":115,"cells":12036},{"EARLY_PHASE1":12037,"PHASE1":12039,"PHASE2":12041,"PHASE3":12047,"PHASE4":12049,"NA":12051},{"trials":12038,"activeCount":101},[],{"trials":12040,"activeCount":101},[],{"trials":12042,"activeCount":101},[12043],{"nctId":1430,"briefTitle":1431,"status":716,"phases":12044,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":12045,"interventions":12046},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"trials":12048,"activeCount":101},[],{"trials":12050,"activeCount":101},[],{"trials":12052,"activeCount":101},[],{"intervention":1440,"totalTrials":115,"cells":12054},{"EARLY_PHASE1":12055,"PHASE1":12057,"PHASE2":12059,"PHASE3":12065,"PHASE4":12067,"NA":12069},{"trials":12056,"activeCount":101},[],{"trials":12058,"activeCount":101},[],{"trials":12060,"activeCount":101},[12061],{"nctId":1430,"briefTitle":1431,"status":716,"phases":12062,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":12063,"interventions":12064},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"trials":12066,"activeCount":101},[],{"trials":12068,"activeCount":101},[],{"trials":12070,"activeCount":101},[],{"intervention":1441,"totalTrials":115,"cells":12072},{"EARLY_PHASE1":12073,"PHASE1":12075,"PHASE2":12077,"PHASE3":12083,"PHASE4":12085,"NA":12087},{"trials":12074,"activeCount":101},[],{"trials":12076,"activeCount":101},[],{"trials":12078,"activeCount":101},[12079],{"nctId":1430,"briefTitle":1431,"status":716,"phases":12080,"primaryCompletion":1433,"completion":1434,"start":1423,"enrollment":1435,"conditions":12081,"interventions":12082},[90],[722],[730,1438,727,708,1439,706,729,704,1440,1441],{"trials":12084,"activeCount":101},[],{"trials":12086,"activeCount":101},[],{"trials":12088,"activeCount":101},[],{"intervention":12090,"totalTrials":115,"cells":12091},"18F-FPPRGD2",{"EARLY_PHASE1":12092,"PHASE1":12094,"PHASE2":12096,"PHASE3":12108,"PHASE4":12110,"NA":12112},{"trials":12093,"activeCount":101},[],{"trials":12095,"activeCount":101},[],{"trials":12097,"activeCount":101},[12098],{"nctId":12099,"briefTitle":12100,"status":132,"phases":12101,"primaryCompletion":12102,"completion":3944,"start":12103,"enrollment":101,"conditions":12104,"interventions":12107},"NCT02995642","Targeted PET\u002FCT and PET\u002FMRI Imaging of Vascular Inflammation",[90],"2020-09","2019-10",[12105,12106],"Aortic Aneurysm, Abdominal","Carotid Atherosclerosis",[12090],{"trials":12109,"activeCount":101},[],{"trials":12111,"activeCount":101},[],{"trials":12113,"activeCount":101},[],{"intervention":12115,"totalTrials":115,"cells":12116},"18F-FSPG",{"EARLY_PHASE1":12117,"PHASE1":12119,"PHASE2":12121,"PHASE3":12132,"PHASE4":12134,"NA":12136},{"trials":12118,"activeCount":101},[],{"trials":12120,"activeCount":101},[],{"trials":12122,"activeCount":101},[12123],{"nctId":12124,"briefTitle":12125,"status":716,"phases":12126,"primaryCompletion":12127,"completion":12127,"start":12128,"enrollment":165,"conditions":12129,"interventions":12131},"NCT03103490","18F-FSPG PET\u002FMRI or PET\u002FCT Imaging of Cardiac Sarcoidosis or Inflammation",[90],"2021-09-28","2017-08-02",[2465,12130],"Myocardial Inflammation",[12115],{"trials":12133,"activeCount":101},[],{"trials":12135,"activeCount":101},[],{"trials":12137,"activeCount":101},[],{"intervention":12139,"totalTrials":115,"cells":12140},"68Ga-FAPI",{"EARLY_PHASE1":12141,"PHASE1":12143,"PHASE2":12145,"PHASE3":12155,"PHASE4":12157,"NA":12159},{"trials":12142,"activeCount":101},[],{"trials":12144,"activeCount":101},[],{"trials":12146,"activeCount":101},[12147],{"nctId":12148,"briefTitle":12149,"status":132,"phases":12150,"primaryCompletion":12151,"completion":12152,"start":6421,"enrollment":101,"conditions":12153,"interventions":12154},"NCT04023240","68-Ga-FAPI PET Imaging in Malignancy",[90],"2023-07-14","2023-12-14",[10755],[12139],{"trials":12156,"activeCount":101},[],{"trials":12158,"activeCount":101},[],{"trials":12160,"activeCount":101},[],{"intervention":3937,"totalTrials":115,"cells":12162},{"EARLY_PHASE1":12163,"PHASE1":12165,"PHASE2":12167,"PHASE3":12173,"PHASE4":12175,"NA":12177},{"trials":12164,"activeCount":101},[],{"trials":12166,"activeCount":101},[],{"trials":12168,"activeCount":101},[12169],{"nctId":3928,"briefTitle":3929,"status":160,"phases":12170,"primaryCompletion":3931,"completion":698,"start":3932,"enrollment":3933,"conditions":12171,"interventions":12172},[90],[3935],[3937,1698,3938],{"trials":12174,"activeCount":101},[],{"trials":12176,"activeCount":101},[],{"trials":12178,"activeCount":101},[],{"intervention":12180,"totalTrials":115,"cells":12181},"68Ga-DOTA-Bombesin",{"EARLY_PHASE1":12182,"PHASE1":12184,"PHASE2":12186,"PHASE3":12196,"PHASE4":12198,"NA":12200},{"trials":12183,"activeCount":101},[],{"trials":12185,"activeCount":101},[],{"trials":12187,"activeCount":101},[12188],{"nctId":12189,"briefTitle":12190,"status":160,"phases":12191,"primaryCompletion":12192,"completion":12192,"start":8251,"enrollment":247,"conditions":12193,"interventions":12195},"NCT02440308","68Ga-DOTA-Bombesin PET\u002FMRI in Imaging Patients With Prostate Cancer",[90],"2015-06-30",[12194],"Prostate Carcinoma",[12180],{"trials":12197,"activeCount":101},[],{"trials":12199,"activeCount":101},[],{"trials":12201,"activeCount":101},[],{"intervention":12203,"totalTrials":115,"cells":12204},"'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT",{"EARLY_PHASE1":12205,"PHASE1":12207,"PHASE2":12209,"PHASE3":12217,"PHASE4":12219,"NA":12221},{"trials":12206,"activeCount":101},[],{"trials":12208,"activeCount":101},[],{"trials":12210,"activeCount":101},[12211],{"nctId":12212,"briefTitle":12213,"status":160,"phases":12214,"primaryCompletion":5647,"completion":5647,"start":5646,"enrollment":197,"conditions":12215,"interventions":12216},"NCT01989195","Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease",[89,90],[10955],[12203],{"trials":12218,"activeCount":101},[],{"trials":12220,"activeCount":101},[],{"trials":12222,"activeCount":101},[],{"intervention":12224,"totalTrials":115,"cells":12225},"Abemaciclib",{"EARLY_PHASE1":12226,"PHASE1":12228,"PHASE2":12230,"PHASE3":12243,"PHASE4":12245,"NA":12247},{"trials":12227,"activeCount":101},[],{"trials":12229,"activeCount":101},[],{"trials":12231,"activeCount":101},[12232],{"nctId":12233,"briefTitle":12234,"status":160,"phases":12235,"primaryCompletion":12236,"completion":12237,"start":12238,"enrollment":759,"conditions":12239,"interventions":12242},"NCT04552769","Abemaciclib in Metastatic or Locally Advanced Anaplastic\u002FUndifferentiated Thyroid Cancer",[90],"2023-04-12","2025-01-05","2020-09-10",[1350,12240,12241],"Anaplastic Thyroid Cancer","Undifferentiated Thyroid Cancer",[12224],{"trials":12244,"activeCount":101},[],{"trials":12246,"activeCount":101},[],{"trials":12248,"activeCount":101},[],{"intervention":12250,"totalTrials":115,"cells":12251},"Calcitriol",{"EARLY_PHASE1":12252,"PHASE1":12254,"PHASE2":12256,"PHASE3":12266,"PHASE4":12268,"NA":12270},{"trials":12253,"activeCount":101},[],{"trials":12255,"activeCount":101},[],{"trials":12257,"activeCount":101},[12258],{"nctId":12259,"briefTitle":12260,"status":716,"phases":12261,"primaryCompletion":4993,"completion":4993,"start":12262,"enrollment":111,"conditions":12263,"interventions":12264},"NCT00383487","A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer",[90],"2005-03",[10434,3388],[12250,12265],"Naproxen-n-butyl nitrate",{"trials":12267,"activeCount":101},[],{"trials":12269,"activeCount":101},[],{"trials":12271,"activeCount":101},[],{"intervention":12265,"totalTrials":115,"cells":12273},{"EARLY_PHASE1":12274,"PHASE1":12276,"PHASE2":12278,"PHASE3":12284,"PHASE4":12286,"NA":12288},{"trials":12275,"activeCount":101},[],{"trials":12277,"activeCount":101},[],{"trials":12279,"activeCount":101},[12280],{"nctId":12259,"briefTitle":12260,"status":716,"phases":12281,"primaryCompletion":4993,"completion":4993,"start":12262,"enrollment":111,"conditions":12282,"interventions":12283},[90],[10434,3388],[12250,12265],{"trials":12285,"activeCount":101},[],{"trials":12287,"activeCount":101},[],{"trials":12289,"activeCount":101},[],{"intervention":12291,"totalTrials":115,"cells":12292},"Dysport",{"EARLY_PHASE1":12293,"PHASE1":12295,"PHASE2":12297,"PHASE3":12309,"PHASE4":12311,"NA":12313},{"trials":12294,"activeCount":101},[],{"trials":12296,"activeCount":101},[],{"trials":12298,"activeCount":101},[12299],{"nctId":12300,"briefTitle":12301,"status":132,"phases":12302,"primaryCompletion":12303,"completion":12303,"start":12304,"enrollment":101,"conditions":12305,"interventions":12308},"NCT03631966","Botulinum Toxin Injection for Functional Popliteal Artery Entrapment Syndrome",[90],"2019-12-31","2019-10-01",[12306,12307],"Functional Popliteal Artery Entrapment Syndrome","Popliteal Artery Entrapment Syndrome",[12291],{"trials":12310,"activeCount":101},[],{"trials":12312,"activeCount":101},[],{"trials":12314,"activeCount":101},[],{"intervention":12316,"totalTrials":115,"cells":12317},"alirocumab",{"EARLY_PHASE1":12318,"PHASE1":12320,"PHASE2":12322,"PHASE3":12333,"PHASE4":12335,"NA":12337},{"trials":12319,"activeCount":101},[],{"trials":12321,"activeCount":101},[],{"trials":12323,"activeCount":101},[12324],{"nctId":12325,"briefTitle":12326,"status":160,"phases":12327,"primaryCompletion":12328,"completion":12328,"start":12329,"enrollment":10753,"conditions":12330,"interventions":12332},"NCT03537742","Cardiac Allograft Vasculopathy Inhibition With Alirocumab",[90],"2025-07-11","2019-05-13",[12331],"Vasculopathy",[12316],{"trials":12334,"activeCount":101},[],{"trials":12336,"activeCount":101},[],{"trials":12338,"activeCount":101},[],{"intervention":7920,"totalTrials":115,"cells":12340},{"EARLY_PHASE1":12341,"PHASE1":12343,"PHASE2":12345,"PHASE3":12351,"PHASE4":12353,"NA":12355},{"trials":12342,"activeCount":101},[],{"trials":12344,"activeCount":101},[],{"trials":12346,"activeCount":101},[12347],{"nctId":7911,"briefTitle":7912,"status":160,"phases":12348,"completion":7914,"start":7915,"conditions":12349,"interventions":12350},[90],[7917],[7919,3956,7920,7921,7922],{"trials":12352,"activeCount":101},[],{"trials":12354,"activeCount":101},[],{"trials":12356,"activeCount":101},[],{"intervention":7921,"totalTrials":115,"cells":12358},{"EARLY_PHASE1":12359,"PHASE1":12361,"PHASE2":12363,"PHASE3":12369,"PHASE4":12371,"NA":12373},{"trials":12360,"activeCount":101},[],{"trials":12362,"activeCount":101},[],{"trials":12364,"activeCount":101},[12365],{"nctId":7911,"briefTitle":7912,"status":160,"phases":12366,"completion":7914,"start":7915,"conditions":12367,"interventions":12368},[90],[7917],[7919,3956,7920,7921,7922],{"trials":12370,"activeCount":101},[],{"trials":12372,"activeCount":101},[],{"trials":12374,"activeCount":101},[],{"intervention":12376,"totalTrials":115,"cells":12377},"Povidone-Iodine 2%",{"EARLY_PHASE1":12378,"PHASE1":12380,"PHASE2":12382,"PHASE3":12394,"PHASE4":12396,"NA":12398},{"trials":12379,"activeCount":101},[],{"trials":12381,"activeCount":101},[],{"trials":12383,"activeCount":101},[12384],{"nctId":12385,"briefTitle":12386,"status":160,"phases":12387,"primaryCompletion":12388,"completion":12388,"start":12389,"enrollment":11192,"conditions":12390,"interventions":12391},"NCT04347954","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)",[89,90],"2020-12-13","2020-08-15",[10567],[12376,12392,12393],"Povidone-Iodine 0.5%","Isotonic saline 0.9%",{"trials":12395,"activeCount":101},[],{"trials":12397,"activeCount":101},[],{"trials":12399,"activeCount":101},[],{"intervention":12392,"totalTrials":115,"cells":12401},{"EARLY_PHASE1":12402,"PHASE1":12404,"PHASE2":12406,"PHASE3":12412,"PHASE4":12414,"NA":12416},{"trials":12403,"activeCount":101},[],{"trials":12405,"activeCount":101},[],{"trials":12407,"activeCount":101},[12408],{"nctId":12385,"briefTitle":12386,"status":160,"phases":12409,"primaryCompletion":12388,"completion":12388,"start":12389,"enrollment":11192,"conditions":12410,"interventions":12411},[89,90],[10567],[12376,12392,12393],{"trials":12413,"activeCount":101},[],{"trials":12415,"activeCount":101},[],{"trials":12417,"activeCount":101},[],{"intervention":12393,"totalTrials":115,"cells":12419},{"EARLY_PHASE1":12420,"PHASE1":12422,"PHASE2":12424,"PHASE3":12430,"PHASE4":12432,"NA":12434},{"trials":12421,"activeCount":101},[],{"trials":12423,"activeCount":101},[],{"trials":12425,"activeCount":101},[12426],{"nctId":12385,"briefTitle":12386,"status":160,"phases":12427,"primaryCompletion":12388,"completion":12388,"start":12389,"enrollment":11192,"conditions":12428,"interventions":12429},[89,90],[10567],[12376,12392,12393],{"trials":12431,"activeCount":101},[],{"trials":12433,"activeCount":101},[],{"trials":12435,"activeCount":101},[],{"intervention":12437,"totalTrials":115,"cells":12438},"Propranolol",{"EARLY_PHASE1":12439,"PHASE1":12441,"PHASE2":12443,"PHASE3":12453,"PHASE4":12455,"NA":12457},{"trials":12440,"activeCount":101},[],{"trials":12442,"activeCount":101},[],{"trials":12444,"activeCount":101},[12445],{"nctId":12446,"briefTitle":12447,"status":160,"phases":12448,"primaryCompletion":7019,"completion":9189,"start":1472,"enrollment":247,"conditions":12449,"interventions":12451},"NCT01222091","Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids",[90],[12450],"Hyperalgesia",[12437,12452],"Remifentanil",{"trials":12454,"activeCount":101},[],{"trials":12456,"activeCount":101},[],{"trials":12458,"activeCount":101},[],{"intervention":12460,"totalTrials":115,"cells":12461},"lapatinib ditosylate",{"EARLY_PHASE1":12462,"PHASE1":12464,"PHASE2":12466,"PHASE3":12479,"PHASE4":12481,"NA":12483},{"trials":12463,"activeCount":101},[],{"trials":12465,"activeCount":101},[],{"trials":12467,"activeCount":101},[12468],{"nctId":12469,"briefTitle":12470,"status":716,"phases":12471,"primaryCompletion":757,"completion":9982,"start":6351,"enrollment":97,"conditions":12472,"interventions":12478},"NCT01868503","Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer",[90],[12473,12474,12475,12476,12477],"Male Breast Cancer","Recurrent Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[12460],{"trials":12480,"activeCount":101},[],{"trials":12482,"activeCount":101},[],{"trials":12484,"activeCount":101},[],{"intervention":12486,"totalTrials":115,"cells":12487},"Ivermectin Pill",{"EARLY_PHASE1":12488,"PHASE1":12490,"PHASE2":12492,"PHASE3":12501,"PHASE4":12503,"NA":12505},{"trials":12489,"activeCount":101},[],{"trials":12491,"activeCount":101},[],{"trials":12493,"activeCount":101},[12494],{"nctId":12495,"briefTitle":12496,"status":132,"phases":12497,"primaryCompletion":3153,"completion":3153,"start":12498,"enrollment":101,"conditions":12499,"interventions":12500},"NCT03553615","Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis",[90],"2030-12-01",[9555],[12486],{"trials":12502,"activeCount":101},[],{"trials":12504,"activeCount":101},[],{"trials":12506,"activeCount":101},[],{"intervention":12508,"totalTrials":115,"cells":12509},"Fulvestrant",{"EARLY_PHASE1":12510,"PHASE1":12512,"PHASE2":12514,"PHASE3":12522,"PHASE4":12524,"NA":12526},{"trials":12511,"activeCount":101},[],{"trials":12513,"activeCount":101},[],{"trials":12515,"activeCount":101},[12516],{"nctId":12517,"briefTitle":12518,"status":160,"phases":12519,"primaryCompletion":220,"completion":5656,"start":1743,"enrollment":247,"conditions":12520,"interventions":12521},"NCT00476645","Fulvestrant in Hormone Refractory Prostate Cancer",[90],[10434,3388],[12508],{"trials":12523,"activeCount":101},[],{"trials":12525,"activeCount":101},[],{"trials":12527,"activeCount":101},[],{"intervention":12529,"totalTrials":115,"cells":12530},"Apixaban 2.5 MG Oral",{"EARLY_PHASE1":12531,"PHASE1":12533,"PHASE2":12535,"PHASE3":12546,"PHASE4":12548,"NA":12550},{"trials":12532,"activeCount":101},[],{"trials":12534,"activeCount":101},[],{"trials":12536,"activeCount":101},[12537],{"nctId":12538,"briefTitle":12539,"status":160,"phases":12540,"primaryCompletion":12541,"completion":12541,"start":10395,"enrollment":9,"conditions":12542,"interventions":12544},"NCT04504318","Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT",[89,90],"2024-06-19",[12543],"Venous Thromboembolism",[12529,12545],"Enoxaparin 40Mg\u002F0.4mL Prefilled Syringe",{"trials":12547,"activeCount":101},[],{"trials":12549,"activeCount":101},[],{"trials":12551,"activeCount":101},[],{"intervention":12545,"totalTrials":115,"cells":12553},{"EARLY_PHASE1":12554,"PHASE1":12556,"PHASE2":12558,"PHASE3":12564,"PHASE4":12566,"NA":12568},{"trials":12555,"activeCount":101},[],{"trials":12557,"activeCount":101},[],{"trials":12559,"activeCount":101},[12560],{"nctId":12538,"briefTitle":12539,"status":160,"phases":12561,"primaryCompletion":12541,"completion":12541,"start":10395,"enrollment":9,"conditions":12562,"interventions":12563},[89,90],[12543],[12529,12545],{"trials":12565,"activeCount":101},[],{"trials":12567,"activeCount":101},[],{"trials":12569,"activeCount":101},[],{"intervention":12571,"totalTrials":115,"cells":12572},"raloxifene",{"EARLY_PHASE1":12573,"PHASE1":12575,"PHASE2":12577,"PHASE3":12585,"PHASE4":12587,"NA":12589},{"trials":12574,"activeCount":101},[],{"trials":12576,"activeCount":101},[],{"trials":12578,"activeCount":101},[12579],{"nctId":12580,"briefTitle":12581,"status":160,"phases":12582,"primaryCompletion":7340,"completion":7655,"start":1500,"enrollment":6978,"conditions":12583,"interventions":12584},"NCT00368459","Raloxifene for Women With Alzheimer's Disease",[90],[2651],[12571],{"trials":12586,"activeCount":101},[],{"trials":12588,"activeCount":101},[],{"trials":12590,"activeCount":101},[],{"intervention":12592,"totalTrials":115,"cells":12593},"Intravitreal Aflibercept",{"EARLY_PHASE1":12594,"PHASE1":12596,"PHASE2":12598,"PHASE3":12608,"PHASE4":12610,"NA":12612},{"trials":12595,"activeCount":101},[],{"trials":12597,"activeCount":101},[],{"trials":12599,"activeCount":101},[12600],{"nctId":12601,"briefTitle":12602,"status":132,"phases":12603,"primaryCompletion":5729,"completion":12604,"start":3944,"enrollment":101,"conditions":12605,"interventions":12607},"NCT04588948","A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema",[90],"2021-12",[12606],"Diabetic Macular Edema",[12592],{"trials":12609,"activeCount":101},[],{"trials":12611,"activeCount":101},[],{"trials":12613,"activeCount":101},[],{"intervention":12615,"totalTrials":115,"cells":12616},"Metolazone",{"EARLY_PHASE1":12617,"PHASE1":12619,"PHASE2":12621,"PHASE3":12632,"PHASE4":12634,"NA":12636},{"trials":12618,"activeCount":101},[],{"trials":12620,"activeCount":101},[],{"trials":12622,"activeCount":101},[12623],{"nctId":12624,"briefTitle":12625,"status":716,"phases":12626,"primaryCompletion":12627,"completion":12627,"start":1596,"enrollment":1766,"conditions":12628,"interventions":12631},"NCT04542304","Efficacy of Diuretics in Kidney Disease",[90],"2023-06-15",[12629,12630],"Chronic Kidney Disease","End Stage Renal Disease",[12615],{"trials":12633,"activeCount":101},[],{"trials":12635,"activeCount":101},[],{"trials":12637,"activeCount":101},[],{"intervention":12639,"totalTrials":115,"cells":12640},"Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys",{"EARLY_PHASE1":12641,"PHASE1":12643,"PHASE2":12645,"PHASE3":12654,"PHASE4":12656,"NA":12658},{"trials":12642,"activeCount":101},[],{"trials":12644,"activeCount":101},[],{"trials":12646,"activeCount":101},[12647],{"nctId":12648,"briefTitle":12649,"status":160,"phases":12650,"primaryCompletion":9065,"completion":6977,"start":1919,"enrollment":247,"conditions":12651,"interventions":12653},"NCT02488070","68Ga-PSMA PET\u002FCT or PET\u002FMRI in Evaluating Patients With Recurrent Prostate Cancer",[89,90],[12652],"Recurrent Prostate Carcinoma",[12639],{"trials":12655,"activeCount":101},[],{"trials":12657,"activeCount":101},[],{"trials":12659,"activeCount":101},[],{"intervention":12661,"totalTrials":115,"cells":12662},"Bexxar",{"EARLY_PHASE1":12663,"PHASE1":12665,"PHASE2":12667,"PHASE3":12676,"PHASE4":12678,"NA":12680},{"trials":12664,"activeCount":101},[],{"trials":12666,"activeCount":101},[],{"trials":12668,"activeCount":101},[12669],{"nctId":12670,"briefTitle":12671,"status":716,"phases":12672,"primaryCompletion":9189,"completion":6351,"start":1423,"enrollment":684,"conditions":12673,"interventions":12674},"NCT00490490","Study of Bexxar \u003CTositumomab> Combined With External Beam Radiation Therapy",[90],[722],[12661,12675],"Potassium Iodide",{"trials":12677,"activeCount":101},[],{"trials":12679,"activeCount":101},[],{"trials":12681,"activeCount":101},[],{"intervention":12675,"totalTrials":115,"cells":12683},{"EARLY_PHASE1":12684,"PHASE1":12686,"PHASE2":12688,"PHASE3":12694,"PHASE4":12696,"NA":12698},{"trials":12685,"activeCount":101},[],{"trials":12687,"activeCount":101},[],{"trials":12689,"activeCount":101},[12690],{"nctId":12670,"briefTitle":12671,"status":716,"phases":12691,"primaryCompletion":9189,"completion":6351,"start":1423,"enrollment":684,"conditions":12692,"interventions":12693},[90],[722],[12661,12675],{"trials":12695,"activeCount":101},[],{"trials":12697,"activeCount":101},[],{"trials":12699,"activeCount":101},[],{"intervention":12701,"totalTrials":115,"cells":12702},"CocoaVia®",{"EARLY_PHASE1":12703,"PHASE1":12705,"PHASE2":12707,"PHASE3":12716,"PHASE4":12718,"NA":12720},{"trials":12704,"activeCount":101},[],{"trials":12706,"activeCount":101},[],{"trials":12708,"activeCount":101},[12709],{"nctId":12710,"briefTitle":12711,"status":160,"phases":12712,"primaryCompletion":2172,"completion":2172,"start":10751,"enrollment":12713,"conditions":12714,"interventions":12715},"NCT03123068","Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery",[89,90],74,[9817],[12701],{"trials":12717,"activeCount":101},[],{"trials":12719,"activeCount":101},[],{"trials":12721,"activeCount":101},[],{"intervention":12723,"totalTrials":115,"cells":12724},"Sorafenib",{"EARLY_PHASE1":12725,"PHASE1":12727,"PHASE2":12729,"PHASE3":12741,"PHASE4":12743,"NA":12745},{"trials":12726,"activeCount":101},[],{"trials":12728,"activeCount":101},[],{"trials":12730,"activeCount":101},[12731],{"nctId":12732,"briefTitle":12733,"status":160,"phases":12734,"primaryCompletion":219,"completion":231,"start":12735,"enrollment":759,"conditions":12736,"interventions":12740},"NCT00854620","Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",[90],"2007-12",[12737,12738,12739],"Carcinoma, Renal Cell","Kidney Disease","Kidney Cancer",[12723],{"trials":12742,"activeCount":101},[],{"trials":12744,"activeCount":101},[],{"trials":12746,"activeCount":101},[],{"intervention":12748,"totalTrials":115,"cells":12749},"Ulinastatin",{"EARLY_PHASE1":12750,"PHASE1":12752,"PHASE2":12754,"PHASE3":12762,"PHASE4":12764,"NA":12766},{"trials":12751,"activeCount":101},[],{"trials":12753,"activeCount":101},[],{"trials":12755,"activeCount":101},[12756],{"nctId":12757,"briefTitle":12758,"status":132,"phases":12759,"primaryCompletion":11635,"completion":11635,"start":11636,"enrollment":101,"conditions":12760,"interventions":12761},"NCT04393311","Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients",[89,90],[10567],[12748],{"trials":12763,"activeCount":101},[],{"trials":12765,"activeCount":101},[],{"trials":12767,"activeCount":101},[],{"intervention":12769,"totalTrials":115,"cells":12770},"99technetium-sulfur colloid radiolabel",{"EARLY_PHASE1":12771,"PHASE1":12773,"PHASE2":12775,"PHASE3":12787,"PHASE4":12789,"NA":12791},{"trials":12772,"activeCount":101},[],{"trials":12774,"activeCount":101},[],{"trials":12776,"activeCount":101},[12777],{"nctId":12778,"briefTitle":12779,"status":160,"phases":12780,"primaryCompletion":12781,"completion":12781,"start":1690,"enrollment":12782,"conditions":12783,"interventions":12784},"NCT01771666","Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer",[90],"2015-03-17",23,[15],[12785,12786,12769],"Indocyanine Green","Isosulfan blue",{"trials":12788,"activeCount":101},[],{"trials":12790,"activeCount":101},[],{"trials":12792,"activeCount":101},[],{"intervention":12794,"totalTrials":115,"cells":12795},"Idebenone",{"EARLY_PHASE1":12796,"PHASE1":12798,"PHASE2":12800,"PHASE3":12811,"PHASE4":12813,"NA":12815},{"trials":12797,"activeCount":101},[],{"trials":12799,"activeCount":101},[],{"trials":12801,"activeCount":101},[12802],{"nctId":12803,"briefTitle":12804,"status":160,"phases":12805,"primaryCompletion":12806,"completion":12806,"start":7966,"enrollment":22,"conditions":12807,"interventions":12810},"NCT04669158","Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis",[89,90],"2023-07-05",[12808,12809],"Non Alcoholic Steatohepatitis","Fibrosis",[12794],{"trials":12812,"activeCount":101},[],{"trials":12814,"activeCount":101},[],{"trials":12816,"activeCount":101},[],{"intervention":750,"totalTrials":115,"cells":12818},{"EARLY_PHASE1":12819,"PHASE1":12821,"PHASE2":12823,"PHASE3":12829,"PHASE4":12831,"NA":12833},{"trials":12820,"activeCount":101},[],{"trials":12822,"activeCount":101},[],{"trials":12824,"activeCount":101},[12825],{"nctId":733,"briefTitle":734,"status":160,"phases":12826,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":12827,"interventions":12828},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"trials":12830,"activeCount":101},[],{"trials":12832,"activeCount":101},[],{"trials":12834,"activeCount":101},[],{"intervention":751,"totalTrials":115,"cells":12836},{"EARLY_PHASE1":12837,"PHASE1":12839,"PHASE2":12841,"PHASE3":12847,"PHASE4":12849,"NA":12851},{"trials":12838,"activeCount":101},[],{"trials":12840,"activeCount":101},[],{"trials":12842,"activeCount":101},[12843],{"nctId":733,"briefTitle":734,"status":160,"phases":12844,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":12845,"interventions":12846},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"trials":12848,"activeCount":101},[],{"trials":12850,"activeCount":101},[],{"trials":12852,"activeCount":101},[],{"intervention":5695,"totalTrials":115,"cells":12854},{"EARLY_PHASE1":12855,"PHASE1":12857,"PHASE2":12859,"PHASE3":12865,"PHASE4":12867,"NA":12869},{"trials":12856,"activeCount":101},[],{"trials":12858,"activeCount":101},[],{"trials":12860,"activeCount":101},[12861],{"nctId":5688,"briefTitle":5689,"status":160,"phases":12862,"primaryCompletion":5656,"completion":5656,"start":5691,"enrollment":1755,"conditions":12863,"interventions":12864},[90],[5693],[5695,5696],{"trials":12866,"activeCount":101},[],{"trials":12868,"activeCount":101},[],{"trials":12870,"activeCount":101},[],{"intervention":12872,"totalTrials":115,"cells":12873},"17-Hydroxyprogesterone Caproate",{"EARLY_PHASE1":12874,"PHASE1":12876,"PHASE2":12878,"PHASE3":12886,"PHASE4":12888,"NA":12890},{"trials":12875,"activeCount":101},[],{"trials":12877,"activeCount":101},[],{"trials":12879,"activeCount":101},[12880],{"nctId":12881,"briefTitle":12882,"status":160,"phases":12883,"primaryCompletion":5550,"completion":5550,"start":11713,"enrollment":2393,"conditions":12884,"interventions":12885},"NCT01050647","Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.",[89,90],[9088],[12872],{"trials":12887,"activeCount":101},[],{"trials":12889,"activeCount":101},[],{"trials":12891,"activeCount":101},[],{"intervention":12893,"totalTrials":115,"cells":12894},"Escitalopram",{"EARLY_PHASE1":12895,"PHASE1":12897,"PHASE2":12899,"PHASE3":12907,"PHASE4":12909,"NA":12911},{"trials":12896,"activeCount":101},[],{"trials":12898,"activeCount":101},[],{"trials":12900,"activeCount":101},[12901],{"nctId":12902,"briefTitle":12903,"status":160,"phases":12904,"primaryCompletion":1801,"completion":1801,"start":2207,"enrollment":232,"conditions":12905,"interventions":12906},"NCT00149825","Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome",[90],[167,1600],[12893],{"trials":12908,"activeCount":101},[],{"trials":12910,"activeCount":101},[],{"trials":12912,"activeCount":101},[],{"intervention":12914,"totalTrials":115,"cells":12915},"CPG 7909",{"EARLY_PHASE1":12916,"PHASE1":12918,"PHASE2":12920,"PHASE3":12928,"PHASE4":12930,"NA":12932},{"trials":12917,"activeCount":101},[],{"trials":12919,"activeCount":101},[],{"trials":12921,"activeCount":101},[12922],{"nctId":12923,"briefTitle":12924,"status":132,"phases":12925,"primaryCompletion":7904,"start":12262,"enrollment":101,"conditions":12926,"interventions":12927},"NCT00226993","Phase I\u002FII Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.",[89,90],[2907],[12914],{"trials":12929,"activeCount":101},[],{"trials":12931,"activeCount":101},[],{"trials":12933,"activeCount":101},[],{"intervention":12935,"totalTrials":115,"cells":12936},"Xolair",{"EARLY_PHASE1":12937,"PHASE1":12939,"PHASE2":12941,"PHASE3":12951,"PHASE4":12953,"NA":12955},{"trials":12938,"activeCount":101},[],{"trials":12940,"activeCount":101},[],{"trials":12942,"activeCount":101},[12943],{"nctId":12944,"briefTitle":12945,"status":160,"phases":12946,"primaryCompletion":12947,"completion":12947,"start":12948,"enrollment":1755,"conditions":12949,"interventions":12950},"NCT02643862","Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients",[89,90],"2016-08-20","2015-03-18",[9536],[12935],{"trials":12952,"activeCount":101},[],{"trials":12954,"activeCount":101},[],{"trials":12956,"activeCount":101},[],{"intervention":12958,"totalTrials":115,"cells":12959},"Atezolizumab",{"EARLY_PHASE1":12960,"PHASE1":12962,"PHASE2":12964,"PHASE3":12975,"PHASE4":12977,"NA":12979},{"trials":12961,"activeCount":101},[],{"trials":12963,"activeCount":101},[],{"trials":12965,"activeCount":101},[12966],{"nctId":12967,"briefTitle":12968,"status":160,"phases":12969,"primaryCompletion":9953,"completion":12970,"start":12971,"enrollment":111,"conditions":12972,"interventions":12974},"NCT04710498","Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma",[90],"2024-02-15","2021-06-22",[12973],"Cutaneous Squamous Cell Carcinoma",[12958],{"trials":12976,"activeCount":101},[],{"trials":12978,"activeCount":101},[],{"trials":12980,"activeCount":101},[],{"intervention":3966,"totalTrials":115,"cells":12982},{"EARLY_PHASE1":12983,"PHASE1":12985,"PHASE2":12987,"PHASE3":12993,"PHASE4":12995,"NA":12997},{"trials":12984,"activeCount":101},[],{"trials":12986,"activeCount":101},[],{"trials":12988,"activeCount":101},[12989],{"nctId":3958,"briefTitle":3959,"status":160,"phases":12990,"primaryCompletion":3961,"completion":3962,"start":1976,"enrollment":791,"conditions":12991,"interventions":12992},[90],[3914],[3965,1698,3966,1699],{"trials":12994,"activeCount":101},[],{"trials":12996,"activeCount":101},[],{"trials":12998,"activeCount":101},[],{"intervention":13000,"totalTrials":115,"cells":13001},"Nirmatrelvir",{"EARLY_PHASE1":13002,"PHASE1":13004,"PHASE2":13006,"PHASE3":13021,"PHASE4":13023,"NA":13025},{"trials":13003,"activeCount":101},[],{"trials":13005,"activeCount":101},[],{"trials":13007,"activeCount":101},[13008],{"nctId":13009,"briefTitle":13010,"status":160,"phases":13011,"primaryCompletion":13012,"completion":13013,"start":13014,"enrollment":13015,"conditions":13016,"interventions":13019},"NCT05576662","Paxlovid for Treatment of Long Covid",[90],"2023-08-14","2023-09-12","2022-11-08",168,[13017,13018],"Post-acute Sequelae of SARS-CoV-2 Infection","Long COVID",[13000,13020],"Ritonavir",{"trials":13022,"activeCount":101},[],{"trials":13024,"activeCount":101},[],{"trials":13026,"activeCount":101},[],{"intervention":13020,"totalTrials":115,"cells":13028},{"EARLY_PHASE1":13029,"PHASE1":13031,"PHASE2":13033,"PHASE3":13039,"PHASE4":13041,"NA":13043},{"trials":13030,"activeCount":101},[],{"trials":13032,"activeCount":101},[],{"trials":13034,"activeCount":101},[13035],{"nctId":13009,"briefTitle":13010,"status":160,"phases":13036,"primaryCompletion":13012,"completion":13013,"start":13014,"enrollment":13015,"conditions":13037,"interventions":13038},[90],[13017,13018],[13000,13020],{"trials":13040,"activeCount":101},[],{"trials":13042,"activeCount":101},[],{"trials":13044,"activeCount":101},[],{"intervention":13046,"totalTrials":115,"cells":13047},"GCSF",{"EARLY_PHASE1":13048,"PHASE1":13050,"PHASE2":13052,"PHASE3":13064,"PHASE4":13066,"NA":13068},{"trials":13049,"activeCount":101},[],{"trials":13051,"activeCount":101},[],{"trials":13053,"activeCount":101},[13054],{"nctId":13055,"briefTitle":13056,"status":716,"phases":13057,"primaryCompletion":13058,"completion":13058,"start":13059,"enrollment":97,"conditions":13060,"interventions":13063},"NCT04514692","Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging",[89,90],"2023-09-27","2021-02-01",[13061,13062],"Cervix Cancer","Endometrial Cancer",[13046],{"trials":13065,"activeCount":101},[],{"trials":13067,"activeCount":101},[],{"trials":13069,"activeCount":101},[],{"intervention":13071,"totalTrials":115,"cells":13072},"Abatacept",{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13077,"PHASE3":13086,"PHASE4":13088,"NA":13090},{"trials":13074,"activeCount":101},[],{"trials":13076,"activeCount":101},[],{"trials":13078,"activeCount":101},[13079],{"nctId":13080,"briefTitle":13081,"status":160,"phases":13082,"primaryCompletion":9189,"completion":9189,"start":906,"enrollment":247,"conditions":13083,"interventions":13085},"NCT00442611","A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)",[89,90],[13084,11125],"Scleroderma, Diffuse",[13071],{"trials":13087,"activeCount":101},[],{"trials":13089,"activeCount":101},[],{"trials":13091,"activeCount":101},[],{"intervention":2047,"totalTrials":115,"cells":13093},{"EARLY_PHASE1":13094,"PHASE1":13096,"PHASE2":13098,"PHASE3":13104,"PHASE4":13106,"NA":13108},{"trials":13095,"activeCount":101},[],{"trials":13097,"activeCount":101},[],{"trials":13099,"activeCount":101},[13100],{"nctId":2036,"briefTitle":2037,"status":160,"phases":13101,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":13102,"interventions":13103},[90],[2042,2043,2044,2045],[2047,2048,2049,2050,1569,1987,1724],{"trials":13105,"activeCount":101},[],{"trials":13107,"activeCount":101},[],{"trials":13109,"activeCount":101},[],{"intervention":2049,"totalTrials":115,"cells":13111},{"EARLY_PHASE1":13112,"PHASE1":13114,"PHASE2":13116,"PHASE3":13122,"PHASE4":13124,"NA":13126},{"trials":13113,"activeCount":101},[],{"trials":13115,"activeCount":101},[],{"trials":13117,"activeCount":101},[13118],{"nctId":2036,"briefTitle":2037,"status":160,"phases":13119,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":13120,"interventions":13121},[90],[2042,2043,2044,2045],[2047,2048,2049,2050,1569,1987,1724],{"trials":13123,"activeCount":101},[],{"trials":13125,"activeCount":101},[],{"trials":13127,"activeCount":101},[],{"intervention":13129,"totalTrials":115,"cells":13130},"valganciclovir",{"EARLY_PHASE1":13131,"PHASE1":13133,"PHASE2":13135,"PHASE3":13145,"PHASE4":13147,"NA":13149},{"trials":13132,"activeCount":101},[],{"trials":13134,"activeCount":101},[],{"trials":13136,"activeCount":101},[13137],{"nctId":13138,"briefTitle":13139,"status":160,"phases":13140,"primaryCompletion":1801,"completion":1801,"start":13141,"enrollment":232,"conditions":13142,"interventions":13144},"NCT00478465","Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)",[89,90],"2007-05",[13143],"Chronic Fatigue Syndrome",[13129],{"trials":13146,"activeCount":101},[],{"trials":13148,"activeCount":101},[],{"trials":13150,"activeCount":101},[],{"intervention":13152,"totalTrials":115,"cells":13153},"Lovastatin",{"EARLY_PHASE1":13154,"PHASE1":13156,"PHASE2":13158,"PHASE3":13166,"PHASE4":13168,"NA":13170},{"trials":13155,"activeCount":101},[],{"trials":13157,"activeCount":101},[],{"trials":13159,"activeCount":101},[13160],{"nctId":13161,"briefTitle":13162,"status":716,"phases":13163,"primaryCompletion":718,"completion":697,"start":4009,"enrollment":232,"conditions":13164,"interventions":13165},"NCT00285857","Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention",[90],[15],[13152],{"trials":13167,"activeCount":101},[],{"trials":13169,"activeCount":101},[],{"trials":13171,"activeCount":101},[],{"intervention":13173,"totalTrials":115,"cells":13174},"apolizumab",{"EARLY_PHASE1":13175,"PHASE1":13177,"PHASE2":13179,"PHASE3":13188,"PHASE4":13190,"NA":13192},{"trials":13176,"activeCount":101},[],{"trials":13178,"activeCount":101},[],{"trials":13180,"activeCount":101},[13181],{"nctId":13182,"briefTitle":13183,"status":160,"phases":13184,"completion":12004,"start":13185,"conditions":13186,"interventions":13187},"NCT00055783","Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma",[90],"2002-07",[1426],[13173],{"trials":13189,"activeCount":101},[],{"trials":13191,"activeCount":101},[],{"trials":13193,"activeCount":101},[],{"intervention":13195,"totalTrials":115,"cells":13196},"Intravitreal injection 440mcg",{"EARLY_PHASE1":13197,"PHASE1":13199,"PHASE2":13201,"PHASE3":13217,"PHASE4":13219,"NA":13221},{"trials":13198,"activeCount":101},[],{"trials":13200,"activeCount":101},[],{"trials":13202,"activeCount":101},[13203],{"nctId":13204,"briefTitle":13205,"status":132,"phases":13206,"primaryCompletion":13207,"completion":13208,"start":13209,"enrollment":101,"conditions":13210,"interventions":13215},"NCT01280669","Intravitreal Sirolimus as Therapeutic Approach to Uveitis",[90],"2024-09","2024-12","2022-09",[13211,13212,13213,13214],"Uveitis","Intermediate Uveitis","Posterior Uveitis","Panuveitis",[13195,13216],"Intravitreal injection of sirolimus 880mcg",{"trials":13218,"activeCount":101},[],{"trials":13220,"activeCount":101},[],{"trials":13222,"activeCount":101},[],{"intervention":13216,"totalTrials":115,"cells":13224},{"EARLY_PHASE1":13225,"PHASE1":13227,"PHASE2":13229,"PHASE3":13235,"PHASE4":13237,"NA":13239},{"trials":13226,"activeCount":101},[],{"trials":13228,"activeCount":101},[],{"trials":13230,"activeCount":101},[13231],{"nctId":13204,"briefTitle":13205,"status":132,"phases":13232,"primaryCompletion":13207,"completion":13208,"start":13209,"enrollment":101,"conditions":13233,"interventions":13234},[90],[13211,13212,13213,13214],[13195,13216],{"trials":13236,"activeCount":101},[],{"trials":13238,"activeCount":101},[],{"trials":13240,"activeCount":101},[],{"intervention":1867,"totalTrials":115,"cells":13242},{"EARLY_PHASE1":13243,"PHASE1":13245,"PHASE2":13247,"PHASE3":13253,"PHASE4":13255,"NA":13257},{"trials":13244,"activeCount":101},[],{"trials":13246,"activeCount":101},[],{"trials":13248,"activeCount":101},[13249],{"nctId":1858,"briefTitle":1859,"status":160,"phases":13250,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":232,"conditions":13251,"interventions":13252},[90],[1865],[1867,1700],{"trials":13254,"activeCount":101},[],{"trials":13256,"activeCount":101},[],{"trials":13258,"activeCount":101},[],{"intervention":13260,"totalTrials":115,"cells":13261},"Serlopitant",{"EARLY_PHASE1":13262,"PHASE1":13264,"PHASE2":13266,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13263,"activeCount":101},[],{"trials":13265,"activeCount":101},[],{"trials":13267,"activeCount":101},[13268],{"nctId":13269,"briefTitle":13270,"status":160,"phases":13271,"primaryCompletion":13272,"completion":9960,"start":13273,"enrollment":1672,"conditions":13274,"interventions":13276},"NCT03836001","A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa",[90],"2021-12-06","2019-04-18",[13275],"Epidermolysis Bullosa",[13260],{"trials":13278,"activeCount":101},[],{"trials":13280,"activeCount":101},[],{"trials":13282,"activeCount":101},[],{"intervention":13284,"totalTrials":115,"cells":13285},"Talazoparib Tosylate",{"EARLY_PHASE1":13286,"PHASE1":13288,"PHASE2":13290,"PHASE3":13301,"PHASE4":13303,"NA":13305},{"trials":13287,"activeCount":101},[],{"trials":13289,"activeCount":101},[],{"trials":13291,"activeCount":101},[13292],{"nctId":13293,"briefTitle":13294,"status":132,"phases":13295,"primaryCompletion":13296,"completion":13296,"start":13297,"enrollment":101,"conditions":13298,"interventions":13300},"NCT04756765","Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer",[90],"2024-12-18","2023-02-23",[15,13299],"Advanced Breast Cancer",[13284],{"trials":13302,"activeCount":101},[],{"trials":13304,"activeCount":101},[],{"trials":13306,"activeCount":101},[],{"intervention":767,"totalTrials":115,"cells":13308},{"EARLY_PHASE1":13309,"PHASE1":13311,"PHASE2":13313,"PHASE3":13319,"PHASE4":13321,"NA":13323},{"trials":13310,"activeCount":101},[],{"trials":13312,"activeCount":101},[],{"trials":13314,"activeCount":101},[13315],{"nctId":753,"briefTitle":754,"status":160,"phases":13316,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":13317,"interventions":13318},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":13320,"activeCount":101},[],{"trials":13322,"activeCount":101},[],{"trials":13324,"activeCount":101},[],{"intervention":768,"totalTrials":115,"cells":13326},{"EARLY_PHASE1":13327,"PHASE1":13329,"PHASE2":13331,"PHASE3":13337,"PHASE4":13339,"NA":13341},{"trials":13328,"activeCount":101},[],{"trials":13330,"activeCount":101},[],{"trials":13332,"activeCount":101},[13333],{"nctId":753,"briefTitle":754,"status":160,"phases":13334,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":13335,"interventions":13336},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":13338,"activeCount":101},[],{"trials":13340,"activeCount":101},[],{"trials":13342,"activeCount":101},[],{"intervention":848,"totalTrials":115,"cells":13344},{"EARLY_PHASE1":13345,"PHASE1":13347,"PHASE2":13349,"PHASE3":13355,"PHASE4":13357,"NA":13359},{"trials":13346,"activeCount":101},[],{"trials":13348,"activeCount":101},[],{"trials":13350,"activeCount":101},[13351],{"nctId":841,"briefTitle":842,"status":716,"phases":13352,"primaryCompletion":718,"completion":718,"start":844,"enrollment":152,"conditions":13353,"interventions":13354},[90],[846],[848,404],{"trials":13356,"activeCount":101},[],{"trials":13358,"activeCount":101},[],{"trials":13360,"activeCount":101},[],{"intervention":13362,"totalTrials":115,"cells":13363},"CD34+ Hematopoietic Progenitor Cells",{"EARLY_PHASE1":13364,"PHASE1":13366,"PHASE2":13368,"PHASE3":13383,"PHASE4":13385,"NA":13387},{"trials":13365,"activeCount":101},[],{"trials":13367,"activeCount":101},[],{"trials":13369,"activeCount":101},[13370],{"nctId":13371,"briefTitle":13372,"status":160,"phases":13373,"primaryCompletion":5200,"completion":5200,"start":13374,"enrollment":10409,"conditions":13375,"interventions":13380},"NCT01660607","Phase 1-2 MAHCT w\u002F TCell Depleted Graft w\u002F Simultaneous Infusion Conventional and Regulatory T Cell",[89,90],"2012-02-09",[13376,13377,10197,722,13378,13379,3727,1522,1523],"Myeloid Leukemia, Chronic","Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia (ALL)","Myeloproliferative Syndrome",[13362,13381,13382],"Regulatory T-Cells","Conventional T-Cells",{"trials":13384,"activeCount":101},[],{"trials":13386,"activeCount":101},[],{"trials":13388,"activeCount":101},[],{"intervention":13381,"totalTrials":115,"cells":13390},{"EARLY_PHASE1":13391,"PHASE1":13393,"PHASE2":13395,"PHASE3":13401,"PHASE4":13403,"NA":13405},{"trials":13392,"activeCount":101},[],{"trials":13394,"activeCount":101},[],{"trials":13396,"activeCount":101},[13397],{"nctId":13371,"briefTitle":13372,"status":160,"phases":13398,"primaryCompletion":5200,"completion":5200,"start":13374,"enrollment":10409,"conditions":13399,"interventions":13400},[89,90],[13376,13377,10197,722,13378,13379,3727,1522,1523],[13362,13381,13382],{"trials":13402,"activeCount":101},[],{"trials":13404,"activeCount":101},[],{"trials":13406,"activeCount":101},[],{"intervention":13382,"totalTrials":115,"cells":13408},{"EARLY_PHASE1":13409,"PHASE1":13411,"PHASE2":13413,"PHASE3":13419,"PHASE4":13421,"NA":13423},{"trials":13410,"activeCount":101},[],{"trials":13412,"activeCount":101},[],{"trials":13414,"activeCount":101},[13415],{"nctId":13371,"briefTitle":13372,"status":160,"phases":13416,"primaryCompletion":5200,"completion":5200,"start":13374,"enrollment":10409,"conditions":13417,"interventions":13418},[89,90],[13376,13377,10197,722,13378,13379,3727,1522,1523],[13362,13381,13382],{"trials":13420,"activeCount":101},[],{"trials":13422,"activeCount":101},[],{"trials":13424,"activeCount":101},[],{"intervention":13426,"totalTrials":115,"cells":13427},"Lymphoseek",{"EARLY_PHASE1":13428,"PHASE1":13430,"PHASE2":13432,"PHASE3":13441,"PHASE4":13443,"NA":13445},{"trials":13429,"activeCount":101},[],{"trials":13431,"activeCount":101},[],{"trials":13433,"activeCount":101},[13434],{"nctId":13435,"briefTitle":13436,"status":716,"phases":13437,"primaryCompletion":13438,"completion":13438,"start":1357,"enrollment":197,"conditions":13439,"interventions":13440},"NCT04511026","Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer",[90],"2021-06-10",[13062],[13426,12785],{"trials":13442,"activeCount":101},[],{"trials":13444,"activeCount":101},[],{"trials":13446,"activeCount":101},[],{"intervention":5660,"totalTrials":115,"cells":13448},{"EARLY_PHASE1":13449,"PHASE1":13451,"PHASE2":13453,"PHASE3":13459,"PHASE4":13461,"NA":13463},{"trials":13450,"activeCount":101},[],{"trials":13452,"activeCount":101},[],{"trials":13454,"activeCount":101},[13455],{"nctId":5653,"briefTitle":5654,"status":716,"phases":13456,"primaryCompletion":5656,"completion":5656,"start":5657,"enrollment":115,"conditions":13457,"interventions":13458},[90],[15],[5660,5634],{"trials":13460,"activeCount":101},[],{"trials":13462,"activeCount":101},[],{"trials":13464,"activeCount":101},[],{"intervention":13466,"totalTrials":115,"cells":13467},"Sildenafil",{"EARLY_PHASE1":13468,"PHASE1":13470,"PHASE2":13472,"PHASE3":13481,"PHASE4":13483,"NA":13485},{"trials":13469,"activeCount":101},[],{"trials":13471,"activeCount":101},[],{"trials":13473,"activeCount":101},[13474],{"nctId":13475,"briefTitle":13476,"status":160,"phases":13477,"primaryCompletion":9709,"completion":834,"start":697,"enrollment":97,"conditions":13478,"interventions":13480},"NCT01290484","A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations",[89,90],[13479],"Lymphangioma",[13466],{"trials":13482,"activeCount":101},[],{"trials":13484,"activeCount":101},[],{"trials":13486,"activeCount":101},[],{"intervention":1783,"totalTrials":115,"cells":13488},{"EARLY_PHASE1":13489,"PHASE1":13491,"PHASE2":13493,"PHASE3":13499,"PHASE4":13501,"NA":13503},{"trials":13490,"activeCount":101},[],{"trials":13492,"activeCount":101},[],{"trials":13494,"activeCount":101},[13495],{"nctId":1774,"briefTitle":1775,"status":160,"phases":13496,"primaryCompletion":1753,"completion":1777,"start":1778,"enrollment":1779,"conditions":13497,"interventions":13498},[90],[1781],[1678,1783],{"trials":13500,"activeCount":101},[],{"trials":13502,"activeCount":101},[],{"trials":13504,"activeCount":101},[],{"intervention":13506,"totalTrials":152,"cells":13507},"sodium selenite",{"EARLY_PHASE1":13508,"PHASE1":13510,"PHASE2":13536,"PHASE3":13538,"PHASE4":13540,"NA":13542},{"trials":13509,"activeCount":101},[],{"trials":13511,"activeCount":101},[13512,13524],{"nctId":13513,"briefTitle":13514,"status":160,"phases":13515,"primaryCompletion":13516,"completion":13516,"start":874,"enrollment":2218,"conditions":13517,"interventions":13523},"NCT02184533","Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer",[89],"2018-05",[13518,13519,13520,13521,763,13522],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer","Plasmacytoma",[13506],{"nctId":13525,"briefTitle":13526,"status":132,"phases":13527,"primaryCompletion":13528,"completion":13529,"start":13530,"enrollment":101,"conditions":13531,"interventions":13533},"NCT04296578","Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone",[89],"2022-10","2023-10","2020-10",[3388,13532],"Castrate Resistant Prostate Cancer",[13534,13535,1504],"Abiraterone Acetate","Sodium Selenite",{"trials":13537,"activeCount":101},[],{"trials":13539,"activeCount":101},[],{"trials":13541,"activeCount":101},[],{"trials":13543,"activeCount":101},[],{"intervention":13545,"totalTrials":152,"cells":13546},"[18F]-FTC-146",{"EARLY_PHASE1":13547,"PHASE1":13559,"PHASE2":13571,"PHASE3":13573,"PHASE4":13575,"NA":13577},{"trials":13548,"activeCount":101},[13549],{"nctId":13550,"briefTitle":13551,"status":160,"phases":13552,"primaryCompletion":13553,"completion":13554,"start":13555,"enrollment":897,"conditions":13556,"interventions":13558},"NCT02753101","[18F]FTC-146 PET\u002FMRI in Healthy Volunteers and in CRPS and Sciatica",[88],"2017-02-09","2017-02-16","2016-02-09",[5452,13557],"Sciatica",[13545],{"trials":13560,"activeCount":101},[13561],{"nctId":13562,"briefTitle":13563,"status":160,"phases":13564,"primaryCompletion":13565,"completion":13566,"start":13567,"enrollment":821,"conditions":13568,"interventions":13570},"NCT03649555","Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls",[89],"2020-03-03","2021-03-03","2019-02-01",[13569],"Healthy Controls",[13545],{"trials":13572,"activeCount":101},[],{"trials":13574,"activeCount":101},[],{"trials":13576,"activeCount":101},[],{"trials":13578,"activeCount":101},[],{"intervention":13580,"totalTrials":115,"cells":13581},"Lansoprazole",{"EARLY_PHASE1":13582,"PHASE1":13584,"PHASE2":13593,"PHASE3":13595,"PHASE4":13597,"NA":13599},{"trials":13583,"activeCount":101},[],{"trials":13585,"activeCount":101},[13586],{"nctId":13587,"briefTitle":13588,"status":160,"phases":13589,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":2393,"conditions":13590,"interventions":13592},"NCT02022280","Effect of Proton Pump Inhibitors on Endothelial Function",[89],[13591],"Endothelial Dysfunction",[13580],{"trials":13594,"activeCount":101},[],{"trials":13596,"activeCount":101},[],{"trials":13598,"activeCount":101},[],{"trials":13600,"activeCount":101},[],{"intervention":13602,"totalTrials":115,"cells":13603},"28 days treatment with Mifepristone.",{"EARLY_PHASE1":13604,"PHASE1":13606,"PHASE2":13614,"PHASE3":13616,"PHASE4":13618,"NA":13620},{"trials":13605,"activeCount":101},[],{"trials":13607,"activeCount":101},[13608],{"nctId":13609,"briefTitle":13610,"status":160,"phases":13611,"primaryCompletion":8086,"completion":8086,"start":1753,"enrollment":12782,"conditions":13612,"interventions":13613},"NCT01988610","Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals",[89],[21],[13602],{"trials":13615,"activeCount":101},[],{"trials":13617,"activeCount":101},[],{"trials":13619,"activeCount":101},[],{"trials":13621,"activeCount":101},[],{"intervention":13623,"totalTrials":115,"cells":13624},"sublingual immunotherapy",{"EARLY_PHASE1":13625,"PHASE1":13627,"PHASE2":13639,"PHASE3":13641,"PHASE4":13643,"NA":13645},{"trials":13626,"activeCount":101},[],{"trials":13628,"activeCount":101},[13629],{"nctId":13630,"briefTitle":13631,"status":160,"phases":13632,"primaryCompletion":857,"completion":857,"start":13633,"enrollment":31,"conditions":13634,"interventions":13638},"NCT01529437","Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies",[89],"2005-01",[13635,13636,13637],"Allergies","Allergic Rhinitis","Asthma",[13623],{"trials":13640,"activeCount":101},[],{"trials":13642,"activeCount":101},[],{"trials":13644,"activeCount":101},[],{"trials":13646,"activeCount":101},[],{"intervention":13648,"totalTrials":115,"cells":13649},"Acetazolamide Pill",{"EARLY_PHASE1":13650,"PHASE1":13652,"PHASE2":13662,"PHASE3":13664,"PHASE4":13666,"NA":13668},{"trials":13651,"activeCount":101},[],{"trials":13653,"activeCount":101},[13654],{"nctId":13655,"briefTitle":13656,"status":160,"phases":13657,"primaryCompletion":13658,"completion":13658,"start":11942,"enrollment":13659,"conditions":13660,"interventions":13661},"NCT03828474","Sickness Evaluation at Altitude With Acetazolamide at Relative Doses",[89],"2019-09-29",108,[8028],[13648],{"trials":13663,"activeCount":101},[],{"trials":13665,"activeCount":101},[],{"trials":13667,"activeCount":101},[],{"trials":13669,"activeCount":101},[],{"intervention":13671,"totalTrials":115,"cells":13672},"18F-C-SNAT4",{"EARLY_PHASE1":13673,"PHASE1":13675,"PHASE2":13684,"PHASE3":13686,"PHASE4":13688,"NA":13690},{"trials":13674,"activeCount":101},[],{"trials":13676,"activeCount":101},[13677],{"nctId":13678,"briefTitle":13679,"status":4049,"phases":13680,"primaryCompletion":1288,"completion":1288,"start":13681,"enrollment":111,"conditions":13682,"interventions":13683},"NCT04017819","Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4",[89],"2024-03-07",[10755,1757],[13671],{"trials":13685,"activeCount":101},[],{"trials":13687,"activeCount":101},[],{"trials":13689,"activeCount":101},[],{"trials":13691,"activeCount":101},[],{"intervention":13693,"totalTrials":115,"cells":13694},"Propofol and Fentanyl administration",{"EARLY_PHASE1":13695,"PHASE1":13697,"PHASE2":13706,"PHASE3":13708,"PHASE4":13710,"NA":13712},{"trials":13696,"activeCount":101},[],{"trials":13698,"activeCount":101},[13699],{"nctId":13700,"briefTitle":13701,"status":160,"phases":13702,"primaryCompletion":13703,"completion":13703,"start":859,"enrollment":208,"conditions":13704,"interventions":13705},"NCT01593397","Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity",[89],"2017-09",[18],[13693],{"trials":13707,"activeCount":101},[],{"trials":13709,"activeCount":101},[],{"trials":13711,"activeCount":101},[],{"trials":13713,"activeCount":101},[],{"intervention":13715,"totalTrials":115,"cells":13716},"Pirfenidone 267 MG [Esbriet]",{"EARLY_PHASE1":13717,"PHASE1":13719,"PHASE2":13732,"PHASE3":13734,"PHASE4":13736,"NA":13738},{"trials":13718,"activeCount":101},[],{"trials":13720,"activeCount":101},[13721],{"nctId":13722,"briefTitle":13723,"status":160,"phases":13724,"primaryCompletion":13725,"completion":13726,"start":13727,"enrollment":232,"conditions":13728,"interventions":13731},"NCT03315741","The Safety and Tolerability of Pirfenidone for BOS After HCT",[89],"2022-02-27","2022-04-27","2018-03-01",[13729,13730],"Bronchiolitis Obliterans","Graft Vs Host Disease",[13715],{"trials":13733,"activeCount":101},[],{"trials":13735,"activeCount":101},[],{"trials":13737,"activeCount":101},[],{"trials":13739,"activeCount":101},[],{"intervention":13741,"totalTrials":115,"cells":13742},"Hyaluronidase",{"EARLY_PHASE1":13743,"PHASE1":13745,"PHASE2":13753,"PHASE3":13755,"PHASE4":13757,"NA":13759},{"trials":13744,"activeCount":101},[],{"trials":13746,"activeCount":101},[13747],{"nctId":13748,"briefTitle":13749,"status":160,"phases":13750,"primaryCompletion":875,"completion":875,"start":874,"enrollment":232,"conditions":13751,"interventions":13752},"NCT02199028","Hyaluronidase Effect on Infusion Set Life",[89],[4917],[13741],{"trials":13754,"activeCount":101},[],{"trials":13756,"activeCount":101},[],{"trials":13758,"activeCount":101},[],{"trials":13760,"activeCount":101},[],{"intervention":13762,"totalTrials":115,"cells":13763},"Oral Triamcinalone",{"EARLY_PHASE1":13764,"PHASE1":13766,"PHASE2":13774,"PHASE3":13776,"PHASE4":13778,"NA":13780},{"trials":13765,"activeCount":101},[],{"trials":13767,"activeCount":101},[13768],{"nctId":13769,"briefTitle":13770,"status":160,"phases":13771,"completion":1742,"start":1863,"enrollment":12782,"conditions":13772,"interventions":13773},"NCT00186108","A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer",[89],[3388],[13762],{"trials":13775,"activeCount":101},[],{"trials":13777,"activeCount":101},[],{"trials":13779,"activeCount":101},[],{"trials":13781,"activeCount":101},[],{"intervention":13783,"totalTrials":115,"cells":13784},"Infusions of young plasma",{"EARLY_PHASE1":13785,"PHASE1":13787,"PHASE2":13797,"PHASE3":13799,"PHASE4":13801,"NA":13803},{"trials":13786,"activeCount":101},[],{"trials":13788,"activeCount":101},[13789],{"nctId":13790,"briefTitle":13791,"status":160,"phases":13792,"primaryCompletion":13793,"completion":13793,"start":9504,"enrollment":737,"conditions":13794,"interventions":13796},"NCT02968433","The Stanford Parkinson's Disease Plasma Study",[89],"2019-12",[13795],"Parkinson Disease(PD)",[13783],{"trials":13798,"activeCount":101},[],{"trials":13800,"activeCount":101},[],{"trials":13802,"activeCount":101},[],{"trials":13804,"activeCount":101},[],{"intervention":13806,"totalTrials":115,"cells":13807},"Nilotinib",{"EARLY_PHASE1":13808,"PHASE1":13810,"PHASE2":13819,"PHASE3":13821,"PHASE4":13823,"NA":13825},{"trials":13809,"activeCount":101},[],{"trials":13811,"activeCount":101},[13812],{"nctId":13813,"briefTitle":13814,"status":160,"phases":13815,"primaryCompletion":834,"completion":834,"start":3502,"enrollment":28,"conditions":13816,"interventions":13818},"NCT01155817","Phase 1 Nilotinib in Steroid Dependent\u002FRefractory Chronic Graft Versus Host Disease",[89],[7826,722,13817],"Lymphoma, T-Cell, Peripheral",[13806],{"trials":13820,"activeCount":101},[],{"trials":13822,"activeCount":101},[],{"trials":13824,"activeCount":101},[],{"trials":13826,"activeCount":101},[],{"intervention":13828,"totalTrials":115,"cells":13829},"Victoza (liraglutide) with dietician monitoring",{"EARLY_PHASE1":13830,"PHASE1":13832,"PHASE2":13844,"PHASE3":13846,"PHASE4":13848,"NA":13850},{"trials":13831,"activeCount":101},[],{"trials":13833,"activeCount":101},[13834],{"nctId":13835,"briefTitle":13836,"status":160,"phases":13837,"primaryCompletion":13838,"completion":13838,"start":6286,"enrollment":3431,"conditions":13839,"interventions":13843},"NCT02650206","Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood",[89],"2019-09-27",[399,13840,13841,13842],"Diabetes Mellitus, Type II","Diabetes Mellitus, Adult-Onset","Inflammation",[13828],{"trials":13845,"activeCount":101},[],{"trials":13847,"activeCount":101},[],{"trials":13849,"activeCount":101},[],{"trials":13851,"activeCount":101},[],{"intervention":13853,"totalTrials":115,"cells":13854},"EpiCeram",{"EARLY_PHASE1":13855,"PHASE1":13857,"PHASE2":13868,"PHASE3":13870,"PHASE4":13872,"NA":13874},{"trials":13856,"activeCount":101},[],{"trials":13858,"activeCount":101},[13859],{"nctId":13860,"briefTitle":13861,"status":160,"phases":13862,"primaryCompletion":13863,"completion":13863,"start":11881,"enrollment":1766,"conditions":13864,"interventions":13866},"NCT03663673","Effect of Different Skin Creams on TEWL",[89],"2019-07-18",[13865],"Dermatitis, Atopic",[13853,13867],"Aveeno Daily Moisturising Sheer Hydration Lotion®",{"trials":13869,"activeCount":101},[],{"trials":13871,"activeCount":101},[],{"trials":13873,"activeCount":101},[],{"trials":13875,"activeCount":101},[],{"intervention":13867,"totalTrials":115,"cells":13877},{"EARLY_PHASE1":13878,"PHASE1":13880,"PHASE2":13886,"PHASE3":13888,"PHASE4":13890,"NA":13892},{"trials":13879,"activeCount":101},[],{"trials":13881,"activeCount":101},[13882],{"nctId":13860,"briefTitle":13861,"status":160,"phases":13883,"primaryCompletion":13863,"completion":13863,"start":11881,"enrollment":1766,"conditions":13884,"interventions":13885},[89],[13865],[13853,13867],{"trials":13887,"activeCount":101},[],{"trials":13889,"activeCount":101},[],{"trials":13891,"activeCount":101},[],{"trials":13893,"activeCount":101},[],{"intervention":13895,"totalTrials":115,"cells":13896},"Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs",{"EARLY_PHASE1":13897,"PHASE1":13899,"PHASE2":13910,"PHASE3":13912,"PHASE4":13914,"NA":13916},{"trials":13898,"activeCount":101},[],{"trials":13900,"activeCount":101},[13901],{"nctId":13902,"briefTitle":13903,"status":4124,"phases":13904,"primaryCompletion":13905,"completion":4116,"start":13906,"enrollment":1977,"conditions":13907,"interventions":13909},"NCT03943238","TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation",[89],"2024-08-01","2020-02-01",[13908],"Living Donor Kidney Transplantation",[13895],{"trials":13911,"activeCount":101},[],{"trials":13913,"activeCount":101},[],{"trials":13915,"activeCount":101},[],{"trials":13917,"activeCount":101},[],{"intervention":10255,"totalTrials":115,"cells":13919},{"EARLY_PHASE1":13920,"PHASE1":13922,"PHASE2":13928,"PHASE3":13930,"PHASE4":13932,"NA":13934},{"trials":13921,"activeCount":101},[],{"trials":13923,"activeCount":101},[13924],{"nctId":10250,"briefTitle":10251,"status":160,"phases":13925,"primaryCompletion":1999,"start":3502,"enrollment":3997,"conditions":13926,"interventions":13927},[89],[763],[10243,10255],{"trials":13929,"activeCount":101},[],{"trials":13931,"activeCount":101},[],{"trials":13933,"activeCount":101},[],{"trials":13935,"activeCount":101},[],{"intervention":13937,"totalTrials":115,"cells":13938},"[18F]flumazenil",{"EARLY_PHASE1":13939,"PHASE1":13941,"PHASE2":13953,"PHASE3":13955,"PHASE4":13957,"NA":13959},{"trials":13940,"activeCount":101},[],{"trials":13942,"activeCount":101},[13943],{"nctId":13944,"briefTitle":13945,"status":716,"phases":13946,"primaryCompletion":13947,"completion":13947,"start":13948,"enrollment":1766,"conditions":13949,"interventions":13952},"NCT04308954","Neuroimaging GABA Physiology in Fragile X Syndrome",[89],"2018-12-06","2016-11-01",[13950,13951],"Fragile X Syndrome (FXS)","Idiopathic Intellectual Developmental Disorder (IDD)",[13937],{"trials":13954,"activeCount":101},[],{"trials":13956,"activeCount":101},[],{"trials":13958,"activeCount":101},[],{"trials":13960,"activeCount":101},[],{"intervention":13962,"totalTrials":115,"cells":13963},"Intratumoral Dendritic Cell Immunotherapy",{"EARLY_PHASE1":13964,"PHASE1":13966,"PHASE2":13975,"PHASE3":13977,"PHASE4":13979,"NA":13981},{"trials":13965,"activeCount":101},[],{"trials":13967,"activeCount":101},[13968],{"nctId":13969,"briefTitle":13970,"status":716,"phases":13971,"primaryCompletion":7168,"completion":7168,"start":271,"enrollment":1977,"conditions":13972,"interventions":13973},"NCT00185874","Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases",[89],[1694],[13962,13974],"autologous dendritic cells",{"trials":13976,"activeCount":101},[],{"trials":13978,"activeCount":101},[],{"trials":13980,"activeCount":101},[],{"trials":13982,"activeCount":101},[],{"intervention":13974,"totalTrials":115,"cells":13984},{"EARLY_PHASE1":13985,"PHASE1":13987,"PHASE2":13993,"PHASE3":13995,"PHASE4":13997,"NA":13999},{"trials":13986,"activeCount":101},[],{"trials":13988,"activeCount":101},[13989],{"nctId":13969,"briefTitle":13970,"status":716,"phases":13990,"primaryCompletion":7168,"completion":7168,"start":271,"enrollment":1977,"conditions":13991,"interventions":13992},[89],[1694],[13962,13974],{"trials":13994,"activeCount":101},[],{"trials":13996,"activeCount":101},[],{"trials":13998,"activeCount":101},[],{"trials":14000,"activeCount":101},[],{"intervention":14002,"totalTrials":115,"cells":14003},"Phentermine\u002FTopiramate-First",{"EARLY_PHASE1":14004,"PHASE1":14006,"PHASE2":14019,"PHASE3":14021,"PHASE4":14023,"NA":14025},{"trials":14005,"activeCount":101},[],{"trials":14007,"activeCount":101},[14008],{"nctId":14009,"briefTitle":14010,"status":160,"phases":14011,"primaryCompletion":14012,"completion":14013,"start":14014,"enrollment":1977,"conditions":14015,"interventions":14018},"NCT02553824","FDA Approved Medication to Reduce Binge Eating and\u002For Purging",[89],"2017-02-23","2017-04-15","2015-10-30",[14016,14017],"Binge Eating Disorder","Bulimia Nervosa",[14002],{"trials":14020,"activeCount":101},[],{"trials":14022,"activeCount":101},[],{"trials":14024,"activeCount":101},[],{"trials":14026,"activeCount":101},[],{"intervention":14028,"totalTrials":115,"cells":14029},"Fluzone® quadrivalent",{"EARLY_PHASE1":14030,"PHASE1":14032,"PHASE2":14049,"PHASE3":14051,"PHASE4":14053,"NA":14055},{"trials":14031,"activeCount":101},[],{"trials":14033,"activeCount":101},[14034],{"nctId":14035,"briefTitle":14036,"status":160,"phases":14037,"primaryCompletion":5871,"completion":5871,"start":14038,"enrollment":3106,"conditions":14039,"interventions":14043},"NCT03312699","Effects of Aging on Primary and Secondary Vaccine Responses",[89],"2017-09-19",[5514,14040,14041,14042],"Hepatitis A","Typhoid","Healthy Adults",[14028,14044,14045,14046,14047,14048],"Fluzone High Dose","Fluad","Vaqta","Typhim Vi","Vivotif",{"trials":14050,"activeCount":101},[],{"trials":14052,"activeCount":101},[],{"trials":14054,"activeCount":101},[],{"trials":14056,"activeCount":101},[],{"intervention":14044,"totalTrials":115,"cells":14058},{"EARLY_PHASE1":14059,"PHASE1":14061,"PHASE2":14067,"PHASE3":14069,"PHASE4":14071,"NA":14073},{"trials":14060,"activeCount":101},[],{"trials":14062,"activeCount":101},[14063],{"nctId":14035,"briefTitle":14036,"status":160,"phases":14064,"primaryCompletion":5871,"completion":5871,"start":14038,"enrollment":3106,"conditions":14065,"interventions":14066},[89],[5514,14040,14041,14042],[14028,14044,14045,14046,14047,14048],{"trials":14068,"activeCount":101},[],{"trials":14070,"activeCount":101},[],{"trials":14072,"activeCount":101},[],{"trials":14074,"activeCount":101},[],{"intervention":14045,"totalTrials":115,"cells":14076},{"EARLY_PHASE1":14077,"PHASE1":14079,"PHASE2":14085,"PHASE3":14087,"PHASE4":14089,"NA":14091},{"trials":14078,"activeCount":101},[],{"trials":14080,"activeCount":101},[14081],{"nctId":14035,"briefTitle":14036,"status":160,"phases":14082,"primaryCompletion":5871,"completion":5871,"start":14038,"enrollment":3106,"conditions":14083,"interventions":14084},[89],[5514,14040,14041,14042],[14028,14044,14045,14046,14047,14048],{"trials":14086,"activeCount":101},[],{"trials":14088,"activeCount":101},[],{"trials":14090,"activeCount":101},[],{"trials":14092,"activeCount":101},[],{"intervention":14046,"totalTrials":115,"cells":14094},{"EARLY_PHASE1":14095,"PHASE1":14097,"PHASE2":14103,"PHASE3":14105,"PHASE4":14107,"NA":14109},{"trials":14096,"activeCount":101},[],{"trials":14098,"activeCount":101},[14099],{"nctId":14035,"briefTitle":14036,"status":160,"phases":14100,"primaryCompletion":5871,"completion":5871,"start":14038,"enrollment":3106,"conditions":14101,"interventions":14102},[89],[5514,14040,14041,14042],[14028,14044,14045,14046,14047,14048],{"trials":14104,"activeCount":101},[],{"trials":14106,"activeCount":101},[],{"trials":14108,"activeCount":101},[],{"trials":14110,"activeCount":101},[],{"intervention":14047,"totalTrials":115,"cells":14112},{"EARLY_PHASE1":14113,"PHASE1":14115,"PHASE2":14121,"PHASE3":14123,"PHASE4":14125,"NA":14127},{"trials":14114,"activeCount":101},[],{"trials":14116,"activeCount":101},[14117],{"nctId":14035,"briefTitle":14036,"status":160,"phases":14118,"primaryCompletion":5871,"completion":5871,"start":14038,"enrollment":3106,"conditions":14119,"interventions":14120},[89],[5514,14040,14041,14042],[14028,14044,14045,14046,14047,14048],{"trials":14122,"activeCount":101},[],{"trials":14124,"activeCount":101},[],{"trials":14126,"activeCount":101},[],{"trials":14128,"activeCount":101},[],{"intervention":14048,"totalTrials":115,"cells":14130},{"EARLY_PHASE1":14131,"PHASE1":14133,"PHASE2":14139,"PHASE3":14141,"PHASE4":14143,"NA":14145},{"trials":14132,"activeCount":101},[],{"trials":14134,"activeCount":101},[14135],{"nctId":14035,"briefTitle":14036,"status":160,"phases":14136,"primaryCompletion":5871,"completion":5871,"start":14038,"enrollment":3106,"conditions":14137,"interventions":14138},[89],[5514,14040,14041,14042],[14028,14044,14045,14046,14047,14048],{"trials":14140,"activeCount":101},[],{"trials":14142,"activeCount":101},[],{"trials":14144,"activeCount":101},[],{"trials":14146,"activeCount":101},[],{"intervention":14148,"totalTrials":115,"cells":14149},"Ulipristal Acetate 30 MG Oral",{"EARLY_PHASE1":14150,"PHASE1":14152,"PHASE2":14163,"PHASE3":14165,"PHASE4":14167,"NA":14169},{"trials":14151,"activeCount":101},[],{"trials":14153,"activeCount":101},[14154],{"nctId":14155,"briefTitle":14156,"status":160,"phases":14157,"primaryCompletion":14158,"completion":14158,"start":14159,"enrollment":1314,"conditions":14160,"interventions":14162},"NCT03354117","On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility",[89],"2019-05-31","2018-03-15",[14161],"Contraception",[14148],{"trials":14164,"activeCount":101},[],{"trials":14166,"activeCount":101},[],{"trials":14168,"activeCount":101},[],{"trials":14170,"activeCount":101},[],{"intervention":14172,"totalTrials":115,"cells":14173},"Fludeoxyglucose F-18",{"EARLY_PHASE1":14174,"PHASE1":14176,"PHASE2":14189,"PHASE3":14191,"PHASE4":14193,"NA":14195},{"trials":14175,"activeCount":101},[],{"trials":14177,"activeCount":101},[14178],{"nctId":14179,"briefTitle":14180,"status":716,"phases":14181,"primaryCompletion":14182,"completion":14182,"start":8251,"enrollment":1810,"conditions":14183,"interventions":14187},"NCT02429804","NaF\u002FFDG PET\u002FMRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer",[89],"2017-05-15",[14184,14185,14186],"Hormone-Resistant Prostate Cancer","Metastatic Malignant Neoplasm in the Bone","Metastatic Prostate Carcinoma",[14172,14188],"Fluorine F 18 Sodium Fluoride",{"trials":14190,"activeCount":101},[],{"trials":14192,"activeCount":101},[],{"trials":14194,"activeCount":101},[],{"trials":14196,"activeCount":101},[],{"intervention":14188,"totalTrials":115,"cells":14198},{"EARLY_PHASE1":14199,"PHASE1":14201,"PHASE2":14207,"PHASE3":14209,"PHASE4":14211,"NA":14213},{"trials":14200,"activeCount":101},[],{"trials":14202,"activeCount":101},[14203],{"nctId":14179,"briefTitle":14180,"status":716,"phases":14204,"primaryCompletion":14182,"completion":14182,"start":8251,"enrollment":1810,"conditions":14205,"interventions":14206},[89],[14184,14185,14186],[14172,14188],{"trials":14208,"activeCount":101},[],{"trials":14210,"activeCount":101},[],{"trials":14212,"activeCount":101},[],{"trials":14214,"activeCount":101},[],{"intervention":14216,"totalTrials":115,"cells":14217},"Empagliflozin 10 MG",{"EARLY_PHASE1":14218,"PHASE1":14220,"PHASE2":14234,"PHASE3":14236,"PHASE4":14238,"NA":14240},{"trials":14219,"activeCount":101},[],{"trials":14221,"activeCount":101},[14222],{"nctId":14223,"briefTitle":14224,"status":160,"phases":14225,"primaryCompletion":14226,"completion":14227,"start":5241,"enrollment":1449,"conditions":14228,"interventions":14233},"NCT05013502","Empagliflozin in Diuretic Refractory Ascites",[89],"2023-05-30","2023-06-30",[11426,14229,14230,14231,14232],"Cirrhosis","Ascites","Ascites Hepatic","Sodium-Glucose Transporter 2 Inhibitors",[14216],{"trials":14235,"activeCount":101},[],{"trials":14237,"activeCount":101},[],{"trials":14239,"activeCount":101},[],{"trials":14241,"activeCount":101},[],{"intervention":14243,"totalTrials":115,"cells":14244},"[18F]FDG",{"EARLY_PHASE1":14245,"PHASE1":14247,"PHASE2":14257,"PHASE3":14259,"PHASE4":14261,"NA":14263},{"trials":14246,"activeCount":101},[],{"trials":14248,"activeCount":101},[14249],{"nctId":14250,"briefTitle":14251,"status":160,"phases":14252,"primaryCompletion":2328,"completion":2328,"start":14253,"enrollment":14254,"conditions":14255,"interventions":14256},"NCT03195270","Use of PET\u002FMR Imaging in Chronic Pain",[89],"2014-11-24",88,[33],[14243],{"trials":14258,"activeCount":101},[],{"trials":14260,"activeCount":101},[],{"trials":14262,"activeCount":101},[],{"trials":14264,"activeCount":101},[],{"intervention":14266,"totalTrials":115,"cells":14267},"Isovue-200",{"EARLY_PHASE1":14268,"PHASE1":14270,"PHASE2":14284,"PHASE3":14286,"PHASE4":14288,"NA":14290},{"trials":14269,"activeCount":101},[],{"trials":14271,"activeCount":101},[14272],{"nctId":14273,"briefTitle":14274,"status":160,"phases":14275,"primaryCompletion":14276,"completion":14276,"start":14277,"enrollment":14278,"conditions":14279,"interventions":14283},"NCT02693080","CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy",[89],"2020-04-29","2016-01-19",19,[14280,1303,14281,14282],"Malignant Lung Neoplasm","Non-Small Cell Lung Carcinoma","Stage IV Lung Cancer",[14266],{"trials":14285,"activeCount":101},[],{"trials":14287,"activeCount":101},[],{"trials":14289,"activeCount":101},[],{"trials":14291,"activeCount":101},[],{"intervention":14293,"totalTrials":115,"cells":14294},"fludeoxyglucose F 18",{"EARLY_PHASE1":14295,"PHASE1":14297,"PHASE2":14310,"PHASE3":14312,"PHASE4":14314,"NA":14316},{"trials":14296,"activeCount":101},[],{"trials":14298,"activeCount":101},[14299],{"nctId":14300,"briefTitle":14301,"status":716,"phases":14302,"primaryCompletion":11589,"completion":11589,"start":1471,"enrollment":115,"conditions":14303,"interventions":14309},"NCT01494012","Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer",[89],[14304,14305,14306,14307,14308],"Recurrent Ovarian Epithelial Cancer","Recurrent Ovarian Germ Cell Tumor","Malignant Tumor of Peritoneum","Stage IV Ovarian Epithelial Cancer","Stage IV Ovarian Germ Cell Tumor",[14293],{"trials":14311,"activeCount":101},[],{"trials":14313,"activeCount":101},[],{"trials":14315,"activeCount":101},[],{"trials":14317,"activeCount":101},[],{"intervention":14319,"totalTrials":115,"cells":14320},"FluMist® Quadrivalent",{"EARLY_PHASE1":14321,"PHASE1":14323,"PHASE2":14335,"PHASE3":14337,"PHASE4":14339,"NA":14341},{"trials":14322,"activeCount":101},[],{"trials":14324,"activeCount":101},[14325],{"nctId":14326,"briefTitle":14327,"status":160,"phases":14328,"primaryCompletion":14329,"completion":14329,"start":14330,"enrollment":14331,"conditions":14332,"interventions":14333},"NCT03088904","Genetic and Environmental Factors in the Response to Influenza Vaccination",[89],"2018-12-12","2014-10-03",109,[5514,193],[14319,14334],"Fluzone® Quadrivalent vaccine",{"trials":14336,"activeCount":101},[],{"trials":14338,"activeCount":101},[],{"trials":14340,"activeCount":101},[],{"trials":14342,"activeCount":101},[],{"intervention":14334,"totalTrials":115,"cells":14344},{"EARLY_PHASE1":14345,"PHASE1":14347,"PHASE2":14353,"PHASE3":14355,"PHASE4":14357,"NA":14359},{"trials":14346,"activeCount":101},[],{"trials":14348,"activeCount":101},[14349],{"nctId":14326,"briefTitle":14327,"status":160,"phases":14350,"primaryCompletion":14329,"completion":14329,"start":14330,"enrollment":14331,"conditions":14351,"interventions":14352},[89],[5514,193],[14319,14334],{"trials":14354,"activeCount":101},[],{"trials":14356,"activeCount":101},[],{"trials":14358,"activeCount":101},[],{"trials":14360,"activeCount":101},[],{"intervention":14362,"totalTrials":115,"cells":14363},"thiazolidinedione",{"EARLY_PHASE1":14364,"PHASE1":14366,"PHASE2":14375,"PHASE3":14377,"PHASE4":14379,"NA":14381},{"trials":14365,"activeCount":101},[],{"trials":14367,"activeCount":101},[14368],{"nctId":14369,"briefTitle":14370,"status":160,"phases":14371,"primaryCompletion":1564,"completion":1564,"start":14372,"enrollment":14254,"conditions":14373,"interventions":14374},"NCT00285844","Integrating the Genetic and Metabolic Faces of Obesity",[89],"2005-10",[36,18,7591],[14362],{"trials":14376,"activeCount":101},[],{"trials":14378,"activeCount":101},[],{"trials":14380,"activeCount":101},[],{"trials":14382,"activeCount":101},[],{"intervention":2018,"totalTrials":115,"cells":14384},{"EARLY_PHASE1":14385,"PHASE1":14387,"PHASE2":14393,"PHASE3":14395,"PHASE4":14397,"NA":14399},{"trials":14386,"activeCount":101},[],{"trials":14388,"activeCount":101},[14389],{"nctId":1994,"briefTitle":1995,"status":716,"phases":14390,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":1766,"conditions":14391,"interventions":14392},[89],[2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015],[2017,2018,2019,2020],{"trials":14394,"activeCount":101},[],{"trials":14396,"activeCount":101},[],{"trials":14398,"activeCount":101},[],{"trials":14400,"activeCount":101},[],{"intervention":14402,"totalTrials":115,"cells":14403},"anti-SARS-CoV-2 IgY",{"EARLY_PHASE1":14404,"PHASE1":14406,"PHASE2":14416,"PHASE3":14418,"PHASE4":14420,"NA":14422},{"trials":14405,"activeCount":101},[],{"trials":14407,"activeCount":101},[14408],{"nctId":14409,"briefTitle":14410,"status":160,"phases":14411,"primaryCompletion":14412,"completion":14412,"start":14413,"enrollment":1755,"conditions":14414,"interventions":14415},"NCT04567810","Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",[89],"2020-12-14","2020-09-18",[3304],[14402],{"trials":14417,"activeCount":101},[],{"trials":14419,"activeCount":101},[],{"trials":14421,"activeCount":101},[],{"trials":14423,"activeCount":101},[],{"intervention":14425,"totalTrials":115,"cells":14426},"T regulatory cells",{"EARLY_PHASE1":14427,"PHASE1":14429,"PHASE2":14439,"PHASE3":14441,"PHASE4":14443,"NA":14445},{"trials":14428,"activeCount":101},[],{"trials":14430,"activeCount":101},[14431],{"nctId":14432,"briefTitle":14433,"status":132,"phases":14434,"primaryCompletion":13209,"completion":13209,"start":14435,"enrollment":101,"conditions":14436,"interventions":14438},"NCT04737161","Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome",[89],"2021-03",[14437,3304],"Acute Respiratory Distress Syndrome",[14425],{"trials":14440,"activeCount":101},[],{"trials":14442,"activeCount":101},[],{"trials":14444,"activeCount":101},[],{"trials":14446,"activeCount":101},[],{"intervention":14448,"totalTrials":115,"cells":14449},"Saquinavir",{"EARLY_PHASE1":14450,"PHASE1":14452,"PHASE2":14460,"PHASE3":14462,"PHASE4":14464,"NA":14466},{"trials":14451,"activeCount":101},[],{"trials":14453,"activeCount":101},[14454],{"nctId":14455,"briefTitle":14456,"status":160,"phases":14457,"enrollment":6633,"conditions":14458,"interventions":14459},"NCT00002111","A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.",[89],[7567],[14448],{"trials":14461,"activeCount":101},[],{"trials":14463,"activeCount":101},[],{"trials":14465,"activeCount":101},[],{"trials":14467,"activeCount":101},[],{"intervention":3459,"totalTrials":115,"cells":14469},{"EARLY_PHASE1":14470,"PHASE1":14472,"PHASE2":14478,"PHASE3":14480,"PHASE4":14482,"NA":14484},{"trials":14471,"activeCount":101},[],{"trials":14473,"activeCount":101},[14474],{"nctId":3450,"briefTitle":3451,"status":716,"phases":14475,"primaryCompletion":2102,"start":1843,"enrollment":152,"conditions":14476,"interventions":14477},[89],[3454,3455,3456],[3458,3459],{"trials":14479,"activeCount":101},[],{"trials":14481,"activeCount":101},[],{"trials":14483,"activeCount":101},[],{"trials":14485,"activeCount":101},[],{"intervention":9840,"totalTrials":115,"cells":14487},{"EARLY_PHASE1":14488,"PHASE1":14490,"PHASE2":14496,"PHASE3":14498,"PHASE4":14500,"NA":14502},{"trials":14489,"activeCount":101},[],{"trials":14491,"activeCount":101},[14492],{"nctId":9833,"briefTitle":9834,"status":132,"phases":14493,"primaryCompletion":2102,"start":9836,"enrollment":101,"conditions":14494,"interventions":14495},[89],[9838],[9840,9841],{"trials":14497,"activeCount":101},[],{"trials":14499,"activeCount":101},[],{"trials":14501,"activeCount":101},[],{"trials":14503,"activeCount":101},[],{"intervention":14505,"totalTrials":115,"cells":14506},"Vancomycin",{"EARLY_PHASE1":14507,"PHASE1":14509,"PHASE2":14519,"PHASE3":14521,"PHASE4":14523,"NA":14525},{"trials":14508,"activeCount":101},[],{"trials":14510,"activeCount":101},[14511],{"nctId":14512,"briefTitle":14513,"status":160,"phases":14514,"primaryCompletion":14515,"completion":7655,"start":13141,"enrollment":6633,"conditions":14516,"interventions":14518},"NCT01322386","Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin",[89],"2010-10",[5020,14517],"Biliary Atresia",[14505],{"trials":14520,"activeCount":101},[],{"trials":14522,"activeCount":101},[],{"trials":14524,"activeCount":101},[],{"trials":14526,"activeCount":101},[],{"intervention":14528,"totalTrials":115,"cells":14529},"Ultra-rapid insulin",{"EARLY_PHASE1":14530,"PHASE1":14532,"PHASE2":14542,"PHASE3":14544,"PHASE4":14546,"NA":14548},{"trials":14531,"activeCount":101},[],{"trials":14533,"activeCount":101},[14534],{"nctId":14535,"briefTitle":14536,"status":160,"phases":14537,"primaryCompletion":14538,"completion":14538,"start":14539,"enrollment":737,"conditions":14540,"interventions":14541},"NCT04416737","Evaluating the Benefits of Physiologic Insulin Delivery",[89],"2023-06-02","2021-11-01",[2104],[14528],{"trials":14543,"activeCount":101},[],{"trials":14545,"activeCount":101},[],{"trials":14547,"activeCount":101},[],{"trials":14549,"activeCount":101},[],{"intervention":14551,"totalTrials":115,"cells":14552},"90Y Ibritumomab tiuxetan",{"EARLY_PHASE1":14553,"PHASE1":14555,"PHASE2":14563,"PHASE3":14565,"PHASE4":14567,"NA":14569},{"trials":14554,"activeCount":101},[],{"trials":14556,"activeCount":101},[14557],{"nctId":14558,"briefTitle":14559,"status":160,"phases":14560,"primaryCompletion":4993,"completion":4993,"start":9553,"enrollment":232,"conditions":14561,"interventions":14562},"NCT00186589","90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL",[89],[722,764],[14551],{"trials":14564,"activeCount":101},[],{"trials":14566,"activeCount":101},[],{"trials":14568,"activeCount":101},[],{"trials":14570,"activeCount":101},[],{"intervention":14572,"totalTrials":115,"cells":14573},"Thermosensitive gel rectal formulation",{"EARLY_PHASE1":14574,"PHASE1":14576,"PHASE2":14585,"PHASE3":14587,"PHASE4":14589,"NA":14591},{"trials":14575,"activeCount":101},[],{"trials":14577,"activeCount":101},[14578],{"nctId":14579,"briefTitle":14580,"status":160,"phases":14581,"primaryCompletion":2101,"completion":2101,"start":3806,"enrollment":334,"conditions":14582,"interventions":14584},"NCT02745678","Localized Therapeutics for the Treatment of Gastrointestinal Disorders II",[89],[14583],"Colitis, Ulcerative",[14572],{"trials":14586,"activeCount":101},[],{"trials":14588,"activeCount":101},[],{"trials":14590,"activeCount":101},[],{"trials":14592,"activeCount":101},[],{"intervention":14594,"totalTrials":115,"cells":14595},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":14596,"PHASE1":14598,"PHASE2":14608,"PHASE3":14610,"PHASE4":14612,"NA":14614},{"trials":14597,"activeCount":101},[],{"trials":14599,"activeCount":101},[14600],{"nctId":14601,"briefTitle":14602,"status":132,"phases":14603,"primaryCompletion":14604,"completion":4296,"start":14605,"enrollment":101,"conditions":14606,"interventions":14607},"NCT03747718","Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children",[89],"2024-12-01","2022-12-01",[1451],[14594],{"trials":14609,"activeCount":101},[],{"trials":14611,"activeCount":101},[],{"trials":14613,"activeCount":101},[],{"trials":14615,"activeCount":101},[],{"intervention":14617,"totalTrials":115,"cells":14618},"visilizumab",{"EARLY_PHASE1":14619,"PHASE1":14621,"PHASE2":14631,"PHASE3":14633,"PHASE4":14635,"NA":14637},{"trials":14620,"activeCount":101},[],{"trials":14622,"activeCount":101},[14623],{"nctId":14624,"briefTitle":14625,"status":160,"phases":14626,"completion":14627,"start":775,"conditions":14628,"interventions":14630},"NCT00006009","Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma",[89],"2003-10",[1426,14629],"Small Intestine Cancer",[14617],{"trials":14632,"activeCount":101},[],{"trials":14634,"activeCount":101},[],{"trials":14636,"activeCount":101},[],{"trials":14638,"activeCount":101},[],{"intervention":14640,"totalTrials":115,"cells":14641},"Autologous tumor cell + CpG vaccine",{"EARLY_PHASE1":14642,"PHASE1":14644,"PHASE2":14654,"PHASE3":14656,"PHASE4":14658,"NA":14660},{"trials":14643,"activeCount":101},[],{"trials":14645,"activeCount":101},[14646],{"nctId":14647,"briefTitle":14648,"status":132,"phases":14649,"enrollment":101,"conditions":14650,"interventions":14653},"NCT00780988","Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer",[89],[14651,14652],"Colorectal Neoplasms","Anal, Colon, and Rectal Cancers",[14640],{"trials":14655,"activeCount":101},[],{"trials":14657,"activeCount":101},[],{"trials":14659,"activeCount":101},[],{"trials":14661,"activeCount":101},[],{"intervention":14663,"totalTrials":115,"cells":14664},"89Zr-panitumumab",{"EARLY_PHASE1":14665,"PHASE1":14667,"PHASE2":14678,"PHASE3":14680,"PHASE4":14682,"NA":14684},{"trials":14666,"activeCount":101},[],{"trials":14668,"activeCount":101},[14669],{"nctId":14670,"briefTitle":14671,"status":132,"phases":14672,"primaryCompletion":14673,"completion":14673,"start":14674,"enrollment":101,"conditions":14675,"interventions":14677},"NCT04833959","Pilot Study of 89-Zr Panitumumab in Pancreas Cancer",[89],"2024-03","2021-03-26",[14676],"Pancreas Cancer",[14663],{"trials":14679,"activeCount":101},[],{"trials":14681,"activeCount":101},[],{"trials":14683,"activeCount":101},[],{"trials":14685,"activeCount":101},[],{"intervention":14687,"totalTrials":115,"cells":14688},"Live attenuated influenza vaccine",{"EARLY_PHASE1":14689,"PHASE1":14691,"PHASE2":14701,"PHASE3":14703,"PHASE4":14705,"NA":14707},{"trials":14690,"activeCount":101},[],{"trials":14692,"activeCount":101},[14693],{"nctId":14694,"briefTitle":14695,"status":160,"phases":14696,"primaryCompletion":5871,"completion":5871,"start":14697,"enrollment":836,"conditions":14698,"interventions":14699},"NCT03898986","The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets",[89],"2019-10-08",[5514],[14687,14700],"Inactivated Influenza Vaccine",{"trials":14702,"activeCount":101},[],{"trials":14704,"activeCount":101},[],{"trials":14706,"activeCount":101},[],{"trials":14708,"activeCount":101},[],{"intervention":14700,"totalTrials":115,"cells":14710},{"EARLY_PHASE1":14711,"PHASE1":14713,"PHASE2":14719,"PHASE3":14721,"PHASE4":14723,"NA":14725},{"trials":14712,"activeCount":101},[],{"trials":14714,"activeCount":101},[14715],{"nctId":14694,"briefTitle":14695,"status":160,"phases":14716,"primaryCompletion":5871,"completion":5871,"start":14697,"enrollment":836,"conditions":14717,"interventions":14718},[89],[5514],[14687,14700],{"trials":14720,"activeCount":101},[],{"trials":14722,"activeCount":101},[],{"trials":14724,"activeCount":101},[],{"trials":14726,"activeCount":101},[],{"intervention":14728,"totalTrials":115,"cells":14729},"Low-dose isoniazid",{"EARLY_PHASE1":14730,"PHASE1":14732,"PHASE2":14747,"PHASE3":14749,"PHASE4":14751,"NA":14753},{"trials":14731,"activeCount":101},[],{"trials":14733,"activeCount":101},[14734],{"nctId":14735,"briefTitle":14736,"status":160,"phases":14737,"primaryCompletion":14738,"completion":14739,"start":14740,"enrollment":9962,"conditions":14741,"interventions":14744},"NCT05413551","Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention",[89],"2025-04-23","2025-06-25","2023-03-23",[14742,14743],"Tuberculosis Infection","Isoniazid Adverse Reaction",[14728,14745,14746],"Standard dose of isoniazid","High-dose isoniazid",{"trials":14748,"activeCount":101},[],{"trials":14750,"activeCount":101},[],{"trials":14752,"activeCount":101},[],{"trials":14754,"activeCount":101},[],{"intervention":14745,"totalTrials":115,"cells":14756},{"EARLY_PHASE1":14757,"PHASE1":14759,"PHASE2":14765,"PHASE3":14767,"PHASE4":14769,"NA":14771},{"trials":14758,"activeCount":101},[],{"trials":14760,"activeCount":101},[14761],{"nctId":14735,"briefTitle":14736,"status":160,"phases":14762,"primaryCompletion":14738,"completion":14739,"start":14740,"enrollment":9962,"conditions":14763,"interventions":14764},[89],[14742,14743],[14728,14745,14746],{"trials":14766,"activeCount":101},[],{"trials":14768,"activeCount":101},[],{"trials":14770,"activeCount":101},[],{"trials":14772,"activeCount":101},[],{"intervention":14746,"totalTrials":115,"cells":14774},{"EARLY_PHASE1":14775,"PHASE1":14777,"PHASE2":14783,"PHASE3":14785,"PHASE4":14787,"NA":14789},{"trials":14776,"activeCount":101},[],{"trials":14778,"activeCount":101},[14779],{"nctId":14735,"briefTitle":14736,"status":160,"phases":14780,"primaryCompletion":14738,"completion":14739,"start":14740,"enrollment":9962,"conditions":14781,"interventions":14782},[89],[14742,14743],[14728,14745,14746],{"trials":14784,"activeCount":101},[],{"trials":14786,"activeCount":101},[],{"trials":14788,"activeCount":101},[],{"trials":14790,"activeCount":101},[],{"intervention":14792,"totalTrials":115,"cells":14793},"[ 18F]F-AraG PET",{"EARLY_PHASE1":14794,"PHASE1":14796,"PHASE2":14806,"PHASE3":14808,"PHASE4":14810,"NA":14812},{"trials":14795,"activeCount":101},[],{"trials":14797,"activeCount":101},[14798],{"nctId":14799,"briefTitle":14800,"status":716,"phases":14801,"primaryCompletion":14802,"completion":14803,"start":12127,"enrollment":152,"conditions":14804,"interventions":14805},"NCT05096234","18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma",[89],"2022-05-09","2023-10-09",[1474],[14792],{"trials":14807,"activeCount":101},[],{"trials":14809,"activeCount":101},[],{"trials":14811,"activeCount":101},[],{"trials":14813,"activeCount":101},[],{"intervention":14815,"totalTrials":115,"cells":14816},"EF5",{"EARLY_PHASE1":14817,"PHASE1":14819,"PHASE2":14831,"PHASE3":14833,"PHASE4":14835,"NA":14837},{"trials":14818,"activeCount":101},[],{"trials":14820,"activeCount":101},[14821],{"nctId":14822,"briefTitle":14823,"status":716,"phases":14824,"primaryCompletion":14825,"completion":14825,"start":697,"enrollment":1672,"conditions":14826,"interventions":14828},"NCT01123005","Imaging and Biomarkers of Hypoxia in Solid Tumors",[89],"2015-08-21",[14827],"Neoplasms",[14815,14829,14830],"Carbogen","Dichloroacetate",{"trials":14832,"activeCount":101},[],{"trials":14834,"activeCount":101},[],{"trials":14836,"activeCount":101},[],{"trials":14838,"activeCount":101},[],{"intervention":14829,"totalTrials":115,"cells":14840},{"EARLY_PHASE1":14841,"PHASE1":14843,"PHASE2":14849,"PHASE3":14851,"PHASE4":14853,"NA":14855},{"trials":14842,"activeCount":101},[],{"trials":14844,"activeCount":101},[14845],{"nctId":14822,"briefTitle":14823,"status":716,"phases":14846,"primaryCompletion":14825,"completion":14825,"start":697,"enrollment":1672,"conditions":14847,"interventions":14848},[89],[14827],[14815,14829,14830],{"trials":14850,"activeCount":101},[],{"trials":14852,"activeCount":101},[],{"trials":14854,"activeCount":101},[],{"trials":14856,"activeCount":101},[],{"intervention":14830,"totalTrials":115,"cells":14858},{"EARLY_PHASE1":14859,"PHASE1":14861,"PHASE2":14867,"PHASE3":14869,"PHASE4":14871,"NA":14873},{"trials":14860,"activeCount":101},[],{"trials":14862,"activeCount":101},[14863],{"nctId":14822,"briefTitle":14823,"status":716,"phases":14864,"primaryCompletion":14825,"completion":14825,"start":697,"enrollment":1672,"conditions":14865,"interventions":14866},[89],[14827],[14815,14829,14830],{"trials":14868,"activeCount":101},[],{"trials":14870,"activeCount":101},[],{"trials":14872,"activeCount":101},[],{"trials":14874,"activeCount":101},[],{"intervention":3473,"totalTrials":115,"cells":14876},{"EARLY_PHASE1":14877,"PHASE1":14879,"PHASE2":14885,"PHASE3":14887,"PHASE4":14889,"NA":14891},{"trials":14878,"activeCount":101},[],{"trials":14880,"activeCount":101},[14881],{"nctId":3461,"briefTitle":3462,"status":160,"phases":14882,"primaryCompletion":3464,"completion":3465,"start":3466,"enrollment":1810,"conditions":14883,"interventions":14884},[89],[3468,3469,3470,3471],[3473,730,727],{"trials":14886,"activeCount":101},[],{"trials":14888,"activeCount":101},[],{"trials":14890,"activeCount":101},[],{"trials":14892,"activeCount":101},[],{"intervention":1804,"totalTrials":115,"cells":14894},{"EARLY_PHASE1":14895,"PHASE1":14897,"PHASE2":14903,"PHASE3":14905,"PHASE4":14907,"NA":14909},{"trials":14896,"activeCount":101},[],{"trials":14898,"activeCount":101},[14899],{"nctId":1797,"briefTitle":1798,"status":716,"phases":14900,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":836,"conditions":14901,"interventions":14902},[89],[15],[1700,1804],{"trials":14904,"activeCount":101},[],{"trials":14906,"activeCount":101},[],{"trials":14908,"activeCount":101},[],{"trials":14910,"activeCount":101},[],{"intervention":14912,"totalTrials":115,"cells":14913},"Food proteins",{"EARLY_PHASE1":14914,"PHASE1":14916,"PHASE2":14924,"PHASE3":14926,"PHASE4":14928,"NA":14930},{"trials":14915,"activeCount":101},[],{"trials":14917,"activeCount":101},[14918],{"nctId":14919,"briefTitle":14920,"status":160,"phases":14921,"primaryCompletion":756,"completion":756,"start":859,"enrollment":1435,"conditions":14922,"interventions":14923},"NCT01490177","Single Center Food Allergy Oral Immunotherapy Study",[89],[9547],[14912],{"trials":14925,"activeCount":101},[],{"trials":14927,"activeCount":101},[],{"trials":14929,"activeCount":101},[],{"trials":14931,"activeCount":101},[],{"intervention":14933,"totalTrials":115,"cells":14934},"talactoferrin",{"EARLY_PHASE1":14935,"PHASE1":14937,"PHASE2":14989,"PHASE3":14991,"PHASE4":14993,"NA":14995},{"trials":14936,"activeCount":101},[],{"trials":14938,"activeCount":101},[14939],{"nctId":14940,"briefTitle":14941,"status":716,"phases":14942,"primaryCompletion":1563,"completion":6351,"start":1498,"enrollment":1810,"conditions":14943,"interventions":14988},"NCT01528137","Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer",[89],[14944,14945,14946,14947,14948,14949,14950,14951,14952,14953,14954,14955,14956,14957,14958,14959,3950,14960,14961,14962,14963,14964,14965,3952,14966,14967,14968,14969,14970,14971,14972,14973,14974,14975,14976,14977,14978,14979,14980,14981,14982,14983,14984,14985,14986,14987],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer",[14933],{"trials":14990,"activeCount":101},[],{"trials":14992,"activeCount":101},[],{"trials":14994,"activeCount":101},[],{"trials":14996,"activeCount":101},[],{"intervention":14998,"totalTrials":115,"cells":14999},"Herbal treatment",{"EARLY_PHASE1":15000,"PHASE1":15002,"PHASE2":15011,"PHASE3":15013,"PHASE4":15015,"NA":15017},{"trials":15001,"activeCount":101},[],{"trials":15003,"activeCount":101},[15004],{"nctId":15005,"briefTitle":15006,"status":160,"phases":15007,"primaryCompletion":15008,"completion":15008,"start":757,"enrollment":2218,"conditions":15009,"interventions":15010},"NCT02442960","Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis",[89],"2017-07-26",[8786],[14998],{"trials":15012,"activeCount":101},[],{"trials":15014,"activeCount":101},[],{"trials":15016,"activeCount":101},[],{"trials":15018,"activeCount":101},[],{"intervention":13534,"totalTrials":115,"cells":15020},{"EARLY_PHASE1":15021,"PHASE1":15023,"PHASE2":15029,"PHASE3":15031,"PHASE4":15033,"NA":15035},{"trials":15022,"activeCount":101},[],{"trials":15024,"activeCount":101},[15025],{"nctId":13525,"briefTitle":13526,"status":132,"phases":15026,"primaryCompletion":13528,"completion":13529,"start":13530,"enrollment":101,"conditions":15027,"interventions":15028},[89],[3388,13532],[13534,13535,1504],{"trials":15030,"activeCount":101},[],{"trials":15032,"activeCount":101},[],{"trials":15034,"activeCount":101},[],{"trials":15036,"activeCount":101},[],{"intervention":1817,"totalTrials":115,"cells":15038},{"EARLY_PHASE1":15039,"PHASE1":15041,"PHASE2":15047,"PHASE3":15049,"PHASE4":15051,"NA":15053},{"trials":15040,"activeCount":101},[],{"trials":15042,"activeCount":101},[15043],{"nctId":1806,"briefTitle":1807,"status":716,"phases":15044,"primaryCompletion":1809,"completion":1809,"start":1754,"enrollment":1810,"conditions":15045,"interventions":15046},[89],[1812,1813,1814,1815],[1700,1817,1818,1699],{"trials":15048,"activeCount":101},[],{"trials":15050,"activeCount":101},[],{"trials":15052,"activeCount":101},[],{"trials":15054,"activeCount":101},[],{"intervention":15056,"totalTrials":115,"cells":15057},"Exenatide 5 and 10 mcg 2 times a day",{"EARLY_PHASE1":15058,"PHASE1":15060,"PHASE2":15069,"PHASE3":15071,"PHASE4":15073,"NA":15075},{"trials":15059,"activeCount":101},[],{"trials":15061,"activeCount":101},[15062],{"nctId":15063,"briefTitle":15064,"status":160,"phases":15065,"primaryCompletion":1564,"completion":1920,"start":15066,"enrollment":382,"conditions":15067,"interventions":15068},"NCT02084654","Exenatide and Weight Loss for Diabetes Prevention",[89],"2007-11",[402,36],[15056],{"trials":15070,"activeCount":101},[],{"trials":15072,"activeCount":101},[],{"trials":15074,"activeCount":101},[],{"trials":15076,"activeCount":101},[],{"intervention":3916,"totalTrials":115,"cells":15078},{"EARLY_PHASE1":15079,"PHASE1":15081,"PHASE2":15087,"PHASE3":15089,"PHASE4":15091,"NA":15093},{"trials":15080,"activeCount":101},[],{"trials":15082,"activeCount":101},[15083],{"nctId":3909,"briefTitle":3910,"status":160,"phases":15084,"primaryCompletion":1862,"start":3912,"enrollment":247,"conditions":15085,"interventions":15086},[89],[3914,1813],[3916,1698],{"trials":15088,"activeCount":101},[],{"trials":15090,"activeCount":101},[],{"trials":15092,"activeCount":101},[],{"trials":15094,"activeCount":101},[],{"intervention":15096,"totalTrials":115,"cells":15097},"111I-n panitumumab",{"EARLY_PHASE1":15098,"PHASE1":15100,"PHASE2":15109,"PHASE3":15111,"PHASE4":15113,"NA":15115},{"trials":15099,"activeCount":101},[],{"trials":15101,"activeCount":101},[15102],{"nctId":15103,"briefTitle":15104,"status":4049,"phases":15105,"primaryCompletion":15106,"completion":15106,"start":11167,"enrollment":1672,"conditions":15107,"interventions":15108},"NCT04840472","Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer",[89],"2027-03",[3914],[15096],{"trials":15110,"activeCount":101},[],{"trials":15112,"activeCount":101},[],{"trials":15114,"activeCount":101},[],{"trials":15116,"activeCount":101},[],{"intervention":15118,"totalTrials":152,"cells":15119},"Hydrocortisone acetate",{"EARLY_PHASE1":15120,"PHASE1":15138,"PHASE2":15140,"PHASE3":15142,"PHASE4":15144,"NA":15146},{"trials":15121,"activeCount":101},[15122,15130],{"nctId":15123,"briefTitle":15124,"status":160,"phases":15125,"primaryCompletion":15126,"completion":9505,"start":6055,"enrollment":15127,"conditions":15128,"interventions":15129},"NCT02837432","The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression",[88],"2019-12-13",192,[21],[15118],{"nctId":15131,"briefTitle":15132,"status":132,"phases":15133,"primaryCompletion":7821,"completion":7821,"start":3944,"enrollment":101,"conditions":15134,"interventions":15135},"NCT04148261","Epinephrine and Cortisol in Depression",[88],[21],[15136,15137],"Hydrocortisone Acetate","Epinephrine Sulfate",{"trials":15139,"activeCount":101},[],{"trials":15141,"activeCount":101},[],{"trials":15143,"activeCount":101},[],{"trials":15145,"activeCount":101},[],{"trials":15147,"activeCount":101},[],{"intervention":15149,"totalTrials":152,"cells":15150},"Transvaginal botulinum toxin A (BTA)",{"EARLY_PHASE1":15151,"PHASE1":15173,"PHASE2":15175,"PHASE3":15177,"PHASE4":15179,"NA":15181},{"trials":15152,"activeCount":101},[15153,15160],{"nctId":15154,"briefTitle":15155,"status":4124,"phases":15156,"primaryCompletion":15157,"completion":15157,"start":7983,"enrollment":821,"conditions":15158,"interventions":15159},"NCT05485207","Transvaginal Botulinum Toxin A for Interstitial Cystitis \u002F Bladder Pain Syndrome",[88],"2025-02-28",[10478,10477],[15149],{"nctId":15161,"briefTitle":15162,"status":160,"phases":15163,"primaryCompletion":15164,"completion":15164,"start":15165,"enrollment":2218,"conditions":15166,"interventions":15172},"NCT05463822","Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder",[88],"2021-09-27","2019-06-20",[15167,15168,15169,15170,15171],"Overactive Bladder","Bladder, Overactive","Urge Incontinence","Urgency Urinary","Urinary Frequency\u002FUrgency",[15149],{"trials":15174,"activeCount":101},[],{"trials":15176,"activeCount":101},[],{"trials":15178,"activeCount":101},[],{"trials":15180,"activeCount":101},[],{"trials":15182,"activeCount":101},[],{"intervention":15184,"totalTrials":152,"cells":15185},"[18F]FP-R01-MG-F2",{"EARLY_PHASE1":15186,"PHASE1":15208,"PHASE2":15210,"PHASE3":15212,"PHASE4":15214,"NA":15216},{"trials":15187,"activeCount":101},[15188,15197],{"nctId":15189,"briefTitle":15190,"status":160,"phases":15191,"primaryCompletion":15164,"completion":14605,"start":15192,"enrollment":2393,"conditions":15193,"interventions":15196},"NCT02683824","Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET\u002FCT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers",[88],"2016-01-12",[15194,15195],"Healthy Subject","Pancreatic Carcinoma",[15184],{"nctId":15198,"briefTitle":15199,"status":160,"phases":15200,"primaryCompletion":15201,"completion":15202,"start":15203,"enrollment":2393,"conditions":15204,"interventions":15207},"NCT03183570","Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET\u002FCT",[88],"2023-04-25","2025-01-25","2017-11-08",[15205,5020,15206],"Idiopathic Pulmonary Fibrosis","Covid19 Pneumonia",[15184],{"trials":15209,"activeCount":101},[],{"trials":15211,"activeCount":101},[],{"trials":15213,"activeCount":101},[],{"trials":15215,"activeCount":101},[],{"trials":15217,"activeCount":101},[],{"intervention":15219,"totalTrials":115,"cells":15220},"vismodegib",{"EARLY_PHASE1":15221,"PHASE1":15231,"PHASE2":15233,"PHASE3":15235,"PHASE4":15237,"NA":15239},{"trials":15222,"activeCount":101},[15223],{"nctId":15224,"briefTitle":15225,"status":160,"phases":15226,"primaryCompletion":15227,"completion":15228,"start":8630,"enrollment":2218,"conditions":15229,"interventions":15230},"NCT01631331","Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)",[88],"2015-09-17","2016-05-31",[9711,1847],[15219],{"trials":15232,"activeCount":101},[],{"trials":15234,"activeCount":101},[],{"trials":15236,"activeCount":101},[],{"trials":15238,"activeCount":101},[],{"trials":15240,"activeCount":101},[],{"intervention":15242,"totalTrials":115,"cells":15243},"Calcium DTPA and Zinc DTPA",{"EARLY_PHASE1":15244,"PHASE1":15256,"PHASE2":15258,"PHASE3":15260,"PHASE4":15262,"NA":15264},{"trials":15245,"activeCount":101},[15246],{"nctId":15247,"briefTitle":15248,"status":132,"phases":15249,"primaryCompletion":15250,"completion":15251,"start":15252,"enrollment":101,"conditions":15253,"interventions":15255},"NCT05359835","DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure",[88],"2024-09-12","2024-09-13","2023-04-11",[15254],"Gadolinium Deposition Disease",[15242],{"trials":15257,"activeCount":101},[],{"trials":15259,"activeCount":101},[],{"trials":15261,"activeCount":101},[],{"trials":15263,"activeCount":101},[],{"trials":15265,"activeCount":101},[],{"intervention":15267,"totalTrials":115,"cells":15268},"Melatonin 5 mg",{"EARLY_PHASE1":15269,"PHASE1":15280,"PHASE2":15282,"PHASE3":15284,"PHASE4":15286,"NA":15288},{"trials":15270,"activeCount":101},[15271],{"nctId":15272,"briefTitle":15273,"status":132,"phases":15274,"primaryCompletion":379,"completion":379,"start":15275,"enrollment":101,"conditions":15276,"interventions":15278},"NCT03879707","Improving Sleep Quality After Total Joint Arthroplasty ( TJA)",[88],"2025-06",[15277],"Pain After TJA",[15267,15279],"Magnesium 500Mg Oral",{"trials":15281,"activeCount":101},[],{"trials":15283,"activeCount":101},[],{"trials":15285,"activeCount":101},[],{"trials":15287,"activeCount":101},[],{"trials":15289,"activeCount":101},[],{"intervention":15279,"totalTrials":115,"cells":15291},{"EARLY_PHASE1":15292,"PHASE1":15298,"PHASE2":15300,"PHASE3":15302,"PHASE4":15304,"NA":15306},{"trials":15293,"activeCount":101},[15294],{"nctId":15272,"briefTitle":15273,"status":132,"phases":15295,"primaryCompletion":379,"completion":379,"start":15275,"enrollment":101,"conditions":15296,"interventions":15297},[88],[15277],[15267,15279],{"trials":15299,"activeCount":101},[],{"trials":15301,"activeCount":101},[],{"trials":15303,"activeCount":101},[],{"trials":15305,"activeCount":101},[],{"trials":15307,"activeCount":101},[],{"intervention":15309,"totalTrials":115,"cells":15310},"F18-FPPRGD2",{"EARLY_PHASE1":15311,"PHASE1":15321,"PHASE2":15323,"PHASE3":15325,"PHASE4":15327,"NA":15329},{"trials":15312,"activeCount":101},[15313],{"nctId":15314,"briefTitle":15315,"status":160,"phases":15316,"primaryCompletion":1471,"completion":834,"start":14515,"enrollment":791,"conditions":15317,"interventions":15320},"NCT01383135","Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2",[88],[15,15318,3366,15319],"Non-Small-Cell Lung Cancer","Other Cancers",[15309],{"trials":15322,"activeCount":101},[],{"trials":15324,"activeCount":101},[],{"trials":15326,"activeCount":101},[],{"trials":15328,"activeCount":101},[],{"trials":15330,"activeCount":101},[],{"intervention":15332,"totalTrials":115,"cells":15333},"Topamax",{"EARLY_PHASE1":15334,"PHASE1":15344,"PHASE2":15346,"PHASE3":15348,"PHASE4":15350,"NA":15352},{"trials":15335,"activeCount":101},[15336],{"nctId":15337,"briefTitle":15338,"status":132,"phases":15339,"primaryCompletion":4296,"completion":15340,"start":9952,"enrollment":101,"conditions":15341,"interventions":15343},"NCT04613024","Beneficial Side Effects of Topiramate in Obese Patients Undergoing Total Joint Arthroplasty",[88],"2027-07-01",[15342,354],"Weight Loss",[15332,818],{"trials":15345,"activeCount":101},[],{"trials":15347,"activeCount":101},[],{"trials":15349,"activeCount":101},[],{"trials":15351,"activeCount":101},[],{"trials":15353,"activeCount":101},[],{"intervention":15355,"totalTrials":115,"cells":15356},"Sitagliptin",{"EARLY_PHASE1":15357,"PHASE1":15367,"PHASE2":15369,"PHASE3":15371,"PHASE4":15373,"NA":15375},{"trials":15358,"activeCount":101},[15359],{"nctId":15360,"briefTitle":15361,"status":160,"phases":15362,"primaryCompletion":905,"completion":4051,"start":15363,"enrollment":737,"conditions":15364,"interventions":15366},"NCT00657280","Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure",[88],"2008-04",[15365],"Heart Failure, Congestive",[15355],{"trials":15368,"activeCount":101},[],{"trials":15370,"activeCount":101},[],{"trials":15372,"activeCount":101},[],{"trials":15374,"activeCount":101},[],{"trials":15376,"activeCount":101},[],{"intervention":15137,"totalTrials":115,"cells":15378},{"EARLY_PHASE1":15379,"PHASE1":15385,"PHASE2":15387,"PHASE3":15389,"PHASE4":15391,"NA":15393},{"trials":15380,"activeCount":101},[15381],{"nctId":15131,"briefTitle":15132,"status":132,"phases":15382,"primaryCompletion":7821,"completion":7821,"start":3944,"enrollment":101,"conditions":15383,"interventions":15384},[88],[21],[15136,15137],{"trials":15386,"activeCount":101},[],{"trials":15388,"activeCount":101},[],{"trials":15390,"activeCount":101},[],{"trials":15392,"activeCount":101},[],{"trials":15394,"activeCount":101},[],{"intervention":15396,"totalTrials":115,"cells":15397},"3% Sodium Chloride",{"EARLY_PHASE1":15398,"PHASE1":15412,"PHASE2":15414,"PHASE3":15416,"PHASE4":15418,"NA":15420},{"trials":15399,"activeCount":101},[15400],{"nctId":15401,"briefTitle":15402,"status":132,"phases":15403,"primaryCompletion":15404,"completion":15404,"start":15405,"enrollment":101,"conditions":15406,"interventions":15409},"NCT03330704","Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation",[88],"2020-01-01","2017-11-28",[15407,15408],"Cerebral Edema","Saline Solution, Hypertonic",[15396,15410,15411],"23.4% Sodium Chloride","8.4% Sodium Bicarbonate",{"trials":15413,"activeCount":101},[],{"trials":15415,"activeCount":101},[],{"trials":15417,"activeCount":101},[],{"trials":15419,"activeCount":101},[],{"trials":15421,"activeCount":101},[],{"intervention":15410,"totalTrials":115,"cells":15423},{"EARLY_PHASE1":15424,"PHASE1":15430,"PHASE2":15432,"PHASE3":15434,"PHASE4":15436,"NA":15438},{"trials":15425,"activeCount":101},[15426],{"nctId":15401,"briefTitle":15402,"status":132,"phases":15427,"primaryCompletion":15404,"completion":15404,"start":15405,"enrollment":101,"conditions":15428,"interventions":15429},[88],[15407,15408],[15396,15410,15411],{"trials":15431,"activeCount":101},[],{"trials":15433,"activeCount":101},[],{"trials":15435,"activeCount":101},[],{"trials":15437,"activeCount":101},[],{"trials":15439,"activeCount":101},[],{"intervention":15411,"totalTrials":115,"cells":15441},{"EARLY_PHASE1":15442,"PHASE1":15448,"PHASE2":15450,"PHASE3":15452,"PHASE4":15454,"NA":15456},{"trials":15443,"activeCount":101},[15444],{"nctId":15401,"briefTitle":15402,"status":132,"phases":15445,"primaryCompletion":15404,"completion":15404,"start":15405,"enrollment":101,"conditions":15446,"interventions":15447},[88],[15407,15408],[15396,15410,15411],{"trials":15449,"activeCount":101},[],{"trials":15451,"activeCount":101},[],{"trials":15453,"activeCount":101},[],{"trials":15455,"activeCount":101},[],{"trials":15457,"activeCount":101},[],{"intervention":15459,"totalTrials":115,"cells":15460},"18F-Florbetaben (Neuraceq®) PET\u002FMRI",{"EARLY_PHASE1":15461,"PHASE1":15473,"PHASE2":15475,"PHASE3":15477,"PHASE4":15479,"NA":15481},{"trials":15462,"activeCount":101},[15463],{"nctId":15464,"briefTitle":15465,"status":160,"phases":15466,"primaryCompletion":15467,"completion":15468,"start":15469,"enrollment":759,"conditions":15470,"interventions":15472},"NCT03119558","PET\u002FMRI Evaluation of Cardiac Amyloid",[88],"2018-08-23","2018-08-28","2016-05-26",[15471],"Cardiac Amyloidosis",[15459],{"trials":15474,"activeCount":101},[],{"trials":15476,"activeCount":101},[],{"trials":15478,"activeCount":101},[],{"trials":15480,"activeCount":101},[],{"trials":15482,"activeCount":101},[],{"intervention":9539,"totalTrials":115,"cells":15484},{"EARLY_PHASE1":15485,"PHASE1":15491,"PHASE2":15493,"PHASE3":15495,"PHASE4":15497,"NA":15499},{"trials":15486,"activeCount":101},[15487],{"nctId":9529,"briefTitle":9530,"status":716,"phases":15488,"primaryCompletion":9532,"completion":9532,"start":9533,"enrollment":191,"conditions":15489,"interventions":15490},[88],[9535,9536],[9538,9539],{"trials":15492,"activeCount":101},[],{"trials":15494,"activeCount":101},[],{"trials":15496,"activeCount":101},[],{"trials":15498,"activeCount":101},[],{"trials":15500,"activeCount":101},[],{"intervention":15502,"totalTrials":115,"cells":15503},"Ulipristal Acetate",{"EARLY_PHASE1":15504,"PHASE1":15515,"PHASE2":15517,"PHASE3":15519,"PHASE4":15521,"NA":15523},{"trials":15505,"activeCount":101},[15506],{"nctId":15507,"briefTitle":15508,"status":160,"phases":15509,"primaryCompletion":15510,"completion":15510,"start":15511,"enrollment":191,"conditions":15512,"interventions":15514},"NCT03802149","Ulipristal Acetate for Cervical Preparation",[88],"2020-04-02","2019-04-16",[15513],"Termination of Pregnancy",[15502],{"trials":15516,"activeCount":101},[],{"trials":15518,"activeCount":101},[],{"trials":15520,"activeCount":101},[],{"trials":15522,"activeCount":101},[],{"trials":15524,"activeCount":101},[],{"intervention":15526,"totalTrials":115,"cells":15527},"Ertugliflozin",{"EARLY_PHASE1":15528,"PHASE1":15538,"PHASE2":15540,"PHASE3":15542,"PHASE4":15544,"NA":15546},{"trials":15529,"activeCount":101},[15530],{"nctId":15531,"briefTitle":15532,"status":160,"phases":15533,"primaryCompletion":5871,"completion":5871,"start":7498,"enrollment":1598,"conditions":15534,"interventions":15537},"NCT04167761","Ertugliflozin: Cardioprotective Effects on Epicardial Fat",[88],[15535,15536,401,36],"Cardiovascular Diseases","Atherosclerosis",[15526],{"trials":15539,"activeCount":101},[],{"trials":15541,"activeCount":101},[],{"trials":15543,"activeCount":101},[],{"trials":15545,"activeCount":101},[],{"trials":15547,"activeCount":101},[],{"intervention":15549,"totalTrials":115,"cells":15550},"Calcium alpha-ketoglutarate",{"EARLY_PHASE1":15551,"PHASE1":15562,"PHASE2":15564,"PHASE3":15566,"PHASE4":15568,"NA":15570},{"trials":15552,"activeCount":101},[15553],{"nctId":15554,"briefTitle":15555,"status":160,"phases":15556,"primaryCompletion":15557,"completion":15557,"start":15558,"enrollment":1766,"conditions":15559,"interventions":15561},"NCT07269704","Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease",[88],"2025-06-10","2023-08-15",[15560],"Eye Diseases",[15549],{"trials":15563,"activeCount":101},[],{"trials":15565,"activeCount":101},[],{"trials":15567,"activeCount":101},[],{"trials":15569,"activeCount":101},[],{"trials":15571,"activeCount":101},[],{"intervention":15573,"totalTrials":115,"cells":15574},"Alda-341",{"EARLY_PHASE1":15575,"PHASE1":15587,"PHASE2":15589,"PHASE3":15591,"PHASE4":15593,"NA":15595},{"trials":15576,"activeCount":101},[15577],{"nctId":15578,"briefTitle":15579,"status":160,"phases":15580,"primaryCompletion":15581,"completion":15582,"start":3766,"enrollment":247,"conditions":15583,"interventions":15586},"NCT04296266","Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery",[88],"2017-12-18","2017-12-21",[15584,15585],"Submandibular Gland Tumor","Parotid Gland Tumor",[15573],{"trials":15588,"activeCount":101},[],{"trials":15590,"activeCount":101},[],{"trials":15592,"activeCount":101},[],{"trials":15594,"activeCount":101},[],{"trials":15596,"activeCount":101},[],{"intervention":15598,"totalTrials":115,"cells":15599},"Platelet-Rich Plasma",{"EARLY_PHASE1":15600,"PHASE1":15610,"PHASE2":15612,"PHASE3":15614,"PHASE4":15616,"NA":15618},{"trials":15601,"activeCount":101},[15602],{"nctId":15603,"briefTitle":15604,"status":132,"phases":15605,"primaryCompletion":15404,"completion":15606,"start":12304,"enrollment":101,"conditions":15607,"interventions":15609},"NCT03774251","A Randomized Controlled Trial of Ultrasound-guided Platelet-Rich-Plasma (PRP) Injection Versus Extracorporeal Shock Wave Therapy (ESWT) for Great Trochanter Pain Syndrome (GTPS) With Gluteus Medius or Minimus Tendinopathy",[88],"2021-01-01",[15608],"Greater Trochanter Pain Syndrome, Gluteus Medius Tendinopathy, Gluteus Minimus Tendinopathy",[15598],{"trials":15611,"activeCount":101},[],{"trials":15613,"activeCount":101},[],{"trials":15615,"activeCount":101},[],{"trials":15617,"activeCount":101},[],{"trials":15619,"activeCount":101},[],{"intervention":7957,"totalTrials":115,"cells":15621},{"EARLY_PHASE1":15622,"PHASE1":15628,"PHASE2":15630,"PHASE3":15632,"PHASE4":15634,"NA":15636},{"trials":15623,"activeCount":101},[15624],{"nctId":7946,"briefTitle":7947,"status":160,"phases":15625,"primaryCompletion":7949,"completion":7949,"start":7950,"enrollment":7951,"conditions":15626,"interventions":15627},[88],[5179,7953,7954,7955],[7957,7941],{"trials":15629,"activeCount":101},[],{"trials":15631,"activeCount":101},[],{"trials":15633,"activeCount":101},[],{"trials":15635,"activeCount":101},[],{"trials":15637,"activeCount":101},[],{"intervention":15639,"totalTrials":115,"cells":15640},"18F-FDG",{"EARLY_PHASE1":15641,"PHASE1":15649,"PHASE2":15651,"PHASE3":15653,"PHASE4":15655,"NA":15657},{"trials":15642,"activeCount":101},[15643],{"nctId":15644,"briefTitle":15645,"status":132,"phases":15646,"primaryCompletion":434,"completion":434,"start":147,"enrollment":101,"conditions":15647,"interventions":15648},"NCT04016818","Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution",[88],[15],[15639],{"trials":15650,"activeCount":101},[],{"trials":15652,"activeCount":101},[],{"trials":15654,"activeCount":101},[],{"trials":15656,"activeCount":101},[],{"trials":15658,"activeCount":101},[],{"intervention":15660,"totalTrials":115,"cells":15661},"herbal topical cream",{"EARLY_PHASE1":15662,"PHASE1":15670,"PHASE2":15672,"PHASE3":15674,"PHASE4":15676,"NA":15678},{"trials":15663,"activeCount":101},[15664],{"nctId":15665,"briefTitle":15666,"status":160,"phases":15667,"primaryCompletion":220,"completion":11713,"start":8371,"enrollment":1977,"conditions":15668,"interventions":15669},"NCT00800098","Effects of an Herbal Topical Cream on Osteoarthritis Symptoms, Biomarkers, and Disease Progression in the Knee",[88],[779],[15660],{"trials":15671,"activeCount":101},[],{"trials":15673,"activeCount":101},[],{"trials":15675,"activeCount":101},[],{"trials":15677,"activeCount":101},[],{"trials":15679,"activeCount":101},[],{"intervention":15681,"totalTrials":684,"cells":15682},"Mifepristone",{"EARLY_PHASE1":15683,"PHASE1":15685,"PHASE2":15687,"PHASE3":15689,"PHASE4":15719,"NA":15721},{"trials":15684,"activeCount":101},[],{"trials":15686,"activeCount":101},[],{"trials":15688,"activeCount":101},[],{"trials":15690,"activeCount":101},[15691,15701,15711],{"nctId":15692,"briefTitle":15693,"status":716,"phases":15694,"primaryCompletion":758,"completion":758,"start":15695,"enrollment":1314,"conditions":15696,"interventions":15700},"NCT00725270","Treatment of Schizoaffective Disorder Using Mifepristone",[90,91],"1998-04",[15697,15698,15699],"Psychotic Disorders","Depressive Disorder, Major","Depressive Disorder",[15681],{"nctId":15702,"briefTitle":15703,"status":160,"phases":15704,"primaryCompletion":15705,"completion":15705,"start":15706,"enrollment":232,"conditions":15707,"interventions":15709},"NCT05097326","Mifepristone for Labor Induction",[91],"2023-04-29","2022-06-27",[15708],"Induced Vaginal Delivery",[15681,15710],"Misoprostol",{"nctId":15712,"briefTitle":15713,"status":716,"phases":15714,"primaryCompletion":758,"completion":758,"start":15715,"enrollment":247,"conditions":15716,"interventions":15718},"NCT00867360","Treatment of Psychotic Major Depression With Mifepristone",[91],"2005-08",[15717,15699],"Affective Disorders, Psychotic",[15681],{"trials":15720,"activeCount":101},[],{"trials":15722,"activeCount":101},[15723,15731,15738,15745,15751],{"nctId":15724,"briefTitle":15725,"status":160,"phases":15726,"primaryCompletion":5647,"completion":6351,"start":1498,"enrollment":1435,"conditions":15727,"interventions":15729},"NCT01615731","Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks",[93],[15728],"Abortion, Induced",[15681,15710,15730],"Intra-amniotic digoxin",{"nctId":15732,"briefTitle":15733,"status":160,"phases":15734,"primaryCompletion":13141,"completion":13141,"start":15735,"enrollment":31,"conditions":15736,"interventions":15737},"NCT00186056","Mifepristone in Refractory Depression",[93],"2003-01",[21],[15681],{"nctId":15739,"briefTitle":15740,"status":132,"phases":15741,"primaryCompletion":7046,"completion":3944,"start":10704,"enrollment":101,"conditions":15742,"interventions":15744},"NCT02679092","Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks",[93],[15743],"Legally Induced Abortion Without Mention of Complication",[15710,15681],{"nctId":15746,"briefTitle":15747,"status":160,"phases":15748,"primaryCompletion":3348,"completion":1544,"start":15735,"enrollment":3997,"conditions":15749,"interventions":15750},"NCT00285818","Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT",[93],[21],[15681],{"nctId":15752,"briefTitle":15753,"status":160,"phases":15754,"primaryCompletion":148,"completion":148,"start":6351,"enrollment":2145,"conditions":15755,"interventions":15756},"NCT01862991","Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services",[93],[15743],[15710,15730,15681],{"intervention":1504,"totalTrials":684,"cells":15758},{"EARLY_PHASE1":15759,"PHASE1":15761,"PHASE2":15767,"PHASE3":15789,"PHASE4":15791,"NA":15793},{"trials":15760,"activeCount":101},[],{"trials":15762,"activeCount":101},[15763],{"nctId":13525,"briefTitle":13526,"status":132,"phases":15764,"primaryCompletion":13528,"completion":13529,"start":13530,"enrollment":101,"conditions":15765,"interventions":15766},[89],[3388,13532],[13534,13535,1504],{"trials":15768,"activeCount":101},[15769,15773,15777,15781,15785],{"nctId":9240,"briefTitle":9241,"status":160,"phases":15770,"completion":1731,"start":9243,"conditions":15771,"interventions":15772},[90],[1426],[9246,9247,9248,2019,9249,9250,9251,9252],{"nctId":4006,"briefTitle":4007,"status":160,"phases":15774,"primaryCompletion":696,"completion":1563,"start":4009,"enrollment":699,"conditions":15775,"interventions":15776},[90],[1502],[1533,1504],{"nctId":9258,"briefTitle":9259,"status":160,"phases":15778,"primaryCompletion":1423,"completion":1777,"start":9261,"enrollment":1435,"conditions":15779,"interventions":15780},[90],[1426],[9264,9247,2048,727,9265,1504,1725,2050],{"nctId":1739,"briefTitle":1740,"status":716,"phases":15782,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":165,"conditions":15783,"interventions":15784},[90],[1734],[1722,1725,730,727,1747,1748,1678,1737,1504],{"nctId":3527,"briefTitle":3528,"status":160,"phases":15786,"primaryCompletion":3530,"completion":3531,"start":3532,"enrollment":3533,"conditions":15787,"interventions":15788},[90],[3535,1426,1734,3536],[1747,730,1722,1504,1748,727],{"trials":15790,"activeCount":101},[],{"trials":15792,"activeCount":101},[],{"trials":15794,"activeCount":101},[15795,15808],{"nctId":15796,"briefTitle":15797,"status":160,"phases":15798,"primaryCompletion":15799,"completion":15799,"start":9065,"enrollment":15800,"conditions":15801,"interventions":15806},"NCT02748070","Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP)",[93],"2019-07-15",81,[15802,15803,15804,15805],"Chronic Rhinosinusitis","Endoscopic Sinus Surgery","Chronic Rhinosinusitis Without Polyps","Oral Steroids",[1504,15807],"Flonase",{"nctId":1495,"briefTitle":1496,"status":160,"phases":15809,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":860,"conditions":15810,"interventions":15811},[93],[1502],[704,1504,1505,1506],{"intervention":1760,"totalTrials":197,"cells":15813},{"EARLY_PHASE1":15814,"PHASE1":15816,"PHASE2":15818,"PHASE3":15841,"PHASE4":15843,"NA":15858},{"trials":15815,"activeCount":101},[],{"trials":15817,"activeCount":101},[],{"trials":15819,"activeCount":101},[15820,15824,15828,15832],{"nctId":1826,"briefTitle":1827,"status":160,"phases":15821,"primaryCompletion":1829,"completion":1829,"start":1472,"enrollment":222,"conditions":15822,"interventions":15823},[90],[1831,1832,1833,1834],[1836,1837,1838],{"nctId":11709,"briefTitle":11710,"status":716,"phases":15825,"primaryCompletion":2102,"completion":11712,"start":11713,"enrollment":836,"conditions":15826,"interventions":15827},[90],[11715,11716],[1760,11700],{"nctId":1750,"briefTitle":1751,"status":160,"phases":15829,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":15830,"interventions":15831},[90],[1757,1758],[1760,1678,1699],{"nctId":15833,"briefTitle":15834,"status":160,"phases":15835,"completion":15836,"start":15837,"conditions":15838,"interventions":15840},"NCT00022048","Bevacizumab in Treating Patients With Myelodysplastic Syndrome",[89,90],"2004-11","2001-08",[740,1524,15839],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[1836],{"trials":15842,"activeCount":101},[],{"trials":15844,"activeCount":101},[15845],{"nctId":15846,"briefTitle":15847,"status":160,"phases":15848,"primaryCompletion":15849,"completion":15849,"start":15850,"enrollment":179,"conditions":15851,"interventions":15857},"NCT02389959","Intranasal Bevacizumab for HHT-Related Epistaxis",[92],"2020-01-23","2014-08-04",[15852,15853,15854,15855,15856],"HHT","Hereditary Hemorrhagic Telangiectasia","Epistaxis","Nose Bleeds","Nasal Bleeding",[1760],{"trials":15859,"activeCount":101},[15860],{"nctId":15861,"briefTitle":15862,"status":160,"phases":15863,"primaryCompletion":219,"completion":835,"start":9799,"enrollment":97,"conditions":15864,"interventions":15867},"NCT00661154","Avastin\u002F[18-F]-5-fluorouracil PET\u002FCT Imaging Feasibility Project",[],[14651,15865,10016,15866],"Colon Cancer","Anal Cancer",[1760],{"intervention":5736,"totalTrials":821,"cells":15869},{"EARLY_PHASE1":15870,"PHASE1":15872,"PHASE2":15874,"PHASE3":15894,"PHASE4":15900,"NA":15902},{"trials":15871,"activeCount":101},[],{"trials":15873,"activeCount":101},[],{"trials":15875,"activeCount":101},[15876,15888],{"nctId":15877,"briefTitle":15878,"status":160,"phases":15879,"primaryCompletion":15880,"completion":15881,"start":15882,"enrollment":15883,"conditions":15884,"interventions":15887},"NCT01965704","Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women",[90],"2020-09-03","2020-09-16","2014-09-09",196,[15885,15886],"Narcotic Addiction","Neonatal Abstinence Syndrome",[5736],{"nctId":15889,"briefTitle":15890,"status":160,"phases":15891,"primaryCompletion":5646,"completion":5646,"start":5801,"enrollment":208,"conditions":15892,"interventions":15893},"NCT01801475","How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women",[89,90],[7319],[5736],{"trials":15895,"activeCount":101},[15896],{"nctId":5725,"briefTitle":5726,"status":160,"phases":15897,"primaryCompletion":5728,"completion":5729,"start":813,"enrollment":149,"conditions":15898,"interventions":15899},[91],[5731],[5714,5733,5734,5735,5736],{"trials":15901,"activeCount":101},[],{"trials":15903,"activeCount":101},[15904,15911],{"nctId":15905,"briefTitle":15906,"status":160,"phases":15907,"primaryCompletion":6351,"completion":6351,"start":696,"enrollment":2218,"conditions":15908,"interventions":15910},"NCT01006707","Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers",[93],[15909],"Substance-Related Disorders",[5736],{"nctId":15912,"briefTitle":15913,"status":160,"phases":15914,"primaryCompletion":8251,"completion":6243,"start":10432,"enrollment":15915,"conditions":15916,"interventions":15919},"NCT01549652","5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence",[93],133,[15917,15918],"Opioid Withdrawal","Physical Dependence",[5736,819,15920,15921],"Naloxone 0.4 mg\u002F70 kg","Naloxone 0.8 mg\u002F70 kg",{"intervention":1568,"totalTrials":821,"cells":15923},{"EARLY_PHASE1":15924,"PHASE1":15926,"PHASE2":15932,"PHASE3":15949,"PHASE4":15951,"NA":15953},{"trials":15925,"activeCount":101},[],{"trials":15927,"activeCount":101},[15928],{"nctId":1994,"briefTitle":1995,"status":716,"phases":15929,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":1766,"conditions":15930,"interventions":15931},[89],[2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015],[2017,2018,2019,2020],{"trials":15933,"activeCount":101},[15934,15938,15945],{"nctId":10186,"briefTitle":10187,"status":160,"phases":15935,"primaryCompletion":9189,"completion":8630,"start":1544,"enrollment":165,"conditions":15936,"interventions":15937},[89,90],[3708,10190],[1568,10177],{"nctId":15939,"briefTitle":15940,"status":716,"phases":15941,"primaryCompletion":7655,"completion":1498,"start":231,"enrollment":821,"conditions":15942,"interventions":15944},"NCT01401322","Single Agent Lenalidomide in Adult Patients With Relapsed\u002FRefractory Acute Lymphoblastic Leukemia",[90],[740,15943],"Relapsed Adult Acute Lymphocytic Leukemia",[1568],{"nctId":10193,"briefTitle":10194,"status":716,"phases":15946,"primaryCompletion":9836,"completion":1843,"start":3503,"enrollment":28,"conditions":15947,"interventions":15948},[90],[740,3708,10197],[10177,1568],{"trials":15950,"activeCount":101},[],{"trials":15952,"activeCount":101},[],{"trials":15954,"activeCount":101},[15955],{"nctId":1560,"briefTitle":1561,"status":160,"phases":15956,"primaryCompletion":1563,"completion":1564,"start":1544,"enrollment":613,"conditions":15957,"interventions":15958},[93],[740,1566],[1568,766,1569],{"intervention":712,"totalTrials":821,"cells":15960},{"EARLY_PHASE1":15961,"PHASE1":15963,"PHASE2":15965,"PHASE3":15983,"PHASE4":15985,"NA":15987},{"trials":15962,"activeCount":101},[],{"trials":15964,"activeCount":101},[],{"trials":15966,"activeCount":101},[15967,15971,15975,15979],{"nctId":693,"briefTitle":694,"status":160,"phases":15968,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":15969,"interventions":15970},[90],[701,702],[704,705,706,707,708,709,710,683,711,712],{"nctId":714,"briefTitle":715,"status":716,"phases":15972,"primaryCompletion":718,"completion":718,"start":719,"enrollment":334,"conditions":15973,"interventions":15974},[90],[721,722,723,724],[704,726,727,708,728,706,729,730,683,711,712,731],{"nctId":733,"briefTitle":734,"status":160,"phases":15976,"primaryCompletion":697,"completion":697,"start":736,"enrollment":737,"conditions":15977,"interventions":15978},[90],[739,740,741,742,743,744,745,746],[748,706,749,750,710,683,751,712],{"nctId":753,"briefTitle":754,"status":160,"phases":15980,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":15981,"interventions":15982},[90],[761,762,763,764],[708,730,766,706,767,768,710,711,683,712],{"trials":15984,"activeCount":101},[],{"trials":15986,"activeCount":101},[],{"trials":15988,"activeCount":101},[15989],{"nctId":15990,"briefTitle":15991,"status":160,"phases":15992,"primaryCompletion":12003,"completion":12003,"start":15993,"enrollment":836,"conditions":15994,"interventions":15995},"NCT00186264","Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?",[93],"2002-08",[15698],[15996,15997],"venlafaxine XR","hydrocortisone",{"intervention":15710,"totalTrials":1810,"cells":15999},{"EARLY_PHASE1":16000,"PHASE1":16002,"PHASE2":16004,"PHASE3":16006,"PHASE4":16012,"NA":16014},{"trials":16001,"activeCount":101},[],{"trials":16003,"activeCount":101},[],{"trials":16005,"activeCount":101},[],{"trials":16007,"activeCount":101},[16008],{"nctId":15702,"briefTitle":15703,"status":160,"phases":16009,"primaryCompletion":15705,"completion":15705,"start":15706,"enrollment":232,"conditions":16010,"interventions":16011},[91],[15708],[15681,15710],{"trials":16013,"activeCount":101},[],{"trials":16015,"activeCount":101},[16016,16020,16024],{"nctId":15724,"briefTitle":15725,"status":160,"phases":16017,"primaryCompletion":5647,"completion":6351,"start":1498,"enrollment":1435,"conditions":16018,"interventions":16019},[93],[15728],[15681,15710,15730],{"nctId":15739,"briefTitle":15740,"status":132,"phases":16021,"primaryCompletion":7046,"completion":3944,"start":10704,"enrollment":101,"conditions":16022,"interventions":16023},[93],[15743],[15710,15681],{"nctId":15752,"briefTitle":15753,"status":160,"phases":16025,"primaryCompletion":148,"completion":148,"start":6351,"enrollment":2145,"conditions":16026,"interventions":16027},[93],[15743],[15710,15730,15681],{"intervention":16029,"totalTrials":1810,"cells":16030},"duloxetine",{"EARLY_PHASE1":16031,"PHASE1":16033,"PHASE2":16035,"PHASE3":16037,"PHASE4":16039,"NA":16051},{"trials":16032,"activeCount":101},[],{"trials":16034,"activeCount":101},[],{"trials":16036,"activeCount":101},[],{"trials":16038,"activeCount":101},[],{"trials":16040,"activeCount":101},[16041,16045],{"nctId":7095,"briefTitle":7096,"status":160,"phases":16042,"primaryCompletion":7098,"completion":7099,"start":7100,"enrollment":5557,"conditions":16043,"interventions":16044},[92],[33],[7103,7082],{"nctId":16046,"briefTitle":16047,"status":716,"phases":16048,"primaryCompletion":1544,"completion":1544,"start":7914,"enrollment":197,"conditions":16049,"interventions":16050},"NCT00398632","Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction",[92],[21],[7103],{"trials":16052,"activeCount":101},[16053,16060],{"nctId":16054,"briefTitle":16055,"status":160,"phases":16056,"primaryCompletion":12003,"completion":12003,"start":16057,"enrollment":897,"conditions":16058,"interventions":16059},"NCT00185575","Duloxetine for the Treatment of Dysthymia",[93],"2004-09",[15699],[16029],{"nctId":16061,"briefTitle":16062,"status":160,"phases":16063,"primaryCompletion":5542,"completion":5542,"start":1743,"enrollment":1449,"conditions":16064,"interventions":16066},"NCT00388414","Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication",[93],[16065],"Low Back Pain",[16029],{"intervention":5765,"totalTrials":1810,"cells":16068},{"EARLY_PHASE1":16069,"PHASE1":16071,"PHASE2":16079,"PHASE3":16085,"PHASE4":16087,"NA":16093},{"trials":16070,"activeCount":101},[],{"trials":16072,"activeCount":101},[16073],{"nctId":16074,"briefTitle":16075,"status":160,"phases":16076,"primaryCompletion":219,"completion":219,"start":1861,"enrollment":247,"conditions":16077,"interventions":16078},"NCT00220584","An Open-Label Trial of Donepezil in Fragile X Syndrome",[89],[5763],[5765],{"trials":16080,"activeCount":101},[16081],{"nctId":5759,"briefTitle":5760,"status":160,"phases":16082,"primaryCompletion":834,"completion":834,"start":220,"enrollment":165,"conditions":16083,"interventions":16084},[90],[5763],[5765,5750],{"trials":16086,"activeCount":101},[],{"trials":16088,"activeCount":101},[16089],{"nctId":1629,"briefTitle":1630,"status":160,"phases":16090,"primaryCompletion":1632,"completion":1632,"start":1633,"enrollment":1634,"conditions":16091,"interventions":16092},[92],[1636],[1638,1606],{"trials":16094,"activeCount":101},[16095],{"nctId":16096,"briefTitle":1630,"status":160,"phases":16097,"primaryCompletion":7904,"completion":12735,"start":3912,"enrollment":436,"conditions":16098,"interventions":16100},"NCT00043589",[93],[16099],"Memory Disorders",[5765],{"intervention":818,"totalTrials":1810,"cells":16102},{"EARLY_PHASE1":16103,"PHASE1":16109,"PHASE2":16111,"PHASE3":16113,"PHASE4":16123,"NA":16136},{"trials":16104,"activeCount":101},[16105],{"nctId":15337,"briefTitle":15338,"status":132,"phases":16106,"primaryCompletion":4296,"completion":15340,"start":9952,"enrollment":101,"conditions":16107,"interventions":16108},[88],[15342,354],[15332,818],{"trials":16110,"activeCount":101},[],{"trials":16112,"activeCount":101},[],{"trials":16114,"activeCount":101},[16115],{"nctId":16116,"briefTitle":16117,"status":716,"phases":16118,"primaryCompletion":6055,"completion":6055,"start":718,"enrollment":16119,"conditions":16120,"interventions":16121},"NCT01067144","Stanford Accelerated Recovery Trial (START)",[91],422,[24,15,1757],[818,16122],"Lorazepam",{"trials":16124,"activeCount":101},[16125],{"nctId":16126,"briefTitle":16127,"status":160,"phases":16128,"primaryCompletion":16129,"completion":16130,"start":16131,"enrollment":7270,"conditions":16132,"interventions":16135},"NCT03472521","Prevention of Persistent Opioid Use in Mothers",[92],"2020-07-02","2021-04-10","2018-09-17",[7504,16133,16134],"Postpartum Disorder","Chronic Pain Syndrome",[818],{"trials":16137,"activeCount":101},[16138],{"nctId":809,"briefTitle":810,"status":160,"phases":16139,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":16140,"interventions":16141},[93],[803],[817,683,818,819,819,819],{"intervention":16143,"totalTrials":1810,"cells":16144},"Magnesium Sulfate",{"EARLY_PHASE1":16145,"PHASE1":16147,"PHASE2":16149,"PHASE3":16155,"PHASE4":16157,"NA":16159},{"trials":16146,"activeCount":101},[],{"trials":16148,"activeCount":101},[],{"trials":16150,"activeCount":101},[16151],{"nctId":292,"briefTitle":293,"status":160,"phases":16152,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":16153,"interventions":16154},[90],[299],[301,141],{"trials":16156,"activeCount":101},[],{"trials":16158,"activeCount":101},[],{"trials":16160,"activeCount":101},[16161,16168,16175],{"nctId":16162,"briefTitle":16163,"status":160,"phases":16164,"primaryCompletion":1861,"completion":4993,"start":16165,"enrollment":15127,"conditions":16166,"interventions":16167},"NCT00185900","Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial",[93],"1999-04",[10682],[16143,10684],{"nctId":16169,"briefTitle":16170,"status":160,"phases":16171,"primaryCompletion":858,"completion":2101,"start":7631,"enrollment":232,"conditions":16172,"interventions":16174},"NCT00186069","Magnesium Sulfate vs Placebo for Placental Abruption",[93],[16173],"Abruptio Placentae",[16143],{"nctId":16176,"briefTitle":16177,"status":160,"phases":16178,"primaryCompletion":1499,"completion":1499,"start":11589,"enrollment":16179,"conditions":16180,"interventions":16182},"NCT01709630","PK\u002FPD Modeling of Magnesium in the Mother and Neonate",[],151,[16181],"Magnesium Sulfate Pharmacokinetics and Pharmacodynamics",[301],{"intervention":10684,"totalTrials":334,"cells":16184},{"EARLY_PHASE1":16185,"PHASE1":16187,"PHASE2":16189,"PHASE3":16195,"PHASE4":16197,"NA":16199},{"trials":16186,"activeCount":101},[],{"trials":16188,"activeCount":101},[],{"trials":16190,"activeCount":101},[16191],{"nctId":10677,"briefTitle":10678,"status":160,"phases":16192,"primaryCompletion":10680,"completion":10680,"start":9212,"enrollment":34,"conditions":16193,"interventions":16194},[89,90],[10682],[10668,10684],{"trials":16196,"activeCount":101},[],{"trials":16198,"activeCount":101},[],{"trials":16200,"activeCount":101},[16201,16208],{"nctId":16202,"briefTitle":16203,"status":160,"phases":16204,"primaryCompletion":1423,"completion":6396,"start":16205,"enrollment":907,"conditions":16206,"interventions":16207},"NCT00185952","Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor.",[93],"2001-11",[10682,8591],[10684],{"nctId":16162,"briefTitle":16163,"status":160,"phases":16209,"primaryCompletion":1861,"completion":4993,"start":16165,"enrollment":15127,"conditions":16210,"interventions":16211},[93],[10682],[16143,10684],{"intervention":16213,"totalTrials":334,"cells":16214},"Memantine",{"EARLY_PHASE1":16215,"PHASE1":16217,"PHASE2":16219,"PHASE3":16227,"PHASE4":16235,"NA":16237},{"trials":16216,"activeCount":101},[],{"trials":16218,"activeCount":101},[],{"trials":16220,"activeCount":101},[16221],{"nctId":16222,"briefTitle":16223,"status":160,"phases":16224,"primaryCompletion":9808,"completion":9808,"start":9928,"enrollment":2218,"conditions":16225,"interventions":16226},"NCT00264238","Memantine Augmentation in Obsessive-Compulsive Disorder",[89,90],[126],[16213],{"trials":16228,"activeCount":101},[16229],{"nctId":16230,"briefTitle":16231,"status":160,"phases":16232,"primaryCompletion":9983,"completion":11713,"start":11073,"enrollment":1766,"conditions":16233,"interventions":16234},"NCT00255086","The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients",[91],[2651],[16213],{"trials":16236,"activeCount":101},[],{"trials":16238,"activeCount":101},[16239],{"nctId":16240,"briefTitle":16241,"status":160,"phases":16242,"primaryCompletion":16243,"completion":9799,"start":16244,"enrollment":3997,"conditions":16245,"interventions":16246},"NCT00186498","Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression",[93],"2006-02","2004-02",[15698],[16247],"memantine",{"intervention":817,"totalTrials":334,"cells":16249},{"EARLY_PHASE1":16250,"PHASE1":16252,"PHASE2":16254,"PHASE3":16256,"PHASE4":16275,"NA":16277},{"trials":16251,"activeCount":101},[],{"trials":16253,"activeCount":101},[],{"trials":16255,"activeCount":101},[],{"trials":16257,"activeCount":101},[16258,16266],{"nctId":16259,"briefTitle":16260,"status":160,"phases":16261,"primaryCompletion":3502,"completion":3502,"start":835,"enrollment":16262,"conditions":16263,"interventions":16265},"NCT01171794","Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)",[91],89,[16264],"Altitude Sickness",[817],{"nctId":16267,"briefTitle":16268,"status":160,"phases":16269,"primaryCompletion":2102,"completion":16270,"start":875,"enrollment":5854,"conditions":16271,"interventions":16274},"NCT02272725","Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances",[91],"2017-01",[2419,16272,16273],"Exercise-associated Hyponatremia","Perceived Exertion",[817],{"trials":16276,"activeCount":101},[],{"trials":16278,"activeCount":101},[16279],{"nctId":809,"briefTitle":810,"status":160,"phases":16280,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":16281,"interventions":16282},[93],[803],[817,683,818,819,819,819],{"intervention":12785,"totalTrials":334,"cells":16284},{"EARLY_PHASE1":16285,"PHASE1":16287,"PHASE2":16289,"PHASE3":16299,"PHASE4":16301,"NA":16303},{"trials":16286,"activeCount":101},[],{"trials":16288,"activeCount":101},[],{"trials":16290,"activeCount":101},[16291,16295],{"nctId":12778,"briefTitle":12779,"status":160,"phases":16292,"primaryCompletion":12781,"completion":12781,"start":1690,"enrollment":12782,"conditions":16293,"interventions":16294},[90],[15],[12785,12786,12769],{"nctId":13435,"briefTitle":13436,"status":716,"phases":16296,"primaryCompletion":13438,"completion":13438,"start":1357,"enrollment":197,"conditions":16297,"interventions":16298},[90],[13062],[13426,12785],{"trials":16300,"activeCount":101},[],{"trials":16302,"activeCount":101},[],{"trials":16304,"activeCount":101},[16305],{"nctId":16306,"briefTitle":16307,"status":716,"phases":16308,"primaryCompletion":16309,"completion":16309,"start":9983,"enrollment":334,"conditions":16310,"interventions":16312},"NCT01034670","Advanced Gastrointestinal Endoscopic Imaging",[93],"2017-09-25",[16311,1832,1834],"Gastrointestinal Diseases",[16313,16314,16315],"fluorescent Peptide","fluorescein","indocyanine green",{"intervention":819,"totalTrials":334,"cells":16317},{"EARLY_PHASE1":16318,"PHASE1":16320,"PHASE2":16322,"PHASE3":16328,"PHASE4":16330,"NA":16332},{"trials":16319,"activeCount":101},[],{"trials":16321,"activeCount":101},[],{"trials":16323,"activeCount":101},[16324],{"nctId":11189,"briefTitle":11190,"status":160,"phases":16325,"primaryCompletion":8630,"completion":8630,"start":5938,"enrollment":11192,"conditions":16326,"interventions":16327},[89,90],[24],[11180,819],{"trials":16329,"activeCount":101},[],{"trials":16331,"activeCount":101},[],{"trials":16333,"activeCount":101},[16334,16338],{"nctId":15912,"briefTitle":15913,"status":160,"phases":16335,"primaryCompletion":8251,"completion":6243,"start":10432,"enrollment":15915,"conditions":16336,"interventions":16337},[93],[15917,15918],[5736,819,15920,15921],{"nctId":809,"briefTitle":810,"status":160,"phases":16339,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":16340,"interventions":16341},[93],[803],[817,683,818,819,819,819],{"intervention":16343,"totalTrials":334,"cells":16344},"Vitamin D",{"EARLY_PHASE1":16345,"PHASE1":16347,"PHASE2":16356,"PHASE3":16364,"PHASE4":16366,"NA":16368},{"trials":16346,"activeCount":101},[],{"trials":16348,"activeCount":101},[16349],{"nctId":16350,"briefTitle":16351,"status":160,"phases":16352,"primaryCompletion":16353,"completion":16353,"start":9004,"enrollment":1755,"conditions":16354,"interventions":16355},"NCT04828031","Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease",[89],"2023-07-01",[5021,8786,1451],[16343],{"trials":16357,"activeCount":101},[16358],{"nctId":16359,"briefTitle":16360,"status":160,"phases":16361,"primaryCompletion":3502,"completion":1800,"start":15363,"enrollment":3933,"conditions":16362,"interventions":16363},"NCT00656019","Development of Vitamin D as a Therapy for Breast Cancer - Phase 2",[90],[15],[16343],{"trials":16365,"activeCount":101},[],{"trials":16367,"activeCount":101},[],{"trials":16369,"activeCount":101},[16370],{"nctId":16371,"briefTitle":16372,"status":132,"phases":16373,"primaryCompletion":15066,"completion":15066,"start":10912,"enrollment":101,"conditions":16374,"interventions":16375},"NCT00482157","Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance",[93],[10434,3388],[16343],{"intervention":1569,"totalTrials":334,"cells":16377},{"EARLY_PHASE1":16378,"PHASE1":16380,"PHASE2":16382,"PHASE3":16388,"PHASE4":16390,"NA":16396},{"trials":16379,"activeCount":101},[],{"trials":16381,"activeCount":101},[],{"trials":16383,"activeCount":101},[16384],{"nctId":2036,"briefTitle":2037,"status":160,"phases":16385,"primaryCompletion":2039,"completion":2040,"start":1844,"enrollment":836,"conditions":16386,"interventions":16387},[90],[2042,2043,2044,2045],[2047,2048,2049,2050,1569,1987,1724],{"trials":16389,"activeCount":101},[],{"trials":16391,"activeCount":101},[16392],{"nctId":7713,"briefTitle":7714,"status":716,"phases":16393,"primaryCompletion":7716,"completion":7716,"start":5422,"enrollment":7717,"conditions":16394,"interventions":16395},[92],[779,7719,7720],[7700,1569],{"trials":16397,"activeCount":101},[16398],{"nctId":1560,"briefTitle":1561,"status":160,"phases":16399,"primaryCompletion":1563,"completion":1564,"start":1544,"enrollment":613,"conditions":16400,"interventions":16401},[93],[740,1566],[1568,766,1569],{"intervention":3318,"totalTrials":334,"cells":16403},{"EARLY_PHASE1":16404,"PHASE1":16406,"PHASE2":16408,"PHASE3":16410,"PHASE4":16412,"NA":16422},{"trials":16405,"activeCount":101},[],{"trials":16407,"activeCount":101},[],{"trials":16409,"activeCount":101},[],{"trials":16411,"activeCount":101},[],{"trials":16413,"activeCount":101},[16414,16418],{"nctId":3310,"briefTitle":3311,"status":716,"phases":16415,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":115,"conditions":16416,"interventions":16417},[92],[3316],[2563,3318],{"nctId":3320,"briefTitle":3321,"status":132,"phases":16419,"primaryCompletion":3323,"completion":3324,"start":3325,"enrollment":101,"conditions":16420,"interventions":16421},[92],[3327,3328,3329],[3318,2563],{"trials":16423,"activeCount":101},[16424],{"nctId":16425,"briefTitle":16426,"status":160,"phases":16427,"primaryCompletion":833,"completion":833,"start":5647,"enrollment":1406,"conditions":16428,"interventions":16430},"NCT02015195","Effective Treatments for Jellyfish Stings",[93],[16429],"Jellyfish Stings",[3318],{"intervention":16432,"totalTrials":334,"cells":16433},"Rosiglitazone",{"EARLY_PHASE1":16434,"PHASE1":16436,"PHASE2":16438,"PHASE3":16440,"PHASE4":16442,"NA":16444},{"trials":16435,"activeCount":101},[],{"trials":16437,"activeCount":101},[],{"trials":16439,"activeCount":101},[],{"trials":16441,"activeCount":101},[],{"trials":16443,"activeCount":101},[],{"trials":16445,"activeCount":101},[16446,16455,16462],{"nctId":16447,"briefTitle":16448,"status":160,"phases":16449,"primaryCompletion":844,"completion":844,"start":16450,"enrollment":11192,"conditions":16451,"interventions":16453},"NCT00186537","Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.",[93],"2003-09",[36,16452],"Hypertriglyceridemia",[16432,16454],"Fenofibrate",{"nctId":16456,"briefTitle":16457,"status":160,"phases":16458,"primaryCompletion":5656,"completion":5656,"start":4993,"enrollment":1314,"conditions":16459,"interventions":16460},"NCT00242619","Insulin Resistance in Patients With Mood Disorder",[93],[21,1601,36],[16461],"rosiglitazone",{"nctId":16463,"briefTitle":16464,"status":716,"phases":16465,"primaryCompletion":1742,"completion":1742,"start":1863,"enrollment":165,"conditions":16466,"interventions":16467},"NCT00225225","Rosiglitazone-Induced Weight Gain",[93],[399],[16432],{"intervention":15730,"totalTrials":152,"cells":16469},{"EARLY_PHASE1":16470,"PHASE1":16472,"PHASE2":16474,"PHASE3":16476,"PHASE4":16478,"NA":16480},{"trials":16471,"activeCount":101},[],{"trials":16473,"activeCount":101},[],{"trials":16475,"activeCount":101},[],{"trials":16477,"activeCount":101},[],{"trials":16479,"activeCount":101},[],{"trials":16481,"activeCount":101},[16482,16486],{"nctId":15724,"briefTitle":15725,"status":160,"phases":16483,"primaryCompletion":5647,"completion":6351,"start":1498,"enrollment":1435,"conditions":16484,"interventions":16485},[93],[15728],[15681,15710,15730],{"nctId":15752,"briefTitle":15753,"status":160,"phases":16487,"primaryCompletion":148,"completion":148,"start":6351,"enrollment":2145,"conditions":16488,"interventions":16489},[93],[15743],[15710,15730,15681],{"intervention":16491,"totalTrials":152,"cells":16492},"Apremilast",{"EARLY_PHASE1":16493,"PHASE1":16495,"PHASE2":16497,"PHASE3":16506,"PHASE4":16508,"NA":16510},{"trials":16494,"activeCount":101},[],{"trials":16496,"activeCount":101},[],{"trials":16498,"activeCount":101},[16499],{"nctId":16500,"briefTitle":16501,"status":132,"phases":16502,"primaryCompletion":3503,"completion":1800,"start":876,"enrollment":101,"conditions":16503,"interventions":16505},"NCT01204138","Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA",[90],[16504],"Arthritis, Rheumatoid",[16491],{"trials":16507,"activeCount":101},[],{"trials":16509,"activeCount":101},[],{"trials":16511,"activeCount":101},[16512],{"nctId":16513,"briefTitle":16514,"status":716,"phases":16515,"primaryCompletion":3503,"completion":5793,"start":11713,"enrollment":821,"conditions":16516,"interventions":16517},"NCT01140503","A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis",[93],[4701],[16491],{"intervention":16519,"totalTrials":152,"cells":16520},"gentamicin",{"EARLY_PHASE1":16521,"PHASE1":16523,"PHASE2":16525,"PHASE3":16527,"PHASE4":16529,"NA":16531},{"trials":16522,"activeCount":101},[],{"trials":16524,"activeCount":101},[],{"trials":16526,"activeCount":101},[],{"trials":16528,"activeCount":101},[],{"trials":16530,"activeCount":101},[],{"trials":16532,"activeCount":101},[16533,16540],{"nctId":16534,"briefTitle":16535,"status":160,"phases":16536,"primaryCompletion":719,"completion":11713,"start":2207,"enrollment":16537,"conditions":16538,"interventions":16539},"NCT00185991","Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis",[93],126,[8632],[16519],{"nctId":16541,"briefTitle":16542,"status":160,"phases":16543,"primaryCompletion":16270,"completion":16270,"start":6610,"enrollment":165,"conditions":16544,"interventions":16546},"NCT02427932","Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients",[],[16545],"Drug Metabolism During Pregnancy",[16547,16548,16549],"Ampicillin","Ampicillin and Gentamicin","Gentamicin",{"intervention":16551,"totalTrials":152,"cells":16552},"Iodine-124",{"EARLY_PHASE1":16553,"PHASE1":16563,"PHASE2":16565,"PHASE3":16567,"PHASE4":16569,"NA":16571},{"trials":16554,"activeCount":101},[16555],{"nctId":16556,"briefTitle":16557,"status":716,"phases":16558,"primaryCompletion":5535,"completion":5535,"start":9799,"enrollment":97,"conditions":16559,"interventions":16562},"NCT00725946","Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET\u002FCT",[88],[15,16560,16561],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","Breast Cancer Metastatic Breast Cancer",[16551],{"trials":16564,"activeCount":101},[],{"trials":16566,"activeCount":101},[],{"trials":16568,"activeCount":101},[],{"trials":16570,"activeCount":101},[],{"trials":16572,"activeCount":101},[16573],{"nctId":16574,"briefTitle":16575,"status":132,"phases":16576,"start":13141,"enrollment":101,"conditions":16577,"interventions":16578},"NCT00373711","Comparison of I-124 PET\u002FCT, F-18 FDG PET\u002FCT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA",[],[1350],[16551,16579,11104],"Iodine-123",{"intervention":11104,"totalTrials":152,"cells":16581},{"EARLY_PHASE1":16582,"PHASE1":16584,"PHASE2":16586,"PHASE3":16592,"PHASE4":16594,"NA":16596},{"trials":16583,"activeCount":101},[],{"trials":16585,"activeCount":101},[],{"trials":16587,"activeCount":101},[16588],{"nctId":11094,"briefTitle":11095,"status":160,"phases":16589,"primaryCompletion":11097,"completion":9564,"start":11098,"enrollment":22,"conditions":16590,"interventions":16591},[90],[11100,11101,11102],[11104,11085],{"trials":16593,"activeCount":101},[],{"trials":16595,"activeCount":101},[],{"trials":16597,"activeCount":101},[16598],{"nctId":16574,"briefTitle":16575,"status":132,"phases":16599,"start":13141,"enrollment":101,"conditions":16600,"interventions":16601},[],[1350],[16551,16579,11104],{"intervention":16603,"totalTrials":152,"cells":16604},"Iohexol",{"EARLY_PHASE1":16605,"PHASE1":16607,"PHASE2":16609,"PHASE3":16611,"PHASE4":16613,"NA":16615},{"trials":16606,"activeCount":101},[],{"trials":16608,"activeCount":101},[],{"trials":16610,"activeCount":101},[],{"trials":16612,"activeCount":101},[],{"trials":16614,"activeCount":101},[],{"trials":16616,"activeCount":101},[16617,16628],{"nctId":16618,"briefTitle":16619,"status":716,"phases":16620,"primaryCompletion":16621,"completion":16621,"start":3502,"enrollment":1314,"conditions":16622,"interventions":16626},"NCT01188486","Pulmonary Interstitial Lymphography in Early Stage Lung Cancer",[93],"2017-04-30",[1757,16623,16624,16625],"Lung Cancer Non-Small Cell Cancer (NSCLC)","Lung Cancer Small Cell Lung Cancer (SCLC)","Mesothelioma",[16603,16627],"Iodixanol",{"nctId":16629,"briefTitle":16630,"status":716,"phases":16631,"primaryCompletion":8630,"completion":8630,"start":5938,"enrollment":197,"conditions":16632,"interventions":16633},"NCT01326364","Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection",[],[1781],[16627,16603],{"intervention":16627,"totalTrials":152,"cells":16635},{"EARLY_PHASE1":16636,"PHASE1":16638,"PHASE2":16640,"PHASE3":16642,"PHASE4":16644,"NA":16646},{"trials":16637,"activeCount":101},[],{"trials":16639,"activeCount":101},[],{"trials":16641,"activeCount":101},[],{"trials":16643,"activeCount":101},[],{"trials":16645,"activeCount":101},[],{"trials":16647,"activeCount":101},[16648,16652],{"nctId":16618,"briefTitle":16619,"status":716,"phases":16649,"primaryCompletion":16621,"completion":16621,"start":3502,"enrollment":1314,"conditions":16650,"interventions":16651},[93],[1757,16623,16624,16625],[16603,16627],{"nctId":16629,"briefTitle":16630,"status":716,"phases":16653,"primaryCompletion":8630,"completion":8630,"start":5938,"enrollment":197,"conditions":16654,"interventions":16655},[],[1781],[16627,16603],{"intervention":16657,"totalTrials":152,"cells":16658},"Intravitreal Injection of Aflibercept",{"EARLY_PHASE1":16659,"PHASE1":16661,"PHASE2":16663,"PHASE3":16665,"PHASE4":16667,"NA":16669},{"trials":16660,"activeCount":101},[],{"trials":16662,"activeCount":101},[],{"trials":16664,"activeCount":101},[],{"trials":16666,"activeCount":101},[],{"trials":16668,"activeCount":101},[],{"trials":16670,"activeCount":101},[16671,16677],{"nctId":16672,"briefTitle":16673,"status":160,"phases":16674,"primaryCompletion":6464,"completion":6464,"start":6013,"enrollment":1449,"conditions":16675,"interventions":16676},"NCT02000102","Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and\u002For Ranibizumab",[],[12606],[16657],{"nctId":16678,"briefTitle":16679,"status":160,"phases":16680,"primaryCompletion":874,"completion":874,"start":7655,"enrollment":8252,"conditions":16681,"interventions":16683},"NCT01526070","Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration",[],[16682],"Exudative Age-related Macular Degeneration",[16684],"Intravitreal injection of Aflibercept",{"intervention":16122,"totalTrials":152,"cells":16686},{"EARLY_PHASE1":16687,"PHASE1":16689,"PHASE2":16691,"PHASE3":16693,"PHASE4":16699,"NA":16701},{"trials":16688,"activeCount":101},[],{"trials":16690,"activeCount":101},[],{"trials":16692,"activeCount":101},[],{"trials":16694,"activeCount":101},[16695],{"nctId":16116,"briefTitle":16117,"status":716,"phases":16696,"primaryCompletion":6055,"completion":6055,"start":718,"enrollment":16119,"conditions":16697,"interventions":16698},[91],[24,15,1757],[818,16122],{"trials":16700,"activeCount":101},[],{"trials":16702,"activeCount":101},[16703],{"nctId":16704,"briefTitle":16705,"status":160,"phases":16706,"completion":15836,"start":8447,"enrollment":19,"conditions":16707,"interventions":16709},"NCT00523185","A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal",[93],[16708],"Alcohol Withdrawal",[16122,16710],"Diazepam",{"intervention":16712,"totalTrials":152,"cells":16713},"Aminophylline",{"EARLY_PHASE1":16714,"PHASE1":16716,"PHASE2":16718,"PHASE3":16720,"PHASE4":16722,"NA":16724},{"trials":16715,"activeCount":101},[],{"trials":16717,"activeCount":101},[],{"trials":16719,"activeCount":101},[],{"trials":16721,"activeCount":101},[],{"trials":16723,"activeCount":101},[],{"trials":16725,"activeCount":101},[16726,16732],{"nctId":16727,"briefTitle":16728,"status":160,"phases":16729,"primaryCompletion":1843,"completion":1843,"start":696,"enrollment":918,"conditions":16730,"interventions":16731},"NCT01245595","Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery",[93],[2419],[16712],{"nctId":16733,"briefTitle":16734,"status":160,"phases":16735,"primaryCompletion":16736,"completion":16737,"start":5608,"enrollment":1435,"conditions":16738,"interventions":16740},"NCT01759862","Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant",[93],"2017-01-05","2017-07-25",[16739],"Function of Renal Transplant",[16712],{"intervention":16742,"totalTrials":152,"cells":16743},"Citalopram",{"EARLY_PHASE1":16744,"PHASE1":16746,"PHASE2":16748,"PHASE3":16757,"PHASE4":16759,"NA":16761},{"trials":16745,"activeCount":101},[],{"trials":16747,"activeCount":101},[],{"trials":16749,"activeCount":101},[16750],{"nctId":16751,"briefTitle":16752,"status":160,"phases":16753,"primaryCompletion":9983,"completion":9983,"start":775,"enrollment":3106,"conditions":16754,"interventions":16756},"NCT00477165","Citalopram in Irritable Bowel Syndrome",[90],[16755],"Irritable Bowel Syndrome",[16742],{"trials":16758,"activeCount":101},[],{"trials":16760,"activeCount":101},[],{"trials":16762,"activeCount":101},[16763],{"nctId":16764,"briefTitle":16765,"status":716,"phases":16766,"primaryCompletion":1753,"completion":858,"start":1472,"enrollment":31,"conditions":16767,"interventions":16769},"NCT00896441","Functional MRI Before and After Treatment for Depression",[93],[21,16768,15699],"Mood Disorders",[16742],{"intervention":16771,"totalTrials":152,"cells":16772},"Etanercept",{"EARLY_PHASE1":16773,"PHASE1":16775,"PHASE2":16777,"PHASE3":16786,"PHASE4":16788,"NA":16790},{"trials":16774,"activeCount":101},[],{"trials":16776,"activeCount":101},[],{"trials":16778,"activeCount":101},[16779],{"nctId":16780,"briefTitle":16781,"status":716,"phases":16782,"primaryCompletion":10911,"completion":10911,"start":1500,"enrollment":791,"conditions":16783,"interventions":16785},"NCT00285779","Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus",[90],[16784],"Lichen Planus",[16771],{"trials":16787,"activeCount":101},[],{"trials":16789,"activeCount":101},[],{"trials":16791,"activeCount":101},[16792],{"nctId":16793,"briefTitle":16794,"status":132,"phases":16795,"primaryCompletion":6243,"completion":6243,"start":858,"enrollment":101,"conditions":16796,"interventions":16799},"NCT02031211","TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial",[93],[16797,16798],"CRPS","Chronic Regional Pain Syndrome",[16771],{"intervention":16801,"totalTrials":152,"cells":16802},"Oxytocin",{"EARLY_PHASE1":16803,"PHASE1":16805,"PHASE2":16807,"PHASE3":16809,"PHASE4":16817,"NA":16819},{"trials":16804,"activeCount":101},[],{"trials":16806,"activeCount":101},[],{"trials":16808,"activeCount":101},[],{"trials":16810,"activeCount":101},[16811],{"nctId":16812,"briefTitle":16813,"status":160,"phases":16814,"primaryCompletion":1597,"completion":1597,"start":833,"enrollment":7229,"conditions":16815,"interventions":16816},"NCT01932060","Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.",[91],[5179],[16801],{"trials":16818,"activeCount":101},[],{"trials":16820,"activeCount":101},[16821],{"nctId":16822,"briefTitle":16823,"status":160,"phases":16824,"primaryCompletion":6055,"completion":6055,"start":2173,"enrollment":1672,"conditions":16825,"interventions":16826},"NCT03140709","Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids",[],[16801,5177],[16801],{"intervention":16828,"totalTrials":152,"cells":16829},"Pramipexole",{"EARLY_PHASE1":16830,"PHASE1":16832,"PHASE2":16834,"PHASE3":16836,"PHASE4":16838,"NA":16846},{"trials":16831,"activeCount":101},[],{"trials":16833,"activeCount":101},[],{"trials":16835,"activeCount":101},[],{"trials":16837,"activeCount":101},[],{"trials":16839,"activeCount":101},[16840],{"nctId":16841,"briefTitle":16842,"status":716,"phases":16843,"primaryCompletion":1920,"completion":1920,"start":11713,"enrollment":737,"conditions":16844,"interventions":16845},"NCT01066897","Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole",[92],[21],[16828],{"trials":16847,"activeCount":101},[16848],{"nctId":16849,"briefTitle":16850,"status":160,"phases":16851,"primaryCompletion":13296,"completion":16852,"start":16853,"enrollment":16854,"conditions":16855,"interventions":16856},"NCT02220309","Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)",[],"2025-04-02","2013-08-11",167,[30,21],[16857],"Pramipexole Oral",{"intervention":16859,"totalTrials":152,"cells":16860},"zoledronic acid",{"EARLY_PHASE1":16861,"PHASE1":16863,"PHASE2":16865,"PHASE3":16874,"PHASE4":16876,"NA":16878},{"trials":16862,"activeCount":101},[],{"trials":16864,"activeCount":101},[],{"trials":16866,"activeCount":101},[16867],{"nctId":16868,"briefTitle":16869,"status":716,"phases":16870,"primaryCompletion":15066,"completion":1472,"start":3807,"enrollment":12782,"conditions":16871,"interventions":16873},"NCT00226954","Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer",[90],[16872],"Urologic Neoplasms",[16859],{"trials":16875,"activeCount":101},[],{"trials":16877,"activeCount":101},[],{"trials":16879,"activeCount":101},[16880],{"nctId":16881,"briefTitle":16882,"status":132,"phases":16883,"primaryCompletion":13703,"completion":16884,"start":1597,"enrollment":101,"conditions":16885,"interventions":16888},"NCT02451462","Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients",[93],"2018-09",[16886,16887],"Hematopoietic Stem Cell Transplant","Bone Marrow Transplant",[16889],"Zoledronic acid",{"intervention":16891,"totalTrials":152,"cells":16892},"Low Dose Naltrexone",{"EARLY_PHASE1":16893,"PHASE1":16895,"PHASE2":16897,"PHASE3":16899,"PHASE4":16901,"NA":16903},{"trials":16894,"activeCount":101},[],{"trials":16896,"activeCount":101},[],{"trials":16898,"activeCount":101},[],{"trials":16900,"activeCount":101},[],{"trials":16902,"activeCount":101},[],{"trials":16904,"activeCount":101},[16905,16912],{"nctId":16906,"briefTitle":16907,"status":132,"phases":16908,"primaryCompletion":1800,"completion":1800,"start":3502,"enrollment":101,"conditions":16909,"interventions":16911},"NCT00855972","Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome",[93],[16910],"Fibromyalgia",[16891],{"nctId":16913,"briefTitle":16914,"status":160,"phases":16915,"primaryCompletion":5542,"completion":5542,"start":1480,"enrollment":22,"conditions":16916,"interventions":16918},"NCT00568555","Effects of Low Dose Naltrexone in Fibromyalgia",[93],[16910,16917],"Persian Gulf Syndrome",[16891],{"intervention":12452,"totalTrials":152,"cells":16920},{"EARLY_PHASE1":16921,"PHASE1":16923,"PHASE2":16925,"PHASE3":16931,"PHASE4":16933,"NA":16935},{"trials":16922,"activeCount":101},[],{"trials":16924,"activeCount":101},[],{"trials":16926,"activeCount":101},[16927],{"nctId":12446,"briefTitle":12447,"status":160,"phases":16928,"primaryCompletion":7019,"completion":9189,"start":1472,"enrollment":247,"conditions":16929,"interventions":16930},[90],[12450],[12437,12452],{"trials":16932,"activeCount":101},[],{"trials":16934,"activeCount":101},[],{"trials":16936,"activeCount":101},[16937],{"nctId":16938,"briefTitle":16939,"status":160,"phases":16940,"primaryCompletion":3502,"completion":3502,"start":9799,"enrollment":3431,"conditions":16941,"interventions":16943},"NCT00672737","Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea",[],[16942],"Sleep Apnea, Obstructive",[12452],{"intervention":16945,"totalTrials":152,"cells":16946},"Ketoprofen",{"EARLY_PHASE1":16947,"PHASE1":16949,"PHASE2":16951,"PHASE3":16953,"PHASE4":16955,"NA":16964},{"trials":16948,"activeCount":101},[],{"trials":16950,"activeCount":101},[],{"trials":16952,"activeCount":101},[],{"trials":16954,"activeCount":101},[],{"trials":16956,"activeCount":101},[16957],{"nctId":16958,"briefTitle":16959,"status":160,"phases":16960,"primaryCompletion":6798,"completion":7167,"start":1809,"enrollment":16961,"conditions":16962,"interventions":16963},"NCT02257970","Lymphedema Study for Arm or Leg Lymphedema",[92],117,[10540],[16945],{"trials":16965,"activeCount":101},[16966],{"nctId":16967,"briefTitle":16968,"status":716,"phases":16969,"primaryCompletion":16970,"completion":16971,"start":16972,"enrollment":152,"conditions":16973,"interventions":16974},"NCT03783715","Characterization of Treatment Responses in Lymphedema",[],"2023-03-31","2023-08-31","2019-06-21",[10540],[16945],{"intervention":16976,"totalTrials":152,"cells":16977},"Valsartan",{"EARLY_PHASE1":16978,"PHASE1":16980,"PHASE2":16982,"PHASE3":16984,"PHASE4":16986,"NA":16995},{"trials":16979,"activeCount":101},[],{"trials":16981,"activeCount":101},[],{"trials":16983,"activeCount":101},[],{"trials":16985,"activeCount":101},[],{"trials":16987,"activeCount":101},[16988],{"nctId":16989,"briefTitle":16990,"status":132,"phases":16991,"primaryCompletion":1472,"completion":1472,"start":1801,"enrollment":101,"conditions":16992,"interventions":16994},"NCT01400256","Blood Pressure Lowering in Acute Stroke Trial",[92],[16993],"Stroke, Acute",[16976],{"trials":16996,"activeCount":101},[16997],{"nctId":16998,"briefTitle":16999,"status":132,"phases":17000,"start":1801,"enrollment":101,"conditions":17001,"interventions":17003},"NCT00627991","Blood Pressure Lowering in Acute Stroke Trial (BLAST)",[93],[17002],"Cerebrovascular Accident",[16976],{"intervention":12786,"totalTrials":152,"cells":17005},{"EARLY_PHASE1":17006,"PHASE1":17008,"PHASE2":17010,"PHASE3":17016,"PHASE4":17018,"NA":17020},{"trials":17007,"activeCount":101},[],{"trials":17009,"activeCount":101},[],{"trials":17011,"activeCount":101},[17012],{"nctId":12778,"briefTitle":12779,"status":160,"phases":17013,"primaryCompletion":12781,"completion":12781,"start":1690,"enrollment":12782,"conditions":17014,"interventions":17015},[90],[15],[12785,12786,12769],{"trials":17017,"activeCount":101},[],{"trials":17019,"activeCount":101},[],{"trials":17021,"activeCount":101},[17022],{"nctId":17023,"briefTitle":17024,"status":160,"phases":17025,"primaryCompletion":858,"completion":8251,"start":5647,"enrollment":1435,"conditions":17026,"interventions":17027},"NCT01898403","Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma",[93],[1946],[17028,12786],"Indocyanine green solution",{"intervention":17030,"totalTrials":152,"cells":17031},"Feraheme",{"EARLY_PHASE1":17032,"PHASE1":17034,"PHASE2":17036,"PHASE3":17038,"PHASE4":17040,"NA":17042},{"trials":17033,"activeCount":101},[],{"trials":17035,"activeCount":101},[],{"trials":17037,"activeCount":101},[],{"trials":17039,"activeCount":101},[],{"trials":17041,"activeCount":101},[],{"trials":17043,"activeCount":101},[17044,17053],{"nctId":17045,"briefTitle":17046,"status":160,"phases":17047,"primaryCompletion":17048,"completion":17048,"start":17049,"enrollment":2393,"conditions":17050,"interventions":17052},"NCT02006108","Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance",[93],"2017-04-11","2012-11-27",[17051],"Renal Transplant Rejection",[17030],{"nctId":17054,"briefTitle":17055,"status":132,"phases":17056,"primaryCompletion":16884,"completion":16884,"start":756,"enrollment":101,"conditions":17057,"interventions":17058},"NCT01973517","High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases",[],[4157],[17030,17059],"Gadolinium-based contrast",{"intervention":17061,"totalTrials":115,"cells":17062},"ALDH2 Genotyping",{"EARLY_PHASE1":17063,"PHASE1":17065,"PHASE2":17067,"PHASE3":17069,"PHASE4":17071,"NA":17073},{"trials":17064,"activeCount":101},[],{"trials":17066,"activeCount":101},[],{"trials":17068,"activeCount":101},[],{"trials":17070,"activeCount":101},[],{"trials":17072,"activeCount":101},[],{"trials":17074,"activeCount":101},[17075],{"nctId":17076,"briefTitle":17077,"status":160,"phases":17078,"primaryCompletion":17079,"completion":17079,"start":17079,"enrollment":907,"conditions":17080,"interventions":17082},"NCT06397716","Public Health Initiative on Alcohol Flushing",[93],"2024-04-25",[17081],"Alcohol Toxicity",[17061],{"intervention":17084,"totalTrials":115,"cells":17085},"Namenda",{"EARLY_PHASE1":17086,"PHASE1":17088,"PHASE2":17090,"PHASE3":17092,"PHASE4":17094,"NA":17096},{"trials":17087,"activeCount":101},[],{"trials":17089,"activeCount":101},[],{"trials":17091,"activeCount":101},[],{"trials":17093,"activeCount":101},[],{"trials":17095,"activeCount":101},[],{"trials":17097,"activeCount":101},[17098],{"nctId":17099,"briefTitle":17100,"status":160,"phases":17101,"primaryCompletion":5656,"completion":5656,"start":2207,"enrollment":1977,"conditions":17102,"interventions":17103},"NCT00242632","Treatment With Namenda in Women at Risk for Cognitive Decline",[93],[8088],[17084],{"intervention":16579,"totalTrials":115,"cells":17105},{"EARLY_PHASE1":17106,"PHASE1":17108,"PHASE2":17110,"PHASE3":17112,"PHASE4":17114,"NA":17116},{"trials":17107,"activeCount":101},[],{"trials":17109,"activeCount":101},[],{"trials":17111,"activeCount":101},[],{"trials":17113,"activeCount":101},[],{"trials":17115,"activeCount":101},[],{"trials":17117,"activeCount":101},[17118],{"nctId":16574,"briefTitle":16575,"status":132,"phases":17119,"start":13141,"enrollment":101,"conditions":17120,"interventions":17121},[],[1350],[16551,16579,11104],{"intervention":17123,"totalTrials":115,"cells":17124},"Typhoid Conjugate Vaccine",{"EARLY_PHASE1":17125,"PHASE1":17127,"PHASE2":17129,"PHASE3":17131,"PHASE4":17133,"NA":17135},{"trials":17126,"activeCount":101},[],{"trials":17128,"activeCount":101},[],{"trials":17130,"activeCount":101},[],{"trials":17132,"activeCount":101},[],{"trials":17134,"activeCount":101},[],{"trials":17136,"activeCount":101},[17137],{"nctId":17138,"briefTitle":17139,"status":160,"phases":17140,"primaryCompletion":6523,"completion":6523,"start":17141,"enrollment":17142,"conditions":17143,"interventions":17147},"NCT03554213","Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India",[],"2018-07-02",17292,[17144,17145,17146],"Enteric Fever","Typhoid Fever","Salmonella Typhi Infection",[17123],{"intervention":17149,"totalTrials":115,"cells":17150},"Regular Insulin via Insulin-Glucose Algorithm",{"EARLY_PHASE1":17151,"PHASE1":17153,"PHASE2":17155,"PHASE3":17157,"PHASE4":17159,"NA":17161},{"trials":17152,"activeCount":101},[],{"trials":17154,"activeCount":101},[],{"trials":17156,"activeCount":101},[],{"trials":17158,"activeCount":101},[],{"trials":17160,"activeCount":101},[],{"trials":17162,"activeCount":101},[17163],{"nctId":17164,"briefTitle":17165,"status":160,"phases":17166,"completion":17167,"start":14372,"enrollment":101,"conditions":17168,"interventions":17170},"NCT00240149","Pilot Study to Evaluate a Method of Controlling High Blood Sugar in the Pediatric Intensive Care Unit",[93],"2006-03",[17169],"Hyperglycemia",[17149],{"intervention":17172,"totalTrials":115,"cells":17173},"Celecoxib",{"EARLY_PHASE1":17174,"PHASE1":17176,"PHASE2":17178,"PHASE3":17180,"PHASE4":17182,"NA":17184},{"trials":17175,"activeCount":101},[],{"trials":17177,"activeCount":101},[],{"trials":17179,"activeCount":101},[],{"trials":17181,"activeCount":101},[],{"trials":17183,"activeCount":101},[],{"trials":17185,"activeCount":101},[17186],{"nctId":17187,"briefTitle":17188,"status":716,"phases":17189,"primaryCompletion":7019,"completion":7019,"start":231,"enrollment":115,"conditions":17190,"interventions":17191},"NCT01284504","Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer",[93],[7917,15865],[17172],{"intervention":17193,"totalTrials":115,"cells":17194},"Terbutaline",{"EARLY_PHASE1":17195,"PHASE1":17197,"PHASE2":17199,"PHASE3":17201,"PHASE4":17203,"NA":17205},{"trials":17196,"activeCount":101},[],{"trials":17198,"activeCount":101},[],{"trials":17200,"activeCount":101},[],{"trials":17202,"activeCount":101},[],{"trials":17204,"activeCount":101},[],{"trials":17206,"activeCount":101},[17207],{"nctId":17208,"briefTitle":17209,"status":160,"phases":17210,"primaryCompletion":1862,"completion":7168,"start":14627,"enrollment":6220,"conditions":17211,"interventions":17213},"NCT00185887","Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation",[93],[17212],"Fetal Distress",[17193],{"intervention":17215,"totalTrials":115,"cells":17216},"Dietary Supplement: LifePak Nano",{"EARLY_PHASE1":17217,"PHASE1":17219,"PHASE2":17221,"PHASE3":17223,"PHASE4":17225,"NA":17227},{"trials":17218,"activeCount":101},[],{"trials":17220,"activeCount":101},[],{"trials":17222,"activeCount":101},[],{"trials":17224,"activeCount":101},[],{"trials":17226,"activeCount":101},[],{"trials":17228,"activeCount":101},[17229],{"nctId":17230,"briefTitle":17231,"status":160,"phases":17232,"primaryCompletion":1730,"completion":7655,"start":7168,"enrollment":860,"conditions":17233,"interventions":17235},"NCT00541931","Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women",[93],[17234],"Skin Diseases",[17215],{"intervention":3390,"totalTrials":115,"cells":17237},{"EARLY_PHASE1":17238,"PHASE1":17240,"PHASE2":17242,"PHASE3":17244,"PHASE4":17246,"NA":17248},{"trials":17239,"activeCount":101},[],{"trials":17241,"activeCount":101},[],{"trials":17243,"activeCount":101},[],{"trials":17245,"activeCount":101},[],{"trials":17247,"activeCount":101},[],{"trials":17249,"activeCount":101},[17250],{"nctId":3383,"briefTitle":3384,"status":3385,"phases":17251,"conditions":17252,"interventions":17253},[],[3388],[3390,1772],{"intervention":17255,"totalTrials":115,"cells":17256},"Mini-glucagon",{"EARLY_PHASE1":17257,"PHASE1":17259,"PHASE2":17261,"PHASE3":17263,"PHASE4":17265,"NA":17267},{"trials":17258,"activeCount":101},[],{"trials":17260,"activeCount":101},[],{"trials":17262,"activeCount":101},[],{"trials":17264,"activeCount":101},[],{"trials":17266,"activeCount":101},[],{"trials":17268,"activeCount":101},[17269],{"nctId":17270,"briefTitle":17271,"status":160,"phases":17272,"primaryCompletion":11589,"completion":11589,"start":1498,"enrollment":16,"conditions":17273,"interventions":17274},"NCT01680653","Testing State of the Art Remote Glucose Monitoring at Diabetes Camp",[93],[2104],[17255],{"intervention":17276,"totalTrials":115,"cells":17277},"sapropterin dihydrochloride",{"EARLY_PHASE1":17278,"PHASE1":17280,"PHASE2":17282,"PHASE3":17284,"PHASE4":17286,"NA":17288},{"trials":17279,"activeCount":101},[],{"trials":17281,"activeCount":101},[],{"trials":17283,"activeCount":101},[],{"trials":17285,"activeCount":101},[],{"trials":17287,"activeCount":101},[],{"trials":17289,"activeCount":101},[17290],{"nctId":17291,"briefTitle":17292,"status":160,"phases":17293,"primaryCompletion":5608,"completion":5608,"start":718,"enrollment":759,"conditions":17294,"interventions":17296},"NCT01135186","Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.",[93],[17295],"Gastroparesis",[17276],{"intervention":17298,"totalTrials":115,"cells":17299},"Raltegravir",{"EARLY_PHASE1":17300,"PHASE1":17302,"PHASE2":17304,"PHASE3":17306,"PHASE4":17308,"NA":17310},{"trials":17301,"activeCount":101},[],{"trials":17303,"activeCount":101},[],{"trials":17305,"activeCount":101},[],{"trials":17307,"activeCount":101},[],{"trials":17309,"activeCount":101},[],{"trials":17311,"activeCount":101},[17312],{"nctId":17313,"briefTitle":17314,"status":160,"phases":17315,"primaryCompletion":1809,"completion":697,"start":7168,"enrollment":1449,"conditions":17316,"interventions":17317},"NCT00523237","RAL-eve Study: Raltegravir Substitution Study",[93],[7567],[17298],{"intervention":16313,"totalTrials":115,"cells":17319},{"EARLY_PHASE1":17320,"PHASE1":17322,"PHASE2":17324,"PHASE3":17326,"PHASE4":17328,"NA":17330},{"trials":17321,"activeCount":101},[],{"trials":17323,"activeCount":101},[],{"trials":17325,"activeCount":101},[],{"trials":17327,"activeCount":101},[],{"trials":17329,"activeCount":101},[],{"trials":17331,"activeCount":101},[17332],{"nctId":16306,"briefTitle":16307,"status":716,"phases":17333,"primaryCompletion":16309,"completion":16309,"start":9983,"enrollment":334,"conditions":17334,"interventions":17335},[93],[16311,1832,1834],[16313,16314,16315],{"intervention":16314,"totalTrials":115,"cells":17337},{"EARLY_PHASE1":17338,"PHASE1":17340,"PHASE2":17342,"PHASE3":17344,"PHASE4":17346,"NA":17348},{"trials":17339,"activeCount":101},[],{"trials":17341,"activeCount":101},[],{"trials":17343,"activeCount":101},[],{"trials":17345,"activeCount":101},[],{"trials":17347,"activeCount":101},[],{"trials":17349,"activeCount":101},[17350],{"nctId":16306,"briefTitle":16307,"status":716,"phases":17351,"primaryCompletion":16309,"completion":16309,"start":9983,"enrollment":334,"conditions":17352,"interventions":17353},[93],[16311,1832,1834],[16313,16314,16315],{"intervention":17355,"totalTrials":115,"cells":17356},"ranitidine or famotidine",{"EARLY_PHASE1":17357,"PHASE1":17359,"PHASE2":17361,"PHASE3":17363,"PHASE4":17365,"NA":17367},{"trials":17358,"activeCount":101},[],{"trials":17360,"activeCount":101},[],{"trials":17362,"activeCount":101},[],{"trials":17364,"activeCount":101},[],{"trials":17366,"activeCount":101},[],{"trials":17368,"activeCount":101},[17369],{"nctId":17370,"briefTitle":17371,"status":132,"phases":17372,"primaryCompletion":8086,"completion":8086,"start":3766,"enrollment":101,"conditions":17373,"interventions":17377},"NCT02700087","In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?",[93],[17374,17375,17376],"Laryngomalacia","Acid Reflux","Stridor",[17355],{"intervention":17379,"totalTrials":115,"cells":17380},"Epoetin alfa",{"EARLY_PHASE1":17381,"PHASE1":17383,"PHASE2":17385,"PHASE3":17387,"PHASE4":17389,"NA":17391},{"trials":17382,"activeCount":101},[],{"trials":17384,"activeCount":101},[],{"trials":17386,"activeCount":101},[],{"trials":17388,"activeCount":101},[],{"trials":17390,"activeCount":101},[],{"trials":17392,"activeCount":101},[17393],{"nctId":17394,"briefTitle":17395,"status":132,"phases":17396,"primaryCompletion":905,"completion":905,"start":8371,"enrollment":101,"conditions":17397,"interventions":17399},"NCT00954486","Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia",[93],[17398],"Anemia",[17379],{"intervention":17401,"totalTrials":115,"cells":17402},"ramipril",{"EARLY_PHASE1":17403,"PHASE1":17405,"PHASE2":17407,"PHASE3":17409,"PHASE4":17411,"NA":17413},{"trials":17404,"activeCount":101},[],{"trials":17406,"activeCount":101},[],{"trials":17408,"activeCount":101},[],{"trials":17410,"activeCount":101},[],{"trials":17412,"activeCount":101},[],{"trials":17414,"activeCount":101},[17415],{"nctId":17416,"briefTitle":17417,"status":160,"phases":17418,"primaryCompletion":8251,"completion":8251,"start":9983,"enrollment":6137,"conditions":17419,"interventions":17420},"NCT01078363","Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy",[93],[838],[17401],{"intervention":17422,"totalTrials":115,"cells":17423},"Anakinra",{"EARLY_PHASE1":17424,"PHASE1":17426,"PHASE2":17428,"PHASE3":17430,"PHASE4":17432,"NA":17434},{"trials":17425,"activeCount":101},[],{"trials":17427,"activeCount":101},[],{"trials":17429,"activeCount":101},[],{"trials":17431,"activeCount":101},[],{"trials":17433,"activeCount":101},[],{"trials":17435,"activeCount":101},[17436],{"nctId":17437,"briefTitle":17438,"status":716,"phases":17439,"primaryCompletion":5646,"completion":5647,"start":1976,"enrollment":191,"conditions":17440,"interventions":17441},"NCT01466764","Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain",[93],[24,13842],[17422],{"intervention":17443,"totalTrials":115,"cells":17444},"Perflutren",{"EARLY_PHASE1":17445,"PHASE1":17447,"PHASE2":17449,"PHASE3":17451,"PHASE4":17453,"NA":17455},{"trials":17446,"activeCount":101},[],{"trials":17448,"activeCount":101},[],{"trials":17450,"activeCount":101},[],{"trials":17452,"activeCount":101},[],{"trials":17454,"activeCount":101},[],{"trials":17456,"activeCount":101},[17457],{"nctId":17458,"briefTitle":17459,"status":160,"phases":17460,"primaryCompletion":17461,"completion":17462,"start":17463,"enrollment":7951,"conditions":17464,"interventions":17466},"NCT01631318","Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases",[93],"2020-08-31","2020-09-30","2012-11-01",[17465,15865],"Liver Metastases",[17443],{"intervention":17468,"totalTrials":115,"cells":17469},"Pine Bark Extract",{"EARLY_PHASE1":17470,"PHASE1":17472,"PHASE2":17474,"PHASE3":17476,"PHASE4":17478,"NA":17480},{"trials":17471,"activeCount":101},[],{"trials":17473,"activeCount":101},[],{"trials":17475,"activeCount":101},[],{"trials":17477,"activeCount":101},[],{"trials":17479,"activeCount":101},[],{"trials":17481,"activeCount":101},[17482],{"nctId":17483,"briefTitle":17484,"status":160,"phases":17485,"primaryCompletion":6396,"completion":6396,"start":719,"enrollment":5156,"conditions":17486,"interventions":17488},"NCT00425945","Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study",[93],[17487],"Hypertension",[17468],{"intervention":16710,"totalTrials":115,"cells":17490},{"EARLY_PHASE1":17491,"PHASE1":17493,"PHASE2":17495,"PHASE3":17497,"PHASE4":17499,"NA":17501},{"trials":17492,"activeCount":101},[],{"trials":17494,"activeCount":101},[],{"trials":17496,"activeCount":101},[],{"trials":17498,"activeCount":101},[],{"trials":17500,"activeCount":101},[],{"trials":17502,"activeCount":101},[17503],{"nctId":16704,"briefTitle":16705,"status":160,"phases":17504,"completion":15836,"start":8447,"enrollment":19,"conditions":17505,"interventions":17506},[93],[16708],[16122,16710],{"intervention":17508,"totalTrials":115,"cells":17509},"Botulinum Toxin A",{"EARLY_PHASE1":17510,"PHASE1":17512,"PHASE2":17514,"PHASE3":17516,"PHASE4":17518,"NA":17520},{"trials":17511,"activeCount":101},[],{"trials":17513,"activeCount":101},[],{"trials":17515,"activeCount":101},[],{"trials":17517,"activeCount":101},[],{"trials":17519,"activeCount":101},[],{"trials":17521,"activeCount":101},[17522],{"nctId":17523,"briefTitle":17524,"status":160,"phases":17525,"primaryCompletion":1844,"completion":1844,"start":12735,"enrollment":17526,"conditions":17527,"interventions":17528},"NCT00725322","Subcutaneous Botulinum Toxin for Cutaneous Allodynia",[93],84,[24],[17508],{"intervention":17530,"totalTrials":115,"cells":17531},"Ondansetron and Placebo crossover",{"EARLY_PHASE1":17532,"PHASE1":17534,"PHASE2":17536,"PHASE3":17538,"PHASE4":17540,"NA":17542},{"trials":17533,"activeCount":101},[],{"trials":17535,"activeCount":101},[],{"trials":17537,"activeCount":101},[],{"trials":17539,"activeCount":101},[],{"trials":17541,"activeCount":101},[],{"trials":17543,"activeCount":101},[17544],{"nctId":17545,"briefTitle":17546,"status":160,"phases":17547,"primaryCompletion":219,"completion":219,"start":221,"enrollment":31,"conditions":17548,"interventions":17550},"NCT00695864","Effect of Ondansetron for Withdrawal Symptoms",[93],[17549],"Substance Withdrawal Syndrome",[17530],{"intervention":17552,"totalTrials":115,"cells":17553},"Metronidazole",{"EARLY_PHASE1":17554,"PHASE1":17556,"PHASE2":17558,"PHASE3":17560,"PHASE4":17562,"NA":17564},{"trials":17555,"activeCount":101},[],{"trials":17557,"activeCount":101},[],{"trials":17559,"activeCount":101},[],{"trials":17561,"activeCount":101},[],{"trials":17563,"activeCount":101},[],{"trials":17565,"activeCount":101},[17566],{"nctId":17567,"briefTitle":17568,"status":716,"phases":17569,"primaryCompletion":8630,"completion":8630,"start":905,"enrollment":152,"conditions":17570,"interventions":17573},"NCT01322971","Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population",[93],[17571,5203,17572],"Vaginosis, Bacterial","Miscarriage",[17552],{"intervention":17575,"totalTrials":115,"cells":17576},"Treprostinil",{"EARLY_PHASE1":17577,"PHASE1":17579,"PHASE2":17581,"PHASE3":17583,"PHASE4":17585,"NA":17587},{"trials":17578,"activeCount":101},[],{"trials":17580,"activeCount":101},[],{"trials":17582,"activeCount":101},[],{"trials":17584,"activeCount":101},[],{"trials":17586,"activeCount":101},[],{"trials":17588,"activeCount":101},[17589],{"nctId":17590,"briefTitle":17591,"status":716,"phases":17592,"primaryCompletion":3944,"completion":3944,"start":1597,"enrollment":7951,"conditions":17593,"interventions":17595},"NCT02498444","Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation",[93],[17594],"Single Ventricle",[17575],{"intervention":17597,"totalTrials":115,"cells":17598},"dextro-amphetamine",{"EARLY_PHASE1":17599,"PHASE1":17601,"PHASE2":17603,"PHASE3":17605,"PHASE4":17607,"NA":17609},{"trials":17600,"activeCount":101},[],{"trials":17602,"activeCount":101},[],{"trials":17604,"activeCount":101},[],{"trials":17606,"activeCount":101},[],{"trials":17608,"activeCount":101},[],{"trials":17610,"activeCount":101},[17611],{"nctId":17612,"briefTitle":17613,"status":160,"phases":17614,"primaryCompletion":1730,"completion":1730,"start":1500,"enrollment":897,"conditions":17615,"interventions":17616},"NCT00363298","Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD",[93],[126],[17597,17617],"Sham Comparison",{"intervention":17617,"totalTrials":115,"cells":17619},{"EARLY_PHASE1":17620,"PHASE1":17622,"PHASE2":17624,"PHASE3":17626,"PHASE4":17628,"NA":17630},{"trials":17621,"activeCount":101},[],{"trials":17623,"activeCount":101},[],{"trials":17625,"activeCount":101},[],{"trials":17627,"activeCount":101},[],{"trials":17629,"activeCount":101},[],{"trials":17631,"activeCount":101},[17632],{"nctId":17612,"briefTitle":17613,"status":160,"phases":17633,"primaryCompletion":1730,"completion":1730,"start":1500,"enrollment":897,"conditions":17634,"interventions":17635},[93],[126],[17597,17617],{"intervention":17637,"totalTrials":115,"cells":17638},"(RS)2-(3-benzoylphenyl)-propionic acid",{"EARLY_PHASE1":17639,"PHASE1":17641,"PHASE2":17643,"PHASE3":17645,"PHASE4":17647,"NA":17649},{"trials":17640,"activeCount":101},[],{"trials":17642,"activeCount":101},[],{"trials":17644,"activeCount":101},[],{"trials":17646,"activeCount":101},[],{"trials":17648,"activeCount":101},[],{"trials":17650,"activeCount":101},[17651],{"nctId":17652,"briefTitle":17653,"status":716,"phases":17654,"primaryCompletion":8251,"completion":8251,"start":756,"enrollment":1449,"conditions":17655,"interventions":17656},"NCT01893879","Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema",[93],[10540,5498],[17637],{"intervention":17658,"totalTrials":115,"cells":17659},"N-13 ammonia",{"EARLY_PHASE1":17660,"PHASE1":17662,"PHASE2":17664,"PHASE3":17666,"PHASE4":17668,"NA":17670},{"trials":17661,"activeCount":101},[],{"trials":17663,"activeCount":101},[],{"trials":17665,"activeCount":101},[],{"trials":17667,"activeCount":101},[],{"trials":17669,"activeCount":101},[],{"trials":17671,"activeCount":101},[17672],{"nctId":17673,"briefTitle":17674,"status":160,"phases":17675,"primaryCompletion":17676,"completion":17677,"start":17678,"enrollment":2218,"conditions":17679,"interventions":17681},"NCT03170817","Quantitative 13N-Ammonia Cardiac Rest\u002FStress Digital PET\u002FCT",[],"2020-03-31","2021-09-01","2017-03-29",[17680],"Coronary Artery Disease",[17658,17682],"Regadenoson",{"intervention":17682,"totalTrials":115,"cells":17684},{"EARLY_PHASE1":17685,"PHASE1":17687,"PHASE2":17689,"PHASE3":17691,"PHASE4":17693,"NA":17695},{"trials":17686,"activeCount":101},[],{"trials":17688,"activeCount":101},[],{"trials":17690,"activeCount":101},[],{"trials":17692,"activeCount":101},[],{"trials":17694,"activeCount":101},[],{"trials":17696,"activeCount":101},[17697],{"nctId":17673,"briefTitle":17674,"status":160,"phases":17698,"primaryCompletion":17676,"completion":17677,"start":17678,"enrollment":2218,"conditions":17699,"interventions":17700},[],[17680],[17658,17682],{"intervention":17702,"totalTrials":115,"cells":17703},"MDMA",{"EARLY_PHASE1":17704,"PHASE1":17706,"PHASE2":17708,"PHASE3":17710,"PHASE4":17712,"NA":17714},{"trials":17705,"activeCount":101},[],{"trials":17707,"activeCount":101},[],{"trials":17709,"activeCount":101},[],{"trials":17711,"activeCount":101},[],{"trials":17713,"activeCount":101},[],{"trials":17715,"activeCount":101},[17716],{"nctId":17717,"briefTitle":17718,"status":160,"phases":17719,"primaryCompletion":17720,"completion":17720,"start":17721,"enrollment":1977,"conditions":17722,"interventions":17723},"NCT04060108","Stanford Regulating Circuits of the Brain Study - MDMA",[],"2024-01-01","2021-11-02",[193],[17702],{"intervention":17725,"totalTrials":115,"cells":17726},"Drisdol (Ergocalciferol) Vitamin D2",{"EARLY_PHASE1":17727,"PHASE1":17729,"PHASE2":17731,"PHASE3":17733,"PHASE4":17735,"NA":17737},{"trials":17728,"activeCount":101},[],{"trials":17730,"activeCount":101},[],{"trials":17732,"activeCount":101},[],{"trials":17734,"activeCount":101},[],{"trials":17736,"activeCount":101},[],{"trials":17738,"activeCount":101},[17739],{"nctId":17740,"briefTitle":17741,"status":160,"phases":17742,"primaryCompletion":1563,"completion":1563,"start":876,"enrollment":179,"conditions":17743,"interventions":17744},"NCT01217840","Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents",[93],[18],[17725],{"intervention":17746,"totalTrials":115,"cells":17747},"Cenegermin-Bkbj",{"EARLY_PHASE1":17748,"PHASE1":17750,"PHASE2":17752,"PHASE3":17754,"PHASE4":17756,"NA":17758},{"trials":17749,"activeCount":101},[],{"trials":17751,"activeCount":101},[],{"trials":17753,"activeCount":101},[],{"trials":17755,"activeCount":101},[],{"trials":17757,"activeCount":101},[],{"trials":17759,"activeCount":101},[17760],{"nctId":17761,"briefTitle":17762,"status":160,"phases":17763,"primaryCompletion":17764,"completion":17764,"start":17765,"enrollment":821,"conditions":17766,"interventions":17768},"NCT04552730","Nerve Growth Factor for the Treatment of Cornea Disease",[],"2021-05-04","2020-10-14",[17767],"Neurotrophic Keratitis",[17746],{"intervention":17770,"totalTrials":115,"cells":17771},"Vitamin D3",{"EARLY_PHASE1":17772,"PHASE1":17774,"PHASE2":17776,"PHASE3":17778,"PHASE4":17780,"NA":17782},{"trials":17773,"activeCount":101},[],{"trials":17775,"activeCount":101},[],{"trials":17777,"activeCount":101},[],{"trials":17779,"activeCount":101},[],{"trials":17781,"activeCount":101},[],{"trials":17783,"activeCount":101},[17784],{"nctId":17785,"briefTitle":17786,"status":160,"phases":17787,"primaryCompletion":1843,"completion":1843,"start":11589,"enrollment":897,"conditions":17788,"interventions":17790},"NCT01477463","Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers",[93],[17789],"Melanoma, Skin",[17770],{"intervention":17792,"totalTrials":115,"cells":17793},"gatifloxacin, moxifloxacin",{"EARLY_PHASE1":17794,"PHASE1":17796,"PHASE2":17798,"PHASE3":17800,"PHASE4":17802,"NA":17804},{"trials":17795,"activeCount":101},[],{"trials":17797,"activeCount":101},[],{"trials":17799,"activeCount":101},[],{"trials":17801,"activeCount":101},[],{"trials":17803,"activeCount":101},[],{"trials":17805,"activeCount":101},[17806],{"nctId":17807,"briefTitle":17808,"status":132,"phases":17809,"start":9212,"enrollment":101,"conditions":17810,"interventions":17812},"NCT00466570","Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application",[93],[17811],"Conjunctical Flora",[17792],{"intervention":17814,"totalTrials":115,"cells":17815},"BCG",{"EARLY_PHASE1":17816,"PHASE1":17818,"PHASE2":17820,"PHASE3":17822,"PHASE4":17824,"NA":17826},{"trials":17817,"activeCount":101},[],{"trials":17819,"activeCount":101},[],{"trials":17821,"activeCount":101},[],{"trials":17823,"activeCount":101},[],{"trials":17825,"activeCount":101},[],{"trials":17827,"activeCount":101},[17828],{"nctId":17829,"briefTitle":17830,"status":716,"phases":17831,"primaryCompletion":1730,"completion":1730,"start":9212,"enrollment":247,"conditions":17832,"interventions":17833},"NCT00568854","Immunobiology of Diabetes and Tuberculosis",[93],[7568,11774],[17814],{"intervention":17835,"totalTrials":115,"cells":17836},"Palonosetron",{"EARLY_PHASE1":17837,"PHASE1":17839,"PHASE2":17841,"PHASE3":17843,"PHASE4":17845,"NA":17847},{"trials":17838,"activeCount":101},[],{"trials":17840,"activeCount":101},[],{"trials":17842,"activeCount":101},[],{"trials":17844,"activeCount":101},[],{"trials":17846,"activeCount":101},[],{"trials":17848,"activeCount":101},[17849],{"nctId":17850,"briefTitle":17851,"status":160,"phases":17852,"primaryCompletion":6396,"completion":6396,"start":15363,"enrollment":247,"conditions":17853,"interventions":17854},"NCT00661674","Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal",[93],[15909],[17835,17855],"Hydroxyzine",{"intervention":17855,"totalTrials":115,"cells":17857},{"EARLY_PHASE1":17858,"PHASE1":17860,"PHASE2":17862,"PHASE3":17864,"PHASE4":17866,"NA":17868},{"trials":17859,"activeCount":101},[],{"trials":17861,"activeCount":101},[],{"trials":17863,"activeCount":101},[],{"trials":17865,"activeCount":101},[],{"trials":17867,"activeCount":101},[],{"trials":17869,"activeCount":101},[17870],{"nctId":17850,"briefTitle":17851,"status":160,"phases":17871,"primaryCompletion":6396,"completion":6396,"start":15363,"enrollment":247,"conditions":17872,"interventions":17873},[93],[15909],[17835,17855],{"intervention":17875,"totalTrials":115,"cells":17876},"L-arginine",{"EARLY_PHASE1":17877,"PHASE1":17879,"PHASE2":17881,"PHASE3":17883,"PHASE4":17885,"NA":17887},{"trials":17878,"activeCount":101},[],{"trials":17880,"activeCount":101},[],{"trials":17882,"activeCount":101},[],{"trials":17884,"activeCount":101},[],{"trials":17886,"activeCount":101},[],{"trials":17888,"activeCount":101},[17889],{"nctId":17890,"briefTitle":17891,"status":160,"phases":17892,"primaryCompletion":1862,"completion":1862,"start":17893,"conditions":17894,"interventions":17896},"NCT00284076","L-Arginine in the Treatment of Peripheral Arterial Disease",[93],"2000-02",[15535,17895],"Peripheral Vascular Diseases",[17875],{"intervention":17898,"totalTrials":115,"cells":17899},"Contigen",{"EARLY_PHASE1":17900,"PHASE1":17902,"PHASE2":17904,"PHASE3":17906,"PHASE4":17908,"NA":17910},{"trials":17901,"activeCount":101},[],{"trials":17903,"activeCount":101},[],{"trials":17905,"activeCount":101},[],{"trials":17907,"activeCount":101},[],{"trials":17909,"activeCount":101},[],{"trials":17911,"activeCount":101},[17912],{"nctId":17913,"briefTitle":17914,"status":132,"phases":17915,"primaryCompletion":1800,"completion":1800,"start":1976,"enrollment":101,"conditions":17916,"interventions":17917},"NCT01379378","Male Stress Urinary Incontinence and Sexual Health",[],[3388],[17898],{"intervention":17919,"totalTrials":115,"cells":17920},"Misoprostol with or without isosorbide mononitrate",{"EARLY_PHASE1":17921,"PHASE1":17923,"PHASE2":17925,"PHASE3":17927,"PHASE4":17929,"NA":17931},{"trials":17922,"activeCount":101},[],{"trials":17924,"activeCount":101},[],{"trials":17926,"activeCount":101},[],{"trials":17928,"activeCount":101},[],{"trials":17930,"activeCount":101},[],{"trials":17932,"activeCount":101},[17933],{"nctId":17934,"briefTitle":17935,"status":160,"phases":17936,"primaryCompletion":12735,"completion":5542,"start":1743,"enrollment":17937,"conditions":17938,"interventions":17940},"NCT00374621","Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate",[93],156,[17939],"Cervical Ripening",[17919],{"intervention":17942,"totalTrials":115,"cells":17943},"Xenon contrast agent",{"EARLY_PHASE1":17944,"PHASE1":17946,"PHASE2":17948,"PHASE3":17950,"PHASE4":17952,"NA":17954},{"trials":17945,"activeCount":101},[],{"trials":17947,"activeCount":101},[],{"trials":17949,"activeCount":101},[],{"trials":17951,"activeCount":101},[],{"trials":17953,"activeCount":101},[],{"trials":17955,"activeCount":101},[17956],{"nctId":17957,"briefTitle":17958,"status":160,"phases":17959,"primaryCompletion":6012,"completion":6012,"start":1544,"enrollment":16537,"conditions":17960,"interventions":17962},"NCT01419275","Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients",[93],[17002,17961],"Moyamoya Disease",[17942],{"intervention":17964,"totalTrials":115,"cells":17965},"3TC and FTC",{"EARLY_PHASE1":17966,"PHASE1":17968,"PHASE2":17970,"PHASE3":17972,"PHASE4":17974,"NA":17976},{"trials":17967,"activeCount":101},[],{"trials":17969,"activeCount":101},[],{"trials":17971,"activeCount":101},[],{"trials":17973,"activeCount":101},[],{"trials":17975,"activeCount":101},[],{"trials":17977,"activeCount":101},[17978],{"nctId":17979,"briefTitle":17980,"status":160,"phases":17981,"completion":15715,"start":13633,"enrollment":179,"conditions":17982,"interventions":17983},"NCT00152061","The Switch Study: The Role of Lamivudine\u002FEmtricitabine (3TC\u002FFTC) in Antiretroviral Regimens",[93],[7567],[17964],{"intervention":16454,"totalTrials":115,"cells":17985},{"EARLY_PHASE1":17986,"PHASE1":17988,"PHASE2":17990,"PHASE3":17992,"PHASE4":17994,"NA":17996},{"trials":17987,"activeCount":101},[],{"trials":17989,"activeCount":101},[],{"trials":17991,"activeCount":101},[],{"trials":17993,"activeCount":101},[],{"trials":17995,"activeCount":101},[],{"trials":17997,"activeCount":101},[17998],{"nctId":16447,"briefTitle":16448,"status":160,"phases":17999,"primaryCompletion":844,"completion":844,"start":16450,"enrollment":11192,"conditions":18000,"interventions":18001},[93],[36,16452],[16432,16454],{"intervention":18003,"totalTrials":115,"cells":18004},"T3",{"EARLY_PHASE1":18005,"PHASE1":18007,"PHASE2":18009,"PHASE3":18011,"PHASE4":18013,"NA":18015},{"trials":18006,"activeCount":101},[],{"trials":18008,"activeCount":101},[],{"trials":18010,"activeCount":101},[],{"trials":18012,"activeCount":101},[],{"trials":18014,"activeCount":101},[],{"trials":18016,"activeCount":101},[18017],{"nctId":18018,"briefTitle":18019,"status":160,"phases":18020,"primaryCompletion":9189,"completion":9189,"start":758,"enrollment":7229,"conditions":18021,"interventions":18022},"NCT00903877","Study of T3 for the Treatment of Fibromyalgia",[93],[16910],[18003],{"intervention":18024,"totalTrials":115,"cells":18025},"Na134I",{"EARLY_PHASE1":18026,"PHASE1":18028,"PHASE2":18030,"PHASE3":18032,"PHASE4":18034,"NA":18036},{"trials":18027,"activeCount":101},[],{"trials":18029,"activeCount":101},[],{"trials":18031,"activeCount":101},[],{"trials":18033,"activeCount":101},[],{"trials":18035,"activeCount":101},[],{"trials":18037,"activeCount":101},[18038],{"nctId":18039,"briefTitle":18040,"status":132,"phases":18041,"primaryCompletion":834,"completion":757,"start":835,"enrollment":101,"conditions":18042,"interventions":18044},"NCT01360177","Radioactive Iodide (131I) Treatment of 124I PET\u002FCT Detected Breast Cancers",[93],[15,18043],"Metastatic Breast Cancer",[18024,18045,18045],"Tri-iodothyronine",{"intervention":18045,"totalTrials":115,"cells":18047},{"EARLY_PHASE1":18048,"PHASE1":18050,"PHASE2":18052,"PHASE3":18054,"PHASE4":18056,"NA":18058},{"trials":18049,"activeCount":101},[],{"trials":18051,"activeCount":101},[],{"trials":18053,"activeCount":101},[],{"trials":18055,"activeCount":101},[],{"trials":18057,"activeCount":101},[],{"trials":18059,"activeCount":101},[18060],{"nctId":18039,"briefTitle":18040,"status":132,"phases":18061,"primaryCompletion":834,"completion":757,"start":835,"enrollment":101,"conditions":18062,"interventions":18063},[93],[15,18043],[18024,18045,18045],{"intervention":18065,"totalTrials":115,"cells":18066},"Ropinirole CR",{"EARLY_PHASE1":18067,"PHASE1":18069,"PHASE2":18071,"PHASE3":18073,"PHASE4":18075,"NA":18077},{"trials":18068,"activeCount":101},[],{"trials":18070,"activeCount":101},[],{"trials":18072,"activeCount":101},[],{"trials":18074,"activeCount":101},[],{"trials":18076,"activeCount":101},[],{"trials":18078,"activeCount":101},[18079],{"nctId":18080,"briefTitle":18081,"status":160,"phases":18082,"completion":7168,"start":9928,"enrollment":1124,"conditions":18083,"interventions":18084},"NCT00285727","Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression",[93],[15698],[18065],{"intervention":18086,"totalTrials":115,"cells":18087},"FLT",{"EARLY_PHASE1":18088,"PHASE1":18090,"PHASE2":18092,"PHASE3":18094,"PHASE4":18096,"NA":18098},{"trials":18089,"activeCount":101},[],{"trials":18091,"activeCount":101},[],{"trials":18093,"activeCount":101},[],{"trials":18095,"activeCount":101},[],{"trials":18097,"activeCount":101},[],{"trials":18099,"activeCount":101},[18100],{"nctId":18101,"briefTitle":18102,"status":160,"phases":18103,"primaryCompletion":12735,"completion":12735,"start":719,"enrollment":232,"conditions":18104,"interventions":18105},"NCT00767273","Investigate Role of Metabolic Imaging in Predicting Tumor Response\u002FOutcome After Pancreatic CA Tx",[93],[1781],[18086,18106],"FDG",{"intervention":18106,"totalTrials":115,"cells":18108},{"EARLY_PHASE1":18109,"PHASE1":18111,"PHASE2":18113,"PHASE3":18115,"PHASE4":18117,"NA":18119},{"trials":18110,"activeCount":101},[],{"trials":18112,"activeCount":101},[],{"trials":18114,"activeCount":101},[],{"trials":18116,"activeCount":101},[],{"trials":18118,"activeCount":101},[],{"trials":18120,"activeCount":101},[18121],{"nctId":18101,"briefTitle":18102,"status":160,"phases":18122,"primaryCompletion":12735,"completion":12735,"start":719,"enrollment":232,"conditions":18123,"interventions":18124},[93],[1781],[18086,18106],{"intervention":278,"totalTrials":115,"cells":18126},{"EARLY_PHASE1":18127,"PHASE1":18129,"PHASE2":18131,"PHASE3":18133,"PHASE4":18135,"NA":18137},{"trials":18128,"activeCount":101},[],{"trials":18130,"activeCount":101},[],{"trials":18132,"activeCount":101},[],{"trials":18134,"activeCount":101},[],{"trials":18136,"activeCount":101},[],{"trials":18138,"activeCount":101},[18139],{"nctId":268,"briefTitle":269,"status":160,"phases":18140,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":18141,"interventions":18142},[],[276],[278,196,140],{"intervention":18144,"totalTrials":115,"cells":18145},"Vedolizumab",{"EARLY_PHASE1":18146,"PHASE1":18148,"PHASE2":18150,"PHASE3":18152,"PHASE4":18154,"NA":18156},{"trials":18147,"activeCount":101},[],{"trials":18149,"activeCount":101},[],{"trials":18151,"activeCount":101},[],{"trials":18153,"activeCount":101},[],{"trials":18155,"activeCount":101},[],{"trials":18157,"activeCount":101},[18158],{"nctId":18159,"briefTitle":18160,"status":716,"phases":18161,"primaryCompletion":18162,"completion":18162,"start":5294,"enrollment":115,"conditions":18163,"interventions":18164},"NCT03802214","Ulcerative Colitis - Vedolizumab- With\u002FWithout Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy",[],"2020-12-11",[8786],[18144],{"intervention":15920,"totalTrials":115,"cells":18166},{"EARLY_PHASE1":18167,"PHASE1":18169,"PHASE2":18171,"PHASE3":18173,"PHASE4":18175,"NA":18177},{"trials":18168,"activeCount":101},[],{"trials":18170,"activeCount":101},[],{"trials":18172,"activeCount":101},[],{"trials":18174,"activeCount":101},[],{"trials":18176,"activeCount":101},[],{"trials":18178,"activeCount":101},[18179],{"nctId":15912,"briefTitle":15913,"status":160,"phases":18180,"primaryCompletion":8251,"completion":6243,"start":10432,"enrollment":15915,"conditions":18181,"interventions":18182},[93],[15917,15918],[5736,819,15920,15921],{"intervention":15921,"totalTrials":115,"cells":18184},{"EARLY_PHASE1":18185,"PHASE1":18187,"PHASE2":18189,"PHASE3":18191,"PHASE4":18193,"NA":18195},{"trials":18186,"activeCount":101},[],{"trials":18188,"activeCount":101},[],{"trials":18190,"activeCount":101},[],{"trials":18192,"activeCount":101},[],{"trials":18194,"activeCount":101},[],{"trials":18196,"activeCount":101},[18197],{"nctId":15912,"briefTitle":15913,"status":160,"phases":18198,"primaryCompletion":8251,"completion":6243,"start":10432,"enrollment":15915,"conditions":18199,"interventions":18200},[93],[15917,15918],[5736,819,15920,15921],{"intervention":18202,"totalTrials":115,"cells":18203},"Attenuvax",{"EARLY_PHASE1":18204,"PHASE1":18206,"PHASE2":18208,"PHASE3":18210,"PHASE4":18212,"NA":18214},{"trials":18205,"activeCount":101},[],{"trials":18207,"activeCount":101},[],{"trials":18209,"activeCount":101},[],{"trials":18211,"activeCount":101},[],{"trials":18213,"activeCount":101},[],{"trials":18215,"activeCount":101},[18216],{"nctId":18217,"briefTitle":18218,"status":160,"phases":18219,"primaryCompletion":7020,"completion":6351,"start":18220,"enrollment":18221,"conditions":18222,"interventions":18224},"NCT00240916","Ontogeny of Measles Immunity in Infants",[],"1993-07",750,[18223],"Measles",[18202,18225],"MMR-II",{"intervention":18225,"totalTrials":115,"cells":18227},{"EARLY_PHASE1":18228,"PHASE1":18230,"PHASE2":18232,"PHASE3":18234,"PHASE4":18236,"NA":18238},{"trials":18229,"activeCount":101},[],{"trials":18231,"activeCount":101},[],{"trials":18233,"activeCount":101},[],{"trials":18235,"activeCount":101},[],{"trials":18237,"activeCount":101},[],{"trials":18239,"activeCount":101},[18240],{"nctId":18217,"briefTitle":18218,"status":160,"phases":18241,"primaryCompletion":7020,"completion":6351,"start":18220,"enrollment":18221,"conditions":18242,"interventions":18243},[],[18223],[18202,18225],{"intervention":15807,"totalTrials":115,"cells":18245},{"EARLY_PHASE1":18246,"PHASE1":18248,"PHASE2":18250,"PHASE3":18252,"PHASE4":18254,"NA":18256},{"trials":18247,"activeCount":101},[],{"trials":18249,"activeCount":101},[],{"trials":18251,"activeCount":101},[],{"trials":18253,"activeCount":101},[],{"trials":18255,"activeCount":101},[],{"trials":18257,"activeCount":101},[18258],{"nctId":15796,"briefTitle":15797,"status":160,"phases":18259,"primaryCompletion":15799,"completion":15799,"start":9065,"enrollment":15800,"conditions":18260,"interventions":18261},[93],[15802,15803,15804,15805],[1504,15807],{"intervention":18263,"totalTrials":115,"cells":18264},"Isoflurane",{"EARLY_PHASE1":18265,"PHASE1":18267,"PHASE2":18269,"PHASE3":18271,"PHASE4":18273,"NA":18275},{"trials":18266,"activeCount":101},[],{"trials":18268,"activeCount":101},[],{"trials":18270,"activeCount":101},[],{"trials":18272,"activeCount":101},[],{"trials":18274,"activeCount":101},[],{"trials":18276,"activeCount":101},[18277],{"nctId":18278,"briefTitle":18279,"status":160,"phases":18280,"primaryCompletion":4105,"completion":4105,"start":18281,"enrollment":18282,"conditions":18283,"interventions":18285},"NCT03882788","The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)",[93],"2013-04-22",153,[5430,2117,18284],"Neurodevelopmental Disorders",[18263,18286,18286],"Fentanyl",{"intervention":18286,"totalTrials":115,"cells":18288},{"EARLY_PHASE1":18289,"PHASE1":18291,"PHASE2":18293,"PHASE3":18295,"PHASE4":18297,"NA":18299},{"trials":18290,"activeCount":101},[],{"trials":18292,"activeCount":101},[],{"trials":18294,"activeCount":101},[],{"trials":18296,"activeCount":101},[],{"trials":18298,"activeCount":101},[],{"trials":18300,"activeCount":101},[18301],{"nctId":18278,"briefTitle":18279,"status":160,"phases":18302,"primaryCompletion":4105,"completion":4105,"start":18281,"enrollment":18282,"conditions":18303,"interventions":18304},[93],[5430,2117,18284],[18263,18286,18286],{"intervention":1493,"totalTrials":115,"cells":18306},{"EARLY_PHASE1":18307,"PHASE1":18309,"PHASE2":18311,"PHASE3":18313,"PHASE4":18315,"NA":18317},{"trials":18308,"activeCount":101},[],{"trials":18310,"activeCount":101},[],{"trials":18312,"activeCount":101},[],{"trials":18314,"activeCount":101},[],{"trials":18316,"activeCount":101},[],{"trials":18318,"activeCount":101},[18319],{"nctId":1477,"briefTitle":1478,"status":160,"phases":18320,"primaryCompletion":1480,"completion":220,"start":1481,"enrollment":1482,"conditions":18321,"interventions":18322},[93],[722,1484,1485,1486,1487,1488,1489,1490,1491],[704,1493],{"intervention":18324,"totalTrials":115,"cells":18325},"Triamcinolone injection, sub-tenon",{"EARLY_PHASE1":18326,"PHASE1":18328,"PHASE2":18330,"PHASE3":18332,"PHASE4":18334,"NA":18336},{"trials":18327,"activeCount":101},[],{"trials":18329,"activeCount":101},[],{"trials":18331,"activeCount":101},[],{"trials":18333,"activeCount":101},[],{"trials":18335,"activeCount":101},[],{"trials":18337,"activeCount":101},[18338],{"nctId":18339,"briefTitle":18340,"status":132,"phases":18341,"enrollment":101,"conditions":18342,"interventions":18343},"NCT00238563","Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery",[93],[2627],[18324],{"intervention":18345,"totalTrials":115,"cells":18346},"Mobile technology intervention",{"EARLY_PHASE1":18347,"PHASE1":18349,"PHASE2":18351,"PHASE3":18353,"PHASE4":18355,"NA":18357},{"trials":18348,"activeCount":101},[],{"trials":18350,"activeCount":101},[],{"trials":18352,"activeCount":101},[],{"trials":18354,"activeCount":101},[],{"trials":18356,"activeCount":101},[],{"trials":18358,"activeCount":101},[18359],{"nctId":18360,"briefTitle":18361,"status":160,"phases":18362,"primaryCompletion":18363,"completion":18363,"start":6523,"enrollment":31,"conditions":18364,"interventions":18365},"NCT04841317","Mobile Technology for Blood Pressure Management",[93],"2021-12-07",[17487],[18345],{"intervention":18367,"totalTrials":115,"cells":18368},"17beta Estradiol",{"EARLY_PHASE1":18369,"PHASE1":18371,"PHASE2":18373,"PHASE3":18375,"PHASE4":18377,"NA":18379},{"trials":18370,"activeCount":101},[],{"trials":18372,"activeCount":101},[],{"trials":18374,"activeCount":101},[],{"trials":18376,"activeCount":101},[],{"trials":18378,"activeCount":101},[],{"trials":18380,"activeCount":101},[18381],{"nctId":18382,"briefTitle":18383,"status":160,"phases":18384,"primaryCompletion":5647,"completion":5647,"start":10912,"enrollment":111,"conditions":18385,"interventions":18387},"NCT01023178","Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure",[93],[18386],"Ovarian Failure, Premature",[18367,18388,18389,18390],"Conjugated estrogens","17Beta Estradiol - transdermal","Progesterone, micronized",{"intervention":18388,"totalTrials":115,"cells":18392},{"EARLY_PHASE1":18393,"PHASE1":18395,"PHASE2":18397,"PHASE3":18399,"PHASE4":18401,"NA":18403},{"trials":18394,"activeCount":101},[],{"trials":18396,"activeCount":101},[],{"trials":18398,"activeCount":101},[],{"trials":18400,"activeCount":101},[],{"trials":18402,"activeCount":101},[],{"trials":18404,"activeCount":101},[18405],{"nctId":18382,"briefTitle":18383,"status":160,"phases":18406,"primaryCompletion":5647,"completion":5647,"start":10912,"enrollment":111,"conditions":18407,"interventions":18408},[93],[18386],[18367,18388,18389,18390],{"intervention":18389,"totalTrials":115,"cells":18410},{"EARLY_PHASE1":18411,"PHASE1":18413,"PHASE2":18415,"PHASE3":18417,"PHASE4":18419,"NA":18421},{"trials":18412,"activeCount":101},[],{"trials":18414,"activeCount":101},[],{"trials":18416,"activeCount":101},[],{"trials":18418,"activeCount":101},[],{"trials":18420,"activeCount":101},[],{"trials":18422,"activeCount":101},[18423],{"nctId":18382,"briefTitle":18383,"status":160,"phases":18424,"primaryCompletion":5647,"completion":5647,"start":10912,"enrollment":111,"conditions":18425,"interventions":18426},[93],[18386],[18367,18388,18389,18390],{"intervention":18390,"totalTrials":115,"cells":18428},{"EARLY_PHASE1":18429,"PHASE1":18431,"PHASE2":18433,"PHASE3":18435,"PHASE4":18437,"NA":18439},{"trials":18430,"activeCount":101},[],{"trials":18432,"activeCount":101},[],{"trials":18434,"activeCount":101},[],{"trials":18436,"activeCount":101},[],{"trials":18438,"activeCount":101},[],{"trials":18440,"activeCount":101},[18441],{"nctId":18382,"briefTitle":18383,"status":160,"phases":18442,"primaryCompletion":5647,"completion":5647,"start":10912,"enrollment":111,"conditions":18443,"interventions":18444},[93],[18386],[18367,18388,18389,18390],{"intervention":18446,"totalTrials":115,"cells":18447},"Final exogenous oxytocin concentration=22.5 μU\u002FmL",{"EARLY_PHASE1":18448,"PHASE1":18450,"PHASE2":18452,"PHASE3":18454,"PHASE4":18456,"NA":18458},{"trials":18449,"activeCount":101},[],{"trials":18451,"activeCount":101},[],{"trials":18453,"activeCount":101},[],{"trials":18455,"activeCount":101},[],{"trials":18457,"activeCount":101},[],{"trials":18459,"activeCount":101},[18460],{"nctId":18461,"briefTitle":18462,"status":160,"phases":18463,"primaryCompletion":9983,"completion":9983,"start":18464,"enrollment":613,"conditions":18465,"interventions":18467},"NCT00788255","In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.",[],"2008-10",[18466],"Anesthesia",[18446,18468,18469],"Final exogenous oxytocin concentration=30.1μU\u002FmL","Final exogenous oxytocin concentration=32.9μU\u002FmL",{"intervention":18468,"totalTrials":115,"cells":18471},{"EARLY_PHASE1":18472,"PHASE1":18474,"PHASE2":18476,"PHASE3":18478,"PHASE4":18480,"NA":18482},{"trials":18473,"activeCount":101},[],{"trials":18475,"activeCount":101},[],{"trials":18477,"activeCount":101},[],{"trials":18479,"activeCount":101},[],{"trials":18481,"activeCount":101},[],{"trials":18483,"activeCount":101},[18484],{"nctId":18461,"briefTitle":18462,"status":160,"phases":18485,"primaryCompletion":9983,"completion":9983,"start":18464,"enrollment":613,"conditions":18486,"interventions":18487},[],[18466],[18446,18468,18469],{"intervention":18469,"totalTrials":115,"cells":18489},{"EARLY_PHASE1":18490,"PHASE1":18492,"PHASE2":18494,"PHASE3":18496,"PHASE4":18498,"NA":18500},{"trials":18491,"activeCount":101},[],{"trials":18493,"activeCount":101},[],{"trials":18495,"activeCount":101},[],{"trials":18497,"activeCount":101},[],{"trials":18499,"activeCount":101},[],{"trials":18501,"activeCount":101},[18502],{"nctId":18461,"briefTitle":18462,"status":160,"phases":18503,"primaryCompletion":9983,"completion":9983,"start":18464,"enrollment":613,"conditions":18504,"interventions":18505},[],[18466],[18446,18468,18469],{"intervention":18507,"totalTrials":115,"cells":18508},"Hydrocortisone Administration",{"EARLY_PHASE1":18509,"PHASE1":18511,"PHASE2":18513,"PHASE3":18515,"PHASE4":18517,"NA":18519},{"trials":18510,"activeCount":101},[],{"trials":18512,"activeCount":101},[],{"trials":18514,"activeCount":101},[],{"trials":18516,"activeCount":101},[],{"trials":18518,"activeCount":101},[],{"trials":18520,"activeCount":101},[18521],{"nctId":18522,"briefTitle":18523,"status":160,"phases":18524,"primaryCompletion":7914,"completion":7914,"start":12262,"enrollment":247,"conditions":18525,"interventions":18528},"NCT00185783","Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis",[],[18526,18527],"Sepsis","Relative Adrenal Insufficiency",[18507],{"intervention":18530,"totalTrials":115,"cells":18531},"Zegerid",{"EARLY_PHASE1":18532,"PHASE1":18534,"PHASE2":18536,"PHASE3":18538,"PHASE4":18540,"NA":18542},{"trials":18533,"activeCount":101},[],{"trials":18535,"activeCount":101},[],{"trials":18537,"activeCount":101},[],{"trials":18539,"activeCount":101},[],{"trials":18541,"activeCount":101},[],{"trials":18543,"activeCount":101},[18544],{"nctId":18545,"briefTitle":18546,"status":716,"phases":18547,"primaryCompletion":835,"completion":697,"start":10911,"enrollment":791,"conditions":18548,"interventions":18550},"NCT01129778","Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus",[93],[18549,10730],"Barrett Esophagus",[18530],{"intervention":18552,"totalTrials":115,"cells":18553},"Ambrisentan",{"EARLY_PHASE1":18554,"PHASE1":18556,"PHASE2":18558,"PHASE3":18560,"PHASE4":18562,"NA":18564},{"trials":18555,"activeCount":101},[],{"trials":18557,"activeCount":101},[],{"trials":18559,"activeCount":101},[],{"trials":18561,"activeCount":101},[],{"trials":18563,"activeCount":101},[],{"trials":18565,"activeCount":101},[18566],{"nctId":18567,"briefTitle":18568,"status":160,"phases":18569,"primaryCompletion":697,"completion":697,"start":9808,"enrollment":111,"conditions":18570,"interventions":18572},"NCT00725361","A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).",[93],[18571,11125],"n Ulcer",[18552],{"intervention":18574,"totalTrials":115,"cells":18575},"Morphine Sulfate",{"EARLY_PHASE1":18576,"PHASE1":18578,"PHASE2":18580,"PHASE3":18582,"PHASE4":18584,"NA":18586},{"trials":18577,"activeCount":101},[],{"trials":18579,"activeCount":101},[],{"trials":18581,"activeCount":101},[],{"trials":18583,"activeCount":101},[],{"trials":18585,"activeCount":101},[],{"trials":18587,"activeCount":101},[18588],{"nctId":18589,"briefTitle":18590,"status":716,"phases":18591,"primaryCompletion":6351,"completion":6351,"start":5542,"enrollment":111,"conditions":18592,"interventions":18593},"NCT01749826","Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans",[93],[13842],[18574],{"intervention":18595,"totalTrials":115,"cells":18596},"Rosiglitazone therapy",{"EARLY_PHASE1":18597,"PHASE1":18599,"PHASE2":18601,"PHASE3":18603,"PHASE4":18605,"NA":18607},{"trials":18598,"activeCount":101},[],{"trials":18600,"activeCount":101},[],{"trials":18602,"activeCount":101},[],{"trials":18604,"activeCount":101},[],{"trials":18606,"activeCount":101},[],{"trials":18608,"activeCount":101},[18609],{"nctId":18610,"briefTitle":18611,"status":716,"phases":18612,"primaryCompletion":12735,"completion":12735,"start":18613,"conditions":18614,"interventions":18616},"NCT00466713","Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy",[93],"2007-03",[18615],"Dilated Cardiomyopathy",[18595],{"intervention":18618,"totalTrials":115,"cells":18619},"Tofacitinib",{"EARLY_PHASE1":18620,"PHASE1":18622,"PHASE2":18624,"PHASE3":18626,"PHASE4":18628,"NA":18630},{"trials":18621,"activeCount":101},[],{"trials":18623,"activeCount":101},[],{"trials":18625,"activeCount":101},[],{"trials":18627,"activeCount":101},[],{"trials":18629,"activeCount":101},[],{"trials":18631,"activeCount":101},[18632],{"nctId":18633,"briefTitle":18634,"status":160,"phases":18635,"primaryCompletion":9065,"completion":9065,"start":757,"enrollment":179,"conditions":18636,"interventions":18640},"NCT02312882","Tofacitinib for the Treatment of Alopecia Areata and Its Variants",[93],[18637,18638,18639],"Alopecia Areata","Alopecia Totalis","Alopecia Universalis",[18618],{"intervention":18642,"totalTrials":115,"cells":18643},"BZDP-Sparing Protocol",{"EARLY_PHASE1":18644,"PHASE1":18646,"PHASE2":18648,"PHASE3":18650,"PHASE4":18652,"NA":18654},{"trials":18645,"activeCount":101},[],{"trials":18647,"activeCount":101},[],{"trials":18649,"activeCount":101},[],{"trials":18651,"activeCount":101},[],{"trials":18653,"activeCount":101},[],{"trials":18655,"activeCount":101},[18656],{"nctId":18657,"briefTitle":18658,"status":160,"phases":18659,"primaryCompletion":18660,"completion":18660,"start":833,"enrollment":232,"conditions":18661,"interventions":18663},"NCT05438641","Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and\u002For Anticonvulsants",[],"2017-08",[18662],"Alcohol Withdrawal Syndrome",[18642,18664],"BZDP-Based Protocol",{"intervention":18664,"totalTrials":115,"cells":18666},{"EARLY_PHASE1":18667,"PHASE1":18669,"PHASE2":18671,"PHASE3":18673,"PHASE4":18675,"NA":18677},{"trials":18668,"activeCount":101},[],{"trials":18670,"activeCount":101},[],{"trials":18672,"activeCount":101},[],{"trials":18674,"activeCount":101},[],{"trials":18676,"activeCount":101},[],{"trials":18678,"activeCount":101},[18679],{"nctId":18657,"briefTitle":18658,"status":160,"phases":18680,"primaryCompletion":18660,"completion":18660,"start":833,"enrollment":232,"conditions":18681,"interventions":18682},[],[18662],[18642,18664],{"intervention":18684,"totalTrials":115,"cells":18685},"aripiprazole",{"EARLY_PHASE1":18686,"PHASE1":18688,"PHASE2":18690,"PHASE3":18692,"PHASE4":18694,"NA":18696},{"trials":18687,"activeCount":101},[],{"trials":18689,"activeCount":101},[],{"trials":18691,"activeCount":101},[],{"trials":18693,"activeCount":101},[],{"trials":18695,"activeCount":101},[],{"trials":18697,"activeCount":101},[18698],{"nctId":18699,"briefTitle":18700,"status":160,"phases":18701,"primaryCompletion":835,"completion":835,"start":219,"enrollment":1314,"conditions":18702,"interventions":18704},"NCT00947154","Trial of Aripiprazole in Trichotillomania",[93],[18703],"Trichotillomania",[18684],{"intervention":18706,"totalTrials":115,"cells":18707},"Cefotetan or Cefoxitin vs placebo",{"EARLY_PHASE1":18708,"PHASE1":18710,"PHASE2":18712,"PHASE3":18714,"PHASE4":18716,"NA":18718},{"trials":18709,"activeCount":101},[],{"trials":18711,"activeCount":101},[],{"trials":18713,"activeCount":101},[],{"trials":18715,"activeCount":101},[],{"trials":18717,"activeCount":101},[],{"trials":18719,"activeCount":101},[18720],{"nctId":18721,"briefTitle":18722,"status":160,"phases":18723,"primaryCompletion":1754,"completion":9808,"start":16450,"enrollment":18724,"conditions":18725,"interventions":18727},"NCT00186082","Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs",[93],147,[18726],"Pregnancy Complications, Infectious",[18706],{"intervention":18729,"totalTrials":115,"cells":18730},"Symbicort",{"EARLY_PHASE1":18731,"PHASE1":18733,"PHASE2":18735,"PHASE3":18737,"PHASE4":18739,"NA":18741},{"trials":18732,"activeCount":101},[],{"trials":18734,"activeCount":101},[],{"trials":18736,"activeCount":101},[],{"trials":18738,"activeCount":101},[],{"trials":18740,"activeCount":101},[],{"trials":18742,"activeCount":101},[18743],{"nctId":18744,"briefTitle":18745,"status":160,"phases":18746,"primaryCompletion":835,"completion":835,"start":220,"enrollment":247,"conditions":18747,"interventions":18748},"NCT01218399","Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations",[93],[13637],[18729],{"intervention":18750,"totalTrials":115,"cells":18751},"F-18 Fluoro-deoxi-glucose",{"EARLY_PHASE1":18752,"PHASE1":18754,"PHASE2":18756,"PHASE3":18758,"PHASE4":18760,"NA":18762},{"trials":18753,"activeCount":101},[],{"trials":18755,"activeCount":101},[],{"trials":18757,"activeCount":101},[],{"trials":18759,"activeCount":101},[],{"trials":18761,"activeCount":101},[],{"trials":18763,"activeCount":101},[18764],{"nctId":18765,"briefTitle":18766,"status":160,"phases":18767,"primaryCompletion":1976,"completion":1471,"start":7168,"enrollment":1766,"conditions":18768,"interventions":18770},"NCT00537056","Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET\u002FCT and DCE MRI",[93],[1865,12737,18769],"Kidney (Renal Cell) Cancer",[18750,18771,18772],"Gadolinium-DTPA","Sunitinib",{"intervention":18771,"totalTrials":115,"cells":18774},{"EARLY_PHASE1":18775,"PHASE1":18777,"PHASE2":18779,"PHASE3":18781,"PHASE4":18783,"NA":18785},{"trials":18776,"activeCount":101},[],{"trials":18778,"activeCount":101},[],{"trials":18780,"activeCount":101},[],{"trials":18782,"activeCount":101},[],{"trials":18784,"activeCount":101},[],{"trials":18786,"activeCount":101},[18787],{"nctId":18765,"briefTitle":18766,"status":160,"phases":18788,"primaryCompletion":1976,"completion":1471,"start":7168,"enrollment":1766,"conditions":18789,"interventions":18790},[93],[1865,12737,18769],[18750,18771,18772],{"intervention":18772,"totalTrials":115,"cells":18792},{"EARLY_PHASE1":18793,"PHASE1":18795,"PHASE2":18797,"PHASE3":18799,"PHASE4":18801,"NA":18803},{"trials":18794,"activeCount":101},[],{"trials":18796,"activeCount":101},[],{"trials":18798,"activeCount":101},[],{"trials":18800,"activeCount":101},[],{"trials":18802,"activeCount":101},[],{"trials":18804,"activeCount":101},[18805],{"nctId":18765,"briefTitle":18766,"status":160,"phases":18806,"primaryCompletion":1976,"completion":1471,"start":7168,"enrollment":1766,"conditions":18807,"interventions":18808},[93],[1865,12737,18769],[18750,18771,18772],{"intervention":18810,"totalTrials":115,"cells":18811},"Sandostatin",{"EARLY_PHASE1":18812,"PHASE1":18814,"PHASE2":18816,"PHASE3":18818,"PHASE4":18820,"NA":18822},{"trials":18813,"activeCount":101},[],{"trials":18815,"activeCount":101},[],{"trials":18817,"activeCount":101},[],{"trials":18819,"activeCount":101},[],{"trials":18821,"activeCount":101},[],{"trials":18823,"activeCount":101},[18824],{"nctId":18825,"briefTitle":18826,"status":160,"phases":18827,"primaryCompletion":15836,"completion":11494,"start":18828,"enrollment":7048,"conditions":18829,"interventions":18830},"NCT00226967","Stress, Diurnal Cortisol, and Breast Cancer Survival",[],"2002-09-08",[15],[18810],{"intervention":18832,"totalTrials":115,"cells":18833},"Biological intervention: Enteropathogenic E. coli",{"EARLY_PHASE1":18834,"PHASE1":18836,"PHASE2":18838,"PHASE3":18840,"PHASE4":18842,"NA":18844},{"trials":18835,"activeCount":101},[],{"trials":18837,"activeCount":101},[],{"trials":18839,"activeCount":101},[],{"trials":18841,"activeCount":101},[],{"trials":18843,"activeCount":101},[],{"trials":18845,"activeCount":101},[18846],{"nctId":18847,"briefTitle":18848,"status":160,"phases":18849,"primaryCompletion":1544,"completion":1544,"start":15715,"enrollment":165,"conditions":18850,"interventions":18852},"NCT00550368","Clinical Experiment of Helicobacter Pylori Transmission",[93],[8205,18851],"Achlorhydria",[18832],{"intervention":1505,"totalTrials":115,"cells":18854},{"EARLY_PHASE1":18855,"PHASE1":18857,"PHASE2":18859,"PHASE3":18861,"PHASE4":18863,"NA":18865},{"trials":18856,"activeCount":101},[],{"trials":18858,"activeCount":101},[],{"trials":18860,"activeCount":101},[],{"trials":18862,"activeCount":101},[],{"trials":18864,"activeCount":101},[],{"trials":18866,"activeCount":101},[18867],{"nctId":1495,"briefTitle":1496,"status":160,"phases":18868,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":860,"conditions":18869,"interventions":18870},[93],[1502],[704,1504,1505,1506],{"intervention":18872,"totalTrials":115,"cells":18873},"Standard-of-care Vascular Endothelial Growth Factor Receptor 2",{"EARLY_PHASE1":18874,"PHASE1":18876,"PHASE2":18878,"PHASE3":18880,"PHASE4":18882,"NA":18884},{"trials":18875,"activeCount":101},[],{"trials":18877,"activeCount":101},[],{"trials":18879,"activeCount":101},[],{"trials":18881,"activeCount":101},[],{"trials":18883,"activeCount":101},[],{"trials":18885,"activeCount":101},[18886],{"nctId":18887,"briefTitle":18888,"status":160,"phases":18889,"primaryCompletion":18890,"completion":18890,"start":18891,"enrollment":1977,"conditions":18892,"interventions":18895},"NCT04508725","Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)",[93],"2023-11-30","2020-12-05",[12739,18893,18894],"Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma",[18872,18896],"Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI",{"intervention":18896,"totalTrials":115,"cells":18898},{"EARLY_PHASE1":18899,"PHASE1":18901,"PHASE2":18903,"PHASE3":18905,"PHASE4":18907,"NA":18909},{"trials":18900,"activeCount":101},[],{"trials":18902,"activeCount":101},[],{"trials":18904,"activeCount":101},[],{"trials":18906,"activeCount":101},[],{"trials":18908,"activeCount":101},[],{"trials":18910,"activeCount":101},[18911],{"nctId":18887,"briefTitle":18888,"status":160,"phases":18912,"primaryCompletion":18890,"completion":18890,"start":18891,"enrollment":1977,"conditions":18913,"interventions":18914},[93],[12739,18893,18894],[18872,18896],{"intervention":3351,"totalTrials":115,"cells":18916},{"EARLY_PHASE1":18917,"PHASE1":18919,"PHASE2":18921,"PHASE3":18923,"PHASE4":18925,"NA":18927},{"trials":18918,"activeCount":101},[],{"trials":18920,"activeCount":101},[],{"trials":18922,"activeCount":101},[],{"trials":18924,"activeCount":101},[],{"trials":18926,"activeCount":101},[],{"trials":18928,"activeCount":101},[18929],{"nctId":3345,"briefTitle":3346,"status":716,"phases":18930,"primaryCompletion":834,"completion":834,"start":3348,"enrollment":821,"conditions":18931,"interventions":18932},[93],[24],[3351,2563],{"intervention":18934,"totalTrials":115,"cells":18935},"Intravenous lidocaine",{"EARLY_PHASE1":18936,"PHASE1":18938,"PHASE2":18940,"PHASE3":18942,"PHASE4":18944,"NA":18946},{"trials":18937,"activeCount":101},[],{"trials":18939,"activeCount":101},[],{"trials":18941,"activeCount":101},[],{"trials":18943,"activeCount":101},[],{"trials":18945,"activeCount":101},[],{"trials":18947,"activeCount":101},[18948],{"nctId":18949,"briefTitle":18950,"status":160,"phases":18951,"primaryCompletion":231,"completion":905,"start":844,"enrollment":6932,"conditions":18952,"interventions":18953},"NCT00725504","Effect of IV Lidocaine Infusions on Pain",[93],[24],[18934],{"intervention":18955,"totalTrials":115,"cells":18956},"salsalate",{"EARLY_PHASE1":18957,"PHASE1":18959,"PHASE2":18961,"PHASE3":18963,"PHASE4":18965,"NA":18967},{"trials":18958,"activeCount":101},[],{"trials":18960,"activeCount":101},[],{"trials":18962,"activeCount":101},[],{"trials":18964,"activeCount":101},[],{"trials":18966,"activeCount":101},[],{"trials":18968,"activeCount":101},[18969],{"nctId":18970,"briefTitle":18971,"status":160,"phases":18972,"primaryCompletion":6012,"completion":6012,"start":835,"enrollment":4504,"conditions":18973,"interventions":18975},"NCT02007577","Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?",[93],[402,18974],"Insulin Resistant",[18955],{"intervention":18977,"totalTrials":115,"cells":18978},"Addition of furosemide 20 mg oral bid to baseline regimen",{"EARLY_PHASE1":18979,"PHASE1":18981,"PHASE2":18983,"PHASE3":18985,"PHASE4":18987,"NA":18989},{"trials":18980,"activeCount":101},[],{"trials":18982,"activeCount":101},[],{"trials":18984,"activeCount":101},[],{"trials":18986,"activeCount":101},[],{"trials":18988,"activeCount":101},[],{"trials":18990,"activeCount":101},[18991],{"nctId":18992,"briefTitle":18993,"status":160,"phases":18994,"completion":12003,"start":7905,"enrollment":232,"conditions":18995,"interventions":18996},"NCT00240019","Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.",[93],[3745],[18977],{"intervention":15996,"totalTrials":115,"cells":18998},{"EARLY_PHASE1":18999,"PHASE1":19001,"PHASE2":19003,"PHASE3":19005,"PHASE4":19007,"NA":19009},{"trials":19000,"activeCount":101},[],{"trials":19002,"activeCount":101},[],{"trials":19004,"activeCount":101},[],{"trials":19006,"activeCount":101},[],{"trials":19008,"activeCount":101},[],{"trials":19010,"activeCount":101},[19011],{"nctId":15990,"briefTitle":15991,"status":160,"phases":19012,"primaryCompletion":12003,"completion":12003,"start":15993,"enrollment":836,"conditions":19013,"interventions":19014},[93],[15698],[15996,15997],{"intervention":19016,"totalTrials":115,"cells":19017},"Heparin sulfate infusion at 10 units\u002Fkg\u002Fhour",{"EARLY_PHASE1":19018,"PHASE1":19020,"PHASE2":19022,"PHASE3":19024,"PHASE4":19026,"NA":19028},{"trials":19019,"activeCount":101},[],{"trials":19021,"activeCount":101},[],{"trials":19023,"activeCount":101},[],{"trials":19025,"activeCount":101},[],{"trials":19027,"activeCount":101},[],{"trials":19029,"activeCount":101},[19030],{"nctId":19031,"briefTitle":19032,"status":160,"phases":19033,"primaryCompletion":15066,"completion":15066,"start":4009,"enrollment":274,"conditions":19034,"interventions":19036},"NCT00779558","Heparin and the Reduction of Thrombosis (HART) Trial",[93],[19035],"Thrombosis",[19016],{"intervention":19038,"totalTrials":115,"cells":19039},"perflutren lipid microspheres",{"EARLY_PHASE1":19040,"PHASE1":19042,"PHASE2":19044,"PHASE3":19046,"PHASE4":19048,"NA":19050},{"trials":19041,"activeCount":101},[],{"trials":19043,"activeCount":101},[],{"trials":19045,"activeCount":101},[],{"trials":19047,"activeCount":101},[],{"trials":19049,"activeCount":101},[],{"trials":19051,"activeCount":101},[19052],{"nctId":19053,"briefTitle":19054,"status":160,"phases":19055,"primaryCompletion":19056,"completion":19056,"start":19057,"enrollment":3997,"conditions":19058,"interventions":19062},"NCT02424955","Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation",[93],"2022-06-30","2014-11-18",[1694,19059,19060,19061],"Liver Tumor","Hepatocellular Carcinoma","Liver Carcinoma",[19038],{"intervention":19064,"totalTrials":115,"cells":19065},"DepoDur following epidural lidocaine",{"EARLY_PHASE1":19066,"PHASE1":19068,"PHASE2":19070,"PHASE3":19072,"PHASE4":19074,"NA":19076},{"trials":19067,"activeCount":101},[],{"trials":19069,"activeCount":101},[],{"trials":19071,"activeCount":101},[],{"trials":19073,"activeCount":101},[],{"trials":19075,"activeCount":101},[],{"trials":19077,"activeCount":101},[19078],{"nctId":19079,"briefTitle":19080,"status":160,"phases":19081,"primaryCompletion":697,"completion":697,"start":844,"enrollment":232,"conditions":19082,"interventions":19084},"NCT00804609","Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery",[93],[19083],"Epidural Analgesia, Obstetric",[19064,19085],"DepoDur following spinal anesthetic",{"intervention":19085,"totalTrials":115,"cells":19087},{"EARLY_PHASE1":19088,"PHASE1":19090,"PHASE2":19092,"PHASE3":19094,"PHASE4":19096,"NA":19098},{"trials":19089,"activeCount":101},[],{"trials":19091,"activeCount":101},[],{"trials":19093,"activeCount":101},[],{"trials":19095,"activeCount":101},[],{"trials":19097,"activeCount":101},[],{"trials":19099,"activeCount":101},[19100],{"nctId":19079,"briefTitle":19080,"status":160,"phases":19101,"primaryCompletion":697,"completion":697,"start":844,"enrollment":232,"conditions":19102,"interventions":19103},[93],[19083],[19064,19085],{"intervention":19105,"totalTrials":115,"cells":19106},"Orlistat\u002Falli program",{"EARLY_PHASE1":19107,"PHASE1":19109,"PHASE2":19111,"PHASE3":19113,"PHASE4":19115,"NA":19117},{"trials":19108,"activeCount":101},[],{"trials":19110,"activeCount":101},[],{"trials":19112,"activeCount":101},[],{"trials":19114,"activeCount":101},[],{"trials":19116,"activeCount":101},[],{"trials":19118,"activeCount":101},[19119],{"nctId":19120,"briefTitle":19121,"status":160,"phases":19122,"primaryCompletion":906,"completion":8371,"start":1632,"enrollment":1766,"conditions":19123,"interventions":19125},"NCT00601354","Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder",[93],[385,19124],"Eating Disorders",[19105],{"intervention":19127,"totalTrials":115,"cells":19128},"Immunotherapy",{"EARLY_PHASE1":19129,"PHASE1":19131,"PHASE2":19133,"PHASE3":19135,"PHASE4":19137,"NA":19139},{"trials":19130,"activeCount":101},[],{"trials":19132,"activeCount":101},[],{"trials":19134,"activeCount":101},[],{"trials":19136,"activeCount":101},[],{"trials":19138,"activeCount":101},[],{"trials":19140,"activeCount":101},[19141],{"nctId":19142,"briefTitle":19143,"status":160,"phases":19144,"primaryCompletion":19145,"completion":19146,"start":19147,"enrollment":165,"conditions":19148,"interventions":19150},"NCT03176173","Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)",[93],"2021-11-24","2025-01-31","2017-06-28",[19149],"Stage IV Non-Small Cell Lung Cancer",[19127],{"intervention":19152,"totalTrials":115,"cells":19153},"18-FDG",{"EARLY_PHASE1":19154,"PHASE1":19156,"PHASE2":19158,"PHASE3":19160,"PHASE4":19162,"NA":19164},{"trials":19155,"activeCount":101},[],{"trials":19157,"activeCount":101},[],{"trials":19159,"activeCount":101},[],{"trials":19161,"activeCount":101},[],{"trials":19163,"activeCount":101},[],{"trials":19165,"activeCount":101},[19166],{"nctId":19167,"briefTitle":19168,"status":160,"phases":19169,"primaryCompletion":5647,"completion":5647,"start":835,"enrollment":247,"conditions":19170,"interventions":19171},"NCT01172041","The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging",[],[1757],[19152],{"intervention":16547,"totalTrials":115,"cells":19173},{"EARLY_PHASE1":19174,"PHASE1":19176,"PHASE2":19178,"PHASE3":19180,"PHASE4":19182,"NA":19184},{"trials":19175,"activeCount":101},[],{"trials":19177,"activeCount":101},[],{"trials":19179,"activeCount":101},[],{"trials":19181,"activeCount":101},[],{"trials":19183,"activeCount":101},[],{"trials":19185,"activeCount":101},[19186],{"nctId":16541,"briefTitle":16542,"status":160,"phases":19187,"primaryCompletion":16270,"completion":16270,"start":6610,"enrollment":165,"conditions":19188,"interventions":19189},[],[16545],[16547,16548,16549],{"intervention":16548,"totalTrials":115,"cells":19191},{"EARLY_PHASE1":19192,"PHASE1":19194,"PHASE2":19196,"PHASE3":19198,"PHASE4":19200,"NA":19202},{"trials":19193,"activeCount":101},[],{"trials":19195,"activeCount":101},[],{"trials":19197,"activeCount":101},[],{"trials":19199,"activeCount":101},[],{"trials":19201,"activeCount":101},[],{"trials":19203,"activeCount":101},[19204],{"nctId":16541,"briefTitle":16542,"status":160,"phases":19205,"primaryCompletion":16270,"completion":16270,"start":6610,"enrollment":165,"conditions":19206,"interventions":19207},[],[16545],[16547,16548,16549],{"intervention":19209,"totalTrials":115,"cells":19210},"Moderate IV Sedation",{"EARLY_PHASE1":19211,"PHASE1":19213,"PHASE2":19215,"PHASE3":19217,"PHASE4":19219,"NA":19221},{"trials":19212,"activeCount":101},[],{"trials":19214,"activeCount":101},[],{"trials":19216,"activeCount":101},[],{"trials":19218,"activeCount":101},[],{"trials":19220,"activeCount":101},[],{"trials":19222,"activeCount":101},[19223],{"nctId":19224,"briefTitle":19225,"status":160,"phases":19226,"primaryCompletion":19227,"completion":19227,"start":19228,"enrollment":14331,"conditions":19229,"interventions":19231},"NCT03187002","Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion",[93],"2019-10-31","2018-01-18",[19230],"Abortion in First Trimester",[19209],{"intervention":17028,"totalTrials":115,"cells":19233},{"EARLY_PHASE1":19234,"PHASE1":19236,"PHASE2":19238,"PHASE3":19240,"PHASE4":19242,"NA":19244},{"trials":19235,"activeCount":101},[],{"trials":19237,"activeCount":101},[],{"trials":19239,"activeCount":101},[],{"trials":19241,"activeCount":101},[],{"trials":19243,"activeCount":101},[],{"trials":19245,"activeCount":101},[19246],{"nctId":17023,"briefTitle":17024,"status":160,"phases":19247,"primaryCompletion":858,"completion":8251,"start":5647,"enrollment":1435,"conditions":19248,"interventions":19249},[93],[1946],[17028,12786],{"intervention":17059,"totalTrials":115,"cells":19251},{"EARLY_PHASE1":19252,"PHASE1":19254,"PHASE2":19256,"PHASE3":19258,"PHASE4":19260,"NA":19262},{"trials":19253,"activeCount":101},[],{"trials":19255,"activeCount":101},[],{"trials":19257,"activeCount":101},[],{"trials":19259,"activeCount":101},[],{"trials":19261,"activeCount":101},[],{"trials":19263,"activeCount":101},[19264],{"nctId":17054,"briefTitle":17055,"status":132,"phases":19265,"primaryCompletion":16884,"completion":16884,"start":756,"enrollment":101,"conditions":19266,"interventions":19267},[],[4157],[17030,17059],{"intervention":19269,"totalTrials":115,"cells":19270},"buccal swab",{"EARLY_PHASE1":19271,"PHASE1":19273,"PHASE2":19275,"PHASE3":19277,"PHASE4":19279,"NA":19281},{"trials":19272,"activeCount":101},[],{"trials":19274,"activeCount":101},[],{"trials":19276,"activeCount":101},[],{"trials":19278,"activeCount":101},[],{"trials":19280,"activeCount":101},[],{"trials":19282,"activeCount":101},[19283],{"nctId":19284,"briefTitle":19285,"status":160,"phases":19286,"primaryCompletion":19287,"completion":19287,"start":19288,"enrollment":19289,"conditions":19290,"interventions":19292},"NCT02787616","Genetic Basis of Rosacea",[],"2018-11-16","2012-04-13",306,[19291],"Rosacea",[19269],{"intervention":19294,"totalTrials":115,"cells":19295},"Telmisartan",{"EARLY_PHASE1":19296,"PHASE1":19298,"PHASE2":19300,"PHASE3":19302,"PHASE4":19304,"NA":19306},{"trials":19297,"activeCount":101},[],{"trials":19299,"activeCount":101},[],{"trials":19301,"activeCount":101},[],{"trials":19303,"activeCount":101},[],{"trials":19305,"activeCount":101},[],{"trials":19307,"activeCount":101},[19308],{"nctId":19309,"briefTitle":19310,"status":716,"phases":19311,"primaryCompletion":4993,"completion":4993,"start":719,"enrollment":232,"conditions":19312,"interventions":19314},"NCT00185705","Treatment of Insulin Resistance in Hypertensive, Obese Adolescents",[93],[17487,36,19313],"Dyslipidemia",[19294]]